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Plasmodium falciparum, the most pestilential of the malaria parasite species, is 
responsible for ~450,000 direct deaths annually. Clinical disease is a consequence 
of the blood stage of the parasite’s lifecycle involving a plethora of host-parasite 
interactions. Key to these interactions are the P. falciparum reticulocyte binding-like 
homologue (PfRh) proteins responsible for binding erythrocyte receptors and 
gaining entry to host cells. For example, PfRh4 binds to human complement 
receptor-1 (CR1) on erythrocytes for sialic-acid-independent invasion. Another 
protein important for invasion is the PfRh5-interacting protein (PfRipr), an 
essential member of the PfRh5-associated invasion complex (PAIN-complex) 
along with CyRPA, the cysteine-rich protective antigen. Loss of function of PfRipr 
in P. falciparum parasites prevents erythrocyte entry and ablates Ca2+-influx into the 
erythrocyte; essential events during invasion. 
 
This study aimed to biochemically and structurally investigate truncated 
recombinant versions of PfRh4 and PfRipr.  Homology modelling suggested that 
PfRh4 is rich in alpha-helical secondary structure. The sequence of PfRipr 
suggested the presence of ten epidermal growth factor-like (EGF) modules, two 
towards the N-terminus and eight in the C-terminal domain. 
 
In this project, monoclonal antibodies made against recombinant PfRh4 were 
shown, via indirect immunofluorescent assays, to localize to the apical tip of 
merozoites. Monoclonal antibody 5H12, raised against PfRh4, reduces parasite 
invasion of erythrocytes by ~75% in growth-inhibition assays with neuraminidase 
pre-treated erythrocytes. Attempts to produce a stable truncated recombinant 
PfRh4 protein for structural studies were unsuccessful. An ELISA-based assay 
using ten alanine-scan mutants suggested the CR1-binding site lies outside of 
amino acids 283 – 341 of PfRh4.  
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PfRipr truncations, defined by the boundaries of EGF-like repeats predicted based 
on sequence homology, were produced recombinantly in Escherichia coli and Pichia 
pastoris. These proteins had a circular dichroism signature suggestive of -strand-
containing proteins with disordered regions. EGF-containing PfRipr truncations 
did not bind recombinant PfRh5 according to ELISA and size-exclusion 
chromatography assays. EGFs 1-2, 5-7 and 7-10 of PfRipr did not bind CyRPA via 
size-exclusion chromatography or NMR. Crystallisation trials performed on EGF 
modules failed to yield crystals suitable for data collection. A 15N isotopically-
labelled sample of EGF5-7 gave good quality HSQC NMR spectra. A suite of 
three-dimensional NMR spectra collected on a 13C,15N-EGF5-7 sample, at three 
different temperatures, allowed for >86% of backbone assignments. T1/T2 
relaxation analysis and heteronuclear NOE data were suggestive of an elongated, 
rigid protein undergoing intermolecular self-association. Further evidence for 
EGF5-7 being an elongated protein was provided via SAXS analysis. Chemical 
shifts facilitated prediction of secondary structure in EGF 5-7 consistent with an 
EGF-like fold. Melting studies performed on EGF5-7 showed no evidence of 
denaturation over the temperature range 20 C - 95 C indicating a thermally-
stable protein. The addition of Ca2+ to the 15N-EGF5-7 sample caused chemical 
shift perturbations consistent with high-affinity binding. The discovery of 
inhibitory monoclonal antibodies recognising a conformational epitope on EGF7 
provided evidence of the functional importance of this region within PfRipr. 
 
The work described in this thesis provides methods for the industrially-scalable 
production and biophysical investigations of P. pastoris or E. coli-produced 
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Introduction: Malaria in the modern world, Plasmodium falciparum biology 







“Where malaria prospers most, human societies have prospered least” 




“Satisfaction consists in freedom from pain, which is the positive element of life” 

















Malaria is an ancient disease poetically known as “the scourge of humanity”, and 
for good reason- since the first confirmed human case of the disease dating back 
to 450 A.D. (Sallares & Gomzi, 2001), it is estimated that half of all people who 
have ever lived have succumbed to this pathogen (Whitfield, 2002). With this 
ancient disease comes a rich and fascinating history, from mankind originally 
thinking the disease originated from so-called miasmas (malaria as a word comes 
from the medieval Italian “mal'aria”, meaning “bad air”) (Hempelmann & Krafts, 
2013), to famous world-changers that are thought to have fallen prey to this 
parasitic infection such as Alaric I, King of the Visigoths who sacked Rome from 
401 A.D (Galassi, et al., 2016). Obviously, it is beyond the scope of this thesis to 
examine the history of malaria (interested parties are directed to (Packard, 2008)), 
however a brief look into two of the major discoveries in the history of malaria 
should be warranted so as to set the tone post-overview.  
 
Pertaining to the idea that malaria was caused by some form of toxic air, it was not 
until the 19th century that the paradigm around the aetiology was shifted thanks to 
the heroic efforts of two military doctors Charles Alphonse Laveran and Ronald 
Ross. During the early days of medical microscopy, Laveran made the discovery 
that blood of malarious patients contained parasites (Laveran, 1893). Initially, he 
observed small, spherical bodies complete with flagella amongst the blood cells 
obtained from an infected patient’s blood sample. Laveran notes “I was still 
hesitating whether these elements were parasites, when on November 6th, 1880, on examining the 
pigmented spherical bodies mentioned above, I observed, on the edge of several of these elements, 
moveable filaments or flagella, whose extremely rapid and varied movements left no doubt as to 
their nature” (Laveran, 1893). This was of course what we know now to be the 
gametocyte form of the Plasmodium parasite, but Laveran would go on to document 
various morphological forms. Ronald Ross was the first to demonstrate definitively 
that mosquitoes were infecting people with malaria, a feat accomplished by two 
years of microscopically examining thousands of mosquitoes fed with infected 
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patient blood (Hempelmann & Krafts, 2013) (Ross, 1923). Upon examination of 
the mosquitoes fed with infected blood (in contrast to the control group), Ross 
could observe the characteristic pigment that we now know today to be 
haemozoin, a metabolic by-product generated from Plasmodium parasites 
conversion of the haem encountered in erythrocytes. Due to the lack of pigment 
observed in the control mosquitoes, it was in 1897 that Ross correctly deduced 
that mosquitoes must be the agent responsible for the transmission of malaria 
parasites.  
 
Both Laveran and Ross went on to be awarded the Nobel Prize in Medicine or 
Physiology (1907 and 1902, respectively) for their paradigm-shifting work. 
Furthermore, these discoveries are of great importance from both a historical and 
philosophical stand-point. Inductively, it makes sense that people had thought 
“bad air” around swamps and marshes led to malaria (or “paludisme” as Laveran 
preferred, which is from the Latin root for swamp); swamps, of course are 
breeding grounds for mosquitoes and those in swamp-dense areas can be at a 
higher risk of contracting malaria (Beck, et al., 1994). However, this is the central 
philosophical problem with inductive reasoning. Just because swampy areas gave 
rise to more suffering from malaria, it does not mean the swamp air was the cause; 
this is a form of post hoc ergo propter hoc fallacy in logic and reasoning. What Laveran 
and Ross were able to do was to take a more scientifically rigorous deductive 
approach that possessed falsifiable hypotheses and methodologies open to 
independent verification. This was indeed the case when the world was initially 
skeptical over the claims made by Laveran; however, once other researchers were 
also able to observe and report on finding parasitic microorganisms in patient 
blood the skepticism subsided (Auterhoff, 1967). Interested readers in the 
philosophy of science, particularly in the superiority of deductive means of 
reasoning over inductive ones, and paradigm shifts are referred to Popper, 1957, 
Kuhn, 1962, and Godfrey & Haggarty-Weir, 2017. 
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The rich history of malaria also encompasses a vast variety of disciplines, from 
epidemiology to economics, from basic biology to biochemistry, drug/vaccine 
development and structural biophysical chemistry. It is these fields that shall be 
examined in more depth with respect to malaria in the introduction to this thesis 
to provide the reader with an integrated understanding of the field of malariology, 
before embarking on an in-depth biophysical and biochemical analysis of key P. 
falciparum invasion ligands that are of interest to anti-malaria vaccine development, 
a development researchers hope will lead to some freedom from parasite-related 
pain, a truly positive element in any life. 
 
 
1.2 Malaria: A Global Problem 
 
For as long as there have been Homo sapiens, there has been malaria. This stems 
from the rich evolutionary history of the Plasmodium species, which emerged 
shortly after the appearance of mammals around 200 million years ago (Rich & 
Ayala, 2006). Whilst there are six species of Plasmodium parasites that can cause 
human disease (P. falciparum, ovale wallikerii, ovale curtisii , vivax, malariae and knowlesi), 
the most malignant, P. falciparum, is thought to have appeared relatively recently in 
evolutionary history, around 5000 - 10 000 years ago (Rich, et al., 2009), which is 
consistent with a relatively recent worldwide expansion of P. falciparum populations 
(Joy, et al., 2003). Current genetic and phylogenetic analysis suggests that human 
falciparum malaria is of gorilla origin, with the parasite species making a single 
cross-transmission from gorilla to human (Liu, et al., 2010). Furthermore, making 
an equally important contribution to the history of human malaria around the 
world is the widespread distribution of the disease vector, female Anopheline 
mosquitoes. There are approximately 70 species of Anopheles mosquitoes with the 
capacity to transmit Plasmodium parasites (Manguin, et al., 2008) allowing for the 
presence of endemic malaria in around 109 countries, with a majority found in 
African, Asian and Latin American regions (Manguin, et al., 2010). Due to the vast 
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geographic spread of these regions, malaria is truly a global problem. We shall now 
examine the distribution, spread and economic impact of malaria. 
 
 
1.2.1 The Distribution and Spread of Malaria 
 
Since 2010, there has been an impressive reduction in global malaria mortality 
from ~1.24 million (Murray et al., 2012), to approximately 429 000 deaths (Alonso, 
2017). This has been attributed to increased access to anti-malarial interventions 
including more diagnostic testing (such as a 77% increase in paediatric malarial 
diagnostic testing in sub-Saharan Africa, the most malarious region on earth), a 
five-fold increase in preventative treatment of pregnant women since 2011, and a 
doubling in the use of insecticide-treated bed nets (WHO, 2016). However, despite 
some important successes, professionals and governmental authorities should not 
rest on their laurels; there were an estimated 212 million new malaria cases in 2015 
and currently, every two-minutes another child dies from malaria (Alonso, 2017). 
Additionally, the World Health Organisation estimates that under half of the 91 
malaria-affected countries will meet the upcoming milestone of a 40% reduction in 
incidence and mortality from the disease by 2020 (WHO, 2016). The current 




Figure 1.1. The Current Global Distribution of Malaria: Whilst progress has occurred in 
limiting the spread of endemic malaria (as shown by the countries in green) from 108 countries in 
2000 to 91 in 2016, half of the world’s population remains at risk (due to the population densities in 
the blue-coloured countries). This figure also highlights the equatorial focus of malaria endemicity. 
Figure from (WHO, 2016). 
 
The actual present situation of global malaria morbidity and mortality may indeed 
be far worse than initially thought. This is due to a combination of under-reporting 
from malaria surveillance programs (in 2015 for example, it is estimated that these 
programs only accounted for 19% of global cases) (WHO, 2016), problems with 
an over-reliance on passive case detection rather than the more rigorous (and 
expensive) active case detection (Griffin, et al., 2014), and the role of infections 
secondary to and exacerbated due to malaria. One example of this is the case of 
the 2008 Mozambique study, where initially 10% of maternal deaths were found to 
be due to malaria, but 13% were secondary to HIV-infection which can be 
exacerbated by coexisting malarial infection (Menéndez, et al., 2008). 
 
The spread of malaria is also affected by factors such as climate change (Tanser, 
Sharp, & Sueur, 2003) and counterfeit drugs (Newton, et al., 2006). Climate change 
is one of the greatest challenges faced by modern man and has a significant impact 
on global disease trends (McMichael, Woodruff, & Hales, 2006). With respect to 
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malaria, modelling indicates a growth in populations at risk due to increased 
climate suitability for the Anopheline mosquitoes that transmit the parasite 
(Caminade, et al., 2014). Regarding the African continent, one recent decade-long 
study concluded that climate change was unlikely to have a significant impact in 
one West African region (with potential reductions in malaria burden) (Yamana, et 
al., 2016), this may be offset by another 2016 publication concluding a likely 
increase in tropical, highland and Eastern regions of Africa (Ngarakana-Gwasira, et 
al., 2016). Whilst there are a lot of uncertainties about the modelling due to 
alterations in population dynamics, government intervention programs, type of 
modelling used, alterations of socio-economic factors and changes in the rates of 
climate change, other studies are in general agreeance with the risk that climate 
change presents to the spread of malaria and suggest that there is cause for 
concern at both the local-level and the wider global-level (Ryan, et al., 2015) 
(Onyango & Oz Sahin, 2016) (Ngarakana-Gwasira, et al., 2016). This should be 
particularly concerning for the African continent due to it not only having the 
most endemic levels of malaria transmission but also having a faster than average 
global warming rate of temperatures, with predictions showing an increase by 
between 3 and 6 C by 2100 (Niang, et al., 2014).  
 
Another factor that influences the spread of malaria is that of counterfeit drugs. 
These can come in one of two major forms; those that consist of sub-clinical doses 
of active ingredient, and those which have no active ingredient in the compound 
sold. Both are problematic for slightly different reasons; the former has the 
potential to lead to the spread of drug-resistant parasites due to the subclinical 
dose of the drug which may fail to clear parasitaemia, and the latter having the 
potential to increase mortality/morbidity directly (Karunamoorthi, 2014). It has 
been estimated that up to half of the anti-malarials in Africa and Southeast Asia are 
of diminished quality, often due to counterfeits (Karunamoorthi, 2014). One of 
the most shocking figures was the revelation in 2003 that 88% of all artesunate in 
the private sector in Laos was fake (Sengaloundeth, et al., 2009). Horrifically, 
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following Latin hypercube sampling (using estimates calculated from the number 
of private sector anti-malarials taken by infected children), around 122 350 malaria-
related deaths of children under the age of five in Africa during 2013 were deemed 
likely to be due to low-quality pharmaceuticals (Renschler, et al., 2015). 
 
Regarding fake anti-malarials and their contribution to drug-resistance amongst 
parasite populations, modelling data does indeed suggest that patients receiving 
sub-standard treatment are likely to help spread resistance or spontaneous 
outbreaks of infection (White, et al., 2009). One case study in particular highlights 
this, the acute 2003 epidemic of malaria on the Pakistan/Afghanistan border was 
due to substandard locally-produced sulfadoxine/pyrimethamine, with lower 
bioavailability than the original manufacturers product (Leslie, et al., 2009). It is for 
the aforementioned reasons that knowingly using, producing or spreading fake 
anti-malarials should be considered a crime against humanity, and something 
governments and regulators must take notice of. Those further interested in the 
use of anti-malarials, the patterns of resistance and the impact on policy, are 
referred to (Kocovski, Godfrey & Elkington et al., 2015). 
 
 
1.2.2 The Economics of Malaria 
 
The cost to human life and well-being is rather self-evident; however, this scourge 
also creates significant socio-economic burdens due to the bi-directional link 
between malaria and poverty. This is particularly the case in endemic African 
nations where up to 40% of an individual health budget may be allocated to 
tackling malaria (Narasimham & Attaran, 2003) (Jowett & Miller, 2005). For 
example, in 2004 it was calculated that the Tanzanian government spent 1% of its 
GDP and almost a third of its resources on malaria (Jowett & Miller, 2005). It is 
important to note that these figures fail to consider the effects on longer-term 
economic growth and development, in addition to the accounting method used to 
arise at these figures, which may be unsuitable when estimating economic strain 
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from areas with a very high malaria transmission rates (Sachs & Malaney, 2002). 
Furthermore, direct medical intervention including diagnosis and treatment of 
people infected with malaria only takes into account part of the economic burden; 
additional costs can also be directed towards preventative measures including 
purchase of anti-mosquito coils, spraying programs, insecticide-treated bed net 
distribution, malaria education, epidemiology research, drug quality control and 
vaccine research and development (Narasimham & Attaran, 2003) (Jowett & 
Miller, 2005) (Sachs & Malaney, 2002) (Phillips & Phillips-Howard, 1996). 
Chronic, longer-term strain on budgets additionally includes effects on both 
microeconomic factors such as the individual household (i.e. migration and 
saving), and macroeconomic stressors consisting of adverse impacts on trade, 
foreign investment and tourism (Sachs & Malaney, 2002). One worrisome figure, if 
many of the aforementioned factors (including life expectancy, location, economic 
policy and initial poverty) are taken into account, shows that nations with endemic 
malaria grew around 1.3% less per person per year than non-endemic regions; 
however, a 10% reduction of malaria corresponds with an 0.3% increase in 
economic growth (Gallup & Sachs, 2001).  
 
In addition to the economic impact of malaria on developing nations, there is of 
course an impact on first-world nations. While this impact is far less devastating 
for the latter, it is still worth a brief mention. Europe was declared free from 
malaria in the 1970’s via a combination of drug use, environmental engineering (i.e. 
swamp draining) and the use of highly effective insecticides, and today most cases 
are imported by international travellers and immigrants (reviewed in Piperaki & 
Daikos, 2016). One study of malaria in the Slovak Republic covering 19 patients 
demonstrated that a preventative approach to the disease via chemoprophylaxis 
offsets costs incurred by direct medical intervention and time away from work, 
with savings of around 63.6% of what one would spend without 
chemoprophylaxis (Svihrova, et al., 2012). Occupational exposure to malaria by 15 
British soldiers stationed in Germany in 2001-2002 (malaria exposure was via a 
short peacekeeping mission in tropical malarious regions) led to a costings estimate 
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of €27 760 for their hospitalizations (Croft, et al., 2005). In the United States of 
America, a country declared malaria-free in 1949, the estimated cost of treating a 
citizen who acquired malaria from abroad is around $25 250 USD (compared to 
prophylactic pre-travel treatment of $161 - $208 USD) (Adachi, et al., 2014). Whilst 
overall these costs pale in comparison to the economic pains malaria gives regions 
such as Africa, South America and Asia, they are all costs which could be largely 
offset by a highly efficacious and affordable vaccine (which as a preventative 
would be more economically efficient than treatment, as demonstrated in the 
analysis by Stack, et al., 2011). Therefore, wealthy nations should have an economic 
(in addition to a moral) interest in the eradication of malaria and a continued 
investment into vaccine development. 
 
 
1.2.3 Anti-Malarial Vaccine Development 
 
The history of anti-malarial vaccine development has been fraught with frustration 
and failure. Many a malariologist has had their dreams of saying “thank you” in 
Swedish (“tack så mycket”) dashed. This section will briefly explore a modern 
historical look at the quest for the proverbial holy grail that is a safe, affordable 
and efficacious malaria vaccine. Due to space considerations and relevancy, 
mosquito-stage transmission-blocking and DNA-based vaccines will not be 
discussed (interested readers are referred to Hill, 2011 and Bergmann-Leitner & 
Leitner, 2013). For a general overview of some of the key developments towards 





Figure 1.2. Key Developments in the Modern History of Malaria Vaccine Research: This 
flow chart focuses on some of the major immunological, molecular biochemistry, vaccinology and 
program developments since the 1940’s. Abbreviations: WRAIR- Walter Reed Army Institute of 




• Inactivated sporozoites show immune responses against malaria in fowl (Russell & Mohan, 1942).
1970
• Immunological Development
• Rodent models of malaria demonstrate immunological cross-protection (Cox , 1970).
1983
• Molecular Biochemistry Development
• The first malaria parasite antigens are cloned (Ellis, et al., 1983).
1984
• Program Launch
• WRAIR and GSK collaborate to produce a malaria vaccine made in E. coli (Young, et al., 1985).
1987
• Immunological and Vaccine Development
• Synthetic proteins used to vaccinate Aotus monkeys; however the adjuvant is hepatotoxic (Patarroyo, et al., 1987).




• Study carried out on multi-stage, multi-component vaccine containing pre-erythrocytic, blood and sexual stage 
antigens (Bathurst, et al., 1993).
1995
• Vaccine Development
• The first RTS,s trial in humans carried out in the USA (Gordon, et al., 1995).
1999
• Program Launch




• In a phase III trial, RTS,s demonstrates a vaccine efficacy of 46% in children and 27% in infants against clinical 
malaria at the 18 month mark (RTS,S Clinical Trials Partnership, 2014).
2017
• Vaccine Development
• Sanaria and University of Tübingen scientists report 100% effectiveness of their irradiated sporozoite vaccine, 
PfSPZ-Cvac, when assessed at the 10 week point post final dose (Benjamin Mordmüller et al., 2017).
• WHO announces that RTS,s will be rolled out in selected areas of Ghana, Kenya and Malawi.
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Modern malaria vaccine design has been borne out of the early research involving 
murine immunizations with parasite material (Cox, 1970), and has undergone 
various Kuhnian-style revolutions (Verhave, 2012) with respect to the best strategy 
in addition to a diversity of approaches used. Many of these revolutions have come 
about from novel understanding of immune responses against malaria, allowing (in 
conjunction with advances in technology such as recombinant protein production 
of vaccine components (Patarroyo, et al., 1987)) for the development of a test 
vaccine that has always ultimately failed due in part to a paucity of more 
immunological knowledge and technological capability. Additional reasons for 
failure have also included a lack of scientific reason or rigour, such as the work by 
(Patarroyo, et al., 1987). When these factors get updated by novel knowledge and 
technological progress, the cycle starts again. 
 
One of the earliest approaches to malaria vaccine development has been the use of 
weakened sporozoite forms of the parasite (typically through irradiation); a whole-
parasite approach. This grew out of the need to move away from killed blood-
stage parasites, due to the requirements for new, effective and safe adjuvants to be 
used alongside them (reviewed in Mata, et al., 2013). In the 1970’s, humans 
inoculated with sporozoites from irradiated mosquitoes did demonstrate 
significant levels of protection, but only after a large number of mosquito bites 
(Clyde, et al., 1975). The other problems with this approach were that not all 
parasites remained non-infective and protection waned after 3 months against P. 
falciparum (Clyde, et al., 1975). More recently, biotech company Sanaria and 
collaborators not only revisited this approach, but improved on it with reports of 
100% protection in 6 patients who were administered the vaccine known as PfSPZ 
(Seder, et al., 2013). However, the problem with this approach was that five doses 
spread over the course of several months had to be used (with four doses, the 
protection fell to around 66% in nine patients where three developed malaria), and 
the vaccine had to be administered via the direct intravenous route (DIV); two 
issues that have practical problems for use of this vaccine for those most in need, 
i.e. very young children. An improved version of PfSPZ was developed, known as 
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PfSPZ-CVac, which consisted of in vivo chloroquine-attenuated sporozoites, that 
allowed dosing to be reduced to three lots in order to show 100% protection 
against malaria ten weeks after the third and final vaccination; though this was still 
via the DIV route (Mordmüller, et al., 2017). As Adrian Hill mentions, additional 
challenges would of course be related to the immense costs involved in vaccine 
production and distribution due to the requirement for a cold-chain (Hill, 2011). 
 
More advanced methods of generating sporozoite-based whole-cell vaccines have 
gathered some interest, such as using genetically-attenuated sporozoites that would 
not be able to break through to the blood-stage of infection, where merozoite 
morphological forms of the parasite cause disease. The first human study using 
genetically-attenuated parasites (GAPs) made use of mosquitoes infected with P. 
falciparum parasites with deletions of the p52 and p36 genes (important for liver 
stage development) (Spring, et al., 2013). However, whilst all six-people remained 
blood-stage negative following low doses of the vaccine, high doses saw one 
person develop the presence of merozoites in peripheral blood. Despite this 
drawback, GAPs are still worth investigating and the use of further genetic 
deletions may prove fruitful. 
 
An alternative version of the whole-parasite approach to malaria vaccine 
development is the use of chemically-attenuated blood-stage merozoites (reviewed 
in-depth in Stanisic & Good, 2015). Using the DNA-binding drug centanamycin to 
prevent parasite replication, P. yoelii-parasitized erythrocytes have been used to 
vaccinate mice, demonstrating nine months of protection against blood-stage 
infection (Raja, et al., 2016). This data is of course early-stage, but somewhat 
encouraging; though the challenges of safely utilizing both DNA-binding drugs 
and P. falciparum-parasitized erythrocytes, in addition to regular immunological and 
efficacy studies remains.  
 
The next major approach is of course the use of recombinant proteins for vaccine 
formulation. Currently, the most advanced is the RTS,s vaccine which is 
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comprised of a truncation of the circumsporozoite protein (CSP), the viral 
envelope protein of the hepatitis B virus and the AS01 chemical adjuvant; the 
latter two components required to increase the efficacy of the vaccine and immune 
responses (Stoute, et al., 1997) (Kester, et al., 2009). Phase III trials involved over 
15 000 African children and after a year following the use of three doses of 
vaccine, yielded a 28% and 18% reduction in clinical malaria cases in young 
children and infants, respectively (RTS,S Clinical Trials Partnership, 2015) 
(Greenwood & Duombo, 2016). Those given a fourth dose demonstrated an 
average of 36.3% reduction in clinical malaria during 48 months of follow-up, 
which was estimated to have averted 1774 cases of clinical malaria per 1000 
children (this number is due to the fact that multiple infections can occur). Whilst 
it has been recommended that the deployment of RTS,s go ahead (Greenwood & 
Duombo, 2016), concern should of course be given to the relatively poor level of 
longer-term protection.  
 
Recently, a large study was published demonstrating the first use of a viral-
vectored anti-malaria vaccine in a dose-escalation phase Ia study using 24 human 
volunteers (Payne, et al., 2017). This study employed the use of the replication-
deficient chimpanzee adenovirus serotype 63, and an attenuated orthopoxvirus-
modified vaccinia virus Ankara (both established viral vectors in mammalian 
vaccine research), which encoded pfrh5 from the 3D7 clone of P. falciparum. The 
vaccine was delivered via the intramuscular route in a heterologous prime-boost 
regimen utilizing an eight-week interval. All vaccinations were reported as being 
well-tolerated (with no serious adverse side-effects), and induced the production of 
anti-PfRh5 antibodies. These serum antibodies were used in a growth inhibition 
assay (GIA) to demonstrate an ablation of parasite invasion of erythrocytes, and 
were later demonstrated to target a mixture of linear and conformational epitopes 
on PfRh5. Interestingly, Payne et al. reported that the PfRh5-specific antibody 
responses were in excess of those seen in African adults with longer-term non-
sterilizing immunity following years of exposure to malaria. What will become 
essential is to follow the immunological memory in each trial volunteer in order to 
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assess how long-lived the immune responses to the vaccine last. However, this 
study does, for the first time, show that a viral-vectored approach to malaria 
vaccine development is able to be legitimately explored in humans. 
 
It should be argued that scientists must aim at developing a malaria vaccine that is 
multi-component and targets multiple stages of the parasite’s lifecycle. This 
approach may help prevent the so-called “leakiness” of vaccines targeting the 
sporozoite (to prevent blood-stage breakthrough), decrease transmission of malaria 
(by targeting the sexual stages of the parasite), and ablate clinical malaria due to the 
blood-stage of parasite asexual development. Proteins that have been targeted as 
vaccine candidates include CSP, Pfs25, 48/45, and 230 (all of which are sporozite 
proteins), apical membrane antigen-1 (AMA-1), and PfRh5 (Cowman, et al., 2016). 
Whilst these candidates should be pursued, proteins found to be essential to the 
blood stages of P. falciparum that are of immunological importance should also be 
further examined, such as PfRipr, which forms a necessary invasion complex with 
PfRh5 (Chen, et al., 2011), (Volz, et al., 2016). This will be further explored in 
section 1.4 - 1.6. However, first a succinct review of the parasite’s life cycle will be 




1.3 Malaria Parasite Lifecycle Biology 
 
Despite various geographical and phenotypic differences amongst malaria parasite 
species, they are all linked by a characteristically complex life cycle including a 
developmental stage taking place inside Anopheles mosquitoes. Refer to figure 1.3 





Figure 1.3. Lifecycle of the Plasmodium Parasite: A summary of the complex lifecycle of  
human malaria parasites. Figure from (Cowman, et al., 2016). Following a mosquito blood meal  
(A), sporozoites move through the human skin to gain entrance to the blood stream in order to  
reach hepatocytes for their first round of asexual development (B). This leads to the emergence of  
merozoite morphological forms of the parasite that asexually reproduce inside erythrocytes (C).  
Sexual stages of the parasite can also emerge from alternative intra-erythrocytic development (D),  
which leads to male and female gametocytes that are taken up by feeding mosquitoes (E).   
 
 
When a mosquito ingests parasitic gametocytes transmitted from a human host, 
they become activated in the insect’s midgut lumen to produce gametes in a 
process that depends on various factors including pH, a temperature drop, 
increased levels of calcium and the presence of xanthurenic acid (Guttery, et al., 
2012). The resulting zygote occurring from the fusion between a male and female 
gamete develops into a highly motile ookinete that penetrates the mosquito’s gut 
wall epithelium, facilitating differentiation into an immobilized oocyst (Guttery, et 
al., 2012) (Doi, et al., 2010). This oocyst becomes the developmental site of new 
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sporozoites that, upon emergence, migrate to mosquito salivary glands where they 
wait to be injected into the next human host when the mosquito’s penetrating 
proboscis strikes host dermal tissue (Doi, et al., 2010). 
 
Up to approximately 120 motile sporozoites will find themselves in the host’s 
dermis, where the parasites spend up to three-hours before trickling into the blood 
stream, and occasionally the lymphatics (Tamauchi, et al., 2007). Once blood-
borne, sporozoites head to the liver, crossing the sinusoidal wall via gliding 
motility, in a process taking as little as two-minutes (Doi, et al., 2010). Sporozoites 
traverse various cell types such as Kupffer cells and fenestrated endothelial cells 
before finally entering a hepatocyte to undergo merogony (Tavares, et al., 2013). 
One of the key signals for hepatocyte invasion to occur is the parasitic recognition 
of highly sulphated forms of heparin sulphate proteoglycans (HSPGs) which 
triggers calcium-dependant protein kinase 6 and the binding of CSP to HSPG and 
subsequently, AMA-1 adhesion (Coppi, et al., 2007) (Herrera, et al., 2015). Once 
inside a hepatocyte, the parasite sets up a parasitophorous vacuole via interactions 
between its p52 and p36 proteins and the hepatocyte receptor EphA2; essential 
molecular events prior to the subsequent two – ten days of merogony 
(Kaushansky, et al., 2015). It should be noted that P. vivax and P. ovale parasites can 
become hypnozoites to establish latent infection (reviewed in detail in (Prudêncio, 
et al., 2006)). 
 
The liver stage of infection is responsible for the asexual production of 
approximately 40 000 merozoites per hepatocyte, which are released into the blood 
following their release from merosomal vesicles (Sturm, et al., 2006). The resulting 
blood-stage of infection is where the symptoms of clinical malaria manifest as 
parasites undergo rapid asexual multiplication inside erythrocytes via a repeating 
sequential process of pre-invasion set-up, active invasion, echinocytosis and host 
cell rupture (Weiss, et al., 2015). The initial steps of blood-stage infection are given 




Figure 1.4. Merozoite Invasion of Erythrocytes: Pre-invasion is a process taking around ten-
seconds, and involves a host of molecular interactions between the merozoite surface coat proteins 
and the erythrocyte surface leading to its deformation. Reorientation occurs so that the apical tip of 
the merozoite is perpendicular to the erythrocyte, with EBA and PfRh proteins (originally stored in 
micronemes and rhoptries) of the former engaging with ligands of the latter. Once PfRh5 of the 
PfRh5-associated invasion complex (PAIN-complex) engages BSG and the AMA-1/RON complex 
is established, the parasite has committed to invasion. Invasion lasts again approximately ten-
seconds and involves the enzymatic shedding of merozoite surface proteins whilst the tight moving 
junction created by the AMA-1/RON complex in addition to reverse mobilization of parasitic 
actomyosin allows the parasite to enter the erythrocyte. During entry, a parasitophorous vacuole is 
established. Figure and text adapted from (Weiss, et al., 2016). 
 
 
The glycophosphatidylinositol (GPI) anchored protein, merozoite-surface protein-
1 (MSP-1), is the predominant surface coat protein the merozoite has been 
hypothesized to use for initial attachment to erythrocytes (Holder, 1994). 
However, evidence from genetic knockdown studies of MSP-1 reveal it has a level 
of redundancy whereby merozoites are still capable of engaging with and invading 
erythrocytes (Das, et al., 2015). It is possible that aside from MSP-1, other 
epidermal growth factor-like module-rich proteins (EGFs) amongst the merozoite 
surface coat are important for the initial attachment events such as MSP2, MSP4, 
Pf’s 12, 38 and 92 (potential candidates are extensively reviewed in Crabb, 2006 
and Beeson, et al., 2016). Nonetheless, after initial attachment, the erythrocyte is 
physically deformed at the point of initial parasitic contact, which is followed by a 
reorientation event resulting in the merozoite’s apical tip lying perpendicular to the 
erythrocyte surface. This reorientation event was until recently (Bargieri, et al., 
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2016) thought to be, at least in part, due to the merozoite thrombospondin-related 
anomalous protein (MTRAP), which binds aldolase (an actin-binding protein) 
through its cytoplasmic domain (Baum, et al., 2006). MTRAP was also believed to 
play a vital role in tight junction formation (Baum, et al., 2006), though is not 
utilized directly for erythrocytic invasion itself (Riglar, et al., 2016). It is now 
understood that both of these claims are inaccurate, as CRISPR/Cas9-based 
genetic disruption work on blood stages revealed no observable defects in parasitic 
growth recently (Bargieri, et al., 2016), so clearly more investigation around the 
reorientation event during invasion is warranted.  
 
Next in the pre-invasion phase of invasion is the binding between apical tip 
proteins and key erythrocyte receptors; important with respect to the former are 
the erythrocyte-binding antigens (EBA’s) and the P. falciparum reticulocyte binding-
like homologs (PfRh’s). EBA proteins bind to host glycophorins and the PfRh 
family of proteins including PfRh4 and PfRh5 engage a variety of receptors such 
as complement receptor 1 (CR1) and BSG, respectively (the PfRh family of 
receptors will be looked at in more detail in section 1.4, those interested in the 
EBA family are referred to Tham, et al., 2012, Cowman, et al., 2016, and Wassmer 
& Carlton, 2016). Significant erythrocyte deformation occurs following the binding 
between EBA-175 and glycophorin A, resulting in a phosphorylation cascade and 
subsequent alterations in host cell cytoskeletal proteins (Sisquella, et al., 2017) 
(Koch, et al., 2017). In addition to the interactions described, Ca2+ signalling inside 
the invading merozoite occurs, with phosphorylation of the cytoplasmic tail of 
PfRh4 taking place during its engagement to CR1 (Tham, et al., 2015). At around 
the same time as host cell deformation is occurring, the erythrocytic BSG gets 
bound to by PfRh5 in the PfRh5-Associated INvasion-complex (PAIN-complex), 
consisting of the cysteine-rich protective antigen (CyRPA) (Reddy, et al., 2015) and 
the P. falciparum Rh5-Interacting PartneR (PfRipr) (Chen, et al., 2011). This step is 
essential for invasion to occur, with potent inhibition of invasion resulting from 
experimental models using bsg knockouts, soluble recombinant BSG or complete 
invasion inhibition via anti-BSG antibodies (Crosnier, et al., 2011).  
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Following the resultant Ca2+ influx into the erythrocyte due to PAIN-complex 
binding (Volz, et al., 2016), the merozoite forms an irreversible tight junction once 
RON2 is inserted into the host cell membrane and binds to AMA-1 found on the 
parasitic cell surface, thus committing the parasite to invasion (Besteiro, et al., 
2011). This results in the formation of the RON/AMA-1 complex and secretion 
from rhoptries of lipid-rich contents (likely involved in the formation of the 
parasitophorous vacuole), merozoite surface coat protein shedding via enzymatic 
cleavage, and activation of the parasitic actomyosin motor (Riglar, et al., 2011). 
Upon entry into the erythrocyte, the parasitophorous vacuole is sealed around the 
parasite, protecting it from the local environment and serving as one of the 
barriers upon which parasitic proteins are exported towards the host cell surface 
via the P. falciparum translocon of exported proteins (PTEX) (Koning-Ward, et al., 
2009). The infected erythrocyte experiences echinocytosis a process defined 
morphologically by cell-shrinkage and formation of spikey protrusions, which may 
be due to the Ca2+-influx that follows PAIN-complex/BSG binding (Weiss, et al., 
2015).  
 
Once invasion has occurred, the parasite begins extensive remodelling of the 
erythrocyte, essentially setting up a temporary “home” from which it can evade the 
host immune system and undergo asexual reproduction in 48-hour cycles leading 
to the development of up to 32 additional merozoites per infected cell (the intra-
erythrocytic stage of development is reviewed extensively in Boddey & Cowman, 
2013). Inside the infected erythrocyte, an extensive protein trafficking network is 
established (see figure 1.5), with the P. falciparum erythrocyte membrane protein 1 
(PfEMP1) being the most important parasitic protein set up on the erythrocyte cell 
surface, subsequently allowing for sequestration onto capillary beds thus evading 
splenic clearance (Su, et al., 1995) (Cranston, et al., 1984). Furthermore, parasitic 
proteins that contribute to host cell remodelling allow the infected erythrocytes to 
withstand higher temperatures that develop due to malarious fever, in addition to 
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being able to tolerate higher shearing forces due to increased rigidity via knob-like 




Figure 1.5. Architecture of the Infected Erythrocyte: This erythrocytic cross-section provides a 
glimpse of the extent of remodelling of the infected host cell. Within the parasite membrane (PM) 
lies various Plasmodium organelles including the endoplasmic reticulum (ER) that facilitates the 
vesicle-mediated transport of proteins to the erythrocyte cytoplasm and cell surface, via PTEX on 
the parasitophorous vacuole (PVM). The food vacuole is responsible for the metabolism of haem, 
which is too toxic to malaria parasites, and so is converted into haemozoin. Abbreviations not 
elsewhere cited: NPP/PSC- new permeability pathways, KAHRP- knob-associated histidine-rich 
protein, EDV- electron-dense vesicles, RBC- red blood cell, RESA- ring-exported surface antigen, 
COP- coat protein. Image and information from (Cowman, et al., 2016).   
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High parasitaemia can develop during the asexual reproduction (schizogony) of P. 
falciparum parasites in the blood due to the exponential development of around 10-
fold parasite populations per 48-hour cycle that facilitates a cytokine-mediated 
inflammatory response correlating with an increase in disease severity (and death) 
(Kwiatkowski, et al., 1990). During schizogony a proportion of parasites switch to 
producing sexual forms termed gametocytes. This switching results from key 
microenvironment changes such as drug exposure (not limited just to antimalarial 
drugs, but also steroid hormones), dense parasitaemia levels, parasitic endoplasmic 
reticulum stress, anaemia (especially sickle-cell anaemia) and erythrocyte 
haemolysis (reviewed extensively in (Ngwa, et al., 2016)). The parasites inside 
infected erythrocytes are capable of signalling each other to allow for an increase in 
gametocytogenesis via extracellular vesicles containing DNA, RNA and proteins 
(Regev-Rudzki, et al., 2013). The egress of these sexual forms of the parasite from 
erythrocytes requires MTRAP in order to lyse the parasitophorous vacuole 
membrane (Bargieri, et al., 2016). Once gametocytes are produced and taken up by 
a feeding mosquito, the entire cycle begins again. 
 
 
1.4 An Examination of Key Apical Merozoite Proteins 
 
As demonstrated previously in figure 1.4 and section 1.3, the EBA and PfRh 
proteins of the merozoite play an important role in binding erythrocyte receptors 
for invasion (figure 1.6), and therefore to this key step in the lifecycle of Plasmodium 
parasites. EBA proteins are secreted from the micronemal organelles, with EBA-
140, 175 and 180 possessing conserved Duffy binding-like domains (referred to as 
F1 and F2) that bind erythrocyte receptors (Adams, et al., 1992) (Adams, et al., 
2001). Erythrocyte glycophorins A, B and C bind to EBA-175, erythrocyte binding 
ligand-1 (EBL-1) and EBA-140, respectively, with EBA-181 potentially interacting 
with the erythrocyte membrane protein band 4.1; though the definitive binding 
partner remains elusive (Sim, et al., 1994) (Mayer, et al., 2008) (Lobo, et al., 2003) 
(Gilberger, et al., 2003) (Lanzillotti & Coetzer, 2006).  
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Figure 1.6. Key P. falciparum Proteins and their Association with Erythrocytic Ligands: A. 
This figure demonstrates the EBA and PfRh family of proteins found on the apical tip of the 
parasite and their cognate erythrocytic binding partners (for those known; the erythrocytic binding 
partners for PfRh1 and 2a/b are as yet unknown, and the binding partner for EBA-181 is assumed 
to be Band 4.1). B. As demonstrated, host cell BSG is engaged by the proteins of the PAIN-
complex on the apical tip of the merozoite, with direct association due to PfRh5. B. One of two 
current models (the other being C) whereby the interaction between the PAIN-complex and the 
merozoite membrane is unknown. C. A recent model developed showing that the PAIN-complex 
is tethered to the merozoite membrane via P113, which also binds PfRh5. Figure made by Mr. 
William Godfrey (with guidance from the author). 
 
Aside from PfRh3 (a transcribed pseudogene), modelling studies based on the 
solved crystal structure of PfRh5 suggest that PfRh’s 1, 2, and 4 share its kite-like 
structure despite low sequence homology (Wright, et al., 2014) (Chen, et al., 2014). 
PfRh5 is unique amongst the PfRh proteins in that it is significantly smaller at 
around 65 kDa compared to >200 kDa for the others, and is refractory to genetic 
deletion in all strains tested (Baum, et al., 2009). PfRh1 functions prior to the other 
proteins, and once bound to the as yet unknown host cell receptor, allows for a 
rise in merozoite Ca2+ levels and subsequent release of EBA-175 from micronemes 
(Gao, et al., 2013). PfRh2a and PfRh2b proteins are mostly identical with respect to 
their N-terminal regions, with significant divergence occurring from 42 and 54 
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kDa, respectively, from the cytoplasmic C-terminus (Jayner, et al., 2001) (Triglia, et 
al., 2011). PfRh4 binds to CR1, specifically the complement control protein (CCP) 
modules 1-3 (Tham, et al., 2010) (Tham, et al., 2011), and is upregulated when there 
is a loss of EBA-175 function (Stubbs, et al., 2005). Due to the focus of this thesis, 
a closer look at PfRh4 and CR1 will be given, followed by an examination of BSG 
and the PAIN-complex proteins. 
 
 
1.4.1 A Closer Examination of PfRh4 and Complement Receptor 1 
 
In vitro studies of P. falciparum blood culture reveal two major erythrocyte invasion 
pathways; sialic acid (SA)-dependent and SA-independent. A variety of 
erythrocytic receptors utilized by Plasmodium parasites possess SA moieties which 
serve to confer a net negative charge to erythrocytes (for example, the 
glycophorins, band 4.1 and BSG); the exception to this is the sialic acid-deficient 
CR1 protein (Tham, et al., 2012). Treating erythrocytes with neuraminidase (NA) 
to catalyze the hydrolysis of SA residues present has been shown to compromise 
the merozoite invasion process (Baum, et al., 2003). However, certain strains of P. 
falciparum, such as W2mef parasites, have demonstrated the ability to switch from 
SA-dependent to SA-independent invasion via continued culturing in NA-treated 
human blood cultures or disruption of EBA-175 (Stubbs, et al., 2005) (Dolan, et al., 
1990). PfRh4 was found to be responsible for the molecular basis of this switching 
(Stubbs, et al., 2005). This was discovered after initially demonstrating that invasion 
pathway switching was reversible (from SA-independent to SA-dependent and 
back again) with clonal lines of W2mef parasites, and then using microarray and 
RT-PCR analysis a 60-80-fold increase of PfRh4 transcription in SA-dependent 
lines compared to SA-independent parasite lines. Next PfRh4 disrupted parasites 
(W2mefΔRh4) were constructed, and from NA-treated blood cultures these 
parasites as well as a variety of SA-dependent P. falciparum lines showed no 
detection of PfRh4 with PfRh4-specific antibodies, in contrast to SA-independent 
strains. Finally, it was revealed that the W2mefΔRh4 parasites could not switch to 
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SA-independent invasion, and that CSL2 clonal lines of P. falciparum parasites 
silence active PfRh4 over time when re-cultured in regular erythrocyte cultures. 
What would be an ideal experiment to still do is to develop a knock-out/knock-in 
model whereby pfrh4 was able to be disrupted, cultured as described above by 
Stubbs et al., then restore functionality of PfRh4 to see if the parasites were able to 
grow again on SA-containing red cell cultures. This would conclusively prove the 
necessity for PfRh4 in SA-dependent invasion of erythrocytes.  
 
Of course, erythrocytes treated with neuraminidase occurs only with in vitro 
conditions rather than what is seen in the field; however, this is analogous to 
situations where the host immune response may prevent certain invasion 
pathways, or polymorphisms affecting erythrocytic surface proteins which affect 
the choice of receptors for the parasite (Tham, et al., 2010). Three types of 
predominant polymorphisms occur for CR1 (as reviewed by Krych-Goldberg & 
and Atkinson, 2001); firstly, the number of complement control protein repeats 
(CCPs) and their amino acid number in each of the four allelic variants of CR1, 
second is the carriage of Knops blood group antigens such as Swain-Langley (Sl or 
Sla) on CR1, and thirdly is the copy number of CR1 on erythrocytes. Of note, Sla- 
individuals may be afforded some level of protection against severe malaria caused 
by P. falciparum erythrocyte membrane protein 1 (PfEMP1)-mediated resetting of 
erythrocytes (Rowe, et al., 1997). Additionally, the presence of the Sla- phenotype is 
approximately 70% in West Africans, 40% in African-Americans and only around 
1% in Caucasians, giving potential evidence in support of the hypothesis that the 
Sla- phenotype has been selected for in malarious regions (Moulds, et al., 2000). 
However, in 2012, research emerged demonstrating a lack of evidence that the 
Knops polymorphisms occurring on the fourth long homologous repeat of the 
CR1 protein are indeed driven by malaria, due to a lack of structural or functional 
modulation of CR1 (Tetteh-Quarcoo, et al., 2012). With respect to copy number, 
certain Papua New Guinean populations in malaria-burdened areas possessed 
around 200 CR1 molecules per erythrocyte (the lowest level in the world), which 
helped confer resistance to severe malaria (Cockburn, et al., 2004). 
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As previously mentioned, no structure of PfRh4 exists. PlasmoDB 
(www.plasmodb.org) lists PfRh4 as having a molecular weight of 205 kDa; 
however, following signal sequence cleavage and proteolytic processing events, a 
180-190 kDa size can be seen on Western blots following the use of samples from 
saponin-treated schizont pellets, and 160 kDa from culture supernatants (Tham, et 
al., 2009). Binding to CR1 occurs through a region in PfRh4 located towards the 
N-terminus, potentially within a 58-amino acid region located between residues 
282 and 340 (Tham, et al., 2009). Further studies are required to further narrow 
down the key residues involved in binding to CR1, in addition to the 3-
dimensional structure of PfRh4. 
 
In contrast to PfRh4, a lot more information is known about CR1, most likely due 
to its well-known role in the immune system as a regulator of complement, and 
because it carries the polymorphic Knops blood group antigens (Moulds, et al., 
2001) (Moulds, et al., 2000), which are of importance in immunohaematology. In 
humans, CR1 is classified as a type 1 transmembrane glycoprotein, with the 
extracellular region existing as a single chain comprised of independently folding 
CCP domains (see figure 1.7A) (Krych-Goldberg & and Atkinson, 2001). Starting 
from the N-terminus, groupings of seven CCP’s at a time comprise four long 
homologous repeats (LHR’s; A-D) in the most common size variant of CR1. 
Erythrocytic CR1 binds opsonized immune complexes for transport to the spleen 
and liver, with C4b binding to CCP1-3 (site 1), and C3b/C4b binding to CCP8-10 
and 15-17 (site 2). Note that this activity of site 1 and 2 are enhanced if key amino 
acids are mutated to confer a positive charge or remove a negative charge at key 




Figure 1.7. Structural Information Regarding CR1: A. Schematic of the overall architecture of 
CR1, which is comprised of 30 CCP modules. Site 1 is responsible for decay accelerating activity 
(with the CCPs responsible for binding to CR1 coloured blue), and site 2 CCP’s are required for 
co-factor activity allowing for cleavage of C3b and C4b complement proteins. B. NMR-derived 
structure of CCP1-3, including key residues involved in binding PfRh4. Figure adapted from 
(Krych-Goldberg and Atkinson, 2001) and (Park, et al., 2013). Abbreviations used: TM, 
transmembrane domain; CYT, cytoplasmic tail; LHR, long homologous repeats.  
 
Aside from erythrocyte CR1 possessing domains crucial to the functioning of the 
immune system, there are regions within the LHR’s exploited by P. falciparum for 
both the development of blood-stage pathology and parasite invasion of 
erythrocytes. LHR’s B and C are required for the formation parasite-infected 
erythrocyte rosettes, with Rowe et al. mapping the binding site of PfEMP1 (the 
parasite protein expressed on the surface of infected erythrocytes) to the C3b-
binding regions that make up site 2 of CR1 (Rowe, et al., 2000). However, with 
respect to PfRh4, site 1 of LHR-A had been identified as the binding site for this 
parasite protein, used to assist merozoite invasion of erythrocytes (Tham, et al., 
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2011). Additionally, evidence for the formation of a ternary complex between 
PfRh4, C4b and site 1 of CR1 had been found, with no apparent effect on the 
affinity for C4b binding, following the complex formed by PfRh4 and CR1 (Tham, 
et al., 2011). Glutamic acids 6, 19 and 21, tryptophan 7, aspartic acid 18 and 
phenylalanine 20 (surface exposed) have all been identified as key residues in 
CCP1-3’s binding site for PfRh4, with the latter two amino acids being absolutely 
essential (see figure 1.7B) (Park, et al., 2013). 
 
 
1.4.2 A Closer Examination of Basigin with Respect to PfRh5 
 
Basigin (BSG) is an antigen of the Ok blood group (defined by an allogenic 
difference of BSG), and is defined as a transmembrane glycoprotein of the 
immunoglobulin superfamily (Muramatsu, 2012). Four isoforms exist due to 
alternative splicing and alternative transcription initiation, with BSG-2 being the 
most common isoform (Muramatsu, 2012). Both BSG-1 and 2 interact with 
PfRh5; however, it is believed that the shorter BSG-2 is the isoform more 
commonly expressed on erythrocytes (Crosnier, et al., 2011). For some time, there 
had been some disagreement as to whether the interaction between BSG and 
PfRh5 is NA-resistant or sensitive. This was based on published results indicating 
said NA-sensitivity (Hayton, et al., 2008). However, Baum et al. presented results 
suggestive of binding occurring in a SA-independent, NA-insensitive manner 
(Baum, et al., 2009) (which complemented independent research demonstrating 
that the aforementioned interaction is refractory to NA treatment (Rodriguez, et 
al., 2008)). Additionally, the fact that recombinant PfRh5 binds to recombinant 
non-glycosylated BSG proves the interaction is NA-insensitive (Crosnier, et al., 
2011). It should also be noted that it is the specificity of BSG for PfRh5 that is 
predominantly responsible for the host tropism of P. falciparum, with chimpanzee 
BSG binding of much lower affinity and no detectable binding of gorilla BSG, as 
shown by AVEXIS and SPR experiments (Wanaguru, et al., 2013). Of note, the 
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sequence similarity between human and either chimpanzee or gorilla BSG is 
approximately 99.03% and 97.09% homologous (Forni, et al., 2015). 
 
As BSG has four isoforms and is highly glycosylated, its molecular weight ranges 
from 43 – 66 kDa (Muramatsu, 2012). The crystal structure of the extracellular 
region was solved in 2008, demonstrating a protein rich in β-sheets (figure1.8) (Yu, 
et al., 2008). The transmembrane region possesses a 23-amino acid segment 
conserved between human, mouse and chicken BSG (Muramatsu, 2012). 
Furthermore, the extracellular domain of BSG-2 contains three possible asparagine 
glycosylation sites (these are regions of differential glycosylation), which may help 
the extracellular portion of the protein stand upright, allowing maximum exposure 
of ligand binding regions (Yu, et al., 2008). BSG is a unique protein with a diverse 
array of functions including membrane-bound association with monocarboxylic 
acid transporters (MCT) for cellular metabolism (actually bound to a BSG dimer), 
integrin binding within the same membrane (including a super-complex of BSG 
dimers, MCT’s and β1-integrin or CD44), cyclophillin A binding via BSG residues 
207-214 of the transmembrane region for regulation of chemotaxis, and 




Figure 1.8. Structure of Basigin: A. The structure shown is of the membrane-distal 
immunoglobulin superfamily region of BSG-2. β-sheets are lettered from A-H, and the amino acids 
listed are locations of naturally-occurring variants. Figure adapted from Crosnier, et al., 2011. B. 
Human BSG (shown in white) bound to PfRh5 (grey). Residue W447 from PfRh5, in addition to 
BSG positively selected sites that interact with PfRh5, are shown in orange; residues involved in the 
interaction are shown in blue. C. Multiple primary sequence alignment of BSG for human and a 
few representative primate species are shown. B and C are adapted from Forni, et al., 2015. 
 
It should be mentioned that the Ok blood group is the result of a polymorphism 
within BSG and that when the glutamic acid residue at position 92 is changed to a 
lysine, the Oka- blood group results (Spring, et al., 1997). The Oka- blood group 
version of BSG has less affinity for PfRh5 and are more resistant to P. falciparum 
infection (Crosnier, et al., 2011). Furthermore, it may be important to note that the 
glutamic acid 92 is located just above the glycan-free β-sheets of the membrane-
distal domain of BSG (as shown in figure 1.8 A), making steric hindrance by 
glycan moieties less likely (Muramatsu, 2012). Additionally, the structure of human 
BSG plays an important role for the species-specific tropism of P. falciparum 
infection. In 2013, Wanaguru et al. identified a lysine amino acid at position 191 in 
human erythrocytic BSG to be important for PfRh5 affinity, and the presence of 
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an oppositely charged glutamic acid residue on chimpanzee erythrocytic BSG 
contributing to far binding lower affinity, and no detection of gorilla BSG binding 
to PfRh5 due to multiple residue differences (figure 1.8 B and C) (Wanaguru, et al., 
2013). This work confirmed previous results (Crosnier, et al., 2011) that both 
immunoglobulin-like domains of BSG are required to recognize and bind PfRh5. 
 
 
1.4.3 A Closer Examination of the PAIN-complex Proteins  
 
PfRh5 is a 63 kDa protein, making it far smaller than its other PfRh family 
members; however, a processed 45 kDa fragment, which appears during invasion 
demonstrates greater stability and shows no expression level variation across 
strains (Rodriguez, et al., 2008) (Chen, et al., 2011) (Baum, et al., 2009). The cleavage 
site for processing the 45 kDa protein exists between residues 125 and 135 of the 
63 kDa protein (Chen, et al., 2011). This fragment has also been demonstrated to 
bind to erythrocytes with greater affinity than full-length PfRh5 (PfRh5FL) and 
was therefore designated to have an important function (Wright, et al., 2014). It 
should also be mentioned that PfRh5 is highly conserved among P. falciparum 
parasites, with a mere five common non-synonymous single nucleotide 
polymorphisms (SNPs) (Williams, et al., 2012) (Bustamante, et al., 2013) (Reddy, et 
al., 2014). Importantly, antibodies against one recombinant PfRh5 variant were 
capable of neutralizing P. falciparum parasites of all heterologous strains tested, 
which contained the aforementioned SNPs (Douglas, et al., 2011) (Williams, et al., 
2012) (Bustamante, et al., 2013). Additionally, natural-acquired anti-PfRh5 
antibodies from the sera of immune individuals are capable of preventing parasite 
growth in vitro via GIA’s and were predictive of protection against severe malaria 
(Tran, et al., 2013). 
 
In 2014, two crystal structures of PfRh5 were published; one a 48 kDa fragment  
(Chen, et al., 2014), the other a 45 kDa fragment bound to BSG  (Wright, et al., 
2014) (figure 1.9). The structures revealed an overall ellipsoid, kite-like structure 
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including a core, formed of nine largely antiparallel α-helices encasing a β-hairpin 
towards the N-terminus. Outermost helices were shown to contain considerable 
kinks and breaks.  The secondary structure of the molecule includes a triplet helical 
coiled-coil domain orientated along the long axis of the ellipsoid, in addition to a 
short three-helix bundle plus short two-helix coiled-coil domains. The domains 
were revealed to be loosely packed within the structure. Two disulfide bonds were 
seen in the structure, one of which holds the two halves of the structure together 
(C345 – C351), the other linking two helices together near a kink (C224 – C317) 
(Chen, et al., 2014). The disulfides were shown to be important to the stability of 
the protein rather than being directly involved in protein interactions. PfRh5FL 
was shown to have six cysteine residues in total in certain parasite lines but only 
five in others, which indicates that cysteine residues may be unpaired or buried 





Figure 1.9. Crystal Structures of PfRh5: A. Ribbon-style representation of PfRh5 with N-
terminus in blue and C-terminus in red, with each α-helix labelled α1-7. The β-hairpin is shown in 
magenta and red spheres indicate cysteines forming disulfide bonds (C345 - C351, and C224 – 
C317). The residues from D294 and S257 are shown to be disordered. B. PfRh5 structure viewed 
from the side. C. PfRh5 in yellow, shown bound the BSG. D. Top-down view of BSG bound to 
PfRh5 displaying both conformations that were displayed in an asymmetric unit (blue and cyan). 
Figures A and B were solved to a resolution of 2.18 Å from X-ray diffraction data (figure adapted 
from Chen, et al., 2014). Figures C and D were from X-ray diffraction data solved at a resolution of 
3.1 Å (figures adapted from Wright, et al., 2014). 
 
PfRh5 lacks a transmembrane domain and cytoplasmic tail, allowing it to be deduced 
that it forms a complex with another protein/s in order for anchoring to the 
merozoite membrane. Previous speculations proposed PfRipr as the anchor (Baum, 
et al., 2009), but later avidity-based extracellular interaction screening (AVEXIS) 
assays appeared to show 19 amino acids of the N-terminal region of PfRh5 
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interacting with the merozoite surface protein P113 (Galaway, et al., 2017). P113 
(also known as Pf113) was initially discovered as a highly abundant protein in 
merozoite high molecular mass complexes during studies aimed at identifying 
detergent-resistant membrane proteins (Sanders, et al., 2007) (Sanders, et al., 2005) 
(Gilson, et al., 2008). The P113 protein is reported to contain a 
glycosylphosphatidylinositol (GPI) anchor, and appeared to be surface localized via 
antibody markers resulting in staining both on non-permeabilized and permeabilized 
merozoites (Gilson, et al., 2008).  
 
The recent AVEXIS and SPR assays appeared to show that P113 can interact with 
the N-terminus of PfRh5 (PfRh5Nt) and PfRh5FL, but not the C-terminal PfRh5Ct 
(Galaway, et al., 2017). This study further provided results showing that only 
PfRh5Nt-coated beads could purify the P113 from parasite culture lysate, in contrast 
to PfRh5Ct-coated beads. Further AVEXIS assay experiments using a truncated 
recombinant PfRh5Nt revealed a 19 residue long linear sequence of PhRh5Nt 
binding a cluster of 14 cysteine residues at the N-terminus of P113 (Galaway, et al., 
2017). The findings were consistent with the formation of a tetrameric P113 
complex with its C-terminus consisting of a coiled-coil region. However, since the 
19-amino acid region of PfRh5Nt is a highly flexible disordered segment, there is 
always the risk that it behaves as a “sticky” protein due to their increased plasticity 
and malleability, which would lead to potential false-positive protein-protein 
interaction results in the experiment performed (Ozbabacan, et al., 2011). 
Furthermore, none of the recombinant P113 proteins were assessed for correct 
folding. This should be considered along with the fact that a 2016 paper reports that 
via a proteomics approach on blood-stage P. falciparum parasites, finding P113 to be 
associated with PTEX (Elsworth, et al., 2016) (aside from being found in the 
parasitophorous vacuole, PTEX can also be found inside the intracellular dense 
granules of the merozoite prior to invasion of host erythrocytes (Bullen, et al., 2012)). 
Finally, other groups have been unable to see what Galaway et al. reports when they 
have carried out experiments (personal communication with Drs. Paul Gilson and 
Hayley Bullen at the Burnet Institute, April 2017). 
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This would appear to be revealing a great deal of conflicting results around P113. 
However, there are several possibilities; firstly, low resolution immunofluorescent 
assays (IFA) shown in (Galaway, et al., 2017) may be making P113 appear to be on 
the surface of the merozoite, when in fact it is still in the dense granules of the 
parasite. Alternatively, P113 may possess dual functions; serving the PTEX complex 
in addition to providing an anchor for the PAIN-complex via PfRh5 binding. It 
would not be the first time that a Plasmodium parasite protein held a dual function 
(for example, the RhopH protein complex (Ito, et al., 2017)). A definitive answer 
should come from further analysis of P113, including further cellular-based assays 
and ultra-resolution microscopy. However, due to the paucity of confirmation 
currently and skepticism over published results, this thesis will not regard P113 as 
part of the PAIN-complex. 
CyRPA has also been suggested to be tethered to the merozoite membrane via a 
GPI-anchor, thus providing the component that holds the PAIN-complex to the 
parasitic cell surface (as the model in figure 1.6 demonstrates (Reddy, et al., 2015)). 
However, several contradicting papers have subsequently been published indicating 
that CyRPA in fact lacks a GPI anchor and is instead a secreted protein (Dreyer, et 
al., 2012) (Chen, et al., 2017) (Favuzza, et al., 2017) (Volz, et al., 2016). Attempts at 
replicating the 2015 studies from Reddy et al. were carried out by (Volz, et al., 2016) 
but were unsuccessful, and an experiment with immunoprecipitated CyRPA (one 
native and one haemagglutinin-tagged) that was analysed via LC-MS/MS revealed 
an absence of GPI. 
 
The crystal structure of CyRPA, both alone and with inhibitory antibodies bound 
was revealed by two groups recently; one achieving a resolution of 2.5 Å (Favuzza, 
et al., 2017), the other to 2.44 Å (Chen, et al., 2017). The crystal structure (figure 1.10) 
reveals a canonical six-bladed β-propeller fold containing four intra-sheet disulfide 
bonds (Cys19-Cys35, Cys90-Cys92, Cys151-Cys169 and Cys229-Cys239) and one 
inter-sheet disulfide bond between Cys274 and Cys298. Each blade of the β-
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propeller consists of a four-stranded anti-parallel β-sheet, each of which are 
connected by loops that have been suggested to have some flexibility in solution. 
The structure of CyRPA shows similarities to viral and bacterial sialidases (although 
some key residues for this activity were absent), though no significant sialidase 
activity was detected when tested (Chen, et al., 2017). CyRPA is also important for 
being the bridge between PfRh5 and PfRipr, as these two proteins are not directly 
associated with one another in the PAIN-complex (personal communication with 
Prof. Alan Cowman, April 2017, and Galaway, et al., 2017). 
 
 
Figure 1.10. Crystal Structure of P. falciparum CyRPA: The ribbon-model of CyRPA that was 
solved from X-ray diffraction data at a resolution of 2.5 Å. Each blade of the β-propeller is labelled 
1-6 starting with the N-terminus in black. Blade 1 consists of a single N-terminal β-strand, plus three 
C-terminal β-strands (shown in red). Disulfide bonds are shown as yellow ball and sticks. One 
conformer is shown in white, the other in black loop regions (refer to the arrows). Image and 
information from Favuzza, et al., 2017. 
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PfRipr is a cysteine-rich protein (87 cysteine residues in total) expressed as a 126 
kDa protein in mature schizonts and stored in the micronemes prior to host cell 
egress and invasion (Chen, et al., 2011). Here it is processed into two ~65 kDa 
polypeptides by a yet unknown enzyme, and when these are run on SDS-PAGE 
gels under both reducing and non-reducing conditions, they appear at the same 
place, suggestive that intramolecular disulfide bonding is not present between 
fragments. The opposite is the case when each individual ~65 kDa fragment is run 
under the same conditions; non-reducing samples have enhanced gel mobility 
which suggest the intramolecular disulfide bonds contribute to tight folding. 
PfRipr additionally has no transmembrane region and is peripherally-associated 
with the cell membrane. The processing of PfRipr most likely occurs in schizonts 
or as merozoites egress from an infected erythrocyte (before a fresh invasion 
event), as evidenced by the presence of processed PfRipr in parasite blood stage 
development. Full-length PfRipr contains ten EGF-like domains, two localized to 
the N-terminus and eight clustered in tandem near the C-terminus. These EGF-
like domains are predicted to contain β-strands as the only secondary structure (as 
determined by prediction software such as the 1D protein structure prediction 
server), and are all linked by three amino acids, aside from EGFs 5 and 6, which 
have an unusual 17 amino acid linker containing two cysteines. Currently however, 
the three-dimensional structure of PfRipr remains elusive.  
 
Due to the paucity of published data on PfRipr from a protein biochemical 
perspective (despite being a key protein in the PAIN-complex), it can be assumed 
that many have tried and failed to produce either a full-length or a partial fragment. 
There is one publication reporting the use of a plant cell expression system to 
produce one of the EGF-like domains of PfRipr, EGF6 (Spiegel, et al., 2015). The 
problem with this work however, was a lack of visualization of the purified protein 
under non-reducing conditions, in addition to a lack of any biophysical 
characterization such as circular dichroism (CD) or nuclear magnetic resonance 
spectroscopy (NMR) to analyse secondary structure and folding. That said, one key 
strength of the work was in their demonstration of the production of an in-tandem 
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approach to vaccine development, with various recombinant malaria antigens from 
several life cycle stages utilized, an approach others in the vaccine development 
community should take heed of. 
 
As previously mentioned, PfRipr binds to CyRPA, however there is no 
information in the current literature regarding potential binding regions. The EGF-
like domains of PfRipr can be assumed to be potentially involved in mediating 
protein-protein interactions within the complex as indeed EGF domains in other 
organisms including other apicomplexan parasites such as Toxoplasma gondii are 
involved in protein complex formation (Meissner, et al., 2002) (Wouters, et al., 
2005). However, this remains mere speculation. Despite the relative paucity of 
biochemical information on PfRipr, its importance as a prospective vaccine 
candidate was recently further confirmed during the functional profiling of the 
Plasmodium genome (Bushell, et al., 2017). The study utilized the common rodent 
model of malaria and P. berghei knockout mutants and measured competitive 




1.4.4. Proteins of the PAIN-complex and Calcium Signalling 
 
Following the initial three events of invasion; attachment, erythrocyte deformation 
and merozoite reorientation, there is a calcium flux into the erythrocyte causing it 
to shrink, an event that appears to both play a key role in invasion and facilitated 
(at least in part) by the proteins of the PAIN-complex upon BSG binding (Volz, et 
al., 2016) (Weiss, et al., 2015). The interaction between erythrocytic BSG and 
parasitic PfRh5 of the PAIN-complex is associated with Ca2+ release and therefore 
has been suggested as essential in the formation of a pore allowing Ca2+flux 
between parasite and erythrocyte (Volz, et al., 2016) (Aniweh, et al., 2017). Recently, 
successful conditional gene deletion research was carried out, reducing the 
expression of the proteins by 60-95% by using dimerizable Cre recombinase 
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(DiCre) to generate RiprloxCre and CyRPAloxCre, and growing parasites in 
rapamycin (Volz, et al., 2016). P. falciparum parasites with conditionally deleted pfripr 
and cyrpa only expressing PfRh5 were shown to attach to and deform erythrocytes, 
but invasion was ablated. This study suggests that neither PfRipr nor CyRPA is 
essential in these initial steps, but supports the idea that they are essential for the 
subsequent internalization of the parasite, potentially by pore formation. This was 
further supported by the observation that merozoites with conditional pfripr and 
cyrpa knockouts did not show the Ca2+spike seen in wildtype parasites at any point 
during interaction with host cells. 
 
 
1.4.5. Invasion Inhibition by Antibodies Against the PAIN-complex 
 
Research has been carried out on vaccines targeting the blood-stage of P. 
falciparum, due to the potentially more pragmatic benefits contrasted to those 
targeting either the sexual stages, or sporozoites. Prospective vaccines targeting 
these aforementioned stages may interrupt either the transmission cycle or 
sporozoites, but problematically would not have a direct effect on an established 
infection in the case of a single sporozoite or ookinete breaking through and 
continuing the pathogenic replicative cycle (Felgner, et al., 2013) (Crompton, et al., 
2010). Attempts to inhibit blood-stage erythrocyte invasion using antibodies to 
several of the P. falciparum complex proteins have so far been relatively successful 
in vitro (reviewed in Crompton, et al., 2010). Additionally, since it is the blood-stage 
of the infection that actually causes disease, it can be argued that it should be 
included in vaccine strategies.  
 
A key extensive study had identified PfRh5 and PfRipr as two of the top blood 
stage targets for vaccine development efforts based on their quality and reactivity 
to human antibodies, in addition to their association with protective immunity 
(Richards, et al., 2013). With respect to CyRPA, even prior to its association with 
the PAIN-complex, it was known as a prospective blood-stage vaccine candidate 
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following screening of conserved P. falciparum proteins that elicited inhibitory 
antibodies (Favuzza, et al., 2012).  
 
Inhibiting the PfRh5-BSG interaction by rabbit anti-PfRh5 polyclonal IgG showed 
that merozoite binding and deformation of erythrocytes occurred as normal, but 
invasion frequency was reduced by around 90% (Weiss, et al., 2015). This was similar 
to the levels of invasion inhibition demonstrated previously (Douglas, et al., 2014). 
Another study using serum from rabbits and rats immunized with rPfRH563 found 
that anti-PfRh5 antibodies blocked erythrocyte binding in a dose-dependent manner, 
with potent binding inhibition of both the native and recombinant PfRH5 protein 
(Reddy, et al., 2014). More recently, anti-PfRh5Nt antibodies developed by Galaway, 
et al., 2017 inhibited invasion and parasite growth in vitro in contrast to Douglas, et 
al., 2014, whose anti-PfRh5 antibodies were directed against an epitope in the N-
terminus of PfRh5 (though this may be due to missing key functional epitopes). The 
most recent work using human-derived anti-PfRh5 antibodies came from the 
previously mentioned vaccine studies by Payne, et al., 2017. The serum antibodies 
from the human volunteers that were vaccinated with PfRh5-encoded viral vectors 
were able to disrupt both the binding between PfRh5 and BSG, but also the 
formation of the PAIN-complex via the interruption of the interaction between 
PfRh5 and CyRPA. It is also important to note that antibody titres to PfRh5 have 
been shown to have a strong correlation with protection against severe clinical 
episodes of malaria amongst a Papua New Guinean population (Chiu, et al., 2014). 
 
Antibodies against other proteins of the PAIN-complex have also shown good 
promise as vaccine candidates. It was shown that CyRPA-specific monoclonal 
antibodies (mAbs) inhibit invasion in vitro and in mice engrafted with human 
erythrocytes (Dreyer, et al., 2012). Further trials showed highly potent invasion 
inhibition using anti-CyRPAFL antibodies, with an EC50 of ∼3 mg/mL total IgG 
and up to 85% inhibition at 10 mg/mL total IgG (Reddy, et al., 2015). 70% 
invasion inhibition with an anti-CyRPA mAb that reacted to a conformational 
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epitope was demonstrated in the structural paper by (Chen, et al., 2017). 
Furthermore, an additive effect was demonstrated when administering both anti-
CyRPA and anti-PfRh5 antibodies to humanized mice infected with malaria, with 
lower levels of parasitaemia developing contrasted to controls (Favuzza, et al., 
2017).  
 
Far fewer studies have been carried out on anti-PfRipr antibodies. In part this is 
due to PfRipr being the youngest of the proteins known in the PAIN-complex 
(Chen, et al., 2011). The first significant study was carried out in 2011, where the 
FCR3 strain of P. falciparum displayed 80% reduced growth in assays utilizing anti-
PfRipr antibodies (Chen, et al., 2011). This study also demonstrated that when a 
combination of anti-PfRipr and anti-PfRh5 antibodies were used, a synergistic 
effect against parasite growth and invasion occurred amongst various strains of P. 
falciparum. These results were further solidified when additional research 
demonstrated anti-PfRipr antibodies provided potent erythrocyte invasion 
inhibition against 3D7 (~63% invasion inhibition) and FVO (~77% invasion 
inhibition) strains of parasites in a GIA (Ntege, et al., 2016). Finally, there is a 
strong association between individuals with high IgG3 antibody subclass levels 
against both PfRipr and PfRh5, and a reduced risk of malaria, suggestive of 
concluding that IgG3 responses against these invasion ligands are important for 
mediating naturally-acquired immunity against clinical malaria (Weaver, et al., 
2016). However, this study was focused on individuals in Papua New Guinea, and 
so it will be important to carry out similar studies on other malarious regions 





This thesis introduction highlights the immense complexity of the malaria parasite 
and the challenges we face in trying to eradicate this great scourge. It should go 
without saying that the global eradication of malaria is highly likely to help usher in 
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further human prosperity based on the established bi-directional link between 
poverty and malaria. Recent research has shed more light on the PfRh family of 
proteins such as PfRh4 and the essential PAIN-complex including PfRh5, CyRPA, 
and PfRipr; all of which are promising potential vaccine targets. The least is 
currently known about PfRipr, with a dearth of current structural and binding site 
information, in addition to immunological data, all things that should be addressed 
to aid better understanding of the protein complex binding. Progress towards a 
clearer image of the full complex and its binding sites will be essential for a 
successful structural vaccinology approach to create a vaccine using these essential 
proteins. It should be clear that going forwards, an important vaccine strategy 
must involve targeting combinations of antigens expressed at the multiple life-
cycle stages, in addition to targeting the PAIN-complex proteins. 
 
Ideally, it needs to be established which parts of these proteins are both essential to 
PAIN-complex formation, invasion and can give rise to inhibitory antibodies, so 
that a protein engineering approach is taken to develop an in-tandem or in 
combination mix to be tested in vaccination trials (similar to the work carried out by 
Speigel, et al., 2015). Further, it would behove the malaria vaccine community to also 
test this alongside and in combination with RTS,s-like vaccines and others 
corresponding to other life-cycle stages.  
 
 
1.6 Thesis Aims 
 
The aims of this doctoral thesis are to contribute to an important body of 
knowledge around several PfRh-family proteins including PfRh4, PfRh5 and the 
difficult to study PfRipr. During the course of this research it emerged that PfRipr 
was a P. falciparum protein of great importance and so the bulk of efforts in this 
thesis is dedicated to an in-depth biophysical chemical analysis of this protein. 
Furthermore, methods for the industrially-applicable scaling up of anti-malaria 
vaccine components was of importance due to the simple fact that it will do the 
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world little good to produce a vaccine whose distribution would be inhibited by an 
inability to scale-up its production in a financially appropriate manner. With that in 
mind, the specific aims of this thesis are: 
 
1. Development of a set of mAbs directed against PfRh4, and attempts at 
elucidating both the structure of PfRh4 and its CR1 binding region. 
 
2. The bacterial production of recombinant PfRipr protein fragments, their 
biophysical characterization, attempts at structural analysis via 
crystallography, and binding studies against PfRh5. 
 
3. The expression of PfRipr fragments in Pichia, their scaled-up production, 
biophysical characterization, and attempts at both elucidation of the 
binding region of PfRipr against CyRPA, in addition to NMR and 




























‘’I have nothing to offer but blood, toil, tears and sweat’’ 
 




















2.1 E. coli-Based Cloning 
 
In silico cloning using DNA Strider software were used to ensure that restriction 
enzyme digests would be compatible for when the synthetic genes were to be 
ligated into their final expression vectors, and to ensure all genes remained in-
frame. Where required, software on www.resitefinder.appspot.com was used to 
search for silent restriction enzyme sites. Synthetic genes were manufactured by 
Integrated DNA Technologies (IDT) or Geneart where specified. The plasmid 
maps for the common expression vectors used in this thesis are shown in figures 






Figure 2.1. Plasmid Map for pET45b(+): Synthetic P. falciparum genes of interest were inserted 




Figure 2.2. Plasmid Map for pProExHTA: Synthetic P. falciparum genes of interest were inserted 
into multiple cloning site, typically via BamHI and XhoI. 
 
 
Lyophilized synthetic genes were reconstituted in 20 – 50 µl of TE buffer, then a 
1:100 dilution prepared using double-distilled H2O (ddH2O) to give a 
concentration of 1 ng/μl. 4 – 5 μl of the diluted DNA was added to 20 μl of 
electrocompetent DH10β E. coli cells and left to incubate on ice for 30-minutes. 
Tube contents were transferred to a pre-chilled 0.1 cm electroporation cuvette and 
electroporation carried out using the following settings on a Bio-Rad Gene Pulser 
II: 1250 V, 25 Ohms, 200 μF. Cuvette contents were transferred to sterile tubes 
containing 0.6 ml of S broth then incubated at 37 ºC for one-hour at 200 rpm. 100 
μl of the culture was plated onto 50 ml LB agar plates containing 50 μl of 100 
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mg/ml carbenicillin (or 40 mg/ml kanamycin where required). A negative control 
was also prepared using H2O only. All plates were grown overnight at 37 ºC. 
 
Resulting colonies were picked and inoculated into 3 ml of S broth containing 3 μl 
of 100 mg/ml carbenicillin (or 40 mg/ml kanamycin where required) and left 
overnight in a 37 ºC shaking incubator (200 rpm). A miniprep-based DNA 
extraction was carried out according to the protocol given in the PureLink™ 
Quick Plasmid Miniprep Kit (ThermoFisher). DNA concentration was calculated 
via NanoDrop.  
 
Restriction enzyme digests were prepared by mixing up to 30 μl of plasmid with 3 
– 5 μl of appropriate NEB buffer (New England Biolabs), 5 μl of 10 x bovine 
serum albumin (BSA), 7 μl of ddH2O and 1.5 μl of each restriction enzyme. The 
reaction mixtures were incubated for 2.5 hours at 37 ºC, then 5 μl of 10 x 
dephosphorylation buffer and 1 μl of alkaline phosphatase was added to the tubes 
as required. Samples were analysed via agarose gel electrophoresis using an 0.8 – 
1.2% agarose gel prepared in 0.5 x TBE (or TAE were required) containing 0.01% 
ethidium bromide (following addition of 4 – 6 μl of 6 x loading dye to each 
sample) and run for 80-minutes at 65 V. 5 μl of Generuler 1 kb molecular weight 
marker (ThermoFisher) were used for size comparisons. Gels were soaked in 0.5 x 
TBE (or TAE were required) with 0.02% ethidium bromide for one-hour and 
analysed via UV visualization, with bands of interest extracted via scalpel blade. 
Gel slices had DNA extracted and purified vie the methods outlined in the 
Invitrogen Purelink® Quick Gel Extraction Kit. 
 
A ligation reaction between the expression vector backbone and the synthetic gene 
insert was carried out by mixing 2 μl and 6.6 μl respectively of the aforementioned 
DNA, 1 μl of 10 x ligation buffer, and 0.4 μl of T4 ligase (a negative control was 
also set up substituting ddH2O instead of the synthetic gene insert), then 
incubating for 17 hours at 16 ºC to generate the final expression plasmid.  
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Next, the DNA was concentrated via a phenol chloroform extraction. This 
involved adding 40 μl ddH2O to the ligation reaction tube, followed by 50 μl of 
phenol chloroform and tube agitation via vortex mixer. Sample tubes centrifuged 
at 10 000 × g for four-minutes, supernatant removed and added to fresh tubes 
containing 50 μl of phenol chloroform, followed by a repeat of this step. The final 
supernatant was added to a tube containing 1 μl of glycogen, 5 μl 3 M sodium 
acetate (pH 5.2), and 130 μl 100% ethanol. The tube was centrifuged at 10 000 × g 
for 30-minutes, supernatant removed and 140 μl of 80% ethanol added to the 
resulting pellet. Tube was vortexed, centrifuged at 10 000 × g for 30-minutes, 
supernatant removed and the pellet air dried before dissolving in 5 μl of ddH2O.  
 
Where ethanol precipitation was used, the following protocol was carried out- one 
tenth the sample volume of 3 M sodium acetate (pH 5.2) and 2.5 x sample volume 
of 100% ethanol added to DNA sample tube, which was incubated at -70 ºC for 
ten-minutes. After incubation, sample centrifuged at 10 000 × g for 15-minutes at 
4 ºC. Removed supernatant and added 2.5 x sample volumes of chilled 80% 
ethanol then gently vortexed. The sample tube was centrifuged at 10 000 × g for 
15-minutes at 4 ºC, supernatant removed, then re-centrifuged for a further five-
minutes. After air-drying, the resulting pellet was resuspended in 5 – 10 μl of 
ddH2O. 
 
Transformation and plating of DH10β E. coli carried out using the final expression 
plasmids with subsequent miniprep and NanoDrop as described above. Using 1 μl 
of the confirmed expression plasmids, a 1:100 aliquot was prepared in 99 μl 
ddH2O, with a 1 μl and a 10 μl volume used for the transformation of 40 μl tubes 







2.2 Production of Electrocompetent BL21 Gold E. coli Cells 
 
Production of electrocompetent BL21 gold E. coli cells involved making a streak 
plate from a glycerol stock then picking a colony into 6 ml of S broth to be left 
shaking at 200 rpm overnight at 37 ºC. The culture was added to 600 ml of S broth 
and grown until the OD600 was 0.4, then the culture flask transferred to wet ice in a 
cold room for 30-minutes, with gently agitation halfway through the incubation. 99  
 
Flask contents centrifuged at 4 ºC for ten-minutes at 3500 × g. Cells resuspended 
in 600 ml chilled ddH2O and left to incubate on wet ice in the cold room for one-
hour. Flask contents re-centrifuged as before and washed twice more in chilled 
ddH2O. Pellet was resuspended in an equal volume of 10% glycerol, chilled on 
wet ice for 30-minutes, centrifuged, and then re-washed in 10% glycerol. After 
careful decanting of supernatant, the pellet was resuspended in 6 ml of 10% 
glycerol. 40 μl aliquots were prepared and stored at -80 ºC until needed. 
 
 
2.3 Glycerol Stock Preparation 
 
Glycerol stocks were prepared by taking 10 ml of an overnight culture grown in 
100 ml of L broth + 100 μl of 100 mg/ml carbenicillin (37 ºC shaking at 200 rpm), 
and centrifuging at ~1200 × g for ten-minutes. After the supernatant was 
discarded, the pellet was resuspended in 10 ml of L broth and re-centrifuged. The 
supernatant was discarded, being replaced with a 15% glycerol mix (sterile and 
prepared in L broth), with the pellet gently resuspended and snap frozen in liquid 







2.4 SDS-PAGE Protein Analysis 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out by adding an appropriate volume of sample (generally to be able to 
visualize 2 µg of protein) with up to 30 µl of 2 x NuPAGE™ LDS sample buffer 
(SB) and 6 μl of dithiothreitol (DTT, thus making reducing SB, or RSB) then 
boiled for up to five-minutes at 95 ºC. For NI and I samples, taking into account 
the dilution, the amount of broth required in μl to set aside as the I sample was 
calculated by using the formula 150/OD600 (this may also be used for the NI 
sample if the OD600 reading is significantly over 0.6). These samples were analysed 
on a 4-12% bis-tris gel (Invitrogen) via sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) run at 150 V in a 5% MOPS buffer for 80-minutes 
(and subsequent gel staining in Coomassie blue buffer prepared as described in 
(Lawrence & Besir, 2009)). Unless otherwise mentioned, all molecular weight 




2.5 Small-Scale Test Expression 
 
Note, this section is adapted from Haggarty-Weir et al., 2017.  
 
After plating freshly transformed E. coli containing the final expression plasmid 
onto LB agar with a suitable selective marker (i.e. kanamycin), an individual colony 
was inoculated into a 50 - 100 ml flask (baffled where possible) with 10 ml of S 
broth plus antibiotic, growing overnight at 37 °C with agitation at 220 rpm. 300 ml 
baffled flasks each with 30 ml of S broth plus antibiotic were prepared and 1 ml of 
the starter culture was inoculated into each and then placed in a 37 °C incubator at 
220 rpm. These cultures were grown until an optical density at 600 nm (OD600) of 
0.6 – 0.8, then were split the flasks so one-third remained at 37 °C, one-third at 
30 °C one-third in an 18 °C incubator (for the latter two incubators, the flasks 
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from the 37 °C incubator were removed when the OD600 was just below 0.6 so as 
to pre-equilibrate the temperature before induction). Of each three lots of flasks, 
one of each were induced with 0.25 mM, 0.5 mM and 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) after taking a 1 ml non-induced (NI) sample. The 
flasks at 37 °C were grown for four hours, with a 1 ml post-induction (I) sample 
taken, harvesting the rest by centrifugation (8 – 10 000 × g for 10-minutes). The 
flasks at 30 °C and 18 °C were grown for 8 and 16 hours respectively before 
collecting the I sample, measuring the final OD600 and harvesting the flask 
contents.  
 
250 μl and 50 μl of each NI sample and I sample (respectively) was taken, 
centrifuged at 10 000 × g for one-minute, supernatant removed then 10 μl of 1 x 
RSB added and SDS-PAGE carried out. Each sample showing evidence of 
induction for recombinant protein production was centrifuged as described and 
resuspended in 2 ml of lysis buffer (50 mM Tris pH 8, 250 mM NaCl, 0.1% triton 
X-100, 2 mM EDTA, spatula tip of lysozyme and 1.5 μl of DNaseI), then 
processed via sonication (90 sec on/100 sec off at 35% amplitude for 7.5-minutes) 
or mechanical cell disruption. 50 μl of the sample post-lysis was centrifuged as 
described above to achieve separation of the supernatant from the pellet. 6 μl of 
the supernatant had 10 μl of 1 x RSB added, and for the pellet, 50 μl of water was 
added, resuspension carried out thoroughly, then 6 μl was taken and added to 10 
μl of 1 x RSB. SDS-PAGE analysis on these samples was carried out to determine 
if any protein was expressed in the inclusion body fraction. Note that scaled-up 




2.6 Processing of Scaled-Up Bacterial Cultures 
 
Flask contents were harvested via centrifugation at around 10 000 × g for ten-
minutes at 4 ºC. After the supernatant was decanted, beakers were placed on ice 
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and the pellet was resuspended in 160 ml of lysis buffer (400 mM NaCl, 40 mM 
Tris pH 8, 100 mM PMSF, 2 mg/ml DNaseI per 40 ml, and 1 Roche cOmplete 
ULTRA EDTA-free protease inhibitor cocktail tablet per 40 ml). Using a cell 
disruptor (Constant Systems Ltd) with pressure set to 26 kPa, cells were lysed by 
two rounds of cell disruption. A 50 μl post-lysis sample was taken and centrifuged 
at 10 000 × g for one-minute. Around 7 μl of the supernatant was taken and added 
to 26 µl of 1 x RSB (thus making the post-induction supernatant sample), with the 
rest of the supernatant decanted. 50 μl of water was added to the resultant pellet 
which was resuspended and 7 μl removed to add to 19 μl of 1 x RSB to make the 
post-induction pellet fraction. These samples were prepared for SDS-PAGE 
analysis as previously described. The lysed bacterial stock was then centrifuged at 
10 000 × g for 30-minutes at 4 ºC. 
 
 
2.7 Nickel-Affinity Purification of His6-Tagged Proteins 
 
The supernatant of the lysed material was then applied to 4 ml of a 50% nickel-
NTA (Ni-NTA) agarose bead slurry (from Qiagen), mixed and allowed to settle, 
and then the flow-through collected. 75 ml of Ni-wash buffer (5 mM imidazole, 
400 mM NaCl, 40 mM Tris pH 8) was applied and collected, then 10 ml of Ni-
elution buffer (500 mM imidazole, 400 mM NaCl, 40 mM Tris pH 8) was applied 
with 2 ml fractions collected. The concentration of the protein in the eluted 
fractions was determined with an A280 nm NanoDrop 1000 Spectrophotometer 
(NanoDrop) using elution buffer as the blank. 2 μl samples from the flow through, 
Ni-wash and Ni-elution fractions were added to 10 μl of 1 x RSB and analysed via 
SDS-PAGE as previously described.  
 
40 μl of a Roche cOmplete™ protease inhibitor solution (1 tablet in 1 ml of sterile 
water + 0.5 mM EDTA) was added to each eluted fraction. Based on SDS-PAGE 
gel results, key fractions were combined and added to a pre-washed and 
equilibrated (with sterile water and Ni-elution buffer, respectively) 30 kDa cut-off 
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protein concentration tube (Merck Amicon Ultra-15 Centrifugal Filter Units). 
Sample was centrifuged at 3500 × g for ten-minute lots at 4 ºC until ~2 ml was 
left. The NanoDrop was used to calculate final protein concentration and to 




2.8 Western Blot Methodology 
 
Western transfers were carried out at 100 V for 60-minutes on ice onto a 
nitrocellulose membrane, which was subsequently blocked with 10 % blocking 
solution (10% skim milk in PBS with 1% Triton-X, PBS-T) for one-hour at room 
temperature. Membranes were washed thrice with PBS-T. A 1:200 dilution of anti-
His5 antibody (Qiagen) was prepared in 1% blocking solution and added to the 
membrane. These samples were left gently rocking at room temperature for one-
hour, then were washed twice with five-minute washes in 1% blocking solution. A 
secondary antibody solution of 1:1000 anti-mouse HRP antibodies were prepared 
in 1% blocking solution and added to the membranes for one-hour, gently rocking 
at room temperature. This was followed by five five-minute wash steps and gentle 
dry-blotting of the membranes. 10 ml of enhanced chemiluminescence ECL 
solution (Amersham) was applied with rigorous mixing for three-minutes followed 
by a one-second exposure and development on X-ray film. 
 
 
2.9. General Chromatography 
 
Concentrated protein samples were centrifuged at 10 000 × g for ten-minutes at 4 
C to clear particulates before injecting the protein onto a size-exclusion 
chromatography (SEC) column (GE Superdex HiLoad 200 16/600 pg) run on an 
ÄKTA purifier system (GE). Flow rate was set at 1 ml/min with 0.8 ml fractions 
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collected and the buffer used was 20 mM MES + 75 mM NaCl, pH 6 (also used to 
equilibrate the column prior to sample loading). Key fractions had the protein 
concentration determined via NanoDrop and 2 μg visualized via SDS-PAGE.  
 
The key fractions were combined and applied to a 5 ml Mono S ion exchange 
chromatography column (GE 5/50 GL) run at a flow rate of 0.5 ml/min 
(collecting 0.5 ml fractions) and using buffer A (20 mM MES pH 5.5) plus an 
increasing gradient of buffer B (20 mM MES pH 5.5 + 1 M NaCl). After SDS-
PAGE analysis of 2 μg of each fraction (concentration determined via 
NanoDrop), another pre-washed and equilibrated protein concentration tube was 































“To live is to suffer, to survive is to find some meaning in the suffering” 
 























This study entailed the production and purification of recombinant truncated 
proteins corresponding to ~89 kDa PfRh4 proteins (PfRh4.9; includes ten alanine 
scan mutants from amino acids 282 - 342 called PfRh46Ala1-10), an 82 kDa deletion 
mutant lacking amino acids 283 – 341 (termed PfRh4.9Δ58), and a 43 kDa 
truncation from amino acids 104 – 465 called PfRh4.18. These proteins were 
selected to isolate the binding site on PfRh4 that interacts with its cognate 
erythrocytic receptor, CR1. PfRh4.18 was selected due to being a small truncation 
possessing the alleged binding region to CCP1-3 of CR1 (Tham, et al., 2009), and 
so it made sense to try and produce it for crystal trials. The rationale was to give 
atomic level detail needed to have definitive elucidation of the binding interface. 
 
To hedge against crystal trial failure and any difficulties with production of 
PfRh4.18, the series of alanine scan mutants and the deletion mutant PfRh4.9Δ58 
(as previously mentioned covering the supposed binding region in PfRh4.19 
(Tham, et al., 2009)) was to be developed for binding studies against CCP1-3. 
These would be used in ELISA assays to look for diminished levels of binding 
overall compared to native PfRh4.9. If a particular mutant/s from PfRh46Ala1-10 
showed a significantly diminished level of binding to CCP1-3 contrasted to 
PfRh4.9, then an estimate of the amino acid residues involved could be 
ascertained. This would open up the door to developing further mutants to further 
narrow the binding site down. However, if no difference in binding affinity was to 
be detected then this would be suggestive that the predicted binding region based 
on the inhibitory antibody screening in Tham, et al., 2009 was inaccurate. 
 
The production of anti-PfRh4.9 mAbs was important given that they could be 
used to screen for the blocking of binding to CR1, and for their use in the 
identification of inhibitory epitopes in the binding interface. Those mAbs which 
were not inhibitory to the interaction between PfRh4.9 and CR1 could be used as 
tools to aid co-crystallization trials. Furthermore, all mAbs which showed high 
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affinity binding to PfRh4.9 could be screened for tight binding to PfRh4.18 with a 
view to use them for crystal trial screening of this protein alone. 
 
 
3.2 Production and Purification of PfRh4.9 for Vaccination Studies 
 
3.2.1 Methods for the Production and Purification of PfRh4.9 
 
Glycerol stocks of PfRh4.9-containing BL21 (DE3) E. coli were produced as 
described in Tham, et al., 2009, with proteins produced and purified as detailed in 
Lim, et al., 2015.  
 
SDS-PAGE performed as described in section 2.4, cultures were processed as 
described in section 2.6, and Ni-affinity purification carried out as per section 2.7. 
Following Ni-affinity purification, SEC and ion-exchange chromatography were 
carried out according to section 2.9 to generate a final, pure sample of PfRh4.9. 
 
 
3.2.2 Methods for PfRh4.9 Vaccination Studies 
 
Methods were carried out as described (Lim, et al., 2015). It should be noted that 
the author also carried out parasite culturing, Western blots, immunofluorescent 
assays, and competition ELISAs (not mentioned in the Lim, et al., 2015 paper in 
the Appendix). The ELISA method used by the author is outlined below. 
 
A competition ELISA was developed to screen the anti-PfRh4.9 mAbs using 96-
well flat-bottomed plates (Maxisorp; Nunc). Wells were coated with 100 μl of 2 
μg/ml CCP1-3 (provided by Dr. Christoph Q Schmidt of Ulm University), or in 
the case of the controls, PBS only, and 2 μg/ml PfRh4.9. After overnight 
incubation at 4 C, plates were washed 3 times with PBS with 1% Tween 20 (PBS-
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T) and blocked with 200 μl of 5% skim milk blocking buffer for one-hour at room 
temperature. During this step, in a regular 96-well plate, 100 μl of 2 μg/ml 
PfRh4.9 was mixed with 100 μl of mAb supernatant supplied by the WEHI 
antibody facility (for the control media and the positive control polyclonal 
antibody supernatant, 100 μl of a 1:50 dilution was used), and left for one-hour at 
room temperature. Following another 3-part PBS-T wash, the ELISA plate had 
the non-ELISA plate contents containing the PfRh4.9+antibody mixes (and 
controls) added for a two-hour incubation at room temperature. Note, after one-
hour, 100 μl of 2 μg/ml PfRh4.9 was added to the CCP1-3 control well, and 
blocking buffer added to other control wells. Further, 50 μl of mouse anti-PfRh4 
mAb 10C9 (1:1000 made up in 5% blocking buffer) was added to the PfRh4.9 
control and CCP1-3+PfRh4.9 wells for one-hour at room temperature. After 3 × 
PBS-T washes, 50 μl of anti-mouse HRP antibodies (1:2000 made in 5% blocking 
buffer) were added to wells for one-hour at room temperature, followed by 3 more 
PBS-T washes. 100 μl of an HRP-substrate reagent 3,3,5,5-tetramethylbenzidine 
(TMB, ThermoFisher) was added to each well until the background signal 
appeared, at which time 50 μl of 2 M phosphoric acid were used to quench the 
reaction. Absorbance was measured at 450 nm.  
 
 
3.2.3 Results for the Production and Purification of PfRh4.9 and 
Vaccination Studies 
 
See the paper in the Appendix under Lim, et al., 2015. Additional results not 
included in the paper are thus: An ELISA was performed to ensure mAb reactivity 
to recombinant PfRh4.9, whereby ELISA plates were coated with PfRh4.9 then 
exposed to a different mAb, followed by detection (Appendix table A1). A 
competition ELISA was done to determine which anti-PfRh4.9 mAbs were 
potentially capable of ablating the interaction between PfRh4.9 and CCP1-3 (figure 
3.1). This identified six potential mAbs; 3A6, 9G9, 5H12, 4C5, 2A7 and 2H9, with 
the latter two demonstrating very prominent levels of CCP1-3 binding inhibition. 
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Figure 3.1. Competition ELISA Screening of αPfRh4.9 mAbs: Detection of PfRh4.9 with 
mouse anti-PfRh4 mAb 10C9 by ELISA following co-incubation of PfRh4.9 with various mAbs 
and their application to CCP1-3-coated wells. Bound antigen-antibody complexes detected with 
anti-mouse HRP. Green and blue bars are the mAbs screened (green are samples taken for further 
experimentation), red bars are controls, yellow stars are the key inhibitory mAbs. Abbreviations: 
CM- negative control media, Poly- polyclonal antibody supernatant AB185 #1232 from fusions 
(positive control), Rh4.9- PfRh4.9-only coated well (positive control), CCP>Rh4.9- positive control 
for CCP1-3 + PfRh4.9 interaction, Buffer- buffer-coated well negative control. 
 
 
3.3 Cloning and Production of PfRh4.18 for Structural Characterization 
 
3.3.1 Methods for the Cloning and Production of PfRh4.18 
 
Cloning, protein test expression, SDS-PAGE, Ni-affinity purification and Western 
blot analysis were all carried out as per section 2. Specific details and changes are 
given below. The pET45b plasmid was used for expression by cloning the 
synthetic gene for PfRh4.18. DNA Strider software was used to ensure a BamHI 
and XhoI restriction enzyme digest was compatible with the synthetic gene going 
from pET45b into pProExHTA (containing an N-terminal His6-polyhistidine tag 
and tobacco etch virus, TEV, enzyme cleavage site) whilst the PfRh4.18 gene 
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remained in frame. The pProExHTA (called ProEx throughout the rest of this 
thesis) was donated by Mr. Tony Triglia. The ligated plasmid of pProExHTA and 
PfRh4.18 will be referred to as ProEx+PfRh4.18.  
 
DNA sequencing was carried out by Applied Genetic Diagnostics, The University 
of Melbourne. 1 μl of each primer used at a concentration of 5 μM, and a 5 μl 
sample of DNA (100 ng/kb) to be sequenced was provided. The primers were: 
 
WH99 (reverse)- GCGctcgagttattacttgatattggtgcattgcagcatcaggtcg 
WH100 (forward)- CGCggatcccctgaaaaccgatatcatcctgaact 
 
 
3.3.2 Results of the Cloning and Production of PfRh4.18 
 
Following plasmid sequencing, transformed BL21 gold cells were used for 4 x 2 L 
cultures split between IPTG concentrations ranging from 0.05 mM to 1 mM. 
Flasks were grown at 37 C and induced at 30 C. The NI, I, pellet and 
supernatant samples were kept for analysis. SDS-PAGE results show a strong 
band around 43 kDa in the pellet fractions of samples induced with 0.25, 0.5 and 1 
mM IPTG. The Western blot showed a weak band in the I and pellet samples of 
the 0.05 mM IPTG-induced sample, and a positive band in the I, supernatant and 
pellet samples of the 1 mM IPTG-induced sample. 
 
 
Figure 3.2. SDS-PAGE of Large-Scale Test Expression of PfRh4.18: 15 μl of each sample was 
loaded onto their respective wells on the gel. The post lysis pellet and supernatant samples here 




Figure 3.3. Western Blot of Large-Scale Test Expression of PfRh4.18: A 1 in 10 dilution of 
the samples that were prepared for the SDS-PAGE were used for the Western blot. The primary 
antibody was Qiagen anti-His5 mouse antibody, the secondary antibody used was anti-mouse HRP. 
Development time of the Western blot was five-seconds. 
 
Next, the effect of dropping the induction temperature (from 30 to 18 C) on 
PfRh4.18 expression was carried out. An IPTG concentration of 0.3 mM was 
used, and samples from both temperatures were taken and analysed via Western 
blot (figure 3.4). Whilst there was a negligible effect on protein band intensity for 
the I samples of each induction temperature, the lower temperature did appear to 
shift a higher proportion of PfRh4.18 into the insoluble pellet fraction. 
 
 
Figure 3.4. Western Blot of PfRh4.18 Comparing IPTG Induction at 18 C and 30 C: 1.5 μl 
of each sample was run. Temperature of induction (either 18 or 30 C) is given next to the sample 
names in the lane legend. The primary antibody was anti-His5 mouse antibody, the secondary was 
anti-mouse HRP. Development time of the Western blot was five-seconds. 
 
Attempts at refolding from inclusion bodies in the pellet of PfRh4.18-expressing 
cells that were reconstituted from glycerol stocks were unsuccessful (methodology 
for the conditions given in Haggarty-Weir, et al., 2017). This may have been due to 
low quality glycerol stocks, so it may have been better to use the ProEx+PfRh4.18 
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DNA to carry out a fresh transformation. However, production of PfRh4.18 for 
structural studies was discontinued due to supervisory interference.  
 
 
3.4 Cloning, Production and Purification of PfRh4.9 Mutants for CR1 
Binding Studies 
 
3.4.1 Methods for the Cloning, Production and Purification of PfRh4.9 
Mutants for CR1 Binding Studies 
 
Hydropathy plots generated with Kyte and Doolittle hydropathy parameter 
software using the key 58 amino acid sequence at the N-terminus of PfRh4 
identified in Tham, et al., 2009, flanked by 21 amino acids either side as shown 





Restriction enzyme digests of the pET45b+PfRh4.9 plasmid for assessing silent 
restriction sites (Tham, et al., 2009) were carried out as previously described in 
section 2.1, but using 1 – 5 μl of pET45b+PfRh4.9, 1 μl of appropriate 
endonuclease buffer (10 x NEB2, 10 x NEB4 or EcoRI buffer), 0.3 – 1 μl of 
restriction enzyme (HindIII, BamHI, XhoI, MfeI and/or EcoRI), 1 – 1.5 μl 10 x 
BSA, and ddH2O as appropriate.  
 
Agarose gel electrophoreses carried out as previously described in section 2.1, with 
the additional use of 5 μl of 100 bp DNA ladder (ThermoFisher). DNA Strider 
software was used to assess in silico cloning. Note that pET45b was used to allow 
for a hexa-histidine tag to be placed on the N-terminus of each protein. 
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DNA Strider was used to design the PfRh4.9 synthetic gene containing the HindIII 
and MfeI restriction sites, in addition to designing each mutant for the alanine scan 
mutagenesis. 11 constructs were also developed including a PfRh4 region from 
residues 154 – 365 but without the key 58 amino acid region containing residues 
283 – 341 (PfRh4.9Δ58; flanked by HindIII and MfeI for cloning into the new 
PfRh4.9 construct), and 10 genes corresponding to residues 282 – 342 with each 
lot of six residues mutated to alanines to produce PfRh4.96Ala1-10. These additional 
synthetic genes also contained the HindIII and MfeI restriction sites.  
 
DNA sequencing of samples was carried out as described in section 3.3.1, using 
the below primers for the new pET45b+PfRh4.9 mutants (WHT 79 and 82 used 
for the deletion mutant, WHT 79 and 80 used for the 6Ala1-8 constructs, and WHT 
81 for 6Ala9-10): 
WHT79 (forward) CGCggatccCagcaaagaaaaga 
WHT80 (reverse) GCGactcgagttattaaaaatgagaacgcagatccg 
WHT81 (forwards) CGCggatccCatcgacagtgaaaacgagaagc 
WHT82 (reverse) GCGctcgagttattaaatctcgttcagcttattcagga 
 
Protein expression and Western blotting was carried out as per sections 2.5 and 2.8 
respectively. SEC methodology remained the same as outlined in section 2.9, 
except 1 ml fractions were collected. Protein concentrators were used to buffer 
exchange from the 20 mM MES pH 6.5 + 100 mM NaCl used in SEC to 1 × PBS 
with 75 mM NaCl (pH 7.5) prior to ELISA setup.  
 
A concentration ELISA using 96-well flat-bottomed plates (Maxisorp; Nunc) was 
carried out to determine the amount of mutant PfRh4.9 protein to use for the 
CCP1-3 binding assay. Plates coated with 150 μl of 16 μg/ml of each PfRh4.9 
mutant protein (and regular PfRh4.9) in triplicate, with a 1:3 serial dilution carried 
over into the next five wells. Three wells had 100 μl of 1 × PBS added as a 
negative control, then all plates incubated overnight at 4 C. Wells washed, then 
blocked for one-hour at room temperature with 200 μl of 5% skim milk made in 
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PBS-T. Washing followed by 50 μl of 1:2000 10C9 mouse anti-PfRh4 mAb 10C9 
(made in 5% blocking buffer) added to each well for one-hour. After washing, 50 
μl of 1:2000 anti-mouse HRP antibodies (made in 5% blocking buffer) added for 
one-hour followed by 3 x PBT-T washes and 2 × PBS washes. 100 μl of an HRP-
substrate reagent 3,3,5,5-tetramethylbenzidine (TMB, ThermoFisher) was added to 
each well until the background signal appeared, then 50 μl of 2 M phosphoric acid 
quenched the reaction. Absorbance was measured at 450 nm. 
 
The protein-protein interaction ELISA was set up by incubating triplicates of 100 
μl of 2 μg/ml CCP1-3, triplicates of 4 μg/ml (100 μl) of each PfRh4.9 protein, and 
triplicates of 100 μl PBS-only into 96-well flat-bottomed plates (Maxisorp; Nunc) 
overnight at 4 C. After 3 × PBS-T washes, 200 μl of 5% blocking solution was 
added to each well and incubated at room temperature for two-hours. Plates 
washed, then a 1:2 dilution series of PfRh4.9 and mutant proteins (previously 
prepared in regular 96-well plates in a volume of 100 μl starting at a concentration 
of 16 μg/ml, and made in triplicate) were added to their respective CCP1-3 and 
buffer-only control wells (all other control wells had 100 μl of PBS added to 
them). After a two-hour incubation at room temperature and washing, 50 μl of 
1:1000 10C9 mouse anti-PfRh4 antibodies (made in 5% blocking buffer) was 
added to each well for 1.5-hours at room temperature. After washing the plates, 50 
μl of 1:2000 anti-mouse HRP antibodies (made in 5% blocking buffer) added to 
each well for one-hour at room temperature, then washed with PBS-T and 2 x 
washes with PBS. Detection was carried out as previously described above. 
 
 
3.4.2 Results: Cloning, Production and Purification of PfRh4.9 Mutants 
for CR1 Binding Studies 
 
Following on from reports of a potential 58 amino acid region within PfRh4 that is 
involved in binding CR1 (Tham, et al., 2009), a hydropathy plot of this region was 
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generated and analysed to assess hydrophobicity of the region and thus if it is more 
or less likely to be surface exposed (figure 3.5). Residues 283 – 341 were highly 
hydrophilic and therefore possessed a lower likelihood of being a region buried in 
a hydrophobic core, thus being indicative of a region of the protein that is surface 
exposed. The spike around position 65 – 70 corresponds to Arg329.  
 
Next, potential unique silent restriction sites had to be identified up- and 
downstream of residues 283 – 341 that would be compatible with engineering and 
cloning into a pET45b vector without changing the reading frame for PfRh4.9 
expression. This would become important for the cloning in of the alanine scan 
mutant genes of PfRh4.18 designed. 
 
 
Figure 3.5. Hydropathy Plot of PfRh4 Residues 262 – 362: The red line indicates the key 58 
amino acid region of PfRh4 (residues 283 – 341) that is potentially involved in CR1 binding. A 
negative score correlates to increasing hydrophilicity and a positive score correlates to increasing 
hydrophobicity.  
 
Four prospective sites were identified with HindIII and MfeI at the 5` and 3` 
regions respectively looking the best in terms of distance from the key 58 amino 
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acid region of the gene. To confirm that these sites would not lead to enzymatic 
digestion of the genes outside of the designated restriction sites, a series of 
restriction enzyme digests were carried out on the pET45b+PfRh4.9 plasmid and 
analysed via agarose gel electrophoresis (figure 3.6). The pET45b+PfRh4.9 
plasmid size is 7526 bp (containing the 1819 bp PfRh4.9 gene), and so if there was 
activity of both the HindIII (or MfeI; neither of these sites should be present in the 
plasmid) and the secondary enzyme (BamHI or XhoI; both sites present in the 
plasmid), then 2 bands would be expected. However, a single band was seen in all 
sample wells, indicating that the prospective silent restriction sites would be 
suitable to use.  
 
 
Figure 3.6. Agarose Gel Electrophoresis of Restriction Enzyme Digested pET45b+PfRh4.9: 
Single bands around 7.5 kb appear in all lanes. Gel is 0.8% agarose in 0.5 x TBE buffer. 
 
Following transformation of DH10β cells with the new IDT plasmids (pIDT), a 
colony count was performed revealing no colonies on the negative control plate, 
64 colonies for the new PfRh4.9, 118 colonies for the deletion mutant, and 
between 200 and 1000 for the 10 alanine mutants. After a DNA miniprep, each 
new synthetic gene was excised from the pIDT for ligation into pET45b.  After 
preparation of the ligated new pET45b+PfRh4.9 vector containing the HindIII 
and MfeI restriction sites, the plasmid was used to transform DH10β cells, yielding 
colonies contained the pET45b+PfRh4.9 plasmid. To confirm the presence of the 
new restriction sites, the DNA from the colony yielding the highest concentration 
(86 ng/μl) was analysed via gel electrophoresis following a MfeI/XhoI and 
HindIII/XhoI restriction digest (figure 3.7). The DNA sequencing also revealed 




Figure 3.7. XhoI and MfeI or HindIII Restriction Digest of pET45+PfRh4.9: The 
XhoI/MfeI double digest shown in lane 2 reveals two bands, one around 6.1 kb, the other around 
1.3 kb, as expected. The XhoI/HindIII double digest in lane 3 shows a band around 5.8 kB and a 
lower band around 1.6 kb, as expected. Samples were run on a 0.8% agarose 0.5 x TBE gel. 
 
Next the new pET45b+PfRh4.9 plasmid underwent a double digest using MfeI 
and HindIII to prepare for the ligation of 6AlaX mutants, and the deletion gene. 
DNA was gel purified, concentration determined (43 – 75 ng/μl in a 10 μl 
volume), then analysed via agarose gel electrophoresis (figure 3.8). The remaining 
DNA was used for ligating into the MfeI/HindIII-cut pET45b+PfRh4.9 plasmid, 
then electroporated into DH10β cells and plated to yield 250 colonies. After 
minipreps of selected colonies, the DNA was used for a XhoI and NotI-Hf 
restriction digest and sequencing (results not shown).  
 
 
Figure 3.8. Concentration Gel of 6Ala and Deletion Mutant Genes: 2 μl of each sample was 
analysed. 6Ala1 – 8 mutant genes are the expected ~330 bp, and the deletion gene appeared at the 
expected ~160 bp (6Ala9 and 6Ala10 were also run on a separate gel but not shown here). 1.2% 
agarose gel prepared in 0.5 x TAE buffer, run at 70 V for 75-minutes. 
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Following the production and transformation of electrocompetent BL21 gold cells 
with each plasmid, a colony count was carried out revealing thousands of colonies 
for all transformants, and zero in the negative control (water only). Test expression 
following cell growth at 37 C and IPTG-mediated induction at 30 C was carried 
out to analyse the NI, I, pellet and supernatant samples for each expressed protein. 
This was examined by Western blot (figure 3.9), revealing all proteins expressed at 
around the same levels, with all pellet samples appearing at a slightly higher 
intensity than the supernatant fractions. Next, for assessing the impact of 
induction temperature on protein expression, the previous text expression 
experiment was carried out but now inducing at 18 C. SDS-PAGE analysis of the 
samples was carried out (figure 3.10). Inducing at 18 C appeared to shift a very 
slight amount of the protein expression into the soluble supernatant fraction, 
leading to a roughly equal level of protein found between here and the pellet. 
 
 
Figure 3.9. Western Blot of PfRh4.96Ala1-10 and PfRh4.9Δ58 Expression: A. Proteins appeared at 
the expected ~90 kDa size, even in the NI samples (likely due to “leaky” expression), with more 
expression visualized in I samples. B. As for A, except the NI samples were over-boiled. C. Pellet 
and Sup samples for PfRh4.96Ala1-5 show increased levels of protein as inclusion bodies in the pellet 
fraction. D. As for C, but shows PfRh4.96Ala6-10 and PfRh4.9Δ58, with the latter protein appearing at 
the expected size of ~82 kDa. Primary antibodies used were anti-hexaHis mouse antibodies, with 
anti-mouse HRP used for the secondary. Development time of the X-ray film was three-seconds. 
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Figure 3.10. SDS-PAGE Results of PfRh4.96Ala1-10 and PfRh4.9Δ58 Test Expression: All 
samples demonstrate the appearance of a significant band around 90 kDa (or ~82 for the deletion 
mutant) following induction with 1 mM IPTG (at 18 ºC), as expected. Abbreviations used: M- 
molecular weight marker (kDa), N- non-induced, I- induced, P-pellet, S-supernatant. 
 
Scale-up expression of each mutant protein in 600 ml of culture medium was 
carried out. Whilst the samples were roughly analogous to what was seen in terms 
of protein expression and division between pellet and supernatant, the PfRh4.9Δ58 
was highly predominant in the pellet fraction (data not shown). This may be the 
result of using half as much IPTG for the induction, as this was the only variable.  
 
The supernatant post-cell lysis was Ni2+-affinity purified, and 5 x 2 ml elutions 
collected (revealing approximately 1 mg of protein in each fraction). Fractions 
were combined and concentrated to under 5 ml for application to SEC. 2 μl of 
each concentrated sample was viewed on a gel via SDS-PAGE revealing the 
presence of some contaminating proteins, many of which could be removed 
during SEC (data not shown). Key fractions were concentrated (figure 3.11); 
however, PfRh4.9Δ58 was unable to be detected via SDS-PAGE or Western blot 
(data not shown). Further attempts at producing PfRh4.9Δ58 were unsuccessful and 




Figure 3.11. SDS-PAGE of Concentrated PfRh4.9 Mutants: Around 3 μg of the final 
concentrated proteins were run under reducing conditions revealing the presence of mostly 
monomer, with small levels of degradation products present.  
 
After performing a concentration ELISA (results not shown) with each protein to 
determine that anti-PfRh4 antibodies could detect the proteins and to evaluate the 
starting concentration for each, a protein-protein interaction ELISA was set up to 
screen the interaction of each mutant protein against CCP1-3, and contrasted to 
PfRh4.9 binding to CCP1-3 (figure 3.12). All mutant interactions were very similar 
to native PfRh4.9 binding to CCP1-3, thus suggesting the binding region of PfRh4 
to be outside of the amino acid region covering residues 283 – 341. 
 88 
 
Figure 3.12. PfRh4.9 Alanine Scan Mutagenesis: PfRh4.9 mutant proteins were screened for 
binding against CCP1-3. Data shown are from triplicate experiments. The buffer control gave an 
absorbance (at 450 nm) of 0.05, CCP1-3-only control was 0.05, protein-only background was 0.15, 
and positive controls for each protein gave a reading of 1.7. Error bars are standard deviation. 
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3.5 Discussion and Conclusions 
 
Until recent evidence came to light demonstrating the essentiality of the PAIN-
complex proteins (Volz, et al., 2016) (Bushell, et al., 2017) and their stability (Chen, 
et al., 2014) (Chen, et al., 2017), PfRh4 was a candidate for vaccine research due to 
its function in sialic acid-independent invasion of erythrocytes via CR1 (Tham, et 
al., 2010), and the correlation between protective antibodies against it in a PNG 
population and protection against severe malaria (Richards, et al., 2013). 
Additionally, for an understanding of fundamental parasite biology, the discovery 
of inhibitory mAbs to PfRh4 is useful. For this reason, the study carried out had 
aimed to produce functionally important mAbs against PfRh4 using a 
recombinantly-produced truncation, PfRh4.9, in addition to developing a smaller, 
more stable truncation (known as PfRh4.18), and using alanine scan mutagenesis 
to elucidate the precise region of PfRh4 involved in binding CR1.  
 
The production of PfRh4.9 revealed an unstable protein despite efforts to prevent 
degradation including the use of protease inhibitors and cold storage. The 
instability of recombinant PfRh4 has been reported elsewhere in the literature 
(Richards, et al., 2013), although one may not have been unable to initially tell due 
to SDS-PAGE results shown closely cropped to the protein band of interest in 
various publications such as (Gaur, et al., 2007). This of course is a significant issue 
for vaccine design as component stability is essential (reviewed in Kumru, et al., 
2014). However, despite the instability of PfRh4.9, a suitable amount of mostly 
monomeric antigen was produced and used for Balb/c mouse vaccinations. Both 
Western blot and IFA analysis (figure 1 of Lim, et al., 2015) demonstrated the sera 
from vaccinated mice to be reactive against PfRh4, as expected. Although, what 
was unexpected was the finding that the antibodies found in the competition 
ELISA in figure 3.1 that prevented PfRh4.9 binding to CCP1-3 (mAbs 2A7 and 
2H9), were not found to be inhibitory (and thus not reported on) in the 
experiments carried out in Lim, et al., 2015 with the mAbs directed against 
PfRh4.9. 5H12, the most significant inhibitory mAb discovered in Lim, et al., 2015 
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was almost selected as a potential mAb by the competition ELISA in figure 3.1, 
but due to time considerations was not selected for further development. It is 
possible that the discrepancy between the two results arose from human error due 
to inexperience, though follow-up experiments replicating those carried out in the 
published paper but using mAbs 2A7 and 2H9, are warranted.  
 
The development of the 5H12 mAb represents the first anti-PfRh4 neutralizing 
antibody reported in the literature (Lim, et al., 2015). Utilizing three PfRh4-CR1 
interaction assays based on ELISA, FRET, and immunoprecipitation, it was shown 
that 5H12 is capable of disrupting the PfRh4-CR1 interaction. Addition of 5H12 
mAbs ablates PfRh4 binding to erythrocytes and inhibits the PfRh4-CR1 pathway 
in follow-up P. falciparum GIA experiments reported in figure 3.C – E of Lim, et al., 
2015. 5H12 would also be an ideal mAb to use in crystal trials that make use of 
recombinant PfRh4 (such as PfRh4.18), as this would potentially allow for accurate 
conformational epitope mapping of the residues responsible for binding to the 
paratope present on CR1 (akin to the strategy used to map the epitope region of 
PfRh5 (Chen, et al., 2014), and CyRPA (Chen, et al., 2017)). 
 
PfRh4.18 was a smaller protein than PfRh4.9, and it was selected for development 
in order to pursue crystallography-based structural studies. Cloning of the gene 
resulted in the transformation of protein-expressing BL21 gold E. coli cells. A 
variety of expression conditions were screened, ultimately revealing two potential 
expression pathways utilizing bacterial cells grown at 37 C then induced with 0.3 
mM IPTG at 18 C. Both of which appeared to produce initially very pure protein 
(figure 3.4, lanes 6 – 9). The next step would be to scale-up to several litres culture 
(to overcome low protein expression) and to obtain soluble protein after 
harvesting the E. coli (as shown in the Western blot in figure 3.4, lane 7). 
Alternatively, the use of refolding from inclusion bodies could be utilized given the 
presence of high levels of protein in the cellular pellet fraction (figure 3.4, lane 9).  
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Initial test expressions had begun utilizing the latter expression pathway but failed 
to yield protein. This may have been due to having a poor-quality glycerol stock, 
and so it was planned to re-transform BL21 gold cells with ProEx+PfRh4.18 
plasmid. Before this was executed in full, the author’s involvement in the PfRh4 
project was discontinued. In the future, one would be recommended to carry out 
refolding trials of PfRh4.18 utilizing various refolding strategies. Alternatively, one 
could consider using a different expression system, such as insect cells, which have 
proven useful for PfRh5 and CyRPA (Chen, et al., 2014) (Chen, et al., 2017). 
 
To probe the potential binding site on PfRh4 that is responsible for interaction 
with CR1, an alanine scan mutagenesis strategy was implemented. This involved 
changing sets of six amino acids at a time to alanine residues from the section of 
the PfRh4 protein covered within residues 282 – 342. It was decided to include the 
flanking amino acids from the 58-amino acid region (283 – 341) identified in 
Tham, et al., 2009 in order to have an easy division of ten mutant constructs. 
Whilst the plan was to also include PfRh4.9Δ58, a suitable quantity of this was 
unable to be produced in time for the protein-protein interaction ELISA. The 
results of said ELISA (figure 3.12) do not reveal any significant aberration of 
binding between CCP1-3 and the titration of each PfRh4.9 protein. Some of the 
minor decreases seen for example in the PfRh4.96Ala1 panel are explained by the 
minor time differences in HRP-TMB reaction quenching. If any of the mutants did 
give rise to an absence of binding, the results would be of more significant levels. 
Given the fact that a recombinantly-produced 58 amino acid peptide comprising 
residues 283 – 341 of PfRh4 fails to bind CR1 (personal communication, Dr. Lin 
Chen, 2013), combined with the results reported here, it is likely that the binding 
region lies elsewhere. It is a possibility that when the 58-amino acid region was 
found via antibody screening, the antibodies were sterically hindering the actual 
binding site to CR1, and not binding directly to the PfRh4 amino acids that 
directly interact with CR1. In the future, the ideal method of elucidating this 





































Once further evidence came out regarding the importance of PfRipr and PfRh5 as 
lead vaccine targets (Richards, et al., 2013) (Chiu, et al., 2014) (Wright, et al., 2014) 
(Volz, et al., 2016) the overall aims of the research shifted away from PfRh4 to 
focus on the first proteins found in the PAIN-complex. This was of particular 
importance given the dearth of structural and biochemical information published 
on PfRipr. This research intended to produce bacterially-expressed PfRipr 
recombinant protein (with a predominant focus on the EGF-like domains), in 
addition to production of PfRh5 from an established insect cell expression system 
(Chen, et al., 2014), in order to assess binding between these two proteins, and to 
screen PfRh5 against potential inhibitory small molecules. 
 
E. coli was selected to produce the PfRipr truncations as soluble protein due to it 
remaining a staunch workhorse for producing recombinant proteins ever since its 
first use by Genentech to develop somatostatin in 1976 (Itakura, et al., 1977). In 
fact, up to 30% of biopharmaceuticals, 50% of commercial proteins and >70% of 
proteins produced in research settings are made in E. coli (Bill, 2014). However, 
due to issues that can arise in bacterially-produced recombinant proteins, especially 
those in possession of disulfide bonds (leading to issues of aggregation for 
example; reviewed in Rosano & Ceccarelli, 2014), refolding of the EGF-like 
domains of PfRipr from inclusion body products was to be explored. The 
advantage of producing recombinant protein from inclusion bodies is that higher 
yields can be attained and often with far less contaminating bacterial protein 
(reviewed in Rosano & Ceccarelli, 2014). For this, a refolding methodology was 
developed followed by extensive biophysical characterization via mass 
spectrometry, CD, thermal shift and NMR spectroscopy. The latter three methods 
are of particular importance for secondary structure information for the evaluation 




CD spectropolarimeters measure the difference in absorbance between the left and 
right circularly polarized elements of a protein, often reporting the results in terms 
of ellipticity of degrees (Kelly, Jess, & Price, 2005). CD signals arise when radiation 
absorption occurs, and with respect to proteins, the key chromophores are the 
peptide bonds, aromatic amino acids and their respective sidechains and disulfide 
bonds, thus allowing spectral bands to be assigned to distinct structural regions of 
a given protein. Given the unique physical-chemical environment of secondary 
structure elements, both the presence of α-helix and/or β-sheet, and their 
approximate quantity can be divulged from analysis of CD spectra. Therefore, CD 
can be utilized as a tool for providing a level of evidence that one does indeed 
have correctly folded protein if you know how much of each secondary structure 
you would approximately expect to see. However, unless using synchrotron 
radiation to allow for analysis of the sample in the far UV region (below 180 nm, 
which provides optimal secondary structure information), the secondary structure 
element estimates will be less reliable and so an additional biophysical method is 
required. 
 
NMR is a good companion to CD analysis of protein samples, especially for 
assessment of folding when dealing with a protein that is non-enzymatic in 
function (whereby the optimal assessment of folding would be substrate-to-
product activity assay). NMR measures magnetic properties of atomic nuclei 
relevant to those found in proteins (including 1H, 15N, and 13C), which possess a 
spin; meaning they can precess around a magnetic field (Receveur-Bréchot, 
Bourhis, Uversky, Canard, & Longhi, 2006). When these nuclear spins absorb 
energy, they are left in an excited state, which over time return to equilibrium; that 
is, the resonance phenomenon. The nuclear spins create an intrinsic magnetic field, 
and the resonance frequency reflects the local magnetic field, therefore providing 
information on the local chemical environment, and hence, the secondary 
structure of a given protein. 
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In addition to protein refolding and biophysical characterization, attempts at 
producing protein crystals of the recombinant PfRipr proteins was a priority given 
the paucity of structural information in the literature. Finally, screening of anti-
PfRh5 and anti-BSG antibodies was carried out in order to identify inhibitory 
antibodies that could be used as general tools and for crystallography. The strategy 
for the production of each truncated PfRipr protein is shown in figure 4.0. The 
progress for each protein made in E. coli is shown below in table 1. 
 
 
Figure 4.0. Strategy for the Recombinant Production of PfRipr: A. The native PfRipr protein 
with EGF-like domains numbered in yellow, non-EGF domains shown in blue (with the N and C-
termini labelled), the long linker between the 5th and 6th EGF-like domains in red and the 
polypeptide processing region dotted in orange in the middle of the protein. B. Doublet EGF-like 
domain truncations. C. Sets of four EGF-like domains in tandem. D. The entire C-terminal region 
of tandem EGF-like domains. E. Non-EGF domain regions. It should be noted that two forms of 
the middle non-EGF domain region of PfRipr were to be developed; one with a polyhistidine tag 
on the N-terminus and one with the tag on the C-terminus. The production of all non-EGF 





















EGF1-2 Y Y Y N N N N N Y Y 
EGF3-4 Y N Y N N N N N Y N 
EGF5-6 Y Y Y Y Y Y Y Y Y N 
EGF7-8 Y N Y N N N N N Y N 
EGF9-10 Y N Y N N N N N Y N 
EGF3-6 Y Y Y Y Y N Y N Y N 
EGF7-10 Y Y Y N N Y Y N Y N 
EGF3-10 Y Y Y N N Y N N Y N 
Ripr21-
297 
N N Y N N N N N N N 
Ripr362-
636ct 
N N Y N N N N N N N 
Ripr978-
1086 
N N Y N N N N N N N 
Table 1. PfRipr Protein Progress Log (E. coli): The yellow highlighted regions indicated where 
a particular examination type was carried out. Abbreviations used: MS, mass spectrometry; WB, 
Western blot; TSA, thermal shift assay; CD, circular dichroism; Cys, cysteine; NMR, nuclear 
magnetic resonance spectroscopy.  
 
 
4.2 Cloning, Production and Purification of PfRipr and PfRh5 Proteins 
 
4.2.1 Methods for Cloning, Production and Purification of PfRipr 
and PfRh5 Proteins 
 
In general, the cloning methodologies followed that described in section 2.1. 
BamHI/XhoI double digests of pMA-T plasmids were prepared containing each 
PfRipr EGF construct (EGFs 1-2, 3-4, 5-6, 7-8, 9-10, 3-6 and 7-10) and each non-
EGF construct (Ripr21-287, Ripr 362-636, Ripr362-636ct, and Ripr978-1086). 
These were ligated into pET45b+ vectors and also in the case of EGF5-6 only, a 
pProExHTA vector.  Transformation of DH5α and BL21 gold E. coli cells, 
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minipreps, DNA agarose gel electrophoresis and nucleic acid purification were 
performed as described in section 2.1. 
 
Test expression and purification of each PfRipr construct, was carried out 
according to the methods outlined in section 2.5. SDS-PAGE analysis and 
preparation of glycerol stocks were carried out as outlined in section 2.4 and 2.3, 
respectively. Initial test expression of proteins was carried out in 50 ml bacterial 
cell cultures with 1 mM IPTG at 30 C (rather than 18 C due to incubator 
availability), and cells were harvested after five-hours. Scaled-up expression of 
PfRipr EGF-like domains was carried out in a 1.2 L bacterial cultures (unless 
otherwise noted) incubated at 37 C until an OD600 of 0.6. At this point in the cell 
growth induction with 1 mM IPTG at 18 C for 16-hours occurred.  
 
A seed stock of P3 virus containing the PfRh5 synthetic gene in a pgpHFT 
plasmid that was used to co-transfect Sf21 insect cells with FlashBAC (Oxford 
Expression Technologies) was donated by Dr. Lin Chen. Protein expression and 
purification was carried out according to methods in (Chen, et al., 2014). 
 
Western blot analyses were carried out according to the protocol listed in section 
2.8. Protein concentration was carried out using 5 or 10-kDa cut-off protein 
concentrator spin columns (GE Vivaspin ®) for double and quadruple-EGF 
containing proteins.  
 
Sample filtration was utilized prior to SEC by using a 0.22 μm Millex-GP syringe 
filter unit (Merck Millipore). SEC was carried out for PfRipr proteins as described 
in section 2.9, but using either a GE Superdex HiLoad 75 16/600 or 200 16/600, 
and collecting 1 ml fractions in HTPBS buffer, pH 7.5.  
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High performance liquid chromatography – elecrospray ionization/mass 
spectrometry (HPLC-ESI/MS) was carried out by the Bio21 Mass Spectrometry 
facility in Melbourne. 
 
 
4.2.2 Results: Cloning, Production and Purification of PfRipr and PfRh5 
Proteins 
 
Initial cloning and transformation of Dh5α E. coli with pMA-T plasmids 
containing the PfRipr EGF-like synthetic genes yielded over 1000 colonies on 
ampicillin enriched agar plates. Following a miniprep and BamHI/XhoI double 
digest, each sample was analysed via gel electrophoresis (data not shown). This 
produced two sets of bands at the predicted sizes for both the pMA-T vector 
backbone and the smaller synthetic PfRipr EGF-like genes. The latter were 
excised, gel purified, and checked on a concentration gel prior to cloning (data not 
shown).  The synthetic genes were each successfully ligated into pET45b+ 
plasmids (and a pProExHTA plasmid for another construct of EGF5-6) and used 
to transform DH5α cells. 
 
All DH5α transformation plates yielded 300 – 400 colonies; two to four of which 
were picked and used to produce cell cultures and subsequent minipreps. The 
minipreps for each colony yielded 49 – 189 ng/μl of DNA. These were subjected 
to a BamHI-HF/ScaI-HF double digest to confirm expected band sizes on an 
agarose gel (figure 4.1). In all cases, major bands of the predicted sizes of ~4 kb 
and 1.6 – 1.8 kb were visible, in addition to some higher bands that were indicative 
of incomplete enzymatic digestion of the plasmids. BL21 gold cells were 
transformed and plated, producing >1000 colonies for each electroporated sample 
carrying double EGF-like genes, and ~200 colonies for cells electroporated with 




Figure 4.1. Agarose Gel Electrophoresis of pET45b+PfRipr Plasmids: 0.8% agarose (0.5 x 
TBE) gel revealing two predominant band sizes of ~4 kb and 1.6 – 1.8 kb, in addition to some 
incompletely digested product. The DNA from each different colony miniprep is found in each 
box. 
 
Test expression revealed bands of approximate size for I fractions when analysed 
on SDS-PAGE, with some proteins such as EGFs 1-2, 5-6, 7-8 and 9-10 running 
slightly higher than expected compared to the molecular weight markers under 
reducing conditions (figure 4.2 A). This may be due to a variety of factors such as 
protein molecule isoelectric point (pI) and the amount of SDS bound to the 
molecule. Induction at 30 C with 1 mM IPTG revealed different levels of protein 
expression in pellet and supernatant fractions depending on the protein (figure 4.2 
B). A Western blot was carried out using anti-penta-His antibodies (as the proteins 
all possessed an N-terminal polyhistidine tag) to confirm what was seen in the 
SDS-PAGE (figure 4.2 C and D). A significant difference appeared to be observed 
with the I sample of EGF3-4, which appeared to run significantly higher in the 
Western blot compared to the SDS-PAGE. However, this difference was not 
observed for the supernatant fraction, likely due to the I sample potentially not 
being properly sonicated and/or reduced (indicated by the significant smearing 
appearing towards the top of the I and NI Western blot). All EGFs aside from 
EGF1-2 and EGF7-8, appeared to predominantly be associated with the pellet 






Figure 4.2. SDS-PAGE and Western Blot Analysis of PfRipr EGF Proteins: A. SDS-PAGE 
gel of NI and I fractions for each protein (15 μl of each sample loaded). B. SDS-PAGE gel of pellet 
and supernatant fractions for each protein. C. Western blot of NI and I fractions for each protein 
(1.5 μl of each sample loaded). The exposure time was three-seconds. D. Western blot of pellet and 
supernatant fractions for each protein. The exposure time was three-seconds. Abbreviations: M- 
molecular weight marker (kDa), N- Non-induced, I- Induced, P- Pellet, S- Supernatant. 
 
Next, a scaled-up production of each protein was carried out. Induction with 1 
mM IPTG following a temperature drop from 37 C to 18 C shifted most of the 
protein from the pellet fractions and into the soluble supernatant fraction (data not 
shown). Initial Ni-affinity chromatography was followed up by protein 
concentration determination for each 2 ml elution fraction then analysed on SDS-
PAGE under reducing conditions (figure 4.3). Ni-affinity chromatography 
produced mostly monomeric protein; dimer present under reducing conditions is 
indicative of covalently-bonded monomers, and thus likely misfolded protein. 
However, some contaminating protein and degradation products remained as seen 




Figure 4.3. Ni-Affinity Purification of PfRipr EGF-like Domains: SDS-PAGE results of 
samples run under reducing conditions. EGF1-2 was produced from a 1.2 L culture and yielded the 
following concentrations of protein in each 4 ml fraction (following NanoDrop, all values in 
mg/ml): E1- 1.43, E2- 1.07, E3- 1.11, E4- 0.97, E5- 0.82. Around 3 μg of protein run for each 
fraction. EGF3-4 was produced from a 1.2 L culture and yielded the following mg/ml 
concentrations of protein in each 2 ml fraction: E1- 2.35, E2- 1.45, E3- 1.34, E4- 1.33, E5- 1.18. 2 
μl of each sample was used to run on the gel. EGF5-6 was produced from a 1.2 L culture and 
yielded the following mg/ml concentrations of protein in each 2 ml fraction: E1- 0.71, E2- 0.62, 
E3- 0.65, E4- 0.63, E5- 0.62. 2 μl of each sample was used to run on the gel. EGF7-8 was 
produced from a 1.2 L culture and yielded the following mg/ml concentrations of protein in each 2 
ml fraction: E1- 1.41, E2- 1.27, E3- 1.23, E4- 1.25, E5- 1.2. 2 μl of each sample was used to run on 
the gel. EGF9-10 was produced from a 300 ml culture and yielded the following mg/ml 
concentrations of protein in each 2 ml fraction: E1- 0.25, E2- 0.25, E3- 0.37, E4- 0.26, E5- 0.23. 2 
μl of each sample was used to run on the gel. EGF3-6 was produced from a 600 ml culture and 
yielded the following mg/ml concentrations of protein in each 2 ml fraction: E1- -.4, E2- 0.17, E3- 
0.16, E4- 0.16, E5- 0.16. 1 μg of each sample was used to run on the gel. EGF7-10 was produced 
from a 600 ml culture and yielded the following mg/ml concentrations of protein in each 2 ml 
fraction: E1- 0.37, E2- 0.23, E3- 0.23, E4- 0.23, E5- 0.24. 2 μl of each sample was used to run on 
the gel. Gel data shown are composites. 
 
Each protein was concentrated to <5 ml and further purification carried out via 
SEC (data not shown). Various samples appeared to undergo significant sample 
loss after SEC, which was likely due to membrane-associated losses in both the 
Vivaspin® concentrators and 0.22 µl Merck filter units used prior to the 
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application of samples to the SEC column. Thereafter, instead of filtration, it was 
decided to remove particles by centrifuging samples at 10 000 × g for 20-minutes 
at 4 C. 
 
 After concentrating key fractions to under 400 μl, they were run on SDS-PAGE 
(figure 4.4). As would normally be expected from disulfide-rich proteins, all EGF-
like proteins ran faster under non-reducing conditions. Significant sample loss was 
seen in the flow-through of EGF3-4. This was due to accidentally using a 10-kDa 
molecular weight cut-off concentration tube rather than a 5-kDa one. It was also 
observed that EGF3-4 rapidly aggregated within a day of purification, with 
aggregation becoming worse over time (data not shown). 
 
 
Figure 4.4. SDS-PAGE of PfRipr EGF-like Domains: None of the samples showed significant 
degradation under reducing or non-reducing conditions. Under NR conditions, EGF7-8 appears as 
two bands close together. EGFs 3-6 and 7-10 show the start of potential minor dimer formation. ~ 
10 μg loaded for each sample. Gel data shown are composites. 
  
 In addition to the production of the EGF-like domains of PfRipr, the N-terminal 
(residues 21 – 287), mid-section (residues 326 – 636) and C-terminal (residues 978 
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– 1086) regions of the protein that were devoid of EGF domains were also of 
interest. The mid-section contains the region of PfRipr where there is enzymatic 
processing at an unknown site. Therefore, in addition to a regular N-terminal 
polyhistidine-tagged Ripr326-636 construct, an additional version was developed in 
silico containing the polyhistidine-tag at the C-terminus instead. This would allow 
for Edman degradation analysis after exposure to parasitic supernatant (containing 
the enzyme/s involved in PfRipr polypeptide processing) to identify the cleavage 
region. After the electroporation of the pME-T plasmids containing the synthetic 
genes into DH10β cells, >1000 colonies were seen on each LB agar plate. After a 
miniprep was carried out on selected colonies and the BamHI/XhoI cut DNA 
isolated and purified (results not shown), ligation into pET45b+ plasmids were 
carried out. The resultant plasmids were used to transform BL21 gold cells 
resulting in thousands of colonies. Using selected colonies, test expression 
inducing at 30 C with 0.25, 0.5 and 1-mM IPTG was performed followed by 
analysis of the results on SDS-PAGE (figure 4.5).  
 
 
Figure 4.5. Test Expression of PfRipr Non-EGF Domain Proteins at 30 C: Regardless of 
IPTG concentration, the majority of expressed protein appeared almost exclusively in the pellet 
fractions (red box highlighting the key bands for samples from 1 mM IPTG induction). 
Abbreviations: M- molecular weight marker (kDa), NI- non-induced sample, I- Induced sample 
(with concentration of IPTG given), P- pellet sample, S- supernatant sample. 
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Given that there was no discernible difference in protein expression regardless of 
IPTG concentration, an attempt to shift the destination of protein products was 
made by inducing with 0.25 mM IPTG at 18 C. Samples were analysed on SDS-
PAGE (figure 4.6). None of the sample appeared to express any detectible level of 
recombinant protein with the exception of Ripr21-287. However, in this case 
expression remained exclusively in the pellet fraction as insoluble inclusion bodies. 
To try and concentrate any protein present in the soluble fraction, the supernatant 
was applied to a Ni-NTA column, with the resulting elution fractions analysed via 
HPLC-ESI/MS (data not shown). However, this revealed no protein of interest. 
Refolding trials of the insoluble inclusion bodies from cultures induced at 30 C 
were planned, however time limitations and the need to focus on the EGF-like 
domains prevented this from being carried out, in addition to planning for the later 
production of full-length PfRipr in either insect cells or Pichia.  
 
 
Figure 4.6. Test Expression of PfRipr Non-EGF Domain Proteins at 18 C: No PfRipr non-
EGF protein was shown to have any discernible protein expression aside from Ripr21-287 (red 
box). Ripr362-636 (and the Ct. version) may be masked by the contaminating E. coli protein around 
37-kDa. 
 
With respect to recombinant PfRh5, samples obtained from insect cell cultures 
were analysed by Western blot with anti-PfRh5 rabbit polyclonal antibodies (figure 
4.7 A). All samples appeared to contain at least some PfRh5 expression. After 
harvesting, the supernatants were loaded onto an anti-flag affinity chromatography 
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column to purify the flag-tagged PfRh5, with no discernible protein loss in the 
flow-through or from protein concentration (figure 4.7 B). 
 
 
Figure 4.7. Western blot and SDS-PAGE of PfRh5: A. 20 μl samples were obtained from cell 
culture supernatant for each 200 ml flask and run on the gel under reducing or non-reducing 
conditions. The Western blot used 1:5000 anti-PfRh5 rabbit polyclonal antibodies and 1:2000 
donkey anti-rabbit HRP. B. SDS-PAGE gel of post-anti-flag tag affinity chromatography 
concentrated sample (in red box) and the wash fraction from the concentration tube (showing no 
discernible sample loss).  
 
The concentrated PfRh5 sample was further purified and buffer exchanged into 1 
× PBS pH8 via SEC, and 2 μg of each fraction was analysed via SDS-PAGE 
(figure 4.8 A and B). Fractions 41 – 48 were combined and concentrated to 3 
mg/ml (in 350 μl). 3.5 μl of the final concentrated PfRh5 protein was analysed on 
SDS-PAGE under reducing and non-reducing conditions to assess protein quality. 
The samples revealed no discernible protein aggregation and only minimal, 
insignificant degradation (figure 4.8 C). Under non-reducing conditions, PfRh5 
runs slightly lower due to the presence of disulfide bonds. The production of 
purified PfRh5 and PfRipr proteins allowed for a variety of binding studies to be 
carried out, in addition to screening potential inhibitory compounds from the 
MMV box against PfRh5. It was also decided to explore an alternative protein 
production strategy for the PfRipr EGF-like modules, namely through refolding 
from inclusion bodies. This was, in part, due to significant batch-to-batch variation 




Figure 4.8. SEC and SDS-PAGE of PfRh5: A. On the SEC chromatogram, the arrow highlights 
the peak of interest. B. 2 μg from fractions 38 – 51 were analysed on an SDS-PAGE gel under 






4.3 Ripr Protein Refolding from Inclusion Bodies 
 
4.3.1 Methods for Ripr Protein Refolding from Inclusion Bodies 
 
Recombinant protein expression, cell preparation and Ni-affinity chromatography 
of EGFs 5-6, 3-6 and 7-10 were carried out as described in sections 2.5, 2.6, and 
2.7, respectively, with refolding as per the methods described in Haggarty-Weir, et 
al., 2017.  
 
The production of EGF3-10 was carried out as follows- Glycerol stocks of BL21 
E. coli containing the EGF3-10 synthetic gene in a pET303 plasmid (glycerol 
stocks and general protein production/refolding methods provided by XtalTM 
Biostructures, USA) were streaked out on LB agar plates containing 40 μg/ml 
kanamycin and grown overnight at 37 C. Colonies were picked into 4 ml of TB 
with 40 μg/ml kanamycin and incubated at 37 C shaking at 250 rpm until the 
OD600 reached 0.5. Tube contents were added to 100 ml of fresh broth, grown as 
above, then 10 ml transferred into 500 ml of fresh broth. An aliquot of 1 mM 
IPTG was added when the OD600 reached 0.5, then the flask left to incubate for 
four-hours. Flask contents were centrifuged at 5000 × g for 15-minutes, 
supernatant decanted and 160 ml of lysis buffer (20 mM Tris pH 8, 200 mM NaCl, 
and four tablets of Roche cOmplete protease inhibitor) added. Sonication was 
carried out on each sample. The lysate was centrifuged at 17 000 × g for 45-
minutes at 4 C followed by separation of pellet and supernatant. The pellet was 
re-solubilized in 200 ml of IB wash buffer 1 (50 mM Tris pH 8, 250 mM NaCl, 1% 
Triton-X-100). After further sonication on ice the sample was re-centrifuged and 
the above two steps repeated. Upon the third time re-solubilizing the pellet, IB 
wash buffer 2 (20 mM Tris pH 8, 200 mM NaCl, and 1 mM CaCl2) was used. The 
final pellet was solubilized in 5 ml/g of pellet of IB solubilisation buffer (6 M 
guanidine HCl, 20 mM Tris pH 8, 1% Triton-X-100, 20 mM βME, and 10 mM 
imidazole). Ni-affinity chromatography was carried out as described section 2.7, 
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but using a step-wise elution process with four elution buffers comprised of 6 M 
guanidine HCl, 20 mM Tris pH 8, 20 mM βME and increasing concentrations of 
imidazole (50, 100, 150, and 300 mM). SDS-PAGE was used to analyse fractions 
which were then concentrated to 8 ml as previously described. 
 
Refolding of EGF3-10 commenced with adding 8 ml of protein solution in a slow, 
drop-wise manner into 400 ml of stirring refold buffer (50 mM Tris pH 10.5, 2 
mM oxidized glutathione, 500 mM arginine, and 1 mM CaCl2). The refold mix was 
incubated at 4 C for 24-hours without stirring, then dialyzed against 8-L of 
dialysis buffer (20 mM Tris pH 8 and 100 mM NaCl) for 24-hours at 4 C; this 
step was then repeated. Post-dialysis, the sample was concentrated to 40 ml, with 5 
ml fractions used for SEC.  
 
Trichloroacetic acid (TCA) precipitation was carried out on 1.1 ml of each sample. 
After 30-minutes centrifugation at 10 000 × g and 4 C, the top 1.0 ml was 
removed and placed into tubes containing 0.1 ml 100% TCA. After a one-hour 
incubation on ice, samples were centrifuged for 15-minutes at 10 000 × g and 4 
C. Supernatant was decanted, 0.5 ml chilled acetone was added and then tubes re-
centrifuged for five-minutes. After the supernatant was decanted, 20 μl of 1 x RSB 
or 1 x NRSB were added and samples analysed via SDS-PAGE (as described in 
section 2.3.1). 
 
Dialysis was done using 3.5 kDa MWCO Spectra/Por™ 7 Membrane tubing 
(Fisher Scientific). Dialysis buffer was 4 x 5 L of 20 mM Tris pH8 and 20 mM 
NaCl. The dialysis was carried out on a magnetic stirrer plate at 4 C, with buffer 
being changed twice a day for two days. 
 
Dialysed proteins were centrifuged at 30 000 × g for 30-minutes before being 
pumped onto a 1 ml HiTrap Q HP anion-exchange column (GE Healthcare) that 
had been washed with elution buffer (20 mM Tris pH 8, 1 M NaCl) and equilibrated 
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with wash buffer (20 mM Tris, pH 8) The flow-through was re-pumped over the 
column before being attached to an ÄKTA pump system. A gradient of 0-100% 
elution buffer at a flow rate of 1 ml/minute was then used to elute the protein in 1 
ml fractions. Key fractions were visualized via SDS-PAGE, combined as appropriate 
and concentrated to <5 ml final volume with a 5-kDa molecular weight cut-off 
Vivaspin® concentration tube (Satorius, Göttingen) via centrifugation at 4,200 × g 
for 15-minute intervals at 4°C.  
 
The concentrated protein samples were then loaded onto an analytical Sigma 10/300 
Sephadex 75 column (GE Healthcare) (S200 16/600 pg used for EGF7-10) that had 
been equilibrated with 1 × PBS pH 8 on an ÄKTA instrument (20 mM Tris pH 8 
and 100 mM NaCl for EGF3-10). Protein was eluted at a rate of 0.8 ml/minute 
using 1× PBS pH 8 and collected in 0.5 or 1 ml fractions. The absorbance at 280 
nM (A280) of protein solutions during purification was used to calculate the minimum 
sample size required to load for SDS-PAGE analysis based on a visualization limit 
of 2 µg of protein on the gel. A280 was measured using the ‘Protein’ setting on an 
Eppendorf Biophotometer. 
 
Western blot analysis was carried out as described in section 2.8, but using a 1:2000 
dilution of rabbit anti-PfRipr polyclonal antibodies for the primary antibody 
(donated by Jenny Thompson at the Walter and Eliza Hall Institute; antibodies 
raised against PfRipr EGF3-10), and a 1:2000 dilution of anti-mouse HRP 
antibodies for the secondary.  
 
 
4.3.2 Results of Ripr Protein Refolding from Inclusion Bodies  
 
The solubilized inclusion bodies prepared from the initial 600 ml of S broth 
(induced with 1 mM IPTG at 37 C) were applied to a Ni-NTA column, and the 
23 x 1.5 ml elutions analysed via SDS-PAGE (figure 4.9). Due to the high level of 
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protein present following batch binding of the flow-through to Ni-NTA resin 
overnight, two more lots of elutions could be carried out over three days, with the 
fractions stored at -20 C. The total amount of protein from the pooled fractions 
from the first elution was 59 mg for EGF5-6 and 55.36 mg for EGF3-6. 
 
 
Figure 4.9. SDS-PAGE of Ni-Affinity Purification of EGF5-6 and EGF3-6: 20 μl loaded onto 
each lane. All fractions combined and stored at 4 C until required. 
 
An aliquot of 1.1 ml from each pooled elution was used for each test refold 
condition attempted (20 ml final volume). The refold trials were carried out over 
three days at room temperature, with 1 ml samples taken for TCA precipitation 
and subsequent SDS-PAGE analyses (figure 4.10). Initial samples (t0) show the 
presence of numerous multimers for both proteins, which are largely not present 
in the t72 hour samples where the only significant band aside from monomer is 
dimer (EGF3-6 still had the presence of some trimer). All samples run with 1 x 
NRSB appear to migrate faster on the gel, indicating the presence of disulfide 
bond formation. There did not appear to be any significant difference between 
samples that underwent refolding in reducing conditions compared to those 
refolded in non-reducing conditions. Additionally, increasing urea concentration 




Figure 4.10. EGF5-6 and EGF3-6 Refolding Trials: Each sample is from a TCA precipitation 
carried out during the refolding period. Above each gel indicates whether the samples prior to 
SDS-PAGE were in R or NR refolding conditions. Numbers atop each gel lane indicate the 
amount of urea used (M). Above this are the conditions the samples were run under; RSB or 
NRSB. Time is in days in bold in the top left-hand corner of each gel.  
 
Next, it was decided to repeat the refolding trial, but using different amounts of 
oxidized glutathione (1, 0.5 or 0.25 mM) to assess its effect on refolding. The 
results for t0 and t72 samples are shown in figure 4.11. For both proteins, it appears 
that using 0.25 mM oxidized glutathione was perfectly sufficient as judged by there 




Figure 4.11. EGF5-6 and EGF3-6 Refolding Trials with Oxidized Glutathione: Each sample 
is from TCA precipitations carried out during the refolding period (day 0 and day 3). Above each 
gel is indicated whether the samples prior to SDS-PAGE were in R or NR refolding conditions. 
Numbers atop each gel lane indicate the amount of oxidized glutathione used (M). 
 
Subsequently, scaled-up production of refolded EGFs 5-6, 3-6, 7-10 and 3-10 (it 
should be noted that the 34.5 ml stock of EGF7-10 contained 49 mg of protein, 
and for the 8 ml of EGF3-10 there was a total of 16 mg) was carried out using 10 
ml of the stock protein solution. After refolding and two days of dialysis to reduce 
the salt content to 20 mM, the samples were analysed by SDS-PAGE (figure 4.12). 
The dialyzed samples do not show any significant loss of protein, but do show 
some slightly stronger trimer and tetramer bands than had been previously been 
seen. This may be the result of a lower salt concentration, namely going from 100 





Figure 4.12. Scale-up Refold of EGFs 5-6 and 3-6, 7-10, and 3-10. Each sample is from TCA 
precipitations carried out (20 μl loaded onto the gel. Sample running conditions (R or NR) for the 
SDS-PAGE is indicated at the top of each sample gel lane. 
 
Anion-exchange chromatography was carried out on each protein (with the 
exception of EGF3-10) to remove the higher order multimers. The results in 
figures 4.13 to 4.15 show that the multimers, with the exception of dimer, could be 
separated from monomer. Fractions 23 and 24 from EGF5-6 (figure 4.13) were 
combined and concentrated down to 0.5 ml. Fractions 25 – 28 from EGF3-6 
(figure 4.14) were combined and concentrated down to 0.5 ml. Fractions 8 – 13 




Figure 4.13. Anion Exchange Chromatography of EGF5-6: Protein elution occurred around 
25% buffer B. Arrow indicates the main peak of interest. 2 ml fractions collected. Around 4 μg 




Figure 4.14. Anion Exchange Chromatography of EGF3-6: Protein elution occurred around 
25% buffer B. Arrows indicate the main peaks of interest. 2 ml fractions collected. Around 4 μg 




Figure 4.15. Anion Exchange Chromatography of EGF7-10: Protein elution occurred around 
15% buffer B. Arrow indicates the main peaks of interest, with the initial, taller and sharper peak 
containing the majority of monomeric protein (the second, broader peak contains a variety of 
multimers).  1 ml fractions collected. Around 4 μg loaded onto the SDS-PAGE gel with 1 x NRSB.  
 
Once all samples were concentrated to appropriate volumes, and after being 
centrifuged at 10 000 × g for ten-minutes at 4 C, they underwent SEC to try to 
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separate the dimers from the monomers. SDS-PAGE analysis was used to 
visualize the key fractions, followed by a Western blot analysis to ensure each 
refolded protein was recognized by anti-PfRipr antibodies. The resultant 
chromatograms, SDS-PAGE gels and Western blot images are shown in figures 
4.16 – 4.19. A slight amount of proteolytically clipped EGF3-6 remained, as did a 
minor proportion of EGF7-10 dimer. EGF5-6 appeared purely monomeric. All 
proteins were recognized by the anti-PfRipr antibodies as expected.  
 
 
Figure 4.16. SEC, SDS-PAGE and Western Blot of EGF5-6: One major peak shown on the 
SEC chromatogram. In each case, 2 μg was analysed on SDS-PAGE under non-reducing 
conditions (centre fraction also analysed with 1 x RSB). Western blot (WB) carried out on 0.1 μg of 








Figure 4.17. SEC, SDS-PAGE and Western Blot of EGF3-6: Three major peaks shown on the 
SEC chromatogram, with the major tall peak indicating the monomer. In each case, 2 μg of protein 
were analysed on the SDS-PAGE gel, under reducing conditions (fraction 8 and 9 also analysed 
with 1 x NRSB). Western blot (WB) carried out on 0.2 μg of protein from fraction 9 run with 1 x 
NRSB with a one-second development time. 
 
 
Figure 4.18. SEC, SDS-PAGE and Western Blot of EGF7-10: Samples were taken across the 
large peak shown (arrow), with 2 μg of fraction 8 analysed on an SDS-PAGE gel under R and NR 
conditions. Western blot (WB) carried out on 0.2 μg of protein from fraction 8 run with 1 x NRSB 




Figure 4.19. SEC, SDS-PAGE and Western Blot of EGF3-10: One major peak with a minor 
shoulder is shown in the chromatogram. Samples were taken to run under NR and R conditions on 
SDS-PAGE from under the centre of the major peak. The Western blot (WB) shown here is 
actually from a prior SEC run corresponding to ~1 μg of fraction 28 here, run with 1 x RSB.  
 
Finally, key fractions of monomeric protein were taken and concentrated to under 
0.3 ml for a final concentration of ~12 mg/ml. This however excluded EGF3-10, 
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which could not be concentrated above 3 mg/ml without precipitating out of 
solution (samples remained at 0.5 mg/ml). Were there was insufficient quantity or 
purity for future experiments, more protein was made with the above protocol, but 
using a 1:25 dilution into the refold buffer rather than 1:100 (same results 
obtained, data not shown). This ensured pure monomeric protein was used for 
future experiments (such as crystallography), with the exception of EGF3-10, 
which (regardless of concentration) always appeared to reform a minor amount of 
dimer; around 5-10% of total protein concentration. After the final purification, 
each protein sample needed to be assessed for correct folding via biophysical 
methods. This was especially important as, whilst each protein could be detected 
by anti-PfRipr antibodies, it is not necessarily indicative of correct folding due to 
the antibodies being polyclonal and targeting both linear and structural epitopes. 
To first ensure sample quality, mass spectrometry was carried out followed by CD 
and NMR to assess the secondary structure and folding of each protein. 
 
 
4.4 Biophysical Characterization of EGF-Rich Modules 
 
4.4.1 Methods for the Biophysical Characterization of EGF-Rich Modules 
 
4.4.1.1 Mass Spectrometry 
 
Mass spectrometry was carried out at the following facilities: Bio21 Mass 
Spectrometry facility (Melbourne, Australia), the Scottish Instrumentation and 
Resource Centre for Advanced Mass Spectrometry (SIRCAMS) at the University 
of Edinburgh School of Chemistry (Scotland, United Kingdom), and the BSRC 
mass spectrometry and proteomics facility of St. Andrews University (Scotland, 
United Kingdom). 
 
Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) spectra 
were collected on a Daltonics ultrafleXtreme™ MALDI-TOF (Bruker) operating in 
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linear positive mode. Protein samples were prepared 1:1 with synapinic acid (50:50 
acetonitrile (ACN):H2O, 0.1% TFA. The lowest laser intensity that gave a clean peak 
was used. 
 
Positive Electrospray Ionisation mass spectra (ESI+/MS) were collected on two 
instruments both equipped with analytical HPLC to identify peaks corresponding to 
the monoisotopic masses predicted for each intact peptide: 
i)  ESI Waters SYNAPT G2 Q-TOF equipped with a SYNAPT™ 
Acquity UPLC using a 1 mm x 250 mm proswift RP4H (PSDVB) 
column and a gradient of 5% A to 60% B (A= 0.1% formic acid (FA) 
in H2O, B = 0.1% FA in ACN).  
ii) 12T Bruker Daltonics solariX FT-ICR equipped with a Dionex™ 
U3000 HPLC using a 500 µm x 100 mm PROSWIFT L4 RP5H 
column and gradient identical to that in i).  
 
 
4.4.1.2 Circular Dichroism 
 
CD measurements were carried out on a JASCO J-180 spectropolarimeter (initial 
analysis at the Bio21 Institute of the University of Melbourne, and further analysis 
carried out at the Edinburgh Protein Production Facility (EPPF) of the University 
of Edinburgh by Roma Galloway with assistance from Dr. Elizabeth Blackburn). 
Far-UV CD spectra (185–260 nm) were collected using a 14 μM protein 
concentration in 10 mM NaPO4 and 100 mM NaF and a 0.2-mm path-length cell. A 
bandwidth of 1 nm was used with a scan speed of 10 nm/min. All CD measurements 
were made at 25°C, and each spectrum was the average of five individual scans. The 
spectra were corrected for buffer contribution. DichroWeb software 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) was used for the quantitative 




4.4.1.3 Thermal Shift Assay 
 
The fluorescence-based thermal shift assay (TSA) was carried out at the Walter and 
Eliza Hall Institute with the assistance of Dr. Isabelle Lucet according to the general 
methods outlined in (Lucet, et al., 2014).  
 
 
4.4.1.4 PfRipr PEGylation 
 
For these experiments, 3 μg of each protein was prepared in duplicate; half of these 
were boiled for one-minute at 95 C. Then 0.5 mM of methoxypolyethylene glycol 
malemide (10, 000 MW average, Sigma Aldrich) was added to each sample followed 
by one-hour incubation at room temperature. The reaction was quenched with 200 
mM DTT, then the samples analysed alongside controls (3 μg of protein with no 
additional reagents) on SDS-PAGE with 1 x RSB. 
 
 
4.4.1.5 Nuclear Magnetic Resonance Spectroscopy 
 
NMR experiments were performed on an AVANCE 800 MHz (Bruker) 
spectrometer using a 5-mm triple resonance cryoprobe. Protein samples were 
between 150 µM - 300 µM in 10% D2O. NMR data was acquired using Bruker 
TOPSPIN 1.2 software and analysed using MestReNova software. The NMR 
experiments on EGF5-6 that was produced from a pProExHTA plasmid were 
carried out alongside Roma Galloway (refer to Galloway, 2016). Juraj Bella, Dr. 
Brian Smith, A/Prof. Matthew Call and Profs. Paul Barlow and Dusan Uhrin 
provided advice on experimental set up. Juraj Bella carried out the Bruker-based 
experimental set up and pulse sequence programming.   
 
Production of 15N isotopically labelled protein was carried out using E. coli grown in 
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minimal media consisting of (per L): 100 μl 1 M CaCl2, 1 ml 2 M MgSO4, 5.96 g 
anhydrous Na2HPO4 dibasic, 3 g KH2PO4 monobasic, 1 g 
15N-NH4Cl, 0.5 g NaCl, 
4 g D-glucose, 4 ml of a Centrum A-Zinc solution (stock: one tablet dissolved in 40 
ml bi-distilled H2O, centrifuged at 5000 × g for 20-minutes then sterile filtered with 
a 0.22 μm filter unit); used to provide trace metals. 
 
 
4.4.2 Results: Biophysical Characterization of EGF-Rich Modules 
 
4.4.2.1 Mass Spectrometry 
 
Mass spectrometry was carried out on all refolded protein samples to ensure 
correct mass identification prior to further biophysical characterization. Figure 
4.20 shows the results for each refolded protein, in addition to EGF1-2 from 
figure 4.4 (a protein produced via soluble expression in E. coli). Each protein was 
identified as having the correct molecular mass, with a slightly higher mass 
observed for EGF3-10; around 0.48 kDa higher. This may in part be due to the 
presence of a cloning artefact from the pET303/CtHis vector, Arg-Ser-Arg at the 





Figure 4.20. Mass Spectrometry Analysis of PfRipr EGF Proteins: Correct mass identification 
of each EGF protein was carried out via LC/ESI-MS, with the exception of EGF3-10 which was 
analysed via MALDI-TOF. Predicted and observed masses given for each sample. 
 
 
4.4.2.2 Circular Dichroism 
 
The amino acids that contribute to the antiparallel β-strand found in EGF 
domains typically account for approximately 17-22% of the primary sequence. The 
PfRipr EGF-like protein truncations produced in this chapter contain tandem 
EGF-like modules, in addition to undefined N- and C-terminal sequences, and in 
the case of EGF5-6 and EGF3-6, a predicted unusual long linker of 17 amino acid 
residues between the 5th and 6th EGF-like modules. CD was employed to analyse 
refolded EGF proteins for both the presence of β-strand (suggestive of correct 
protein folding), and to assess if any other secondary structure was present. CD 
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analysis of EGF3-10 was not carried out at this point in the project, due to the 
decision to attempt production of this protein in a Pichia expression system (where 
refolding would be unnecessary). Due to equipment repairs carried out on the 
Bio21 Institute CD machine, refolded EGF7-10 could not be analysed 
(additionally, this protein was going to be moved to a Pichia expression system). 
The initial CD analysis of EGF5-6 and EGF3-6 is shown in figure 4.21. 
 
 
Figure 4.21. Initial CD Analysis of EGFs 5-6 and 3-6: A. CD of 14 µM EGF5-6 in a buffer 
comprised of 20 mM Tris pH 8, 100 mM NaF (plus some Roche protease inhibitor). B. CD of 10 
µM EGF3-6 in the same buffer. C. An example of various secondary structure CD spectra traces, 
in addition to examples of folded and denatured proteins (adapted from (Greenfield, 2006)). D. 
Example of a CD spectra obtained from refolded EGF modules of a P. falciparum micronemal 
protein, cbEGF7-9 (Periz, et al., 2005). CD spectra for both EGF5-6 and 3-6 were corrected by 
subtraction of spectra acquired for the buffer-only. 
 
The CD spectrum of EGF5-6 and EGF3-6 displays minimums of ~198 nm and 
~195 (respectively), which is characteristic of a protein in a predominantly random 
coil structure. No evidence for α-helix was shown for either protein, given the 
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absence of a double-dip starting around 220 nm and ending around 205 nm, in 
addition to the paucity of highly positive ellipticity at 190 nm. A positive peak is 
seen 195 and 193 nm for EGF5-6 and EGF3-6, respectively, with both dipping 
back down towards the furthest end of the UV spectrum. This is similar to the 
general peak shape shown for the β-sheet-containing protein in figure 3.30 C.  
However, the jagged peak structure towards this far UV end of the CD spectrum 
is also likely to have had a significant contribution from the sample buffer. It was 
also obvious that neither protein was predominantly β-sheet due to a lack of peak 
minima around 218 nm, which was expected.  
 
A second sample of 14 µM EGF5-6 was prepared in 10 mM NaPO4 + 100 mM 
NaF (no protease inhibitors) and re-analysed via CD (figure 4.22). Secondary 
structure content for EGF5-6 was estimated using the CONTIN deconvolution 
algorithm on the DichroWeb server (Whitmore & Wallace, 2004). This revealed 
the protein to be around 60% disordered, ~22% β-strand, with ~15% comprised 
of turns (plus a negligible amount of potential helical content). The peak minima 
remained at ~198 nm. This was in-line with the triple-EGF repeat protein CD 
shown in figure 3.30 D. The “goodness of fit” parameter NRMSD (normalised 
root mean square deviation) of EGF5-6 in figure 4.22 was reported as being 0.043. 
This is the most useful single measure of how well the theoretical CD spectrum 
calculated from the derived secondary structure composition matches the given 
experimental data over the wavelength range recorded (Kelly, Jess, & Price, 2005). 
NRMSD ranges from 0 (perfect fit) to 1 (no fit), with values lower than 0.1 (ideally 
lower than 0.05) to be deemed reliable (Kelly, Jess, & Price, 2005). Given this, the 
CD spectra for EGF5-6 should be regarded as high quality in terms of how 






Figure 4.22. Far UV CD Spectra of EGF5-6: The DichroWeb-generated CD spectrum for a 14 
µM EGF5-6 (10 mM NaPO4 + 100 mM NaF) sample including quantitative analysis information. 
Residuals of the fit to solutions from a reference data set (Sreerama & Woody, 2000) (pink) indicate 
a good agreement between experimental and reconstructed data. 
 
 
4.4.2.3 Thermal Shift Assay 
 
To assess both the folding and thermal stability of the refolded EGFs 5-6 and 3-6, 
a TSA using the fluorophore CYPRO Orange that binds to hydrophobic patches 
on proteins was employed (figure 4.23). Both proteins were judged to be folded 
and highly stable, with little binding of the dye (i.e. exposure of hydrophobic 
residues) below 65 °C. The EGF3-6 sample had a slightly higher melting 
temperature than the EGF5-6 sample (78 C for EGF5-6 and 79.5 C for EGF3-
6), though both displayed a similar profile. A side hump on the melting curve was 
seen at around 74 C for both samples. This could be due to differential melting 
temperatures for the component domains or possibly due to a proportion of dimer 
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in the sample. However, overall, the TSA revealed the proteins to have evidence of 
being folded; unfolded protein would take up the dye faster at an earlier time point 
leading to a saturation of fluorescent signal. 
 
 
Figure 4.23. TSA of EGFs 5-6 and 3-6: Increasing concentrations of both EGF5-6 and EGF3-6 
were used for a comparative analysis. Temperature raised 1 C per 0.5-minutes. 
 
 
4.4.2.4 PfRipr PEGylation 
 
In order to assess the presence of free cysteine residues, a PEGylation reaction was 
carried out using methoxypolyethylene glycol malemide that would increase the 
molecular weight of each protein by 10 kDa per free cysteine bound. Refolded 
EGFs 5-6, 7-10 and 3-10 were analysed via SDS-PAGE (figure 4.24). Regarding 
the control samples (no PEG), both EGFs 5-7 and 7-10 appeared as monomers 
(as expected), whilst EGF3-10 showed a small percentage of dimer at around 100 
kDa (as had been seen previously). With respect to the experimental samples, 
denaturation via boiling had no observable effect on the extent of PEGylation, 
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which manifested as faint bands running around 10 kDa higher than the respective 
non-PEGylated proteins. All proteins contain an even number of cysteines that are 
predicted to be forming disulfide bonds. These results suggest that only a small 
proportion of the protein (probably <5%) has a free cysteine following refolding, 
which is not uncommon. This data supports the case for successful refolding of 
more than 95% of the protein in the sample, which is sufficient for most analyses. 
 
 
Figure 4.24. PEGylation of Refolded PfRipr Proteins: 3 μg of each protein was analysed on 
SDS-PAGE using 1 x RSB for each sample. Control samples are in lanes 2 – 4, denatured samples 
are in lanes 5 – 7, and non-denatured samples are in lanes 8 – 10. 
 
 
4.4.2.5 Nuclear Magnetic Resonance Spectroscopy 
 
NMR is a powerful technique that can be utilized for the assessment of folding of 
protein molecules (Kwan, Mobli, Gooley, King, & Mackay, 2011). A common 
experiment being the 1D 1H-NMR spectrum that contains signals for each non-
degenerate hydrogen atom. A folded protein will possess a well-dispersed set of 
signal peaks as opposed to broad signals indicative of an unfolded/denatured 
protein. Additionally, evidence of secondary structure can be elucidated, such as 
the presence of β-sheet. For these reasons initial NMR analysis was carried out on 
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the refolded EGFs 5-6, 3-6 and 7-10; EGF3-10, at over 50 kDa, was deemed too 
large for NMR-based analysis.  
 
An initial 1D NMR of EGF5-6 (figure 4.25) reveals evidence of folding due to the 
good peak dispersion seen, particularly in the aromatic, side chain and backbone 
amide regions, as well as the carbon-associated hydrogens of the side-chains. Close 
examination of the amide-proton region at 8.2 - 9.8 ppm revealed 1H peaks with 
good dispersion; this suggests that the protons are in unique chemical 
environments due to a well folded tertiary structure of the protein. The peaks are 
generally sharp, consistent with a lack of self-association or intermediate exchange 




Figure 4.25. 1D 1H-NMR of EGF5-6 in Tris/NaCl: 150 μM sample of EGF5-6 in 20 mM Tris 
pH 8 + 200 mM NaCl and 10% D2O. 64 scans taken at an experimental temperature of 25 ºC. 
Inlaid in the figure is a zoom-in of the amide proton region displaying highly dispersed peaks. 
Abbreviations: W- Tryptophan, aa- amino acid. Figure developed by Roma Galloway and the 
author. 
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In order to increase the signal-to-noise ratio and to lessen the effect of the high 
NaCl concentration (that degrades sensitivity) and artefacts generated from the 
water and Tris (which was potentially obscuring further peak analysis around 4.7 - 
5 ppm), a second sample was produced and buffer-exchanged via dialysis into 1 × 
PBS from the original Tris/NaCl buffer. A second sample was produced rather 
than buffer exchanging the existing sample due to the presence of dimer formation 
over time (data not shown). A sample of around twice the concentration was used 
with lowered pH from 8 to 7.5 (to sharpen the amide-proton signals by reducing 
their exchange rate with solvent water). The NMR spectrum of this sample (figure 
4.26) shows some potential contamination of Tris (indicated by the peak around 
4.7 ppm, likely from around 2 mM of Tris remaining) indicating insufficient buffer 
exchange, however this resulted in no significant issues with interpretation of the 
rest of the spectra. Some α-H signals can be seen between 4.8 and 5.5 ppm, which 
are indicative of the presence of α-protons in a β-sheet in the protein. Narrower 
peaks were also generated by the slight lowering of the pH from 8 to 7.5 due to a 





Figure 4.26. 1D 1H-NMR of EGF5-6 in 1 × PBS: 280 μM EGF5-6 in 1 × PBS pH 7.5 (with 40 
mM NaCl) + 10% D2O (and ~2 mM Tris contaminant). Inlaid in the figure is a zoom-in of the 5 – 
5.5 ppm region of the spectra. The experiment acquired 64 scans at 25 ºC. Figure adapted from 
(Galloway, 2016). 
 
Next, the effect of temperature on the 1D NMR spectra of EGF5-6 in 1 × PBS 
was investigated. A sample was dialyzed into an acidic pH (pH 6.5) PBS buffer to 
further improve spectra quality due to lower proton exchange in the amide region 
further. However, an initial sample that was prepared in 1 × PBS without NaCl (to 
evaluate the effect of removing salt on the sample) ended up precipitating out of 
solution when analysed at 37 ºC. Due to this it was decided to keep the salt 
concentration at 80 mM. The results in figure 4.27 show that as the temperature 
increased from 25 ºC, through 32 ºC to 37 ºC, further peak separation is revealed. 
This extra resolution is particularly evident around the region of 9.2 – 9.7 ppm, in 
addition to the peak/s at ~8.4 ppm. The increased sharpness of the spectra is 




Figure 4.27. 1D 1H-NMR of EGF5-6 Across Varying Temperatures: The 230 μM sample of 
EGF5-6 (buffer: 1 × PBS pH 6.5, 80 mM NaCl, 2 mM Tris and 10% D2O) analysed at 25 ºC 
(purple), 32 ºC (green), and 37 ºC (maroon). 
 
The proton NMR spectrum of a sample of refolded EGF3-6 is shown in figure 
4.28. Additional very strong and sharp peaks such as those seen at ~8.5 ppm and 0 
ppm were likely due to the presence of protease inhibitors added to the sample for 
when it was kept in storage at 4 C. As in the spectrum of EGF5-6, good peak 
dispersion was seen, including in the backbone amide region. Evidence of β-sheet 
in the protein was likewise seen at around 5 ppm. It seems likely that most of the 
EGF3-6 sample was folded but the quality of this spectrum is not as high as that 
of EGF5-6.  Before more NMR-based analysis of EGF3-6 was able to be carried 
out, the sample was used for other assays. Instead of producing more, the choice 




Figure 4.28. 1D 1H-NMR of EGF3-6 in 1 × PBS: 171.5 μM sample of EGF3-6 (in 1 × PBS, pH 
8 + 10% D2O + Roche protease inhibitor cocktail) produced in the pET45b+ plasmid was 
analysed on an 800 MHz NMR spectrometer. Inlaid in the figure is the zoom-in of the amide 
region. Experiment carried out at 25 ºC with 64 scans taken. As expected, no tryptophan peak was 
seen as the protein does not contain any W residues.  
 
Next, 1D-NMR analysis was performed on the refolded EGF7-10 sample (figure 
4.29). As was the case with EGF3-6, additional strong peaks at ~8.2 ppm and 0 
ppm were likely due to the presence of protease inhibitors added to the sample for 
when it was kept in storage at 4 C. Some contaminating glycerol is present at 3.8 
ppm, likely from the concentrator tubes used in protein sample preparation. The 
presence of well-dispersed α-H signals in the backbone region indicated the 
presence of β-sheet as expected. This, along with the overall sharp, clear dispersion 
of peaks in both the carbon and amide region demonstrates that most of the 




Figure 4.29. 1D 1H-NMR of EGF7-10 in 1 × PBS: 129 μM (in 1 × PBS, pH 8 + 10% D2O + 
Roche protease inhibitor cocktail) produced in the pET45b+ plasmid was analysed on an 800 MHz 
NMR spectrometer. Inlaid in the figure is the zoom-in of the backbone Hα region. 
 
Next, the effect of both temperature and pH were investigated on a new sample of 
refolded EGF7-10 that had been produced. The best spectrum was obtained at 
310 K, with mild improvement on peak sharpness, particularly at around 4.25 ppm 
(figure 4.30). A reduction of pH had a more significant effect on resolution, with 
the sample in pH 4.5 showing better signal dispersion in the backbone Hα-region 




Figure 4.30. 1D 1H-NMR of EGF7-10 Across Varying Temperatures: The 123.7 μM sample of 
EGF7-10 (buffer: 1 × PBS pH 7.5, 80 mM NaCl, and 10% D2O) analysed at 15 ºC (violet), 25 ºC 







Figure 4.31. 1D 1H-NMR of EGF7-10 pH Screen: The 123.7 μM EGF7-10 sample at pH7.5 was 
in 1 × PBS pH 7.5, 80 mM NaCl, and 10% D2O (green spectra). The 111 μM EGF7-10 sample at 
pH4.5 was in 1 × PBS (pH 4.5 via adjustment with acetic acid), 80 mM NaCl, and 10% D2O (blue 
spectra). Experiment carried out at 25 ºC for 64 scans. 
 
2D NMR experiments on the non-isotopically labelled EGF5-6 refolded protein 
was decided upon to provide further evidence for protein folding, but to inform 
on prospective future experiments with isotopically-labelled sample for further 
structural studies. A natural abundance 15N-1H heteronuclear single quantum 
coherence (HSQC) NMR spectrum was obtained using the EGF5-6 sample 
prepared in PBS. The results (figure 4.32) gave relatively limited information, 
however the dearth of overlapping peaks indicated that the sample had not 
aggregated over the ~40-hour period of the experiment. With respect to evidence 
for folding, there are well dispersed peaks as would be expected that also 
corroborate the evidence for folding from the 1D experiments. Increasing the 
temperature further increased the sharpness of the signals, though the sample was 
analysed for less time so fewer signals were observed.  
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Figure 4.32. Natural Abundance 15N-1H HSQC NMR Spectrum of EGF5-6: Signals were 
from a 280 μM sample (in 1 × PBS pH 7.5, 40 mM NaCl, 2 mM Tris and 10% D2O) analysed at 25 
ºC over 40-hours.  
 
A 1H-1H nuclear Overhauser effect spectroscopy (NOESY) experiment was 
performed to reveal through-space proximities between protons as another way to 
assess folding (figure 4.33). A well-populated NOESY spectrum was obtained for 
the EGF5-6 sample with good dispersion. Cross-peaks between, for example, α-
protons and NH protons and between aromatic and methyl protons are definitive 
evidence for a folded proton. The lack of clumps of cross-peaks in this spectrum 
suggests there is little unfolded material in the sample. Overall, the results for 
EGF5-6 were very promising and suggested that it would be worthwhile to 





Figure 4.33. 1H-1H NOESY NMR Spectrum of EGF5-6: The 280 μM sample (in 1 × PBS pH 
7.5, 2 mM Tris, 40 mM NaCl, and 10% D2O) was exposed to a temperature of 25 ºC during the 
experiment. Key regions of proton interactions are highlighted in the figure. Figure adapted from 
(Galloway, 2016). 
 
HSQC and NOESY experiments were initially carried out on an unlabelled sample 
of EGF7-10, however the quality of the spectra was poor (data not shown for 
HSQC experiments; see figure 4.34 for the NOESY). This may be due to the 
protein being having an elongated rod-like shape (i.e. a large Stokes radius) leading 
to slow molecular tumbling. Moreover, low sample concentration resulting from 
sample loss during preparative steps and proton exchange with the H2O in the 
buffer. While some cross-peaks in the NOESY spectrum suggested protein folding 
(such as those in the long-range methyl region), they were relatively weak, 
especially contrasted to equivalent peaks seen for the EGF5-6 spectrum in figure 
4.33. To reduce the size of EGF7-10, attempts were made to cleave the 
polyhistidine tag from the N-terminus of the protein via EK (which comprised 2.2 
kDa of the full size of the recombinant protein, or roughly 9.1% of the total amino 
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acid sequence). Despite varying enzyme concentration, time of EK exposure and 
temperature of the reaction, this was ultimately unsuccessful (data not shown). 
Instead of re-cloning the EGF7-10 gene into a pProExHTA expression system 
(containing a TEV cleavage site for removal of the polyhistidine tag), it was 
ultimately decided to move to a Pichia-based expression system where refolding 
would not be necessary. 
 
 
Figure 4.34. 1H-1H NOESY NMR Spectrum of EGF7-10: The 123.7 μM EGF7-10 sample at 
pH7.5 was in 1 × PBS pH 7.5, 80 mM NaCl, and 10% D2O was exposed to a temperature of 25 ºC 
during the experiment. Poor signal intensity is revealed for long-range methyl-associated protons, 
aromatic proton interactions and the interaction between the backbone amide protons and α-H 
through space.  
 
It was attempted to produce EGF5-6 from E. coli grown in minimal media en route 
to preparing an isotopically labeled sample. This was unsuccessful likely due to the 
glycerol stock being unreliable. Rather than perform a fresh transformation of 
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BL21 (DE3) E. coli, it was decided to move exclusively into a Pichia system to 
produce proteins containing the 5th and 6th EGF-like domain of PfRipr. 
 
 
4.5 Binding Studies between PfRipr Constructs and PfRh5 
 
4.5.1 Methods for PfRipr – PfRh5 Binding Studies 
 
4.5.1.1 ELISA Assays 
 
Flat-bottomed 96-well plates (Maxisorp, Nunc) were coated with a 1:2 serial 
dilution starting with 200 μl of 64 μg/ml recombinant PfRipr protein made up in 
PBS (across eight wells and set up in triplicate). Controls in triplicate were also set 
up including a PBS-only negative control, PBS-only for exposure to antibodies 
only (negative control), protein-only positive controls, and a 1:2 dilution series of 
100 μl BSG in PBS at 8 mg/ml (positive control). Plates were incubated overnight 
at 4 C. 
 
Following incubation, plates were washed 3 x with PBS-T, blocked with 200 μl of 
5% w/v dry skimmed milk powder in PBS-T for at least one-hour at room 
temperature. After another wash step, 100 μl of 5 μg/ml PfRh5 (prepared in 1 × 
PBS) was added to all appropriate wells for an incubation period of two-hours at 
room temperature. Plates were then washed and 50 μl of primary antibody added 
(a 1:10 000 dilution of mouse anti-PfRh5 antibody made up in blocking solution; 
for the positive control only samples, rabbit anti-PfRipr, rabbit anti-BSG, or 
mouse anti-pentahistidine antibodies were used at a 1:2000 dilution).  
 
After a 90-minute incubation and subsequent washing, 50 μl of the secondary 
antibody was added (either anti-mouse HRP or anti-rabbit HRP at a 1:2000 
dilution). Plates were further incubated for one-hour and washed thrice with PBS-
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T then twice with HTPBS. 100 μl of equal parts TMC peroxidase substrate and 
peroxidase substrate solution B (Sigma Aldrich) were added to each well for a one- 
to ten-minute development in the dark. The reaction was quenched with 50 μl of 
phosphoric acid (from stock: 17 ml of pure H3PO4 in 250 ml pure H2O). Plates 




4.5.1.2 Coimmunoprecipitation Assays 
 
For the co-immunoprecipitation (coIP) assay between PfRipr proteins and PfRh5, 
two methods were employed. The first method involved the use of 10 μl of anti-
Flag beads (donated by Dr. Lin Chen at the Walter and Eliza Hall Institute) per 
protein sample to be used. 10 μg of each protein was added to 35 μl of PBS, 
mixed, then an aliquot of 5 μl of this was kept to run on a gel as the input sample. 
The protein samples were added to anti-Flag beads and mixed overnight at 4 C. 
After incubation, samples were centrifuged at 500 × g for 30-seconds at 4 C, 
collecting the unbound fraction to run on a gel. Three washes with 1 ml of PBS 
were carried out, followed by two elution steps using 20 μl of elution buffer 
(containing Flag peptide), further centrifugation, followed by loading 20 μl of the 
elution fractions onto a gel. 
 
The second method consisted of the following steps: At 4 C, 1 μg of each protein 
was mixed together and incubated overnight. Control samples were to receive no 
primary antibody in order to evaluate any non-specific association of the protein 
with protein G beads. Rabbit polyclonal anti-PfRh5 antibody in a 3:1 ratio was 
added and incubated for two-hours at room temperature. An aliquot of 25 μl of 
protein G beads from Qiagen (after washing them in PBS) were added and mixed 
at for two-hours at 4 C. Samples were centrifuged at 1500 × g for one-minute, 
then spun at 10 000 × g for ten-seconds, collecting unbound fraction. 3 - 5 x 200 
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μl PBS washes were carried out (keeping the wash fractions). Next, 25 μl of 1 x 
RSB was added, samples were boiled for two-minutes, then centrifuged at 10 000 
× g for one-minute. An SDS-PAGE and a Western blot were carried out as per 
the general methods outlined in section 2.2.1, using 100 ng of PfRh5 and PfRipr as 
standards, probing with mouse anti-pentahistidine antibodies. Where magnetic 
beads were used, they were Dynabeads (ThermoFisher) used with a magnetic stand 
(FastGene MagnaStand 1.5) donated by Dr. Anthony Hodder at the Walter and 
Eliza Hall Institute. 
 
 
4.5.1.3 Gel Filtration Binding Assays 
 
A sample consisting of 50 - 100 μg of each protein was analysed both individually 
and mixed together (for either two-hours at room temperature or overnight in a 
cold room) then loaded onto on a calibrated Superdex 200 10/300 GL SEC 
column with the assistance of Dr. Lin Chen. The contents of each collected 
fraction were analysed by SDS-PAGE and Western blot using the methods 
outlined in section 2.8. 
 
 
4.5.2 Results for PfRipr – PfRh5 Binding Studies 
 
4.5.2.1 ELISA Assays 
 
Several attempts to optimise the ELISA assay for protein-protein binding were 
made using a range of protein concentrations, wash conditions, antibody dilutions 
and incubation times (data from optimization phases not shown). Eventually, 
promising results were obtained by using the method described in section 3.5.1.1 
(see figure 4.35). It should be noted that EGF3-10 was not used in the assay as it 
had not been developed successfully at the time these experiments were 
performed. None of the EGF-rich PfRipr proteins tested gives a dose response 
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curve (like that seen with the BSG then Rh5 positive control), except EGFs 5-6 
and 3-6, appearing to bind with a similar response to each other. The binding here 
appears to be around one-fifth of the intensity seen in the positive control. 
However, the control PfRh5 samples that were exposed to PBS instead of PfRipr 
then had regular antibody detection gave an average signal of 0.378 +/- a standard 
deviation of 0.229; potentially quite high but with a wide deviation. Due to this 
high background and its potential implications for the results shown, it was 
decided to repeat the assay.  
 
 
Figure 4.35. ELISA Binding Assay of PfRh5 and PfRipr EGF-Rich Proteins: A reference 
positive binding result is shown in the “BSG then Rh5” panel, in which a concentration series of 
BSG was exposed to 100 μl of 5 μg/ml PfRh5. The error bars represent the standard error. All 
results have been adjusted for the background noise of the negative controls. Positive controls for 
each protein gave strong absorbance readings (~1.5) at 450 nm, whilst the anti-PfRh5 antibodies 
did not appear to cross-react with PfRipr control samples as the signal remained in the background 
noise. However, these antibodies gave rise to an absorbance signal of 0.518 within the BSG control 
well likely due to using too much protein at 8 μg/ml rather than 1 μg/ml (data not shown). All 
EGF-rich PfRipr proteins used in the assay were from the soluble material produced in section 3.2, 
rather than refolded material. 
 
 145 
Unfortunately, this high background issue persisted despite attempts to optimize 
the assay. These included the use of a variety of blocking agents (BSA, 
SuperBlock™ blocking reagent and gelatin mix), temperatures (room temperature, 
cold room, 30 and 37 C), and blocking time (6-, 24- and 48-hours). Except for 
EGF3-4 (which perpetually aggregated out of solution), all proteins appeared 
intact when analysed via SDS-PAGE under R and NR conditions, and via mass 
spectrometry (data not shown); whenever any proteins appeared degraded, a fresh 
batch was prepared. Once refolded proteins had been produced, they were used in 
numerous repeats of the assay, albeit still with negative results (i.e. a lack of 
binding that was originally seen) aside from the positive control of PfRh5 binding 
BSG. This included attempts whereby the plate was coated with PfRh5 and then 
PfRipr EGF-rich proteins were titrated in with detection using rabbit polyclonal 
anti-PfRipr antibodies (this resulted in a high background). Nonetheless, the 
possibility remained that PfRipr constructs (EGF 3-6 and EGF 5-6), i.e. those 
containing the 5th and 6th EGF-like domains, bound to PfRh5. To assess their 
possibility further, alternative binding experiments were attempted. 
 
 
4.5.2.2 Coimmunoprecipitation Assays  
 
The initial coIP assay for the PfRh5:EGF5-6 interaction utilized controls of Flag-
tagged PfRh5, refolded EGF5-6 and a mix of PfRh5 and EGF5-6 with anti-Flag 
beads (figure 4.36). Here, each control protein is shown at their correct relative 
sizes in each input sample. The positive control Flag-tagged PfRh5 protein 
however, failed to bind to the anti-Flag bead resin (rendering the experiment itself 
useless), with what appears to be the entirety of the protein found in the unbound 
fraction and none in the eluted fraction. This was postulated to be potentially due 
to proteolytic degradation of PfRh5 (some faint bands below the PfRh5 input 




Figure 4.36. Initial CoIP Test Between PfRh5 and EGF5-6: 10 μg of each protein (3.3 μl of 
Flag-tagged PfRh5 and 7.57 μl of EGF5-6) in 35 μl of 1 × PBS (pH 8) was used for the assay, with 
5 μl being used for the input (I) samples on the SDS-PAGE. The sample binding was carried out 
over three-hours at room temperature on a rotary mixer. As expected, the non-Flag-tagged EGF5-6 
was only found in the unbound fraction (U). Other abbreviations: E- eluted fraction. 
 
In an attempt to rectify this, a pure sample of PfRh5 that had previously been 
verified to contain the Flag-tag (via Western blot) was donated by Dr. Lin Chen. 
The coIP experiment (figure 4.37) was carried out with overnight incubations in an 
attempt to ensure a sufficient amount of time was allowed for the binding of 
PfRh5 to the resin. In this experiment, PfRh5 was not found in the unbound 
fraction but nor was it seen in the eluted fraction. This suggested the PfRh5 might 
have been removed during the wash steps, yet upon analysis of wash fractions by 
SDS-PAGE, no PfRh5 was detected (results not shown). This may have been due 
to the large volume of the wash fraction and the consequent limits to detectability 
of PfRh5. The experiment was therefore repeated but using only one-tenth (0.1 
ml) of the previously used volume of PBS for the wash (figure 4.38). Despite an 
overnight incubation with mixing at 4 C, much of the Flag-tagged PfRh5 
remained unbound, while the majority of the protein was found in the first wash 
fraction. These results suggest that despite nominally having a Flag-tag, our PfRh5 
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protein produced did not bind to the resin used. Therefore, this coIP method was 
unsuitable for further binding studies between PfRh5 and PfRipr proteins. 
 
 
Figure 4.37. Second CoIP Test Between PfRh5 and EGF5-6: Sample binding was carried out 
overnight at 4 C. The fractions analysed on the SDS-PAGE gel suggest that the PfRh5 sample has 
been lost along the way, possibly during the wash steps. 
 
 
Figure 4.38. CoIP Optimization for PfRh5: This experiment was carried out to troubleshoot and 
optimize conditions for the anti-Flag beads to capture the Flag-tagged PfRh5 protein (shown with a 
small amount of dimer present in the input (I) fraction. Each wash step was carried out with 0.1 ml 
of PBS. The first elution (E1) utilized the Flag peptide, the second (E2) utilized 0.25 M glycine pH 
2.6 + 0.75 M Tris pH 9.5. 
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It was decided to try an alternative coIP strategy, using rabbit polyclonal anti-
PfRh5 antibodies (donated by Dr. Lin Chen) to capture the PfRh5, and protein G 
for antibody capture on the resin. However, whilst assessing the experimental 
system for any potential flaws, it was revealed that the PfRh5 binds to the protein 
G beads non-specifically (figure 4.39, lane 3). This is hence an unusable assay with 
the prospect of false positive results. To try and get around this problem, a 
method of pre-clearing the PfRh5 sample was attempted, whereby the protein and 
protein G beads would be co-incubated then centrifuged at high speed, keeping 
the supernatant with PfRh5 for antibody capture followed by a second incubation 
with the beads. 
 
 
Figure 4.39. Protein G Test for PfRh5 CoIP: This Western blot was developed using a mouse 
anti-PfRh5 antibody and a goat anti-mouse HRP antibody, both at a dilution of 1:1000. Lane 1 
shows marks corresponding to the associated MW markers. Lane 2 is a positive control for PfRh5. 
Lane 3 corresponds to a sample of PfRh5 incubated with protein G. Lane 4 corresponds to the 
rabbit polyclonal anti-PfRh5 antibodies incubated with protein G. Lane 5 shows the PfRh5 + the 
anti-Rh5 antibody. Development time was one-second. 
 
To limit the potential of pipetting error, magnetic Dynabeads were used. The 
experiment from figure 4.39 was repeated, but this time with pre-clearing that 
sample as described above. The results in figure 4.40 show that unfortunately the 
PfRh5 protein still bound to the bead matrix. Due to this remaining a problem 
with respect to protein-protein interaction studies, it was decided to attempt to 
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study binding via FRET, BN-PAGE and/or SEC. To note, the positive control 
for the FRET assay was unable to be established and so this method was 
abandoned. Further, the BN-PAGE data were inconclusive; therefore, neither of 
the data for these experiments are sown in this thesis.  
 
 
Figure 4.40. Pre-Cleared PfRh5 Test for CoIP: This Western blot was developed using a mouse 
anti-PfRh5 antibody and a goat anti-mouse HRP antibody, both at a dilution of 1:1000. 
Development time was 20-seconds. 
 
 
4.5.2.3 Gel Filtration Binding Assays 
 
SEC was employed to look for evidence of a complex being formed between 
either EGF3-6 or EGF3-10 and PfRh5. This experiment would be able to at least 
provide a relatively conclusive answer for if a reasonably strong complex is formed 
between the EGF-rich region of PfRipr and PfRh5. First, EGF3-6 was loaded 
onto a calibrated Superdex 200 10/300 GL column followed by PfRh5 to establish 
the normal peak placement of each protein in the gel filtration elution profiles 
(figure 4.41). Following a 2.5-hour incubation at room temperature, the PfRh5 + 
EGF3-6 mix was analysed via SEC (figure 4.42). No significant peak shift was seen 




Figure 4.41. SEC of EGF3-6 and PfRh5 on an S200 10/300 GL Column: A. The SEC 
chromatogram of 100 μg of EGF3-6. A small shoulder peak is seen at 14.62 ml which corresponds 
to a small amount of dimer, whilst the major peak at 15.80 ml is the monomeric protein. B. The 
SEC chromatogram of 18.5 μg of PfRh5. The major peak at 16.75 ml is where the monomeric 




Figure 4.42. SEC of EGF3-6 + PfRh5 on an S200 10/300 GL Column: 50 μg of EGF3-6 was 
mixed with 18.5 μg of PfRh5 and injected onto the gel filtration column.  
 
To assess if the time of incubation made any difference, a protein mixture was 
prepared and incubated overnight. A different gel filtration column was used and, 
each individual protein was analysed as before (figure 4.43). Again however, once 
the mix of proteins were applied to the gel filtration column, no evidence of a tight 




Figure 4.43. SEC of EGF3-6 and PfRh5 on an S75 10/300 GL Column: A. The SEC 
chromatogram of 100 μg of EGF3-6. Two small shoulder peaks are seen at 9.31 and 8.33 ml which 
corresponds to small amount of dimer and trimer (respectively), whilst the major peak at 10.83 ml 
is the monomeric protein. B. The SEC chromatogram of 18.5 μg of PfRh5. The major peak at 




Figure 4.44. SEC of EGF3-6 + PfRh5 on an S200 10/300 GL Column: 50 μg of EGF3-6 was 
mixed with 18.5 μg of PfRh5 and injected onto the gel filtration column.  
 
A sample of EGF3-10 was used to assess if the entire backend of PfRipr could 
form a tight complex with PfRh5. If so, this would suggest that the binding sites 
for PfRh5 might lie outside EGF modules 5 and 6. Each protein was first passed 
individually over the SEC column (figure 4.45), then they were mixed together, 
incubated for two-hours at room temperature and passed through the column 




Figure 4.45. SEC of EGF3-10 and PfRh5: A. Molecular weights standards shown (in kDa). B. 
16.8 μg of EGF3-10 with the monomeric protein eluting at 14.65 ml as expected. Total sample 
injection volume was 100 μl. B. 32 μg of PfRh5 with the monomeric fraction eluting at 18.99 ml 
and dimer around 16.07 ml (both as approximately expected). Total sample injection volume was 
100 μl. Column used was an analytical S200 10/300. 
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Figure 4.46. SEC of EGF3-10 + PfRh5: 16.8 μg of EGF3-6 was mixed with 32 μg of PfRh5 and 
injected onto the gel filtration column. Total sample injection volume was 200 μl. Column used was 
an analytical S200 10/300. 
 
Based on the chromatogram in figure 4.46, no significant evidence was obtained in 
support of a tight complex between EGF3-10 and PfRh5. However, the twofold 
increase in mAU of the shoulder peak at around 13 ml (corresponding to a 
molecular weight of approximately 150 kDa) and its increased prominence 
compared to the shoulder for EGF3-10 in figure 4.45 B, motivated an analysis of 
the eluted fractions by SDS-PAGE and Western blot (figure 4.47). It was hoped 
that fractions 25 and 26 would contain both partners; however, no bands could be 
detected. Whilst there is a band around 100 kDa for the anti-PfRipr and anti-
pentahistidine detected samples in fraction 26, the same is not the case when 
detecting with anti-PfRh5 antibodies. These results therefore do not support 




Figure 4.47. SDS-PAGE and Western Blot Analysis of EGF3-10 + PfRh5 SEC Fractions: A. 
Coomassie-stained gel of fractions 25 – 38 analysed with 1 x NRSB. B. Anti-PfRipr antibodies used 
for detection. C. Anti-pentahistidine antibodies used for detection. D. Anti-PfRh5 antibodies used 
for detection. Western blots in B – D all developed within two-seconds.   
 
 
4.6 PfRh5 and BSG Antibody Screens 
 
4.6.2 Methods for PfRh5 and BSG Antibody Screens 
 
For initial antibody screening, 100 μl of 0.5 μg/ml PfRh5 or BSG was prepared in 
PBS pH 7.5 and added to 96-well flat-bottomed plates (Maxisorp; Nunc) for 
overnight incubation at 4 C. Plates were washed with PBS-T and then 200 μl of 
5% w/v skim milk powder blocking solution made up in PBS-T was added, 
followed by incubation for 2.5-hours at room temperature, with mixing. Plates 
were then washed with 100 μl of each antibody hybridoma supernatants (supplied 
by Jenny Thompson (Walter and Eliza Hall Institute) for the anti-PfRh5 
supernatants and from Dr. Anthony Hodder (Walter and Eliza Hall Institution) for 
the anti-BSG supernatants) were applied and incubated for one-hour at room 
temperature (the positive control polyclonal antibody was prepared in a 1: 10 000 
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blocking solution). Plates were washed, then incubated for two-hours at room 
temperature with 50 μl of a 1:2000 dilution of anti-mouse HRP. Development of 
the signals and analysis were carried out according to section 3.2.2, except 100 μl 
of acid was used for quenching. The BSG used was donated by Dr. Lin Chen. The 
PfRh5 used was from the previously described baculovirus batch production or an 
E. coli-produced version (Gennova) which was originally used to vaccinate the 
mice. 
 
Protein G purification of antibodies was carried out in sterile conditions. Aliquots 
of 1.0 ml from each antibody hybridoma supernatant was mixed with 60 μl of a 
50% protein G slurry (Qiagen) overnight at 4 C. The sample was centrifuged at 
1200 × g for one-minute, supernatant decanted, then two washes with cold PBS 
were carried out. After decanting the PBS, 45 μl of elution buffer was added (0.5 
M NaCl, 0.1 M glycine, pH 2.6), mixed and centrifuged to recover the supernatant, 
which was added to tubes containing 5 μl of 1 M Tris pH 9.5 for neutralization. 
Samples were analysed via NanoDrop using a solution of 10% neutralization 
buffer and 90% glycine elution buffer. 
 
For the G protein purified antibody screen, the same protocol as above was 
carried out but using the antibodies in a 1:100, 1:1000 and 1:10 000 dilution 
prepared in blocking solution. 
 
The BSG inhibitory antibody ELISA screen was set up by coating 96-well flat-
bottomed plates with 100 μl of 1 μg/ml PfRh5 made up in 1 × PBS, with an 
overnight incubation at 4 C. A 1:2 dilution series of BSG was prepared across the 
lanes of a regular 96-well plate with a starting concentration of 10 μg/ml, whilst 
down each row various antibody dilutions were screened including 1:50, 1:100, 
1:500, 1:1000, 1:2000, and 1:4000, in a final volume of 100 μl. The antibody + 
BSG mix was incubated at room temperature for two-hours. The rest of the 
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ELISA method was carried out as described above. The PfRh5 inhibitory mAb 
screen was carried out as described above but using EGF3-10 to coat the plate. 
 
 
4.6.2 Results for PfRh5 and BSG Antibody Screens 
 
The development of mAbs against PfRh5 and BSG was of interest for the 
identification of inhibitory mAbs acting against the receptor ligand interaction, in 
addition to the development of tools to be potentially used for crystal trials and 
various assays. After the generation of the hybridoma supernatants from PfRh5-
vaccinated mice, screening for reactivity to PfRh5 was carried out (figure 4.48). 
The screen was carried out to compare results from the initial ELISA performed 
by Jenny Thompson using an E. coli-produced PfRh5, and the PfRh5 produced 
from baculovirus batches described in section 4.2. Relatively (taking into account 
differential maximum absorbance intensity), the results matched overall for the 
supernatants that gave the highest signals with the exception of sample 7E1. All 
samples in series 2 that showed an absorbance of over 3.5 were selected to be 
developed into mAbs. Several ELISA assays were set up to screen the supernatants 
for their ability to inhibit the PfRh5 – BSG interaction (results not shown); 
however, a successful assay remained elusive due to a perpetual problem of the 
control media giving high background noise and the positive control of BSG-





Figure 4.48. Initial Anti-PfRh5 Antibody Screen ELISA: Series 1- results of the antibody screen 
against E. coli-produced PfRh5 tested at the WEHI Antibody screening facility at Bundoora. Series 
2- results from the antibody screen against the baculovirus-produced PfRh5. Abbreviations used: 
CM- control media (a negative control), FS 1:3200- fusion supernatant in a dilution of 1:3200 (a 
positive control).  
 
After confirming the reactivity of hybridoma supernatants from BSG-vaccinated 
mice and concentrating the antibodies via protein G to around 0.06 mg/ml (results 
not shown), various dilutions of each antibody was tested for their reactivity to 
BSG (figure 4.49). Most mAbs were highly reactive, except for 4B5, 4C7, 4D3, 
6E4, 5D11, 5E3, 6A5, 6B4, 4E4, 6F6, 7A3, and 8D12. Given that mAbs 8H3 and 
5F7 showed the strongest reactivity against BSG, these were selected for follow-up 













































































































Figure 4.49. Anti-Basigin Antibody Reactivity ELISA: Results from the 1:10 000 dilution are 
not shown for both space consideration and the fact that this dilution reduced signal to negative 
control background level. Negative controls using 50 μl of 0.5 μg/ml BSG (detected with anti-
mouse HRP) and PBS-only produced signals at 0.049 and 0.058, respectively. Yellow stars highlight 
the most effective antibodies. 
 
A titration of BSG mixed with different dilutions of the F57 and 8H3 mAbs was 
applied to a PfRh5-coated ELISA plate to assess the effect of both BSG and mAb 
concentration (figure 4.50). Interestingly, as the concentration of BSG diminished, 
an increased signal was to be detected for both mAbs regardless of their dilution. 
This initially was suggestive that the mAbs were binding to the pFRh5 indirectly, 
however the controls in lanes 6 and 7 of figure 4.50 C do not reflect this. Clearly 
the experiment required repeating, however time and prioritization of other phases 
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Figure 4.50. ELISA Screen of Anti-Basigin mAbs 5F7 and 8H3: A. Various concentrations of 
BSG that had been pre-incubated with various dilutions of the 5F7 anti-BSG mAb applied to 1 
μg/ml of PfRh5 (then detected with anti-mouse HRP). B. Various concentrations of BSG that had 
been pre-incubated with various dilutions of the 8H3 anti- BSG mAb applied to 1 μg/ml of PfRh5 
(then detected with anti-mouse HRP). C. Controls used. Each were detected with HRP-conjugated 
antibodies. Development time of lanes 1 and 2 took around 90-seconds before quenching (the rest 
of the controls were quenched after 30-minutes). Each absorbance reading given is the average of a 
triplicate. Abbreviations used: BSG- basigin, Ab- antibody, CM-control media. 
 
 
4.7 MMV Malaria Box Compound Screen 
 
4.7.2 MMV Malaria Box Compound Screen Methods 
 
Approximately 1 mg of the PfRh5 produced in section 3.2 was used for screening 
against plates of the Medicines for Medicines for Malaria Venture (MMV) Box 
Compound Library (see https://www.ebi.ac.uk/chemblntd and Spangenberg, et al., 
2013) with assistance from A/Prof. Naomi Morrissette and Dr. Isabelle Lucet. A 
1:100 stock dilution of each drug compound was used along with SYPRO Orange 
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dye (ThermoFisher) according to the general methods outlined in Lucet, et al., 
2014. 
 
4.7.3 Results for the MMV Malaria Box Compound Screen 
 
PfRh5 was screened against the MMV box in a TSA to look for any compounds 
that appeared to bind to the protein. Whilst many the compounds showed no 
evidence of this, or appeared to destabilise the protein, four potential hits were 
discovered (figure 4.51) after repeating their screening after an initial TSA was 
carried out. Originally the plan was to repeat these experiments with other dyes in 
addition to screening compounds produced by Dr. Brad Sleebs (of the Walter and 
Eliza Hall Institute); however, time and prioritization of other phases of the overall 








Figure 4.51. TSA Screen of PfRh5 and MMV Box Compounds: All screens show the chemical 
structure of each compound tested. A. Screen against compound MMV665827 (from MMV box B, 
well G10). When this compound was screened against P. falciparum parasites, the EC50 was 119 nM. 
36 and 37 (red/orange) are the DMSO controls, 6 and 46 (blue) are repeats, 14 and 54 (brown) are 
1:10 dilution repeats. B. Screen against MMV665807 (from MMV box B, well C11). 36 and 37 (red) 
are the DMSO controls, 17 and 57 (blue) are repeats, 25 (purple) is the 1:10 dilution. C. Screen 
against compound MMV000972 (from MMV box C, well E6). 36 and 37 (orange/red) are the 
DMSO controls, 21 and 61 (blue) are the repeats, 29 (brown) is the 1:10 dilution. D. Screen against 
compound MMV000911 (from MMV box C, well D7). 36 and 37 (orange/red) are the DMSO 







4.8 Discussion and Conclusions 
 
Due to the necessity of PfRipr in the PAIN-complex and the dearth of 
information about this protein in contrast to the binding partners, it was important 
to develop tools for exploring this molecule. These tools first and foremost took 
the form of recombinantly-produced truncations of the full-length protein, with a 
focus predominantly on the EGF-like domains, given the role these domains 
commonly play in protein – protein interactions (Lin, et al., 2001). The decision to 
concentrate on producing truncations of PfRipr was twofold; first, it might allow 
identification of a binding region for PfRh5. Second, their recombinant production 
would likely be far easier than trying to produce the large ~123 kDa full-length 
PfRipr protein, complete with its 87 cysteines that mostly form disulfide bonds. To 
this end, a set of seven EGF-rich proteins were produced in a soluble form in E. 
coli. The author’s initial suggestion of utilizing an N-terminal polyhistidine tag, a 
maltose transporter subunit (MalE), maltose-binding protein (MBP) then a 
tobacco etch virus (TEV) enzymatic site before the N-terminal of each protein 
(MalE for transport to the periplasm in the E. coli, MBP for enhanced solubility 
and TEV for easy tag cleavage (Rosano & Ceccarelli, 2014)) was rebuffed in favor 
of a simpler design of each protein, whereby only the polyhistidine tag was kept. 
Fortunately, the simpler strategy worked for production of usable levels of 
recombinant protein. Initial purification was straightforward due to the presence 
of the N-terminal polyhistidine tag that allowed Ni-NTA affinity chromatography.  
 
Four non-EGF truncated regions of PfRipr were also developed, including the 
middle section of the protein between the second and third EGF-like domains, of 
interest due to the yet unknown enzymatic cleavage point. Unfortunately, each of 
the non-EGF constructs demonstrated the need to be refolded, which at the time 
became a lower priority due to the decision to focus more exclusively on the EGF-
rich regions. Returning to the EGF-rich regions, a standard purification protocol 
was developed to separate the multimers that were commonly seen after post Ni-
affinity purification. This involved SEC, which typically resulted in a batch of pure, 
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monomeric protein, apart from EGF3-4, which over a short space of time, 
aggregated to make it unusable. As expected, each EGF-rich protein migrated 
faster on SDS-PAGE gels under NR conditions than R conditions, indicative of 
disulfide bonds being present which are one of the defining features of EGF 
domains.  
 
The decision to move to an exploration of refolding some of the EGF-rich 
proteins was made due to the presence of highly concentrated and relatively pure 
protein in the pellet fraction (where insoluble inclusion bodies are found) when 
IPTG-induced at a high temperature, the protective effect against proteases when 
producing proteins as inclusion bodies (a significant amount of proteolytic 
degradation was seen in some samples previously), and due to some constructs 
having mixed batch to batch variation. Extensive refolding trials were performed 
to isolate the key conditions required to produce quality, monomeric and folded 
protein. Figures 4.11 and 4.12 show that over the three days of refolding, 
multimers began collapsing into mostly monomeric protein. To exploit differences 
in surface charge of monomer and resulting multimers, ion exchange 
chromatography was utilized (with SEC used to remove any contaminating dimer).  
 
Once the proteins were refolded and purified, it was imperative to assess that they 
were the correct MW, had evidence of folding, and evidence of their predicted 
secondary structure (to assist in garnering confidence that misfolded protein had 
not been produced). Ideally, an activity assay would be carried out; however, since 
the PfRipr EGF-like regions had no evidence for enzymatic activity, nor a known 
binding partner, this was unable to be done. Therefore, following mass 
spectrometry, CD was utilized to reveal an elliptical signature of EGFs 5-6 and 3-6 
highly similar to another β-sheet containing P. falciparum protein comprised also of 
tandem EGF domains. With respect to EGF5-6, a more quantitative analysis of 
the CD spectrum revealed that, as expected, the majority of the protein was likely 
disordered with ~22% being β-strand. This was reasonable evidence that the 
protein was not only folded, but contained the amount and type of secondary 
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structure typical of an EGF-like domain. Further evidence for folding of EGFs 5-6 
and 3-6 came from the melting curve generated by the TSA (figure 4.23) since if 
the proteins were unfolded, they would generally bind dye molecules at low 
temperatures, leading to an increased fluorescence signal that would not change 
significantly as the temperature was raised.  
 
To assess the presence of any free cysteines in EGFs 5-6, 7-10 and 3-10, a 
PEGylation experiment was carried out whereby the maleimide would bind any 
reduced cysteines, and the attached PEG group would slow the electrophoretic 
mobility of the protein during SDS-PAGE, presenting as a defined, higher MW 
band (Lu & Deutsch, 2001). As shown in figure 4.24, around 95% of the protein 
remains in the original position on the gel, suggesting that only a small proportion 
of the sample has free cysteines (indicative of the protein being misfolded or 
partially unfolded), which is not uncommon in a sample of refolded recombinant 
protein (as mentioned and reviewed in Singh & Panda, 2005). 
 
Finally, the use of NMR was important for assessing the refolding of proteins 
since one can make use of 1D and 2D NMR to see strong evidence of protein 
folding by looking for good peak dispersion (1D and HSQC), and evidence of β-
sheet. Figures 4.26, 4.28 and 4.29 demonstrate both good peak dispersal in the 
carbon and amide regions, in addition to presenting evidence for secondary 
structure in the form of alpha protons in β-sheet at a chemical shift of around 5 
ppm. Overall, and as is common for proteins undergoing NMR analysis, a higher 
temperature and lower pH yielded better quality spectra with respect to sharper 
peaks and better resolution. As the initial plan was to pursue NMR-based 
structural studies on the EGFs that gave rise to the best spectra, a natural 
abundance HSQC and NOESY were carried out on EGF5-6 and 7-10, with the 
spectra from EGF5-6 yielding the clearest spectra for each experiment. The 1H-1H 
NOESY of EGF5-6 additionally displayed evidence of folding due to the presence 
of many cross peaks between key regions such as long-range methyl protons 
coupling with aromatic protons, amide – amide protons, and αH to amide protons. 
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The excellent-looking 2D NMR experiments for EGF5-6 thus indicated it may be 
an ideal protein on which to pursue for NMR-based structural studies. This would 
have been pursued further if the decision to move into a Pichia-based recombinant 
protein production system had not been made.  
 
It should be noted that numerous attempts at crystallization were attempted but 
ultimately failed to yield protein crystals. The failure of these crystallization 
attempts was potentially due to the proteins containing highly flexible regions. This 
can lead to thermodynamically unfavourable conditions for reaching the energy 
minima needed to facilitate a protein crystalizing. Further, at the time of 
experiments, no mAbs against PfRipr had been developed which could have 
facilitated successful crystallography. Protein quality is also another consideration 
that may have impeded successful crystallization attempts. 
 
The significance of refolding (and subsequent biophysical characterization of) 
these recombinantly-produced EGF-rich proteins that has been demonstrated 
must not be underestimated; proteins are both complex and dynamic entities. 
Bacterial expression systems can be effective at rapid production of proteins in 
large quantities, but can be poor at forming native disulfide bonds, which are 
inconsistent with producing a native protein conformation. Furthermore, the 
paucity of PfRipr biochemical publications making use of recombinant protein 
production (at the time of the original research outlined in this thesis) are highly 
suggestive that other scientists have had difficulty in both producing and 
convincingly validating their PfRipr proteins. The work in this chapter therefore 
represents the first time recombinant PfRipr proteins have been produced with 
biophysical characterization. Hence, the methods outlined in this thesis should be 
of interest and use to other malariologists and protein biochemists in particular. 
 
With respect to the PfRh5 – PfRipr interaction studies, these become problematic 
due to a variety of factors, including the “stickiness” of the recombinant PfRh5 
with the bead matrix used in coIP assays and in ELISAs. The initial ELISA in 
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figure 4.35 appeared to show convincing results of an interaction between PfRh5 
and either EGF5-6 or EGF3-6, due to a dose-response curve that was being 
searched for. However, the lack of ability to repeat the results convincingly was 
problematic and led to two possibilities; either the initial result was correct and 
perpetual human error occurred in the rest of the repeats, or, applying Occam’s 
razor and the knowledge of the focusing and anchoring effect in bias, all the 
negative results were in fact real. As of February 2017, the scientific community 
now knows that PfRh5 and PfRipr do not in fact form a tight complex (Galaway, 
et al., 2017). However, this work was carried out between 2013 and 2016, and due 
to the possibility that either the fifth and/or sixth EGF-like domain were indeed 
responsible for binding to PfRh5 (or at least, elsewhere on PfRipr), a variety of 
other assays were pursued.  
 
After moving away from coIP assays, FRET analysis was attempted but failed 
likely due to one or both of the fluorophores binding at or near the binding region 
between BSG and PfRh5, thus preventing a positive control being established. The 
BN-PAGE results (data not shown) were suggestive that no binding event was 
taking place between the PfRipr EGF-like domains and PfRh5. However, since the 
positive control was not shown to conclusively work, these results remained 
inconclusive. It was therefore decided to see if a tight complex was formed 
between either PfRh5 and EGF3-6 or EGF3-10 which could be detected via 
SEC/gel filtration. Due to the potential of weaker protein complexes destabilizing 
during their permeation and movement through the resin in a SEC column, the 
method is only able to inform one on if a tight complex is formed between two 
biomacromolecules. In the case of PfRh5 and the PfRipr proteins, this was 
conclusively ruled out, thus representing the first evidence that PfRipr does not in 
fact associate with PfRh5, in agreeance with the published work that came out later 
by Galaway, et al., 2017. Unfortunately for the author and the scientific community 
at large, publishing negative data on its own is still discouraged in academia (and is 
spoken about more than it is actually done (Young, et al., 2008) (Collins & Tabak, 
2014)).   
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In the future, it would be of interest to produce a batch of the PfRipr EGF-rich 
constructs, divide the batch in two; one of which would have the polyhistidine tag 
removed (with TEV, given that EK cleavage was unsuccessful with pET45b+ 
plasmid produced samples). Then one would be able to conduct an EGF – EGF 
interaction ELISA to screen using anti-pentahistidine antibodies. Because it may in 
fact be the case that the EGF domains of PfRipr are binding to one another to 
hold the two large post-cleaved polypeptides of the protein together in the PAIN-
complex. 
 
The development of both inhibitory compounds against the formation of the 
PAIN-complex proteins and tools to further probe said complex was of interest. If 
mAbs could be generated they could be utilized in crystallography studies (for 
example, by helping stabilize a protein or proteins), or epitope mapping studies 
similar to those in Lim, et al., 2015 and as described in section 3.2. An initial 
selection of eight hybridoma supernatants containing anti-PfRh5 antibodies was 
made following an ELISA to assess their reactivity against PfRh5. It was however 
a shame that both the anti-PfRh5 antibody supernatants and the anti-BSG mAbs 
gave inconclusive results in the ELISA assays to assess their potential of inhibiting 
the interaction between BSG and PfRh5. This was the result of a high background 
signal to noise ratio produced by indirect interaction of the PfRh5, and the 
antibodies with the ELISA assay. It was decided to provide aliquots of these 
antibodies to Drs. Wai-Hong Tham and Anthony Hodder to conduct alternative 
assays, such as the FACS-based assay described in Lim, et al., 2015. 
 
With respect to the screening of the MMV box compounds against PfRh5 via the 
TSA, what one is looking for is initial evidence of binding between the small 
molecule and the protein. This is demonstrated when (compared to the control 
with DMSO instead of the compound of interest) there is a protein melting curve 
shift to the right, indicating that more energy is required to denature the protein, 
which has become somewhat stabilized due to the compound binding. The four 
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compounds identified in figure 4.51 display this to varying degrees. Of course, the 
experiment would need to be repeated with the use of an alternative dye to make 
sure that was not a contributing factor, then the compounds would need to be 
tested in a parasite invasion assay. Further, some of the compounds may require 
some medicinal chemistry to make them more “druggable”. However, in favour of 
these molecules is that none of them violate any of Lipinski’s rule of 5 (Lipinski, 
1997). Though, MMV665827 and MMV665807 violate one of the rules of 3, 
namely that they are over 300 Da and the former compound has over three 
hydrogen bond donors/acceptors (although, the rule of 3 is more important for 
lead compounds) (Congreve, et al., 2003).  
 
Due to significant time constraints, it was decided to focus exclusively on the 
production of PfRipr proteins in a P. pastoris system, using a proprietary strain 
developed by Dr. Andrew Herbert in the Barlow lab at the University of 
Edinburgh to avoid the need to work with refolding, and to ensure disulfide bond 
formation. The direction of the project was therefore altered to be focused on new 
protein production/purification, crystal trial screens of larger PfRipr constructs, 
additional biophysical characterization, binding studies between PfRipr proteins 























“The struggle itself towards the heights is enough to fill a man's heart. One must imagine 
Sisyphus happy”. 
 




















5.1 Overview  
 
The choice to move into a P. pastoris-based protein production system was made 
primarily due to the ability to use a proprietary strain (dubbed the “superstrain” 
(SS) Pichia) that had been genetically-engineered by members of the Barlow group 
at the University of Edinburgh. This had been designed specifically for the 
production of disulfide-rich proteins that are exported into the culture media at 
potentially high levels. This would avoid costly protein refolding protocols as 
required in E. coli and provide the possibility of producing larger PfRipr constructs, 
including the full-length protein.  
 
Compared to E. coli, P. pastoris has other benefits as a eukaryotic expression system, 
including the ability to glycosylate proteins (however, this can be disadvantageous 
as glycans added are dissimilar to mammalian glycans), other post-translational 
modifications, and correct proteolytic processing (Cregg, et al. 2000) (Cereghino & 
Cregg, 2000). Furthermore, P. pastoris is highly amenable to large-scale 
fermentation, allowing for economically viable production of recombinant proteins 
of high quality and in large quantities (Cereghino, et al. 2002). This is particularly 
interesting to those wanting to develop industrially scalable methods of producing 
protein-based vaccine components. P. pastoris belongs to a group of 
methylotrophic yeasts, i.e. they use methanol as their sole carbon source. The 
metabolism of methanol involves several steps, starting with alcohol oxidase 
(AOX) which oxidises the methanol into formaldehyde and hydrogen peroxide. 
The latter product is a harmful by-product that is isolated in the peroxisome and 
processed into gaseous oxygen and H2O via the activity of catalase. Given that 
AOX has a low affinity for O2 and is produced in high quantities by the cell, the 
promoters concerned are particularly strong, and hence effective for use in 
producing high levels of recombinant protein. 
 
P. pastoris utilises two AOX genes; aox1 and aox2. The former is responsible for 
more effective metabolism of methanol and therefore overall cell growth, whilst 
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being regulated at the transcriptional level. This regulation involves repression, de-
repression or induction. With respect to repression, when glucose is present, the 
activity of aox1 is significantly reduced even when methanol is also present. 
Therefore, use of a glucose-rich medium provides a convenient way of growing 
cells to a high density initially.  When induction of AOX1 is required for 
recombinant gene translation, one simply swaps out the glucose-rich media for one 
containing methanol. There are two phenotypes of P. pastoris that utilise methanol; 
MUTS and MUT+.  The former lacks aox1 (and therefore lacks most AOX activity) 
and relies on AOX2 for slow growth with methanol. The latter, MUT+, grows on 
methanol-only sources like their wild-type counterparts.  
 
The base-strain type of Pichia used in this study was SuperMan5, belonging to the 
MUTS phenotype. However, for some initial trial experiments the KM71 (of the 
MUT+ phenotype) base-strain was used. To exploit the AOX1 promoter, the 
plasmid pPICZαβ was used as a vector. This vector possesses DNA coding for the 
α-factor secretion-signal peptide which is fused to the inserted gene of interest to 
ensure the recombinant protein product is secreted. For removal of the α-factor 
signal sequence, the kex2 gene product cleaves between the Arg and Gln in the 
sequence- Glu-Lys-Arg|Glu-Ala-Glu-Ala (Brake, et al. 1984). This is followed by 
STE13-mediated cleavage of the Glu-Ala repeats; though this can be inefficient, 
leaving N-terminal non-native repeats on the protein of interest (Julius, et al. 1983). 
 
This chapter overall aims to show the production of EGF-rich domains of PfRipr 
in the aforementioned P. pastoris system, with varying degrees of success. Only the 
proteins that showed definitive signs of stable expression were pursued for further 
development, including biophysical characterization and structural studies. Of 
those that were successful, one (EGF5-7) could be taken to the stage of double 
and triple resonance NMR experiments using a 15N/13C-labeled protein that 
proved to be stable over time and a range of temperatures. This yielded data that 
should lead to a 3D molecular structure (personal communication with Dr. Brian 
Smith, June 2017).  
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Small angle X-ray scattering (SAXS) coupled to homology replacement modelling 
was used to generate a 3D structural model of EGF5-7, that will also be of use in 
the future for validation of NMR-based structural modelling. SAXS is a structural 
technique for monochromatix X-ray beam analysis of a sample in solution. The 
scattered intensity [I] is recorded as a function of the scattering vector 223 
s=4πsinθ/λ where 2θ is the angle between the incident and the scattered beam. 
Scattering generated from the solvent is measured separately and then subtracted 
to give the final data set. This background-corrected intensity [I](s) is proportional 
to the scattering of a particle averaged over each molecular orientation. Various 1-
D curves can be extracted from the [I](s) information, providing important 
parameters directly related to the molecule’s size, oligomeric state and overall 
shape. Analysis of the scattering patterns allows for ab initio molecular shape 
reconstruction and rigid body modelling in addition to analysis of potential 
molecular flexibility. In lieu of a crystal or NMR-based structure, SAXS can be 
utilized for a level of validation of homology-based molecular modelling and the 
confirmation of molecular rigidity that one gains from relaxation data generated 
from NMR experimentation. Further, SAXS provides useful information that can 
be used to refine NMR-based structural data. 
 
In addition to garnering structural information, it was imperative to screen 
proteins for binding to CyRPA and to assess the potential of calcium cation 
binding due to the importance of Ca2+ activity demonstrated by the PAIN-
complex (Volz, et al. 2016). Finally, the development and screening of inhibitory 
mAbs against PfRipr was of importance for validation of recombinant PfRipr as a 
vaccine candidate, and for the identification of where in PfRipr inhibitory mAbs 
bind. This would form the first steps towards epitope mapping. The list of where 























EGF1-2 N N N N N N N N N N N N 
EGF3-5 N N N N N N N N N N N N 
EGF5-7 Y Y Y Y Y Y Y Y Y Y Y Y 
EGF7-10 Y Y N N N Y N Y N N Y Y 
EGF3-10 N N N N N N N N N N N N 
Ripr21-
1086 
N N N N N N N N N N N Y 
Ripr21-
604 
N N N N N N N N N N N N 
Ripr604-
1086 
N N N N N N N N N N N N 
Table 2. PfRipr Protein Progress Log (SS Pichia): The yellow highlighted regions indicated 
where a particular examination type was carried out. 
 
 
5.2 Cloning, Test Expression and Purification of PfRipr Constructs in 
Pichia pastoris 
 
5.2.1 Methods for the Cloning, Test Expression and Purification of PfRipr 
Constructs in Pichia pastoris 
 
LB agar plates containing 500 μg/ml zeocin (500Z) of freshly re-streaked KM71 
and SuperMan5 (engineered to produce proteins with Man5[GlcNAc]2 Asn-linked 
glycans) SS Pichia were available in the Barlow group. Synthetic genes subcloned 
into pPICZαβ plasmids were expression-optimised and provided by Geneart 
(ThermoFisher). They included C-terminal hexahistidine tagged PfRipr from 
amino acids 21 – 1086 (Ripr21-1086), 21 – 604 (Ripr21-604) and 604 – 1086 
(Ripr604-1086), in addition to non-tagged (due to an engineered-in stop codon at 
the C-terminus) EGFs 1-2, 3-5, 5-7, 7-10 and 3-10.   
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All plasmids from Geneart were resuspended in 50 μl of ultrapure H2O (generating 
a stock of 0.1 μg/μl plasmids), with 1 μl pipetted into 49 μl of ultrapure H2O 
(generating the usable stock at a concentration of 2 ng/μl). 1 μl of the stable stock 
was added to a 50 μl tube of competent Top10 E. coli cells (ThermoFisher), 
incubated on ice for 30-minutes then heat-shocked at 42 C for 30-seconds. Tubes 
were placed back on ice for one-minute, 0.25 ml SOC medium added then 
incubated at 37 C for one-hour. Aliquots of 20 and 100 μl of the culture was 
plated onto 25Z low-salt LB agar plates and incubated at 37 C overnight. 
Maxipreps were carried out on picked colonies as per manufacturer instructions 
(Qiagen CompactPrep Plasmid Maxi Kit).  
 
Restriction enzyme digests were carried out using 0.5 ml of plasmid DNA from 
maxipreps, 5 μl SacI-Hf and 45 μl of CutSmart® buffer (New England Biolabs). 
The mix was incubated at 37 C for one-hour, then analysed on a 1% or 1.2% agar 
TAE gel with 0.01% Sybr Safe added (ThermoFisher), with 15 μl of a 1 kb DNA 
ladder (New England Biolabs) added to lane 1, and 1.5 μl of digested plasmid in 10 
μl of 1 x loading dye distributed in the other lanes. The gel was run at 100 mA for 
45-minutes. Phenol-chloroform extraction and ethanol precipitation was carried 
out as per section 2.1.  
 
Pichia transformations were carried out with Roma Galloway and Ella Svahn 
according to the protocol outlined in section 2.1.15.3 (Makou, 2013) using a Bio-
Rad Gene Pulser for the elecroporations. Once visible colonies were seen they 
were restreaked onto 300 then 500Z yeast extract peptone dextrose (YPD) media. 
 
Test expression was carried out with Ella Svahn, according to the general protocol 
outlined in section 2.1.15.5 of (Makou, 2013), with the following changes- 100 ml 
of buffered complex medium containing glycerol (BMGY) used for starter 
cultures, and 25 ml of buffered complex medium containing methanol used for 
culture resuspension. Recipes for the standard media used were found in the 
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EasySelectTM Pichia Expression Kit 2010 (Invitrogen). Glycerol stocks were 
prepared according to the protocol in section 2.3. 
 
For the prediction of potential glycosylation sites, the NetNGlyc 1.0 Server was 
used (http://www.cbs.dtu.dk/services/NetNGlyc/). For deglycosylation tests, 1 -
5 μl of Endo-Hf or Endo-Hr (New England Biolabs) was added to each post-
harvest 20 μl supernatant sample for up to one-hour at 37 C. This enzyme was 
used for removing mannose-rich N-linked carbohydrate moieties from the 
recombinant proteins by cutting between the two first GlcNAc molecules thus 
leaving the protein with one GlcNAc moiety per glycosylation site. 
 
SDS-PAGE and Western blot analysis was carried out with occasional assistance 
from Ella Svahn, as described in section 2.8 using 12.5% acrylamide NuPAGE 
Novex gels or Bolt Bis-Tris Plus gels (Invitrogen), in 10% NuPAGE 20x MES or 
MOPS buffer and electrophoresed at 185 V for 45 – 55-minutes using an X-cell 
Sure Lock apparatus (Invitrogen). Western blots made use of rabbit polyclonal 
anti-PfRipr antibodies (1:2000 dilution) and goat anti-rabbit HRP (1:1000 dilution), 
with development either via nitrocellulose and X-ray film or 3,3`-diaminobenzidine 
tablets (DAB; Sigma-Aldrich) on a methanol-activated PVDF membrane (GE Life 
Sciences).  
 
Ni-affinity purification was carried out using 50 μl of Ni-NTA beads (Roche) per 1 
ml of Pichia supernatant, with a one-hour incubation on a rotor at room 
temperature. Samples were centrifuged at 1200 × g for one-minute, supernatant 
carefully removed via pipette and then three 0.2 ml washes with wash buffer were 
carried out, followed by elution with 100 μl of elution buffer. A 35 μl sample was 
analysed via SDS-PAGE and Western blot using methods described in section 2.4 
and 2.8 (respectively).  
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Cation exchange chromatography was carried out as per the general methods 
outlined in section 2.2.6 of (Makou, 2013). Buffer A contained 20 mM sodium 
acetate (at either pH 4 or 6) and buffer B containing the same as A but with the 
addition of 1 M NaCl. Aliquots of 20 ml of each supernatant were diluted with 
ddH2O by a factor of 1:1, 1:2, 1:3, or 1:5. 5 ml elutions were collected, and of 
those 20 μl was analysed via SDS-PAGE under reducing conditions. Ella Svahn 
provided occasional assistance with the chromatography of EGF5-7. 
 
 
5.2.2 Results of the Cloning, Test Expression and Purification of PfRipr 
Constructs in Pichia pastoris 
 
After transformation, plating and incubation of Top10 E. coli with the various 
plasmids, it was found that Ripr21-604 gave rise to 250 colonies on the 100Z plate, 
Ripr604-1086 gave rise to ~600 colonies, Ripr21-1086 gave rise to 21 colonies, 
EGF3-10 gave rise to 100 colonies, EGFs 1-2, 3-5, 5-7 and 7-10 gave rise to 
thousands of colonies on each plate. Around 130 μg of DNA was obtained per 
maxiprep (in a volume of 0.55 ml), and ran according to their expected sizes once 
the purified plasmids were linearized with SacI-Hf and analysed by agarose gel 
electrophoresis (data not shown). Following the P. pastoris transformation, clear 
individual colonies appeared on each plate (data not shown), with those on the 
500Z plates used for test expression and resulting analysis via SDS-PAGE (figure 
5.1). Both EGF5-7 and 7-10 yielded up to ~1 mg/ml for some colonies screened. 
As EGF7-10 was predicted to contain a single possible glycosylation site, a replica 
gel of each sample was run after the supernatant had been incubated with Endo-Hf; 
however, no difference was visualized upon examination indicating that the 




Figure 5.1. Test Expression of Pichia-Produced PfRipr Proteins: A. EGF5-7 cultures pre- and 
post-induction over four days with each culture from a separate colony from individual plates 
(numbers 1 – 6) screened via SDS-PAGE. B. EGF7-10 cultures pre- and post-four days of 
induction with each culture from a separate colony from individual plates (numbers 1 – 7) screened 
via SDS-PAGE. C. To assess if Endo-Hf made a difference to the EGF7-10 bands, another SDS-
PAGE gel was prepared as per B, but with 1 μl of Endo-Hf enzyme added to each sample. 10 μl of 
supernatant added to each lane for gels A - C, expected sizes are highlighted in the red box. 
 
With respect to EGFs 1-2, 3-5, 3-10 and Ripr21-604, Ripr604-1086 and Ripr21-
1086, no bands were visualized on an SDS-PAGE gel, even following a ten-fold 
Ni-NTA-based concentration was attempted on each Ripr protein containing a C-
terminal hexahistidine tag (data not shown). A Western blot was carried out on 
each of these samples in case the protein was being expressed in very low levels. 
Only Ripr21-1086 showed bands indicative of protein production (figure 5.2 A), 
with all induced samples giving a band migrating around 175 – 200 kDa (the 
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expected size was 130 kDa, however 11 glycosylation sites were predicted). Figure 
5.2 B and C show the presence of EGFs 5-7 and 7-10. Unfortunately, the original 
plate with the Ripr21-1086 colonies had become contaminated and became 
unusable. After numerous re-transformations to generate more Pichia colonies to 
screen, none turned up any evidence of protein expression (Ripr21-604 initially 
appeared to show expression, but mass spectrometry analysis (data not shown) 
revealed the protein to be Factor H, therefore the KM71 Pichia I was given had 
been the wrong type), so after 18 months of various attempts, they were dropped 
from the project so as to focus on the Pichia-produced proteins that looked 




Figure 5.2. Western Blot Detection of Ripr21-1086: A. Detection of Ripr21-1086 from three 
colonies and EGF7-10 from a single colony. B. Detection of EGF5-7 from two colonies. All 
samples run under reducing conditions. Rabbit polyclonal anti-PfRipr antibodies used for 
detection, and DAB for development. 
 
Colony 2 for SS Pichia strains expressing EGFs 5-7 and 7-10 was maintained via 
monthly re-streaking and glycerol stocks prepared. To optimize cation-exchange 
chromatography of these proteins, cell culture supernatant-dilution factor and pH 
tests were performed. An example of the results is given in figure 5.3 (EGF5-7 
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results looked the same, data not shown). There was a demonstrable increase in 
protein bound then eluted when the dilution was increased. Varying the pH had a 
negligible effect between 5 and 6, so going forwards it was decided to use the 




Figure 5.3. SDS-PAGE Analysis of Test Cation Exchange Conditions for EGF7-10: A. 
Samples from five 2 ml elutions at various dilution factors using a sodium acetate/NaCl buffer at 
pH 6. S- supernatant, loaded neat. B. Samples from five 2 ml elutions at various dilution factors 







5.3 Scale-Up Production and Purification of Lead EGF-Rich Modules 
 
5.3.1 Methods for the Scale-Up Production and Purification of Lead EGF-
Rich Modules 
 
Scale-up protein production was performed as per protocols listed in sections 
2.1.15.6 and 2.1.15.7 (with the change of using 10 L culture media in a 12 L instead 
of a 3-L fermenter, carried out by Dr. John White) in Makou, 2013. SDS-PAGE 
and Western blot analysis was carried out as described in section 4.2.1 of Makou, 
2013. Where protein concentration was required, pre-washed and equilibrated 5 
kDa cut-off protein concentration tubes (Merck Amicon Ultra-15 Centrifugal 
Filter Units) were used in a chilled centrifuge, spinning for 20-minute periods at 
3500 × g until the desired volume was reached. Protein concentration was 
determined via NanoDrop as described in section 2.7. 
 
For producing 15N-labeled proteins in SS Pichia, a two-day starter culture (10 ml) of 
BMG media (100 mM potassium phosphate pH 6, 1.34% YNB, 4 × 10–5% biotin, 
2 g/L 15N-ammonium sulfate, and 1% glycerol) was grown in a 30 °C incubator at 
220 rpm, then transferred to 1-L of BMG media until the cell growth was around 
an OD600 of 14 – 18. At this point the cells were centrifuged at 3500 × g for 30-
minutes at 4 C and resuspended in 250 ml BMM (with 0.5% methanol and 0.5 g 
15N ammonium sulfate), then incubated at 18 °C. Twice daily feeds were carried 
out with 1.25 ml methanol for three days, with 0.1 mM Pefabloc® (Sigma Aldrich) 
added on day 3. Final cell harvest (day 4) to obtain supernatant was via 
centrifugation at 10 000 × g for 30-minutes at 4 C (then repeated). 
 
For producing a double-labelled (15N/13C) protein sample of EGF5-7 in SS Pichia, 
a two-day starter culture (10 ml) of BM media (100 mM potassium phosphate pH 
6, 1.34% YNB, 4 × 10–5% biotin, 2 g/L 15N-ammonium sulfate, and 5 g/L 13C-U-
D-glucose) was grown in a 30 °C incubator at 220 rpm, then transferred to 1-L of 
BM media containing 0.5 ml antifoam agent 204 (Sigma Aldrich) until the cell 
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growth is arrested. At this stage 1 g of 13C-U-glycerol was added which allowed the 
cells to reach an OD600 of 14. At this point the cells were centrifuged at 3500 × g 
for 30-minutes at 4 C and resuspended in 250 ml BMM (with 0.25 ml antifoam 
agent 204, 1.25 ml 13C methanol and 0.5 g 15N ammonium sulfate), then incubated 
at 18 °C. Twice daily feeds were carried out with 1.25 ml 13C methanol for four 
days. Final cell harvest (day 4) to obtain supernatant was via centrifugation at 10 
000 × g for 45-minutes at 4 C (then repeated). The double-labelled-like (dll) 
sample was made as above but with non-isotopically labelled carbon sources. 
 
For cation exchange chromatography of unlabelled samples, diluted supernatant 
had the pH checked and adjusted to pH 4 before being slowly pumped onto a 38.5 
ml XK 26 column preparative column (GE Life Sciences) containing negatively 
charged SP-Sepharose (in the cold room), then washed (buffer A, 20 mM sodium 
acetate pH 4) and eluted using a gradient up to 100% of buffer B (20 mM sodium 
acetate pH 4 and 1 M NaCl) on an ÄKTA-Pure 25 FPLC system (pump P-920, 
UV detector unit UPC-900) using Unicorn 7.1 control software at the EPPF. 
Fractions of 15 ml were collected during a flow rate of 3.5 ml/minute. For 
isotopically labelled samples, a 5 ml FF SP cation exchange column (GE 
Healthcare) was used, collecting 0.5 ml fractions at a flow rate of 10 ml/minute. 
 
Size-exclusion chromatography was performed as a subsequent purification step 
using a HiLoad 26/60 Superdex 75 preparative grade (GE Healthcare). Prior to 
loading the column was equilibrated with 1.1-1.6 column volumes of the 
appropriate buffer (typically 20 mM sodium acetate pH 4 and 100 mM NaCl). 
Elutions were in 1.5 ml volumes collected at a flow rate of 2.5 ml/minute. Where 
required, a HiLoad 16/60 Superdex 75 column was used at a flow rate of 1 
ml/minute, collecting 1 ml fractions. 
 
Where further purification was required, either MonoQ 5/50 GL cation 
chromatography (using buffer A and B) with a 1 ml column was used following 
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tenfold sample dilution and collecting 0.25 ml fractions, or reverse phase high 
performance liquid chromatography (RP-HPLC) was carried out collecting 0.5 ml 
fractions (as carried out by Dr. Martin Wear at the EPPF). With respect to the RP-
HPLC, 100 μl of protein was loaded onto a Source15 RPC 4.6/100 ST column 
that was pre-equilibrated in 0.065% trifluoroacetic acid (TFA) and 8% acetonitrile 
(ACN). A 20 – column volume gradient (1.6 ml column volume) was used with the 
gradient from 0.065% TFA + 8% ACN to 0.05% TFA + 80% ACN.  
 




5.3.2 Results for the Scale-Up Production and Purification of Lead EGF-
Rich Modules 
 
Following on from the successful test expression and purification of EGF5-7 and 
7-10, a 10-L fermentation was carried out to generate a total of ~10 g of each SS 
Pichia-produced protein. The resultant supernatants were purified via cation 
exchange chromatography with SDS-PAGE analysis of the key fractions (figure 
5.4). EGF5-7 eluted at around 15 – 20% buffer B (or, 150 – 200 mM NaCl), with 5 
ml each of fractions A9 – B2 pooled and concentrated to 6 ml. The results shown 
for EGF7-10 are from the flow-through of the initial batch binding to the column 
being put back over and eluted (hence the lower mAU values compared to EGF5-
7). Here, EGF7-10 is shown to elute at around 20 – 25% buffer B, with 5 ml each 




Figure 5.4. Cation Exchange Chromatography of EGFs 5-7 and 7-10: A. Chromatogram of 
EGF5-7 with 5 μl of the key fractions taken from the region of the orange arrow analysed via SDS-
PAGE (black labelled are under NR conditions and red is with RSB). B. Chromatogram of EGF7-
10 with 25 μl of the key fractions analysed via SDS-PAGE under R and NR conditions. Fraction 1 
corresponds to B1, 2 to B6 and 3 to B10. 
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After concentration, the samples underwent further purification via SEC (data not 
shown). The total yield of the EGF5-7 monomeric fractions was 22 mg, and for 
EGF7-10 the total yield was 27.6 mg of protein obtained in total.  
 
Due to a broken 3 L fermenter, and the considerable expense of 10 L of minimal 
media isotopic reagents, a shaker flask method was utilized to produce 250 ml of 
15N-labelled EGF5-7 and 7-10. A variety of conditions were tried in attempts to 
optimize the yield of protein, including incubator shaker speed (180 versus 220 
rpm), the type of 15N ammonium used (chloride versus sulfate) and induction at 18 
C instead of room temperature (data not shown). The best results were from 
using the conditions underlined above (figure 5.5). 15N-EGF5-7 could be produced 
at around 0.35 mg/ml of supernatant (approximately a third of that which was 
produced unlabelled), whilst there was a more significant decrease in yield for the 
15N-EGF7-10 (in contrast to unlabelled protein) of around 0.1 mg/ml; a ten-fold 
decrease. However, in a volume of 250 ml, this meant that there would still be 
enough protein for NMR-based analysis (with an estimated 8 mg in 1 ml and 2.5 





Figure 5.5. SDS-PAGE of 15N-labeled EGFs 5-7 and 7-10: 30 μl of each sample (after 96-hours 
post induction) was loaded onto each lane. T0- the NI Pichia sample. All samples were run under 
reducing conditions. 
 
The supernatant from each protein production run was purified via cation-
exchange chromatography using SDS-PAGE to analyse the key fractions (data not 
shown). Once the relevant fractions of 15N-EGF5-7 and 15N-EGF7-10 were 
combined and concentrated, SEC was carried out for further sample purification 
(required due to contaminating Pichia proteins). This allowed for the majority of 
the proteins of interest to be isolated (data not shown); however, the presence of 
minor proteolytic fragments of only a few amino acids difference of 15N-EGF5-7 
warranted a final purification step that was to be carried out via RP-HPLC. 
 
The 15N-EGF5-7 was applied to RP-HPLC (several gradients were used for 
testing, ultimately settling on a shallow gradient), giving rise to an unusual elution 
profile on the chromatograph (figure 5.6). However, significantly improved 
separation of monomeric protein was achieved, with fractions F11 – F3 
undergoing lyophilization and resuspension in 20 mM sodium acetate pH 4, 50 
mM NaCl. Two protein concentrations were tested via SDS-PAGE to ensure the 
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final product was not only devoid of contaminating proteins, degradation products 
or dimers, but to also assess if the protein would precipitate at a high 
concentration (figure 5.7). 
 
 
Figure 5.6. RP-HPLC of 15N-EGF5-7: A. Chromatograph showing elution of the protein begins 
around 16% ACN. B. NR samples (3 μg) of fractions E11 – F1. C. NR samples (3 μg) of fractions 
G1 –G10 and R samples for fractions F9 and G3 (red box). The mAU reading of the highest peak 




Figure 5.7. SDS-PAGE Analysis of Final 15N-EGF5-7 Sample: 0.5 μg of protein was assessed 
under both R and NR conditions from a 48 μM sample of 15N-EGF5-7. 3 μg of protein was 
assessed under both R and NR conditions from a 1.3 mM sample of 15N-EGF5-7 (this gel is a 
composite). 
 
15N-EGF7-10 was split into two samples, one for further purification via cation 
exchange, and one for RP-HPLC (data not shown). Figure 5.7 shows the results of 
the RP-HPLC of 15N-EGF7-10, showing pure, monomeric protein to be obtained. 
The key fractions from both chromatography runs were saved for future analysis 
by techniques such as NMR. 
 
 
Figure 5.8. SDS-PAGE Analysis of Final 15N-EGF7-10 Samples: 3 μg of protein was loaded 
under NR conditions. The samples were obtained from RP-HPLC purification of 15N-EGF7-10. 
 
Due to time and cost limitations, it was decided to pursue only EGF5-7 for 
structural analysis via NMR, therefore a double-labelled (15N/13C) sample had to 
be prepared. Before this, it was vital to ensure the final quality protein level that 
could be obtained in 250 ml of dll conditions (prepared in shaker flasks due to a 
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broken small-scale fermenter), that would yield a 15N-EGF5-7 sample. The time 
points of the SS Pichia production of protein over three days is shown in figure 5.9. 
Based on the 20 μl volume of sample loaded, there was an estimated 65 mg of 
protein in the supernatant. 
 
 
Figure 5.9. Induction of SS Pichia to Produce DLL 15N-EGF5-7: 20 μl was loaded into each 
well. R refers to reducing conditions and N here refers to non-reducing. Time-points are given in 
hours (t with a subscripted number). The actual harvest occurred at 72-hours, with a small batch 
left to look at the 96-hour time point. 
 
Following the harvest and dilution of the supernatant, cation exchange 
chromatography and subsequent SEC were carried out (data not shown). The 
cation exchange resulted in 31.5 mg of protein from combining and concentrating 
fractions C9 – D6 to 9 ml. Following SDS-PAGE analysis of the SEC fractions 
(figure 5.10 B), all the fractions were seen to contain some putative proteolytic 
products appearing as bands under the main monomeric protein. This was likely 
due to the use of less protease inhibitors during the production of the protein 
(only Pefabloc was added after 72-hours). Less inhibitors had been used since the 
actual double-labelled sample would be produced without them so as to not risk 




Figure 5.10. Purification of DLL-15N-EGF5-7: A. 5 ml cation exchange column collecting 2 ml 
fractions from the area covering the orange arrow resulted in the chromatogram shown. The centre 
of the peak (fraction D7) contained an estimated 7.62 mg of protein. SDS-PAGE gels show the 
result of running ~3 μg of protein from each relevant fraction under NR conditions. B. SEC 
resulted in two peaks with the prominent eluting at ~174 ml (central peak fraction contains around 
2.96 mg of protein; fractions taken from area covered by the green arrow). 2 μg of each protein 
fraction analysed via SDS-PAGE. Abbreviations: RP- reduced pre-SEC sample, NP- non-reduced 
pre-SEC sample. SEC column was an S75 26/600 preparative column collecting 1 ml fractions. 
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RP-HPLC was once again used to obtain ultra-pure monomeric protein that could 
withstand lyophilization and be reconstituted at a high concentration of > 1 mM 
(figure 5.11). Based on the protein quality, concentration obtained and the NMR 




Figure 5.11. RP-HPLC Fractions and Final Sample DLL-15N-EGF5-7 SDS-PAGE: A. 
Approximately 2 μg of protein from each relevant RP-HPLC fractions (chromatogram not shown) 
were loaded in with 1 x NRSB. These fractions were lyophilized and combined after being 
dissolved in 125 μl of an acetate buffer (20 mg/ml concentration). B. An estimated 3 μg of protein 
from the final reconstituted sample was run under both R and NR conditions. The first lane in each 
case contains an aliquot from the 20 mg/ml sample and the second lane is from a diluted sample of 
5 mg/ml. 
 
Copying the same production strategy used for the DLL sample, a cell culture was 
set up to produce 15N/13C-EGF5-7 and closely monitored (figure 5.12). The 
decision was made to harvest at 72-hours, following analysis via SDS-PAGE, 
because a fourth day was judged to unneeded and would likely just introduce 
protease-related issues (given that the culture remained free of protease inhibitor 
until after harvest). The protein concentration matched that seen in figure 5.9 (of 




Figure 5.12. Induction of SS Pichia to Produce 15N/13C-EGF5-7: 20 μl was loaded into each 
well. Abbreviations: NI- non-induced, I- induced (including the hours after induction). 
 
Post-harvest, the sample was purified via cation exchange, then two rounds of 
SEC (data not shown). This procedure yielded mostly monomeric protein; 
however, the presence of minor proteolytic fragments warranted the sample 
undergo a final round of cation exchange purification. Relevant SEC fractions 
were combined, diluted 1:10 and applied to a 1 ml MonoS 5/50 GL column to 
attempt a high-resolution separation of the major and minor forms of the protein.  
 
The results show that excellent separation was achieved, with ultra-pure 
monomeric protein being obtained, with separation of both minor fractions and 
those containing contaminating lower molecular weight products (figure 5.13). 
Fractions B7 – C1 were combined, buffer exchanged (20 mM sodium acetate, 50 
mM NaCl, 0.01% sodium azide and 10% D2O) and concentrated to a final volume 
of 350 μl at a concentration of 0.5 mM (a faulty batch of concentrators caused 




Figure 5.13. Final Purification of 15N/13C-EGF5-7: The protein began eluting at around 15% 
buffer B (~150 mM NaCl) into 0.5 ml fractions. ~1 μg of each key fraction was analysed via SDS-
PAGE under R and NR conditions (see inlaid figure). 
 
After concentration, the protein was assessed via SDS-PAGE with a relatively high 
amount of protein loaded onto the gel (5 μg) under R and NR conditions so that 
the presence of significant break-down products, contaminants or dimer could be 
assessed (figure 5.14). The protein demonstrated none of these issues and 
appeared to be highly pure monomer. This sample of 15N/13C-EGF5-7 was stored 




Figure 5.14. Final 15N/13C-EGF5-7 Sample: ~5 μg of protein was used to load onto the gel 
under R and NR conditions.  
 
 
5.4 Biophysical Characterization of EGF-Rich Modules 
 
5.4.1 Methods for the Biophysical Characterization of EGF-Rich Modules
  
5.4.1.1 Mass Spectrometry 
 
Mass spectrometry was carried out as per section 3.4.1.1 at the SIRCAMS facility 
and St. Andrews University.  
 
 
5.4.1.2 Circular Dichroism 
 
CD was carried out as per section 3.4.1.2 at the University of Edinburgh with 
assistance from Dr. Elizabeth Blackburn. The CD Analysis & Plotting Tool 
(CAPITO) from Leibniz-FLI (http://capito.nmr.leibniz-fli.de/) was used for data 
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plotting for data with buffer subtracted. Dichroweb software 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) used for data analysis. 
 
 
5.4.1.3 Thermal Analysis via TSA and NMR 
 
Thermal stability was assessed, as per section 3.4.1.3, at the University of 
Edinburgh using either a BioRad IQ5 ICycler (with experimental help provided by 
Dr. Elizabeth Blackburn) or by NMR (with the assistance of Juraj Bella for 
experimental set up).  
 
 
5.4.1.4 1D and 2D NMR Analysis 
 
NMR was carried out as per section 3.4.1.5 at the University of Edinburgh with 
experimental set up performed by Juraj Bella, and advice given by Profs. Paul N 





Crystallography was carried out, as per section 3.4.1.6, at the EPPF. Ella Svahn 
aided the initial crystallization trials with advice provided by Dr. Atlanta Cook. Six 
96-well plates were screened for crystal growth under various conditions (provided 
by the EPPF; Index, Structure Screen, JCSG+, MIDAS, PEGION and Salt Rx) 
using a highly purified sample of EGF5-7 at a concentration of 15 mg/ml in a 
buffer consisting of 20 mM sodium acetate, pH 4, and 50 mM NaCl.  
Crystallisation trials were also carried out on a sample of 10 mg/ml EGF7-10 in 




5.4.1.6 Homology-Based Modelling and SAXS Methods 
 
Homology modelling was carried out using the I-TASSER Protein Structure & 
Function Predictions software suite (https://zhanglab.ccmb.med.umich.edu/I-
TASSER/), and Swiss-Model software developed for the Biozentrum Universitat 
Basel Center for Molecular Life Sciences 
(https://swissmodel.expasy.org/interactive). Proteins sequences were edited to 
have cloning artefacts removed. Advice on modelling was provided by Dr. Dinesh 
Soares. 
 
A 0.5 mM sample of EGF5-7 in 20 mM sodium acetate pH 4 and 75 mM NaCl 
was prepared and analysed by Dr. Haydyn Mertens of the BIOSAXS group at the 
European Molecular Biology Laboratory (EMBL), Hamburg (Germany). The 
methods utilized a 1M PILATUS pixel detector (Dectris, Switzerland) and eight 
frames of 15-s exposure time. The sample-to-detector distance was 2.7 m, covering 
a range of momentum transfer 0.08 ≤ s ≥ 6.0 nm-1 (where s=4πsin(θ)/λ with 2
θ being the scattering angle and λ=0.15 nm being the wavelength). Dr. Mertens 
performed the processing of the data, with analysis carried out with the assistance 
of the author (fit of the homology model to the SAXS data, analysis of flexibility, 
and ab initio shape determination). 
 
 
5.4.1.7 Assessment of Free Cysteines and Disulfide Mapping 
 
Samples of EGF5-7 were provided to Dr. David Clark and Lavrentis 
Galanopolous for a mass spectrometry-based analysis of the presence of free 
cysteines and for disulfide mapping. Briefly, N-ethylmaleimide (NEM, Thermo 
Fisher) was used to mix with EGF5-7 (either with or without tris[2-
carboxyethyl]phosphine, TCEP) prior to ESI-MS analysis (methods as per (Hill, et 
al., 2009). Disulfide mapping was attempted with trypsin and pepsin according to 
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the general methods outlined in (Hodder, et al., 1996). All reagents were purchased 
from Sigma-Aldrich unless otherwise stated. All solvents were LC-MS grade unless 
stated otherwise. More specific methodology below was provided kindly by 
Lavrentis Galanopolous. 
 
The EGF5-7 protein (500 μl, 1 mg/ml) was pre-concentrated by ultrafiltration. 
The preconcentrated solution (33 μl, 3 mg/mL) was added to a PBS pH 6.8 
solution (77 μl, 10 mM NaCl).  A 50 μl aliquot was added to ammonium 
bicarbonate solution (NH4HCO3) (50 μl, 50 mM). Trypsin (1 μg/μl) was added to 
give an enzyme to protein ratio of 1:50 and 1:10 by weight. The resulting solution 
was incubated at 37 °C overnight. For the peptic digest, the pre-concentrated 
protein solution was diluted into a PBS pH 1.5 solution (50 μl, 10 mM NaCl).  
Pepsin (1 μg/μl) was added to give an enzyme to protein ratio of 1:50 and 1:10 by 
weight and the solution was incubated at room temperature overnight.   
 
Alkylation reagent stock NEM and TCA were stored as 100 mM and 20 % (w/v) 
solution (in water), respectively, at -20 C. For protein alkylation with NEM, the 
stock solution was diluted to either 5 or 20 mM concentrations, and the alkylations 
were conducted for half an hour at room temperature in the dark. For protein 
alkylation with TCA, the TCA stock was diluted in a 1:10 and 1:2 ratio to protein 
solutions and the alkylations were conducted for 15 min at 75 °C in the dark.  
 
ZipTip® (EMD Millipore) pipette tips were used before the injection of the 
proteolysed samples in the FT ICR MS. This ensured sample desalting, 
concentration and purification. Each C18 ZipTip was pre-washed twice with 100% 
ACN (100 μl) and 0.1 % formic acid (100 μl). The sample was passed through the 
tip ten times and then washing twice with 0.1 % formic acid (100 μl). Finally, it 
was eluted in 50 μl of 66 % ACN 0.1 % formic acid.  
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All LC/MS-ESI carried out in the SIRCAMS facility as described in section 3.4.1.1, 
using a solariX FT-ICR mass spectrometer coupled to a 12 Tesla superconducting 
magnet (Bruker Daltonics) and Ion Mobility Q-TOF Waters Synapt spectrometer 
(Bruker Daltonics). The apparatus was run in the positive-ion mode with a 
capillary voltage of 4 kV. The drying gas was set to 180 °C and 4-L/min. The 
nebulizer gas pressure was 5 bar. Parameters were optimised according to the 
experiment under investigation using the operating software, solariX control. FT-
ICR data were interpreted using Data Analysis (Bruker Daltonics). MS/MS was 
also performed on a solariX FT-ICR mass spectrometer. Specific ion species were 
isolated employing the mass resolving quadrupole (Q), and MS/MS was conducted 
applying either collision-induced dissociation (CID) or electron capture 
dissociation (ECD). Ion accumulation time was raised to at least one- to two-
seconds to escalate ion abundance. Fragmentation spectra were the sum of 50 - 
100 acquisitions over an m/z range of 200 - 3800. 
 
 
5.4.2 Results of the Biophysical Characterization of EGF-Rich Modules
  
5.4.2.1 Mass Spectrometry 
 
To ascertain whether the sample had the expected mass and to estimate the 
number of disulfide bonds present, a 30 μl aliquot of EGF5-7 was analysed via 
LC/ESI-MS (figure 5.15). With an error margin 0.1234 Da, the MW matched up 
perfectly with the simulated mass that was calculated based on subtracting 20 Da 
(for each assumed disulphide bond formed between Cys residues) from the 
predicted MW of the sequence in Expasy ProtParam and subtracting the Ala-Gly 
cloning artefact that P. pastoris sometimes adds to the N terminus of the protein 
due to incomplete Kex cleavage. The results suggest that all 20 Cys residues are 
forming disulfide bonds, including those found in the predicted long linker region 





Figure 5.15. LC/ESI-MS Analysis of EGF5-7: Shown in red is the actual mass obtained in a 
series of charge states. Below, in black, is the simulated mass predicted based on all 20 cysteines 
forming disulfide bonds.  
 
For correct mass identification of EGF7-10, MALDI-MS was used (due to 
machine availability). A 30 μl aliquot of EGF7-10 was utilized (figure 5.16). With 
an error margin of 0.11 Da, the MW matched up perfectly with the simulated mass 
that was calculated based on subtracting 24 Da from the predicted MW of the 
sequence in Expasy ProtParam and subtracting the Ala-Gly cloning artefact as 
before for EGF5-7. The results suggest that all 24 Cys residues are forming 
disulfide bonds, which is expected from a protein comprised of four EGF-like 




Figure 5.16. MALDI-MS of EGF7-10: Shown in red is the actual mass obtained in a series of 
charge states. Below, in black, is the simulated mass predicted based on all 24 cysteine residues 
forming disulfide bonds. 
 
Once the 15N-EGF5-7 sample had been produced, it was likewise important to 
ensure correct mass identification. However, due to the 15N isotope uniformly 
labelling the protein, the mass estimation would be less accurate. In this case it was 
more important the mass matched overall (between 16.3 and 16.5 kDa, depending 
on the proportion of protein with cloning artefact present, and assuming an 
enrichment of 99.9%). Figure 5.17 shows the results of the LC/ESI-MS of a 
sample of 15N-EGF5-7, demonstrating the roughly expected mass of 16.5 kDa, 
corresponding to the predicted mass of the protein where all nitrogen atoms 




Figure. 5.17. LC/ESI-MS Analysis of 15N-EGF5-7: Shown in black is the actual results and in 
red are the predicted results of the mass analysis. Key charge states are given above their peaks. 
 
 
5.4.2.2 Circular Dichroism 
  
CD was employed to assess the extent and nature of secondary structure in the P. 
pastoris-produced EGF5-7. The data could be compared with predictions on the 
basis of homology and with CD data for EGF5-6 produced in E. coli. Further, 
whilst EGF5-7 should be folded by way of expression and secretion from SS. 
Pichia, it is always good practice to ensure there is evidence for protein folding via 
CD and NMR (an activity assay should be additionally used if producing an 
enzyme or a protein with a known binding partner). The far-UV CD spectrum on 
a sample of EGF5-7 (figure 5.18 A) had a minimum at ~198 nm, and was similar 
to the CD spectrum collected on EGF5-6 (figure 5.18 B). As expected, analysis of 
the spectrum predicted that β-strand is the predominant secondary structure (over 
35%), with less than 5% predicted to be α – helical. The remainder comprised of 
~19% turns, and 41% disordered or unstructured (41%). However, the NRMSD 
value was several orders of magnitude higher than that seen for the CD of EGF5-
6 (figure 4.22), which reflected a poor fit of the spectra obtained compared to the 
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reference spectra used by Dichroweb (reference set 7). For this reason, a set of 
reference spectra from CAPITO (a web server-based analysis and plotting tool 
used for CD data) were identified that had similar levels of α-helix, β-strand and 
unordered regions. This gave an improved NRMSD value of up to 0.92. Finally, 
the EGF5-7 protein overall takes on the same CD curve shape as the P. falciparum 
triple EGF repeat protein fragment, cbEGF7-9, as shown in figure 4.21 D, albeit 
with a slight positive maxima around 227 nm, possibly a contribution from a small 
α-helical region. Differences between these two proteins could also be due, in part, 











Figure 5.18. Far UV CD Spectra of 15N-EGF5-7: A. The CAPITO-generated CD spectrum for 
EGF5-7 including quantitative analysis information from Dichroweb. B. Comparison of CD 




5.4.2.3 Thermal Analysis via TSA and NMR 
  
Unlike E. coli-produced EGFs 3-6 and 5-6 (see figure 4.23), P. pastoris-produced 
EGF5-7 did not appear to denature in the TSA (data not shown). This suggested 
that the protein was either not binding the dye molecules to give a significant 
relative fluorescence signal, or the addition of EGF7 made the protein significantly 
more thermostable. Due to the possibility of the former, two tests were conducted; 
boiling an aliquot of EGF5-7 for one-minute to see if any precipitant could be 
observed (thus indicating the lack of thermostability of the protein), and 
assessment of the sample via NMR, with the temperature being increased every 
30-minutes and a record of the HSQC obtained. With respect to the former, no 
precipitation was observed by eye. 
 
With respect to NMR analysis (figure 5.19 – 5.21), the spectrometer was only able 
to go from 25 C to 70 C due to the need to avoid damage to the probe at higher 
temperatures, so an exact temperature comparison to the TSA was unable to be 
carried out. Figure 5.19 shows how each cross peak (corresponding to an NH 
group, mostly in the backbone) migrated across the spectrum over the course of 
the experiment, moving from left to right as the temperature increased. This 
reflects the change in referencing relative to the water, whose peak position is 
temperature sensitive, not a genuine change in chemical shift, despite movement 
occurring in both the 1H and 15N dimensions. As the temperature increased, peaks 
appeared much faster, with the most pronounced changes occurring at 70 C. This 
is particularly seen when comparing and contrasting the HSQC data sets obtained 
at 40 C and 70 C. Both side chains and various residues had appeared from the 
spectra at the latter temperature, suggestive of changes in the local chemical 
environment, contributed in part from certain amide regions undergoing faster 
exchange. Alternatively, these changes are reflective of the sensitivity of the water 
peak to the temperature (likely changing more rapidly between 65 and 70 C), and 
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Figure 5.19. NMR-Based Temperature Shift for 15N-EGF5-7: HSQC spectra were obtained 
from a 15N-EGF5-7 sample over 30-minutes for each temperature (25 and 40 – 70 C). An example 
of the peak position at each temperature for one backbone amide group is shown inlaid in the 
figure. These spectra include folded peaks. 
 
Despite the excellent quality of HSQC spectra at 70 C, consistent with fully 
folded protein, there was evidence of a cloudy precipitate in the sample tube after 
exposure to this temperature. Examination of 1D spectra (figure 5.20) likewise 
indicated potential evidence for temperature-related loss of folding. Focusing on 
the amide region of the 1D NMR, the relative intensity of the peaks from 6.25 – 
9.5 ppm diminishes as the temperature increases, with up to 75 % less peak 
intensity at 70 C compared to the spectra obtained at 40 C (a specific example 
would be the peak at 8.5 ppm). In the methyl region, a complete abolition of the 
peak at ~0.25 ppm occurred by 60 C. However, no significant peak intensity 
alteration is discernible in the β-sheet backbone Hα region around 5 – 5.5 ppm 
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(except for a peak at ~5.25 ppm in spectra collected at 65 – 70 C). This is 
somewhat expected given the EGF domains are comprised of β-sheet with 
disulfide bonds that are generally high temperature resistant. This is indicative and 
consistent with a proportion of protein no longer in 100% native state that is 
precipitating out of solution (or at least a minor proportion of it doing so).  
 
 
Figure 5.20. 1D NMR Analysis of 15N-EGF5-7 from 40 to 70 C: Each spectrum is matched in 
colour to the temperature at which the experiment was performed. 
 
 
5.4.2.4 1D and 2D NMR Analysis 
 
Due to the aim of pursuing structural analysis via NMR, it was important to assess 
how EGF5-7 behaved under a variety of conditions such as pH/buffer type, salt 
concentration, protein concentration and temperature. First, a variety of buffers 
were tested to assess the impact of pH on the sample. This is important since a 
low pH generally results in better quality NMR spectra as it increases the rate of 
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backbone amide proton exchange with solvent.  Despite this, a pH as high as 6.5 
or 7.5 is desirable as it emulates physiological conditions. In figure 5.21, the 
sharpness and resolution of peaks at the lower pH (as expected). It appears that 
acetate and MES buffers give better spectra than PBS. 
 
 
Figure 5.21. Effects of pH/Buffer on 15N-EGF5-7: A. 1D NMR spectra of EGF5-7 in different 
buffers with different pH levels, as indicated by the colour coding. B. Zoom-in on the amide 
region. 
 
Screening to ascertain the minimum ionic strength of the buffer that our proteins 
can tolerate can be important for obtaining optimal signal-to-noise, especially 
when using a cryoprobe, which is adversely affected by salt. When a sample of 
EGF5-7 was dialysed into a zero-salt buffer, a precipitant quickly formed. Hence, 
50 mM and 100 mM NMR buffers were utilised. As shown in figure 5.22, 50 mM 
NaCl sample at pH 4 produced a high-quality 1D 1H spectrum. It was decided to 
use this concentration for future NMR experiments in order to increase the ease of 
tuning and matching of the solvent deuterium signal, and to reduce the longer 90 
pulse durations with the use of the cryoprobe. 
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Figure 5.22. Effects of Salt Concentration on 15N-EGF5-7: A. 1D NMR spectra of EGF5-7 in 
100 mM NaCl (red) and 50 mM NaCl (blue). B. Zoom-in on the amide region. 
 
Having identified the best buffer, the next step was to assess the effect of protein 
concentration on collection of NMR spectra. Obviously, a higher concentration 
would cut acquisition times, but protein aggregation is more likely at higher 
concentrations. Initially, a 1.3 mM sample of EGF5-7 was analysed to obtain 
“standard” 1D, NOESY and HSQC spectra, with the latter experimental data 
collected on a 1:2 diluted sample (figure 5.23). The 1D spectra showed good peak 
dispersion, similar to that of the 0.35 mM sample (in the 50 mM NaCl buffer) in 
the same buffer in figure 5.22 A. The NOESY spectrum shows clear evidence of 
long-range methyl protons in spatial proximity with aromatic protons, as well as 
αH-NH cross peaks; both these features are consistent with a folded protein; 
consistent with prior HSQC spectra. Minor differences were seen between the 
HSQC spectra of a 1.3 mM sample and a 0.65 mM sample of EGF5-7 (figure 5.23 
C and D respectively. Whilst both display well-dispersed peaks at the same 
locations, loss of peaks began to occur when the sample was at 1.3 mM, suggesting 
that mild self-association had potentially commenced. This indicated that 
concentrations below 1.3 mM should be used for 3D-structural data acquisition 




Figure 5.23. Effects of 15N-EGF5-7 Concentration on NMR Data Obtained: A. .1D NMR 
spectra of EGF5-7 at 1.3 mM acquired over 0.65-seconds. B. 2D NOESY on the 1H - 1H plane of 
EGF5-7 at 1.3 mM. Mixing time was 120 milliseconds (msec), acquisition time was 0.1-seconds 
indirectly and 26 msec in 15N plane plus 14.5 msec in indirect proton plane. C. 2D HSQC spectra 
of 1.3 mM EGF5-7 obtained over five-minutes. D. 2D HSQC spectra of 0.65 mM EGF5-7 
obtained over 55-minutes. 
 
Next, an assessment of temperatures and their impact on NMR data acquisition 
was required. Whilst previously (section 5.4.2.3), a range of higher temperatures 
(up to 70 C) was explored to assess thermal stability, the goal here was to 
optimise, over a 25 to 37 °C range, the temperature to be used for data acquisition 
(figures 5.24A and 5.24B, respectively). At 37 C, the peaks in the 1D spectra 
became significantly better resolved, particularly in the β-sheet backbone H α 
region (around 5 – 5.6 ppm). Likewise, the HSQC showed that the peaks 
sharpened up at 37 °C. However, spectra were judged to be almost as sharp and 
well-resolved at 25 C.  It was decided, on balance, to use the lower temperature 
(25 °C) for initial collection of 3D NMR data. This should lessen the danger of 
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proteolytic degradation that might occur over the extended period (up to a month) 
required to acquire the full suite of spectra needed for structure determination. 
Subsequently, if the sample remained intact, other temperatures could be used for 
the collection of further NMR spectra.  This strategy could provide a range of data 
sets that might be useful, particularly if there were significant issues with 
intermediate exchange at a particular temperature for a particular residue. Overall, 
the data generated here reveal a range of conditions that looked promising for 
acquiring spectra for a double-labelled sample of EGF5-7, particularly the variety 




Figure 5.24A. 1D NMR of 15N-EGF5-7 at 25, 32 and 37 ºC: A. 1D NMR spectra of EGF5-7 at 
25 C (green), 32 C (red) and 37 C (blue). B. Zoom-in on the amide region for each. 128 scans 




Figure 5.24B. HSQC of 15N-EGF5-7 at 25, 32 and 37 ºC: The HSQC shows the peak shift as 
temperature increases from 25 C (blue) to 32 C (red) and 37 C (purple). The HSQC includes 
folded peaks (dark green, violet and bright green for temperatures 25, 32 and 37 C, respectively). It 
should be noted that the spectra were referenced to water.  
 
With respect to EGF7-10, a pH/buffer screen was carried out using 50 mM NaCl 
in each buffer (figure 5.25). The buffer with the lowest pH (the acetate buffer) 
yielded the best peak separation in the β-sheet backbone H α region (around 5.5 – 
5.75 ppm). However, each EGF7-10 sample provided relatively poor-quality 
spectra when assessed in HSQC (for a temperature shift experiment like in figure 
5.24, which also showed the peaks getting sharper at higher temperatures; data not 
shown) and particularly poor quality spectra from the NOESY experiments (data 
not shown). This was likely due to the presence of some minor aggregates and 
proteolytic fragments, in addition to the larger size of the protein (~20 kDa, which 
may be elongated thus having a reduced tumbling speed). Due to this, and the time 
constraints, it was decided to focus on EGF5-7 for further work, including 




Figure 5.25. Effects of pH/Buffer on 15N-EGF7-10: 1D NMR spectra of EGF7-10 in different 
buffers with different pH levels, each indicated by their colour coding. 
 
However, a fresh 15N-EGF7-10 sample was prepared in a MES buffer for later use 
in calcium cation binding assays. This sample yielded a well-dispersed set of proton 
peaks in the 1D NMR (figure 5.26 A), and well-resolved amide signals on the 
HSQC, which were likewise wee-dispersed (figure 5.26 B). However, the NOESY 
shown in figure 4.35 C was still relatively weak compared to the one obtained for 
EGF5-7 in figure 4.31 B; although the presence of through-space cross peaks is 
still able to be visualized. Nonetheless, through-space cross peaks between side-
chain methyl groups and backbone amides, consistent with folded protein, are 
visible in this spectrum.  This sample was judged to be of sufficient quality for use 
in the calcium-binding studies described in section. 5.7. 
 215 
 
Figure 5.26. 1H, HSQC and NOESY NMR of 15N-EGF7-10: A. 1D NMR spectra of 32 μM 
EGF7-10 (20 mM MES, 75 mM NaCl, pH 6.55). B. HSQC spectra obtained over 60-minutes. C. 





No potential crystals were observed for the EGF7-10 sample, indicating it would 
require further optimization for crystallization. After initial crystallization trials 
with a 12 mg/ml sample of EGF5-7 failed to yield any protein crystals (as 
determined by synchrotron analysis, data not shown), more concentrated EGF5-7 
samples (25 mg/ml) were screened, with three wells yielding potential crystals 
(figure 5.27). When cryoprotectant was added to the well shown in figure 5.27 A, 
salt crystals rapidly formed indicating the cryoprotectant was unsuitable for mixing 
with the buffer in the well, and rendering the sample useless (unfortunately, due to 
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delays from the EPPF facility over several months, the well partially dried out, 
making it difficult to remove a sample of the contents that could have been used 
to first check this procedure). The hexagonal crystal in the well shown in figure 
5.27 B was successfully loaded into a loop and sent to the synchrotron for analysis, 
revealing the presence of what appeared to be small molecules, not protein (data 
not shown). In attempting to load into a loop the potential crystal shown in figure 
5.27 C, it crumbled into powdery pieces in a way that indicated it might have been 
a protein crystal (personal communication, Atlanta Cook, June 2017). Based on the 
encouraging results for two of the three potential crystals, a set of screening 
conditions was set up around the contents of the wells from figure 5.27 A and C. 
However, after three months, whilst precipitation occurred in over 50% of the 




Figure 5.27. Second Crystal Screen of EGF5-7: A. A cluster of fractal-like crystals. Conditions- 
40% v/v ethanol/5% w/v PEG 1000 (precipitant), no salt, 0.1 M phosphate/citrate pH 4.2. B. A 
single hexagonal crystal. Conditions- 1.8 M ammonium phosphate monobasic, 0.1 M Sodium 
acetate trihydrate pH 4.6. C. A single brownish crystal shaped like a triangular log. Conditions- 4.3 








5.4.2.6 Homology-Based Modelling and SAXS Analysis 
 
Using SWISS-Model (and confirming overall structural similarity with another 
modelling program, I-Tasser), homology-based models for EGFs 5-7 and 7-10 
were generated with the final selection based on the best Global Model Quality 
Estimation (GMQE) and QMEAN scores (figure 5.28 A and B). For both 
proteins, the GMQE scores (a measure of quality estimation combining qualities 
of target template alignment, in which higher numbers indicating higher quality; 
numbers between 0 and 1) reflected a mediocre level of model quality when 
compared to the library of PDB structures used to assess the model against. 
Likewise, the QMEAN scores (a type of composite scoring based on various 
geometrical properties to give an absolute quality estimate on the basis of a single 
molecule model) of both proteins reflect a model of potentially low quality; any 
QMEAN is said to be of unreliable quality if the value is below -4.0. Due to the 
various primary sequences that can give rise to EGF-like domains, the alignments 
and comparisons to libraries of proteins used by SWISS-Model may have had a 
significant impact on the scores retrieved. Due to this, a basic comparison between 
the CD data from figure 5.18 (for EGF5-7) and the modelling data was carried out 
to assess the amount of secondary structure each gave (table 4). This revealed that 
the CD data overall best matched the SWISS-Model results rather than I-Tasser, 
showing each to have approximately the same level of α-helix and β-strand in 
terms of percentage of residues analysed, with the CD data estimating slightly 
higher levels of secondary structure than the modelling predicted (however this 
may be due to the model only being able to cover 84% of the protein sequence). 
The I-Tasser model data gave a more accurate match of α-helix, but was 
significantly lower for the estimated amount of β-strand, with almost half as much 
predicted. 
 
Both protein models of EGF5-7 and 7-10 contained β-strand in each linker region 
between the EGF-like domains. Characteristic anti-parallel β-strand were predicted 
to lie within these domains. Both proteins were predicted to be elongated rather 
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than globular, as also observed in many other proteins comprised of in-tandem 
EGF-like domains. However, it should be mentioned that the program assumes 
that the disulfide bonds are in the regular order as found in most EGF-like 
domains; that is Cys1-Cys3, Cys2-Cys4 and Cys5-Cys6. If this assumption turns 
out to be false, it degrades the usefulness of the model, particularly since it impacts 
on the predictions of domain boundaries. Nonetheless, the model generated here 
could be useful for estimating the surface positions of any molecular partner 
interactions mapped by chemical shift perturbations (in lieu of a high-resolution 
crystal or NMR structure).  
 
Next, SAXS-based analysis was carried out on a sample of EGF5-7 (0.5 mM 
protein in 20 mM sodium acetate pH 4 and 75 mM NaCl). After the collection of 
data, the homology based model for EGF5-7 from figure 4.38 A was used to fit 
the SAXS data using the program CRYSOL (Appendix figure A1) to yield a χ2 
value of 1.0, which lies within the acceptable range of 0.9 and 1.2 (Franke, 
Jefferies, & Svergun, 2015). Due to the goodness of fit between experimental and 
collected data, an ab initio approach was taken using the homology-based model 
generated in figure 4.38 A using the modelling program DAMMIF, and the 
resultant models superimposed over each other (figure 5.28 C and D). The overall 
SAXS model shows an elongated, tick-shaped molecule and an overall good fit 
when superimposed with the space-filling model of EGF5-7 (figure 5.28 C). 
Interestingly, the original structure derived from homology-based modelling best 
fits into the ab initio SAXS model when linker flexibility allows for increased 










Figure 5.28. Homology Modelling and SAXS Models: A. The model generated for EGF5-7. 
The N-terminal (N) domain starts with Ser 723 of EGF5, ending at Ile 753, before the start of the 
linker commences at Cys 754. Each EGF-like domain’s anti-parallel β-strand is highlighted by the 
green boxes. The C-terminus (C) ends at Lys 846. 69% of the sequence was given computational 
coverage. The GMQE is 0.40 and the QMEAN score is -5.57. The model generated is based on 
homology with Neurogenic Notch Homologue Protein1 (5FMA in the PDB). B. The model 
generated for EGF7-10. The N-terminus starts with Tyr 818 of EGF7, and ends with Asn 1005 at 
the C-terminus. 88% of the sequence was given computational coverage. The GMQE is 0.53 and 
the QMEAN score is -4.78. The model generated is based on homology with Neurogenic Notch 
Homologue Protein1 (5FMA in the PDB). C. The average fitted ab initio model of EGF5-7 
produced via SAXS modelling. Grey spheres are from the analysed SAXS data whilst the orange 
spheres are the fitted-in data from the homology-based model derived from (A), with adjustments 
made for the potential flexibility of the long linker region. D. Rigid body modelling of the 
homology-model structure of EGF5-7 from (A), with adjustments made for the potential flexibility 
of the long linker region with fitting into the SAXS-derived data via special alignment.  
 
 Swiss model data I-Tasser data CD data 
α-helix 3.03% 5% 4.8% 
β-strand 31.06% 17.85% 35.3% 
Table 4. Computational Modelling and CD Data Comparison. Data given are for EGF5-7. 
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5.4.2.7 Assessment of Free Cysteines and Disulfide Mapping 
 
Despite the PfRipr proteins having been produced in P. pastoris, a eukaryotic 
expression system (preferably, in numerous ways, to the use of a bacterial host that 
would necessitate re-folding in many cases), it was important to assess the 
potential that the cysteines found in the linker were oxidized as a disulfide bridge 
as opposed to being reduced and free cysteine residues. Further, a eukaryotic-
expression system is not always guaranteed to produce correctly-folded 
recombinant protein; therefore, it becomes important to still assess these proteins 
for evidence of correct folding (covered in more detail in (Gasser, et al., 2007)). A 
sample of EGF5-7 was used to assess the presence of free cysteine residues by 
exposing a third of the sample to NEM (which would associate with free thiols), a 
third to a reducing agent, then NEM, and a third as a control. The results in figure 
5.29 show that all cysteines form disulfide bonds based on the fact that no size 
change is detected from the control sample. However, due to the paucity of 
molecular weight increase when EGF5-7 was mixed with NEM and TCEP (figure 
5.29 C), this suggests a failure to reduce the protein with the TCEP used.  
 
 
Figure 5.29. MS-ESI Assessment of Free Cysteines in EGF5-7: A. Native EGF5-7. B. EGF5-7 
+ NEM. C. EGF5-7 reduced with TCEP + NEM. 
 
Pepsin was used, initially, to enzymatically process EGF5-7 prior to disulfide 
mapping using MS, however the results obtained suggested incomplete digestion 
(data not shown). Trypsin, likewise, produced an incomplete enzymatic digest. 
Trypsin preferentially works at a pH of 6.8, potentially explaining its poor activity 
when EGF5-7 was presented as substrate in an acetate buffer at pH 4. A buffer-
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exchange was attempted on a small size-exclusion column, but this did not appear 
to go to completion based on the final pH of the sample. A mini dialyzer was 
chosen for efficient buffer exchange so that the tryptic digest could be carried out 
again; however, at the time of writing this experiment is on-going.  
 
 
5.5 1D, 2D and Triple-Resonance NMR Analysis of 15N/13C-Labeled 
EGF5-7 
 
5.5.1 Methods: 1D, 2D and Triple-Resonance NMR Analysis of 15N/13C-
Labeled EGF5-7 
 
NMR was carried out as per section 4.4.1.5 at the University of Edinburgh using 
the 600 MHz Bruker AVANCE 14.1 – Tesla NMR spectrometer. The 800 MHz 
spectrometer was used to collect data for T1/T2 relaxation and heteronuclear 
1H-
15N NOE experiments (all relaxation experiments carried out at 25 ºC). CCPNMR 
Analysis software version 2.4.2 (http://www.ccpn.ac.uk/v2-
software/software/analysis) was used. Dr. Brian Smith at the University of 
Glasgow provided training and help with the data analysis. The suite of 
experiments carried out for 3D structure determination included- 15N HSQC, 13C 
HSQC, CBCA(CO)NH, CBCANH, HBHANH, HBHA(CO)NH, HN(CA)CO, 
HNCO, NOESY HSQC NH, NOESY HSQC 13C, HCC(CO)NH, HCCH, 
HBCBGCDHD, HBCBCGCDCEHE, HSQC CTET, and 15N-edited TOCSY 
HSQC. Experiments were first carried out at 25 ºC then repeated at 40 ºC. An 
overview of resonance assignment and assignment of backbone resonances can be 
found in sections 2.3.4.3 and 2.3.4.4, respectively, (Makou, 2013).  
 
Relaxation data plotting using Prism was carried out by William Godfrey at the 




5.5.2 Results: 1D, 2D and Triple-Resonance NMR Analysis of 15N/13C-
Labeled EGF5-7 
 
For 3D structure determination by NMR of a sizeable protein, a plethora of 2D 
and 3D experiments must be carried out on a 15N/13C-labeled sample. The 1H,15N-
HSQC serves as the reference spectrum.  Each cross peak in the HSQC that 
corresponds to a backbone amide group, must be carefully picked by the software 
with manual intervention, and then catalogued using the software. The produces a 
table which contains chemical shifts in both the nitrogen dimension and in the 1H 
dimension for each backbone amide and the main initial task is to assign each 
cross-peak to a sequence-specific amino acid residue. The results of the initial 15N-
HSQC of 15N/13C-EGF5-7 are shown in figure 5.30. Approximately 120 peaks 
were visible, excluding significantly overlapped peaks and the peaks corresponding 
to side chain amide groups of asparagine and glutamine residues. No significant 
differences were noted between the 15N/13C-labeled sample and the dll sample that 





Figure 5.30. 15N-HSQC of 15N/13C-EGF5-7 at 25 C: A. The protein was at a concentration of 
0.5 mM and in a buffer comprised of 20 mM sodium acetate pH 4 + 45 mM NaCl + 10% D2O. 
Folded peaks are shown in green and the orange box highlights the location of the Asn/Gln NH2 
peaks. B. An overlay with the HSQC spectra obtained from the dll-EGF5-7 sample (red spectra is 
15N/13C-EGF5-7, blue is dll-EGF5-7). 
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After using the automated peak picking tool, manually removing the erroneously 
picked peaks, and finding hidden peaks (validated by confirming signals present in 
each of the CBCA(CO)NH, CBCANH, HNCO and HN(CA)CO spectra), the 
total peak count was at 138. The 15N/13C-EGF5-7 protein is comprised of 144 
amino acids including the Ala-Gly-Ile-Pro cloning artefact at the N-terminus (a 
proportion of the protein molecules will have an additional Glu-Ala in front of 
this), with four proline residues that will not produce an HSQC signal due to them 
not possessing an amide group. Therefore, one would expect to be able to count 
139 peaks if the N-terminal Ala residue is undergoing intermediate exchange; 
otherwise 140 peaks should be seen. Given that 138 peaks were located, this 
indicates another residue may be in intermediate exchange, or the C-terminal Glu 
residue is missing from the protein. Further, to complete the peak identification, 
data from repeating the aforementioned NMR experiments at 40 C were used, as 
this resulted in better peak separation. For this a temperature scan was taken from 
10 – 40 C to track the peaks and transfer the picked peaks accordingly (figure 
5.31). At the higher temperature there was a significant improvement in the quality 
of the spectra, with improved resolution of peaks that were clustered together or 
overlapping. This led to a significant improvement in the level of accurate peak 
picking that would facilitate the in-depth analysis of the type of amino acid most of 
these peaks represented. Once a peak was picked, the atoms of the amide group of 




Figure 5.31. 15N-HSQC Temperature Scan for 15N/13C-EGF5-7: A. An overlay of HSQC 
spectra from 10 C to 40 C, going up in 5 C increments (the inlaid box show which peaks were 
acquired at which temperature in C). B. The overlay of the HSQC spectra for samples tested at 25 
C and 40 C. C. A zoomed-in example of what appeared to be a single peak from the HSQC 
acquired at 25 C. D. The peak in (C) contained a group of three overlapping peaks that was 
revealed in the HSQC run at 40 C. Spectra were acquired over the course of one-hour for each 
temperature point. 
 
In order to garner further information about each peak, two complementary pairs 
of experiments were used (CBCANH + CBCA(CO)NH, and HNCO + 
HN(CA)CO), providing signals for the Cα, Cβ, and carbonyl atoms (the carbon of 
the CO group). An example of this is shown in figure 5.32. The base amide signal 
serves as the “i” amino acid residue (that is, the residue of interest), with the 
CBCANH experiment revealing its Cβ and Cα atoms. Where a peak appears in 
both the CBCANH and CBCA(CO)NH spectra, it will overlap, indicating this is 
the Cβ and Cα atoms of the previous amino acid (i-1). The HN(CA)CO and 
HNCO spectra combined gave rise to three peaks; a larger single peak in the 
HNCO spectra representing the i-1 13C(O), and two peaks in the HN(CA)CO, 
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with the smaller overlapping with the HNCO peak and the other belonging to the 
13C(O) of the i-amino acid. 
 
 
Figure 5.32. Cα, Cβ and C(O) Assignment: A. The base amide peak from the HSQC experiment 
shown in figure 4.41 B (40 C data set). Navigation from this peak to the carbon dimension reveals 
the peaks seen in B – D. This base amide signal is amino acid “i”. B. A pair of Cβ carbons with the 
brown peak belonging to the results of the CBCA(CO)NH data (therefore representing the i-1 
amino acids’ Cβ) and the green peak belonging to the CBCANH data (therefore, this Cβ belonging 
to the i-amino acid). C. A pair of Cα carbons with the i-1 Cα (brown) and the i Cα (pink). D. A pair 
of C(O) peaks; i-1 in blue and i in red. 
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After peaks in the triple resonance NMR spectra described above were picked and 
the atom resonance and type assigned, the next step was to commence the 
backbone assignment by either going in the i-1 or i+1 direction. This involved 
setting up “strips” corresponding to amide route resonances, for the linking of 
sequential residues using the 13C experiments. This “walk” between residues allows 
for increased confidence with assignments using the CCPNMR Analysis tool. 
Shown in figure 5.33 is an example of one such walk, with assigned residues K775 




Figure 5.33. Sequential Strips Walking Along the Backbone of K775 – N779: The strips have 
been placed in sequential order and correspond to residues K775 – N799 of PfRipr. Each Cβ, Cα 
and C(O) atom has been labelled for their respective residue. Solid lines join the i-amino acid with 
the i+1 residues, whilst the dotted lines connect the i-1 residue to the i-amino acid within the same 
strip. 
 
Regarding the data acquired at 40 C, this method was utilized to attain 86% of the 
backbone assignment (up from 70% with the original 25 C data), with 
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confirmation of various difficult to assign residues made via the additional 
incorporation of HBHA(CO)NH, HBHANH, HC(CCO)NH and NH-NOESY 
experiment spectra. These experiments allowed for an investigation of the side-
chain protons, increasing confidence as to the type of amino acid residue assigned 
to a given HSQC peak. The chart shown in figure 5.34 shows the primary 
sequence of EGF5-7 indicating the extent of NH and NH Cα and Cβ assignments 
along with HSQC showing assignments for 124 out of 144 amino acids residues. 








Figure 5.34. Assigned 1H-15N-HSQC Spectrum of EGF5-7: Sidechains of NH resonances for 
Gln and Asn residues are connected by orange lines. Folded peaks are shown in yellow. Where the 
amino acid type is assigned, but not the location in the protein, the 3-letter code is used. Below the 
HSQC is the assignment log; green letters are assigned residues, black are unassigned, prolines are 
in bold, linker regions are italicised, and each EGF-like domain is underlined. 
 
All of the unaccounted for residues are predicted to be in flexible loop regions of 
the protein (based on the SWISS-Model generated structure shown in figure 4.38 
A), with the exception of C766 and I767 which are predicted to be at the end of a 
putative β-strand in the long linker region between EGFs 5 and 6. Due to 
numerous delays out of the control of the author, completion of the 3D structure 
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of EGF5-7 was unable to be carried out in the time allowed. However, once the 
side-chains become assigned, the missing residues may be teased out. If this does 
not occur, then analysis of the data from the experiments carried out at 10 C may 
help reveal additional connecting peaks in the carbon dimension experiments.  
 
However, given the level of backbone assignment a simple histogram could be 
generated for the mobility of each known amino acid (specifically, the proton delta 
chemical shift) during the temperature shift between 25 and 40 C, based on the 
data in figure 5.31 B (see figure 5.35 for the results of the plot). The largest peak 
shift was seen with V797 in EGF6 at just under 0.2 ppm, predicted to be in a 
flexible loop connecting the anti-parrallel β-strands. No discernable shift was seen 
in N791, which is predicted to be at the tip of the first anti-parrallel β-sheet. Using 
a cut-off of 0.1 ppm, the EGF-like domain that had the lowest percentage of 
significant shift during the temperature increase (significant here defined as a shift 
over 0.1 ppm) was EGF6, with 60% of the assigned residues not undergoing a 
signficant shift. EGF5 had 60% of the assigned residues undergoing significant 
chemical shifts, and EGF7 had slightly over 55% undergoing a significant chemical 




Figure 5.35. Residue Shifts From 25 – 40 C: The demarcation of each EGF-like domain is 
given at the bottom of the histogram. Each arrow highlights the residue that was least affected by 
the increase in temperature; purple is D721, green is N791, and blue is K850. The largest shift is 
highlighted was V797. Shift distance is in ppm. Histogram made with CCPNMR Analysis. 
 
To further understand the dynamics of EGF5-7, T1 (spin-lattice), T2 (spin-spin), 
and heteronuclear (1H-15N) NOE relaxation experiments were carried out at two 
magnetic field strengths; 600 MHz and 800 MHz (so as to create a comparison of 
the data sets). An analysis of these parameters should help identify and 
differentiate between mobile and rigid amino acids residues, which can be 
discussed in the context of the homology-based structual model of the protein. 
The results are summarised in figures 5.36 – 5.38.  
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Figure 5.36. 15N Relaxation Data for 15N/13C-EGF5-7 (800 MHz): Plots are shown for the 
relaxation times measured in milliseconds (ms) for the 15N spin-lattice (T1) and 15N spin-spin (T2) 
experiments, in addition to the heteronuclear (1H, 15N) NOE values, plotted against residue 
number. Error bars are given in standard deviation. 
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Figure 5.37. 15N Relaxation Data for 15N/13C-EGF5-7 (600 MHz): Plots are shown for the 
relaxation times measured in ms for the 15N spin-lattice (T1) and 15N spin-spin (T2) experiments, in 
addition to the heteronuclear (1H, 15N) NOE values, plotted against residue number. No error bars 




Figure 5.38. Histogram of 15N Relaxation Data for 15N/13C-EGF5-7 (800 MHz V 600 MHz): 
Plots are shown for the relaxation times measured in ms for the 15N spin-lattice (T1) and 15N spin-
spin (T2) experiments, in addition to the heteronuclear (1H, 15N) NOE values, plotted against 
residue number. Data in blue is that from the 800 MHz spectrometer whilst the maroon data is 
from the 600 MHz spectrometer. Each EGF-like domain boundaries are shown atop the figure. 
 
Data collected from both fields shared the overall same pattern; more disorder in 
the first four residues that comprise the floppy N-terminal region (N714, K715, 
C716, and D717) as reflected by the long T1 and T2 values combined with the 
negative heteronuclear NOE values, relatively uniform NOE levels with a drop in 
the C-terminus (indicative of some flexibility), and an overall pattern of a high T1 
to T2 ratio indicative of structural rigidity, with the T1 values highest in the second 
EGF-like domain of EGF5-7. The one anomaly is the increased T2 signal in the 
600 MHz data for residue N823. The anomalous T2 value (in the 600 MHz data) 
for residue N823 is likely to be an artefact of the fitting process. 
 
More specifically, long T1 values that are correlated with short T2 measurements 
indicate molecular rigidity, however, these generally are scaled together; the 
residues from 770 to 810 (of EGF6) have longer T1 values than the residues in 
EGF5 or 7, yet the T2 values remain the same overall. Given the protein size of 
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16.52 kDa, one might expect the T2 values to be around 100 ms for these residues 
if there were scaled proportionally to the T1 increases. This indicates that not only 
is the region inflexible but that it is likely self-associating with other molecules of 
EGF5-7 in solution. Given that the T1 ratio increase is not present in the residues 
of the other EGF domains, EGF5-7 is probably undergoing intermolecular 
association via the central EGF domain whilst the protein as a whole does not 
behave as one entity. Given that this dimerization was not seen on gel filtration 
analysis, it is likely this association (if truly occurring) is due to the relatively high 
protein concentration of 0.5 mM. The combination of flexible regions of the 
protein and intermolecular association may also explain why crystallography 
continued to fail despite testing a variety of protein concentrations and crystal 
buffer conditions.  
 
With respect to the overall uniformity of the NOE, the mean measurement of 
non-terminal residues analysed was 0.56 (0.51 for the 600 MHz data), indicative of 
a relatively rigid protein (the closer the value to 1, the more rigid, whilst the inverse 
is true). The residues that significantly dropped below this value in the NOE (aside 
from the aforementioned N- and C-terminal residues) include: K736, Q737 and 
C739 in EGF5, G763 in the long linker between EGFs 5 and 6, and E793 in 
EGF6, K842 and G843 in the C-terminus of EGF7. By looking at the zoom-in of 
the previously established SWISS-Model predicted structure of EGF5-7, all of 
these residues are found in loop regions of the protein, which would make sense if 




Figure 5.39. Location of Residues with Low Heteronuclear NOE Values: The above model 
shows the predicted structural regions of some residues identified as having a below average 
heteronuclear NOE score relative to the rest of the residues comprising EGF5-7 (excluding N- and 
C-terminal flexible regions. All are predicted to be found in loop regions. Model made with SWISS-
Model. 
 
Unfortunately, lack of time prevented follow up studies including the total 
correlation calculations or measurement of residual dipolar coupling (RDC). 
However, an NMR-based assessment of the stability of 15N/13C-EGF5-7 over time 
was carried out using 1D and 2D NMR techniques. Figure 5.40 display the 1D 
spectra obtained from three points in time over a ~9-month period, where the 
sample had spent ~40 days at 25 C, 10 days at 40 C and the rest of the time at 4 
C. No anomalies are found in the amide region, but there are two minor 
additional peaks that appear in the methyl region at around 3.8 and 1.8 ppm after 
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the 4.5 months. However, these peaks were very slightly present on the shoulders 
of the main peaks they are found on even at the beginning of the experiment and 
do not overtly look like the products of any protein degradation. Additional 
evidence for a dearth of sample degradation was a lack of relative loss of intensity 




















Figure 5.40. 1D NMR Monitoring of 15N/13C-EGF5-7 Over Time: A. The amide region 
zoomed in from when the 25 C experiments commenced (blue), after one week of continuous 
sample exposure to the 800 MHz spectrometer (red), and during the 40 C experiments (green). B. 
The methyl region zoomed in. Asterisks’ highlight anomalous peaks. The April measurements were 
taken under a week before commencing the relaxation experiments on the 600 MHz spectrometer 




As an additional test of sample quality and robustness, a series of HSC spectra 
were also recorded (figure 5.41). No peak shifts or loss of signal over time were 
observed, and all peaks remained well dispersed. These observations indicate the 
protein remained natively folded over many weeks. This data is suggestive of a 
strong and stable protein, which is of benefit for follow-up studies in the future. 
 
 
Figure 5.41. 15N-HSQC Monitoring of 15N/13C-EGF5-7 Over Time: An overlay of each HSQC 










5.6 EGF-Rich PfRipr Protein Binding Assays to CyRPA 
 
5.6.1 Methods: EGF-Rich PfRipr Protein Binding Assays to CyRPA 
 
5.6.1.1 Gel-Filtration Based Binding Assays 
 
Experiments were carried out at the University of Edinburgh by the author, and 
repeated at the Walter and Eliza Hall Institute by Dr. Wilson Wong using the 
PfRipr EGF-rich recombinant proteins produced in Edinburgh. Ripr EGF 
domains (10 μg for EGF1-2, 10.6 μg for EGF5-7; 15 μg for EGF7-10; 10 μg 
EGF3-10) were incubated with CyRPA (30 μg) at equal molar ratio in 1 × PBS at 
room temperature for one-hour. Samples were separated on a size exclusion 
column (Superose 6 10/300) in elution buffer (20 mM Tris, 150 mM NaCl, pH8) 
and peak fractions were analysed by reducing SDS-PAGE. The use of increased 
protein amounts was also attempted (for example, 40 μg of CyRPA and 80 μg of 




5.6.1.2 ELISA-Based Binding Assays 
 
ELISA assays carried out using midisorp 96-well plates (Tomtec) and a 
SpectraMax M5 multimode plate reader at the EPPF. All proteins were prepared in 
PBS, blocking steps carried out using 5% w/v skimmed milk powder made up in 
SuperBlock (ThermoFisher). Washing steps and detection was done using 
methods described in section 3.2.2. Unless otherwise stated, all steps were carried 
out at room temperature. Wash steps were carried out between each step. Two 
methods were employed. 
 
The first method involved coating the plates with 2 μg of CyRPA (donated by Dr. 
Wilson Wong) overnight at 4 C, then blocking for one-hour. 4 μg of the EGF 
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proteins (EGFs 1-2, 3-6, 5-7, 7-10, 3-10) was titrated out in a 1:2 dilution series 
then added to the CyRPA-coated wells and incubated for 1.5-hours. A 1:4000 
dilution of rabbit polyclonal anti-PfRipr antibodies was added (a 1:1000 solution of 
anti-EGF1-2 antibodies used for the EGF1-2 sample) and incubated for one-hour, 
followed by the addition of the HRP-conjugated antibody (1:2000) for another 
hour, then developed. Controls included CyRPA>Rh5>αRh5>detection (positive 
control), CyRPA>BSG>αBSG>detection (negative control), Rh5>BSG> 
αBSG>detection (positive control), each protein on their own detected with their 
cognate antibody, blank coating (only receiving antibodies and detection reagent), 
and blocking solution>each protein>protein detection. 
 
The other way the ELISA was set up was to do as above but coat plates with 5 μg 




5.6.1.3 NMR-Based Binding Assays 
 
A sample of 15N-EGF5-7 was prepared and aliquoted into four 0.5 ml Eppendorf 
sample tubes at a concentration of 50 μM in 20 mM MES pH 6.55, 75 mM NaCl, 
10% v/v D2O (this was the buffer matching the CyRPA sample). A 1D and 2D 
15N-HSQC experiment was carried out on the sample for the starting control (45-
minute acquisition time at 25 C), then 50 μl of 1, 5 and 10 molar excess of 
CyRPA was added to each of the three remaining sample tubes containing 15N-
EGF5-7, these were incubated at room temperature for ten-minutes, then analysed 
for chemical shift perturbations in HSQC spectra. Topspin software was used to 





5.6.2 Results: EGF-Rich PfRipr Protein Binding Assays to CyRPA 
 
5.6.2.1 Gel-Filtration Based Binding Assays 
 
None of the PfRipr EGF-rich proteins tested (EGFs 1-2, 5-7, 7-10 and 3-10) 
showed evidence of binding to CyRPA (full data not shown). An example of the 
negative results obtained is shown in figure 5.42, using EGF5-7 produced in SS 
Pichia (other proteins were produced in E. coli aside from EGF7-10). These results 
may be indicative that a non-EGF region of PfRipr is involved in binding to 
CyRPA. However, since EGF3-10 was the product of protein refolding and was 
never fully biophysically characterized, it cannot be ruled out that EGF3 or 4 is 
not involved in binding. Unfortunately, the refolded EGF3-6 material that was 
produced had been used up by the time of testing, and time did not permit further 
purification. Another alternative explanation is that the complex formed is 
relatively weak and unstable/transient. Due to this it was decided to pursue an 








Figure 5.42. SEC-Based Binding Assay Between CyRPA and PfRipr EGF-Rich Proteins: A. 
CyRPA only. B. EGF5-7 only. C. CyRPA + EGF5-7. D. SDS-PAGE gel of various fractions taken 
from under the curve. E. Molecular weight size standards given in kDa and where they elute. 
 
 
5.6.2.2 ELISA-Based Binding Assays 
 
After numerous attempts, the initial ELISA set-up yielded positive results for the 
controls only (aside from EGF1-2 which was not detected); no experimental wells 
yielded any results as all appeared to show equal levels of positive signal come 
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through at the same strength (data not shown). This also occurred when the 
alternative set up of the ELISA was carried out (data not shown). This was 
suggestive that perhaps the protein concentration or antibody concentration was 
not optimal. However due to the focus on NMR-based studies, this was unable to 
be followed up. 
 
 
5.6.2.3 NMR-Based Binding Assays 
 
NMR can be a powerful tool for screening the weak interactions between 
biomacromolecules (Vinogradova & Qin, 2012). It was decided to utilize this 
approach as the SEC results implied that any interactions between CyRPA and 
EGF fragments are likely to be weak. Given the abundance of 15N-EGF5-7 that 
had been produced, and there was only enough CyRPA to carry out the one 
experiment (ergo, no 15N-EGF7-10 was able to be tested). However, no peak shift 
or intensity change was shown when comparing each CyRPA titration to the 15N-
EGF5-7-only sample (data not shown). This became conclusive evidence that the 
EGF5-7 region of PfRipr was not involved in forming either a tight or weak 
intermolecular complex with CyRPA. 
 
 
5.7 Ca2+ Titration Study of PfRipr Proteins 
 
5.7.1 Ca2+ Titration Study Methods 
 
NMR experiments were performed on an AVANCE 800 MHz (Bruker) 
spectrometer using a 5-mm triple resonance cryoprobe, with experimental set-up 
performed by Juraj Bella. NMR data was acquired using Bruker TOPSPIN 1.2 and 
analysed using MestReNova software and CCPNMR Analysis. Advice on the 
design of the titration study was provided by Prof. Dusan Uhrin and Dr. Andrew 
Herbert. Five 0.5 ml aliquots of 40 µM 15N-EGF5-7 were prepared in 20 mM MES 
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pH 6.55, 50 mM NaCl, 10% v/v D2O. 50 μl samples of CaCl2  were prepared in 
the same buffer as the protein sample at concentrations of 2, 5, 10, and 20 mM. 
Data acquisition took place over 45-minutes.  
 
 
5.7.2 Ca2+ Titration Study Results 
 
5.7.2.1 Ca2+ Titration Study Results for 15N-Labeled EGF5-7 
 
Given the role that PfRipr appears to play in Ca2+-signally during erythrocyte 
invasion, and the fact that EGF-like domains are well-known for binding divalent 
cations, an NMR-based titration study was carried out starting with adding a 
physiologically relevant concentration of Ca2+ (with respect to the levels found in 
the blood) and titrating up to a concentration where any 15N-HSQC-based peak 
shifts became ablated. When 2 mM of the CaCl2 solution was added to the protein, 
a peak shift became apparent, leading to a continuation of the titration up until 20 
mM (figure 5.43). It is evident that EGF5-7 was binding to the Ca2+ as significant 
chemical shift perturbations were seen for certain residues (i.e. E776 and D821) 
but not all, and the shifts were occurring in different dimensions (the 1H 
dimension on the X-axis of figure 5.43 for E776, and both the 1H and 15N 




Figure 5.43. Ca2” Titration of 15N-EGF5-7 via NMR: 15N-HSQC of a Ca2+ titration into a 
solution of 15N-EGF5-7. 0 mM Cacl2 shown in turquoise, 2 mM in purple, 5 mM green, 10 mM 
blue, and 20 mM red. An example of two restudies that underwent a significant chemical shift 
perturbation during the titration are highlighted, with a zoom in for E776 and D821. Folded peaks 
shown in pink and orange. 
 
To map and identify all residues that underwent a significant or minor chemical 
shift (significant defined as at least 0.1 ppm, and minor defined as at least 0.035 
ppm; using a more conservative cut-off than that provided in (Bardelli, et al., 
2015)), a histogram plot was produced, as shown in figure 5.44. Six residues were 
identified has having at least undergone a minor chemical shift perturbation, one 
of which (N779) was only just included, and E776 displaying a major chemical 
 248 
shift. The majority of residues identified were found in EGF7; D821, K847, N849 
and E856 (the latter three all lie towards the C-terminus of the protein sequence). 
 
 
Figure 5.44. Histogram of 15N-EGF5-7 Residue Shifts During Ca2+ Titration This plot 
demonstrates the chemical shift differences between cross peaks in spectra acquired in the presence 
of 0 mM and 20 mM of Ca Cl2. The overall shift distance through both proton and nitrogen 
dimensions is given on the Y axis, which residues and where they are found in each EGF-like 
domain shown in the X-axis in in the plot, respectively. The blue dotted line shows the arbitrary 
cut-off of where a residue’s shift perturbation was classed as “minor”. The green dotted line is 
where the shift perturbation was considered “major”. Residues that experienced at least a minor 
chemical shift perturbation are labelled. 
 
 
Next, CCPNMR Analysis was used to determine a KD value for each instance 
where a residue’s chemical shift was measurably perturbed by Ca2+ binding. (figure 
5.45). Overall, the fit of the data was relatively good, with E776 showing the best 
fit with the data. The residue showing the weakest affinity (that is, the highest KD 
value) and the largest error margin was N779, which makes sense given that it 
showed the lowest shift distance in figure 4.54. The tightest binding affinity was 
with residue D821, with a KD of 2.75 μM. All the residues identified displayed a 
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binding affinity around 100-times tighter than some other EGF-like domains in 











Figure 5.45. Binding Affinities for Each Ca2+-Binding Residue of 15N-EGF5-7: Each plot 
shows the fitting and the data points. Fitting functions for all used the equation 
A(B+xsqrt/((B+x)^2-4x)). A. The fitted graph for the shift distance of E776 as CaCl2 was titrated 
into the solution. The insert shows the KD value including the error margin. The value for the data 
point at 5 mM CaCl2 was absent due to an unknown software issue. B. The fitted graph for the 
shift distance of N779 as CaCl2 was titrated into the solution. C. The fitted graph for the shift 
distance of D821 as CaCl2 was titrated into the solution. D. The fitted graph for the shift distance 
of K847 as CaCl2 was titrated into the solution. E. The fitted graph for the shift distance of K849 
as CaCl2 was titrated into the solution. F. The fitted graph for the shift distance of E856 as CaCl2 
was titrated into the solution.  
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5.8 Mapping of Inhibitory mAbs to PfRipr 
 
5.8.1 Methods for the Mapping of Inhibitory mAbs to PfRipr 
 
The mAbs developed at the Walter and Eliza Hall Institute had been screened via 
a GIA using standard methods as described in Lim, et al., 2015. In brief- 
Trophozoite stage parasites at 0.1% parasitaemia were grown in a 50 μl culture at 
2% haematocrit in 96-well round bottom microtitre plates (Falcon) with doubling 
dilutions of antibody. After incubation for 96-hours each well was fixed at room 
temperature for 30-minutes with 50 μl of 0.25% glutaraldehyde (ProSciTech) 
diluted in PBS. Following centrifugation at 900 × g rpm for two-minutes, 
supernatants were discarded and trophozoite stage parasites were stained with 50 
μl of 5 X SYBR Green (Invitrogen) diluted in PBS. The parasitemia of each well 
was determined by counting 50 000 cells by flow cytometry using a Cell Lab 
Quanta SC – MPL Flow Cytometer (Beckman Coulter). Growth was expressed as 
a percentage of the parasitaemia obtained using a non-immune rabbit IgG control. 
All samples were tested in triplicate. 
 
Identification of mAbs that recognise a conformational or linear epitope was 
carried out via Western blotting (using standard methods as previously described) 
using R and NR FL-PfRipr (10 ng). 
 
E. coli-produced EGF1-2 and SS. Pichia-produced EGFs 5-7 and 7-10 were 
provided to Jenny Thompson for analysis alongside FL-PfRipr (produced in a 
Drosophila expression system) to test reactivity via Western blotting using mAbs 
raised against EGF3-10, and rabbit polyclonal anti-FL-PfRipr antibodies. This was 






5.8.2 Results for the Mapping of Inhibitory mAbs to PfRipr 
 
Following on from the development of mAbs raised from animals inoculated with 
EGF3-10, a GIA was carried out to assess which mAbs (if any) inhibited invasion 
by 3D7 P. falciparum parasites entering human erythrocytes (figure 5.46). The 
results of the GIA demonstrated two mAbs, 5G6 and 1G12, that led to ~75% less 
parasite survival at an IgG concentration of 2 mg/ml. The antibody concentration 
where 50 % of parasites had perished was ~0.45 mg/ml for 1G12 and ~ 0.6 
mg/ml for 5G6. 
 
 
Figure 5.46. GIA Assay for Screening Anti-PfRipr mAbs: Parasite survival (Y-axis) is plotted 
against the total concentration of mAb IgG used (X-axis) for each mAb. Results are from the mean 
results from experiments carried out in triplicate, the error bars representing standard error. 
 
Next, to test which mAbs recognised a conformational or linear epitope on 
PfRipr, a Western blot was carried out on R and NR FL-PfRipr. If antibodies 
bound only the NR form of the protein, they were judged to be recognising a 
conformational epitope. The results shown in figure 5.47 show that both inhibitory 
mAbs (5G6 and 1G12) identify a conformational epitope on PfRipr given the 
dearth of signal seen in R lanes. This is in contrast to mAbs 3C3 and 4A8, where 





Figure 5.47. Identification of mAbs that Recognize a Conformational Epitope of PfRipr: 
Each mAb is listed atop the figure, with FL-PfRipr run on the gels under N and NR conditions. 
The lane denoted by a red asterisks (*) is a positive control for EGF3-10, detected by the 
polyclonal antibodies raised to it.  Exposure time was 2.5-minutes. Molecular weight marker regions 
are given on the far left side. 
 
Having established that 5G6 and 1G12 were inhibitory mAbs that bound to a 
conformational epitope of PfRipr, somewhere in the 3-10 region (indicating that 
there was a functional element somewhere here that the parasite relied on for 
survival in the blood stage of infection), it was important to narrow this down to 
either a non-EGF region, or if it did in fact bind to an EGF-containing region, 
which EGF the mAb bound to. For this the library of EGF-rich constructs were 
screened including EGF1-2 for a negative control (since the mAbs had been raised 
to the EGF3-10 region of PfRipr), FL-PfRipr as a positive control (and to serve as 
an identification of EGF3 or EGF4 if the mAbs did not recognise EGFs 5 – 10), 
EGF5-7 and EGF7-10 produced in SS. Pichia. Whilst there were no recombinant 
proteins of the non-EGF regions of PfRipr or the peptide that served as the linker 
between EGFs 5 and 6, it could be inferred as a possibility that the mAbs bound a 
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non-EGF region if they only bound FL-PfRipr and EGF5-7 (in addition to the 
possibility that the region being recognized was EGF5 or 6); if this were to be the 
result it would highlight the necessity of developing a refolding method for the 
non-EGF region-producing clones of E. coli described in section 3.2 of this thesis 
(or developing these constructs in SS. Pichia), and making the 17 amino acid 
peptide that comprised the long linker between EGF5 and 6.  
 
The results in figure 5.48 show that only the inhibitory mAbs 5G12 and 5G2 
bound to EGFs 5-7 and 7-10, with all other mAbs detecting only FL-PfRipr. The 
commonality between these proteins is the presence of the 7th EGF-like domain of 
PfRipr.  These results suggest that the invasion-inhibiting mAbs bind to a 
conformational epitope present in EGF7. Furthermore, from the results of the 
GIA, it can be inferred that EGF7 is responsible for a key functional role during 
the process of invasion with the PAIN-complex. This should be regarded as a 
significant find, which is why a co-crystal screen has now been set up between 




Figure 5.48. Inhibitory mAb Screening of PfRipr Proteins: The Western blots show each 
PfRipr protein screened for recognition by the anti-PfRipr (EGF3-10) mAbs. Here, “Ripr” denotes 
the FL-PfRipr protein. R1632 is a rabbit poly clonal anti FL-PfRipr antibody used as a positive 
control for detection of each protein. The red box highlights the EGF5-7 and EGF7-10 proteins 
detected by mAbs. As expected, no mAbs detected EGF1-2 (only the polyclonal raised to FL-
PfRipr did). Exposure time for development was 2.5-minutes. These are the results of the second 
Western blot carried out, using less protein in an attempt to avoid over-loading the lanes. 
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5.9 Discussion and Conclusions 
 
While it was unfortunate that FL-PfRipr was unable to be produced in the SS. 
Pichia system (along with EGFs 1-2, 3-5, 3-10, and the front half of PfRipr), two 
high-protein expressing clones were able to be developed; EGF5-7 and EGF7-10. 
Very likely it was merely a case of not obtaining any successful integrants with 
respect to the SS. Pichia transformed with the linearized plasmids (aside from the 
one Ripr21-1086/FL-PfRipr that was detected by Western blot in figure 5.2 A that 
unfortunately become contaminated and irretrievable). This could potentially be 
amended by scaling up the test expression from a handful of colonies to ~100.  
 
However, the successful production of the malaria antigens comprising EGFs 5-7 
and 7-10 in a Eukaryotic system should not be seen as overly trivial; competing 
malaria research groups using Eukaryotic systems for protein expression have had 
great difficulty with not only getting a malaria parasite protein produced, but 
produced in large quantities for in-depth biochemical and biophysical 
characterization (Dr. Julian Rayner, University of Cambridge, personal 
communication August 2017). Additionally, whilst generally recombinant proteins 
in these systems will be produced in their folded state, there is no guarantee of this 
to always be the case (depending on various factors such as intracellular stress 
during protein production cycles). In P. pastoris, low yields and proteolytic digestion 
of recombinant proteins have been reported to prevent the successful production 
of several proteins (reviewed in Ahmad, et al., 2014).  
 
The results of this chapter overall show that regions of PfRipr (a notoriously 
difficult protein to work with as demonstrated by this thesis and the personal 
communications received from Prof. Alan Cowman and Dr. Julian Rayner) were 
successfully produced using the SS. Pichia system that allowed for 1 g of protein 
produced per L of supernatant (figure 5.1). Further, both EGF5-7 and 7-10 were 
not produced in a glycosylated state, a common problem for recombinant proteins 
produced in Eukaryotic systems. This in combination with the ability to utilize 
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large-scale fermenters present a significant cost-saving benefit for those with an 
interest in industrially-scalable systems of vaccine production.  Additionally, the 
high yield of protein compensated for the loss of yield that often accompanies 
growth of cells in minimal media allowing facile uniform 15N and 13C isotopic 
labelling (figure 5.5 shows the high quantity of protein produced in minimal 
media). 
 
As mentioned above, biophysical characterization of the proteins was of high 
importance. Once the correct mass had been confirmed, the evidence for correct 
protein folding needed to be gathered; the best evidence for this came from the 
NMR analysis of the 1D and the 15N-HSQC spectra showing clear peak dispersion, 
lack of clustering of peaks in the HSQC (figure 5.23 A and C for EGF5-7, and 
figure 5.25 A and B for EGF7-10). Further confirmation of correct folding came 
from the assessment of free cysteine residues via the ESI-MS analysis of NEM and 
NEM + TCEP-treated EGF5-7. If the protein was not folded, or incorrectly 
folded then NEM would be able to react with and alkylate the free thiol on each 
cysteine. This was clearly not the case as shown in figure 5.29, where no increase in 
mass was detected.  
 
The use of CD allowed for the probing of information about the secondary 
structure of the proteins that would help complement the NMR analysis, and 
provide some evidence as to the accuracy of the 3D modelling (via the homology-
based modelling). Overall, the CD data in figure 5.18 suggested that EGF5-7 had a 
mostly unordered structure devoid of secondary structural elements, with the 
exception of β-strands that made up an estimated 35% of the protein. This 
approximately matched the SWISS-Model modelling data that gave an estimate of 
~31% β-strand present in the protein (table 4), which was seen on the model that 
was processed in figure 5.28 A. Both EGF5-7 and 7-10 models showed elongated 
proteins comprised of EGF-like domains in tandem which in turn are composed 
of loops and β-sheets. Additionally, evidence of β-sheet for both proteins was seen 
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in 1D NMR spectra, where the 1H peaks in the 5 – 5.5 ppm region are indicative 
of Hα atoms in a β-sheet.  
 
One interesting pair of results were the comparison of the CD with that of the 
relaxation experiments including the heteronuclear NOE for EGF5-7. The CD of 
course suggested a highly unordered protein (usually suggestive of a flexible 
protein), meanwhile both sets of data (from the 600 and 800 MHz field strength 
NMR spectrometers) from the T1, T2 and heteronuclear NOE measurements in 
figures 5.36 – 5.38 showed strong evidence that the protein was in fact quite rigid 
(which was also observed in the SAXS data shown in figure 5.28 C and D), 
particularly in the EGF6 domain. This seemingly contradictory set of data may in 
fact be explained by the concentration of protein used in the experiments, with a 
significantly high concentration (~0.5 mM) used for the NMR experiments as 
compared to the much lower concentration used in the CD experiments. It may be 
that at higher concentrations, EGF5-7 undergoes a level of intermolecular self-
association via EGF6. This would explain why the SEC analysis of the protein size 
did not show the presence of dimer when compared to the size standards in figure 
5.42 E.  
 
A follow up experiment should repeat the relaxation experiments with a protein at 
a lower concentration to look for evidence of self-association. Further, SEC-
MALS (multi-angle light scattering) would be informative for this purpose 
(unfortunately due to a combination of equipment being unable to be used and a 
paucity of time, this was not able to be carried out). Additionally, in the future, 
relaxation experiments should be performed on EGF7-10 at both high and low 
concentrations to compare and contrast the results with that of EGF5-7 in order 
to evaluate the rigidity of the EGF-like domains at the very end of the C-terminus 
of the PfRipr protein. Finally, the relaxation data did indeed reveal that there were 
more flexible regions interspersed throughout EGF5-7, mostly in the flanking 
EGF-domains and the N- and C-termini. Various loop regions may also be 
stabilized by divalent cations; a follow up experiment would be to perform NMR 
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and CD analysis on samples with and without these ions, such as Ca2+ cations (via 
the use of a chelation agent). 
 
The evidence for EGF5-7 being rigid conflicts with the original hypothesis that the 
reason all the crystallization attempts had failed was due to the protein being 
flexible. However, as mentioned above there was flexibility within the protein at 
various points, and these in combination with a partially self-associating protein 
would still potentially present thermodynamically unfavourable conditions for 
crystallography, particularly when the trials used proteins significantly over 0.5 mM 
in concentration (including ~1.5 mM). This would be particularly true if there was 
heterogeneous intermolecular self-association, since homologous oligomerization 
would actually promote crystal formation (W. Nicholson Price, et al., 2009). Due to 
the discovery of mAbs that bind to EGF5-7 and 7-10 (as shown in figure 5.48), it 
will be worth screening crystal conditions using both antibodies and various 
protein concentrations, particularly lower concentrations.  
 
Other findings from the biophysical characterization of the proteins described in 
this chapter include the evidence that the protein is relatively stable over time (as 
evidenced from the lack of spectra changes via 1D and 2D NMR analysis in 
figures 5.40 and 5.41 respectively), and also at high temperatures. The lack of 
denaturation at 40 – 70 C as shown by the NMR temperature experiment in 
figures 5.19 – 5.21 was quite remarkable, although there was evidence that when 
kept at a higher temperature the protein would precipitate. However, after the 
sample conditions had been optimized, it was good knowing that EGF5-7 could 
happily tolerate the 25 - 40 C temperatures, so that a full set of triple-resonance 
NMR experiments could be carried out at a variety of temperatures for the 




Regarding the 15N/13C-EGF5-7 sample, it has been a great shame that the 3D 
structure has not been able to be solved. This was due to a paucity of resources 
leading to a lack of time towards the end of the research project. However, all the 
experimental data from several temperatures have been collected that would allow 
for this to be solved in the near future. Furthermore, high-quality SAXS data 
(figure 5.28 D) will help refine future structural models that come from 
completion of the 3D-NMR structure. Regarding the NMR analysis, the backbone 
amino acid assignment sits at 86% (as shown in figure 5.34) and will be improved 
once the side-chains become mapped out. Further, the backbone assignment had 
proven invaluable in the analysis of the Ca2+-binding data, with figures 5.43 and 
5.44 highlighting clear peak shifts during the titration of increasing concentrations 
of CaCl2, and the residues involved. This is the first step taken to confirm that 
PfRipr may indeed utilize Ca2+ during the invasion process. Initial work in Volz, et 
al., 2016 revealed using a calcium-sensitive fluorescence indicator, Fluo-4AM, that 
Ca2+ intensity was increased between the apical tip (where the PAIN-complex is 
located) of invading merozoites and the erythrocyte. This was followed up by 
demonstrating that PfRipr-deficient merozoites (developed with the lox-cre 
recombinase system) showed no measurable Ca2+-spike when interacting with 
erythrocytes. This suggested of course a role for PfRipr in the calcium-signalling. 
Figure 5.45 reveals the affinity (via KD measurements) of the key residues of 
EGF5-7 that bind calcium, which are tighter than EGF-like domains in the 
literature that are called “high affinity” binders of Ca2+. Of course, the next steps 
will be to examine the other regions of PfRipr to assess their interaction with Ca2+ 
and to then develop parasite strains with selective amino acid mutations in these 
regions to be used in repeat experiments of the ones described in (Volz, et al., 
2016). 
 
Of course, one of the aims of this research was to identify the region of PfRipr 
that binds to CyRPA. Unfortunately, EGFs 1-2, 5-7 and 7-10 all failed to show an 
interaction with CyRPA, and there was not enough EGF3-10 or 3-6 left to test. 
This does however narrow down the binding region to EGF3-4 or a non-EGF 
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region. Therefore, more EGF3-6 and 3-10 should be refolded and purified for 
binding studies via SEC plus microscale thermophoresis which can detect weaker 
interaction between proteins without the need for isotopic labelling or the addition 
of a chemical tag (for use with NMR and FRET, respectively). Furthermore, the 
non-EGF regions of PfRipr should be produced to carry out binding studies via 
the aforementioned techniques. 
 
Initially, the identification of a pair of inhibitory mAbs that bind EGF7 could have 
been suggestive of this region being involved in the association with CyRPA; 
however, the negative data from the repeats of the SEC binding studies suggest 
this to be unlikely unless the interaction is very weak. More likely, the inhibitory 
mAbs are interfering with another functional aspect of the protein. Given that 
PfRipr is processed into two polypeptides that then self-associate (as shown in 
Chen, et al., 2011) and form a complex with CyRPA, a leading hypothesis would be 
that the mAbs may be interfering with this intermolecular self-association. This 
could be tested by first screening the PfRipr EGF-rich protein constructs for 
binding amongst each other (via SEC), then applying each inhibitory mAb and re-
doing the SEC-binding assay with SDS-PAGE and Western blot analysis of the 
eluted fractions. It should be mentioned that the fact that the 1G12 and 5G6 
mAbs recognize a conformational epitope is of significance since epitopes that are 
recognized by neutralizing antibodies are structured 3D electrostatic landscapes (as 
discussed in Dormitzer, et al., 2008). This is positively correlated with the 
development of high-titre neutralizing antibodies. 
 
Since inhibitory mAbs have identified key immunologically relevant regions of 
CyRPA and PfRh5 including their epitope mapping (due to co-crystal structures 
reported in Favuzza, et al., 2017, Chen, et al., 2017 and Wright, et al., 2014), and the 
EGF7 domain of PfRipr has now been identified as the region where inhibitory 
mAbs bind, it will be important to establish and map out the exact epitope. These 
mAbs have now been used for co-crystal trials with EGF5-7, which if sufficient 
resolution were to be obtained (assuming crystals can be obtained), would reveal 
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the exact conformational epitope within EGF7. However, in lieu of a crystal 
structure, the NMR data garnered from the backbone assignment of 15N/13C-
EGF5-7 can be used for epitope mapping studies. Even though the backbone 
assignment is incomplete for the whole of EGF5-7, the entirety of EGF7 has been 
mapped. Therefore, it will be imperative to perform a titration study on a 15N-
EGF5-7 sample using the mAbs, or preferably, either a Fab fragment (production 
being relatively easy via enzymatic digestion of a mAb) or a single chain variable 
fragment (more challenging and sometimes impossible to produce as they must be 
made recombinantly), and record 15N-HSQC spectra to identify peak changes (as 
described in Bardelli, et al., 2015). Alternatively, a 13C-HSQC could be carried out 
on the 15N/13C-EGF5-7 sample, which has the advantage of analysing the CH 
groups which outnumber NH groups in a protein. Of interest, both a B-cell 
epitope (BCE) and T-cell epitope (TCE) have been bioinformatically predicted 
within EGF7 (Kariuki, 2014). The predicted BCE consists of residues 823 – 852, 
whereas the TCE consists of residues 853 – 861 (with the last five residues 
comprising the linker and start of EGF8) for CD8+ T-cell epitopes, and residues 
828 – 845 for CD4+ T-cell epitopes. 
 
Finally, in the near future, the optimization of the disulfide mapping using a buffer 
suited to tryptic digest will yield the disulfide bond patterns found in EGF5-7. This 
will help inform the NMR-based structural calculations which may be highly 
inaccurate if one assumes the typical disulfide pattern of most EGFs of C1-C3, 
C2-C4, and C5-6. Further, the unusual long linker between EGFs 5 and 6 may not 
be forming a disulfide bond between each other, but could in fact be disulfide-

















“Let me tell you the secret that has led me to my goal. My strength lies solely in my tenacity” 





















This thesis has described a complex project encompassing a variety of 
multidisciplinary fields (such as parasitology, biochemistry, immunology, 
biophysics, biophysical chemistry and structural biology) which changed directions 
as new evidence emerged. The project started with an examination of PfRh4 that, 
at the time of commencing the research, was deemed a viable vaccine candidate. It 
was considered important to elucidate the binding site for CR1 on PfRh4.9, solve 
the structure of PfRh4.18 and develop a set of inhibitory mAbs. The CR1-binding 
region remained elusive because each PfRh4.9 alanine-scan mutant bound with 
approximately the same affinity to CR1 as the native protein. This observation 
implied that the mAbs that had been used to map a candidate binding region 
comprising 58 residues within PfRh4.9, were not competing directly for binding 
with CR1 but were impeding CR1 access to a nearby binding site via steric 
hindrance, due to the size of the antibody molecule. The failure of this approach 
suggested structure determination as an alternative. As PfRh4.9 was too unstable 
for use in crystal trials the production of PfRh4.18 was undertaken, but this 
required a refolding protocol that required significant optimization. 
 
At this point, more literature was appearing that encouraged a shift in focus 
towards the proteins of the PAIN-complex as potential top vaccine candidate 
against P. falciparum malaria. Of particular importance was the finding that IgG 
responses against PfRh5 and PfRipr were strongly associated with protective 
immunity (Richards, et al., 2013). In fact, the median protective association for 
anti-PfRh5 and anti-PfRipr antibodies were significantly better than any other P. 
falciparum antigen that had reached phase-1 or phase-2 vaccination trials. Notably, 
whilst the Richards paper still listed PfRh4 among the top nine prospective vaccine 
candidates, there are key differences between it and the proteins of the PAIN-
complex. Crucially, the PAIN-complex contains PfRh5 that was not amenable to 
genetic knock-out (Baum, et al., 2009). Furthermore, work in the Cowman lab at 
WEHI was, at this time, showing that all proteins in the PAIN-Complex are 
essential; this work was published several years later (Volz, et al., 2016). Taken 
together, the essential nature of the PAIN-complex proteins, their ability to induce 
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strain-transcending inhibitory antibodies, the clinical relevance of the findings by 
Richards, et al., 2013 and the novel idea from Richards that there was a trend 
between newer malaria antigens discovered and their increased importance as 
vaccine candidates (superseding competing antigens that had been under 
development for longer) suggested the legitimacy of the PAIN-complex proteins 
as the best vaccine targets.  
 
The final piece of indirect evidence that convinced the author the association 
stated by Richards was not merely a post hoc ergo proper hoc fallacy was the 
observation that, despite PfRipr being identified as a lead prospective vaccine 
candidate, no publications focused on it had come out since the original paper by 
Chen et al. in 2011, which was a space of more than 3 years by the time this 
doctoral research focused away from PfRh4 towards PfRipr. This suggested that 
the protein was perhaps quite difficult to work, which was shown to indeed be the 
case. Most protein biochemists would likely agree that PfRipr was not an ideal 
protein to try to work on since it had both a large proportion of cysteines and an 
odd amount (87), with most cysteines predicted to be involved in disulfide 
bonding (making correct folding a challenge in any recombinant system). 
Additionally, PfRipr is relatively large at ~123 kDa, and is enzymatically processed 
into two self-associating polypeptides, meaning that trying to express the full-
length protein may not work without the presence of the enzyme that led to the 
cleavage event, and this enzyme is still unknown. It was therefore decided to focus 
more exclusively on the PfRipr protein. However, with that said, PfRh4 remains a 
biologically fascinating protein, and should form part of further studies aimed at 
generating a full structural library of P. falciparum invasion ligands. 
 
To tackle the proverbial beast that was PfRipr, it was decided to chop the protein 
up into potentially more manageable components. Truncations comprised of the 
EGF-like domains were deemed an attractive starting place since EGF-like 
domains are widely known for their involvement in protein-protein interactions 
and being tractable to recombinant production and structure determination. This 
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led to the production of a library of protein fragments that were produced in both 
E. coli and P. pastoris expression systems. This library now contains EGF1-2 (E. 
coli), EGF3-6 (E. coli), EGF5-6 (E. coli), EGF5-7 (P. pastoris), EGF7-8 (E. coli), 
EGF9-10 (E. coli), EGF7-10 ((E. coli and P. pastoris) and EGF3-10 (E. coli). The 
examples of EGFs 5-6, 3-6, 5-7 and 7-10 are the first PfRipr fragments to be 
produced in relatively large quantities and biophysically characterized. 
Furthermore, the results in figure 5.48 show for the first time, the use of 
functionally active inhibitory mAbs (that allay parasite survival in vitro) mapping a 
specific region within PfRipr that is inferred to be of significant functional 
importance for this protein in the PAIN-complex (based on the deleterious effect 
these mAbs had on parasite survival in the GIA shown in figure 5.46). From a 
pure vaccinology perspective, the fact that EGF5-7 remains stable over a long 
period of time is a bonus. Whilst the protein proved stable at 40 C for almost a 
month, future work should test the stability at this temperature over a series of 
several months. 
 
Whilst in its own right, the aforementioned work is of significance, the next step 
for EGF5-7 will be to combine the biophysical characterization described in this 
thesis (CD, NMR, mass spectrometry, NEM alkylation-based disulfide analysis, 
T1/T2 relaxation measurements and heteronuclear NOE data), the Ca
2+-binding 
evidence, backbone assignment of the HSQC and mAb data with a completed 3D 
NMR structure (attainable given the quality of the NOESY spectra, data not 
shown, personal communication with Dr. Brian Smith), mapping the 3D structure 
onto the cryo-electron microscopy derived PAIN-complex structure (work in 
progress from the Cowman lab), NMR-based epitope mapping, recognition of 
EGF5-7 by human immune sera (from a pool of individuals with non-sterilizing 
immunity to P. falciparum, and complete disulfide mapping. Recently, SAXS data 
have been collected on the EGF5-7 sample, which should help with the structure 
determination and in particular defining spatial arrangements of the suspected 
EGF-like domains. Additionally, if possible, a co-crystal structure of EGF5-7 (or 
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EGF7 alone) with either 1G12 or the 5G6 mAb will be ideal for confirmation on 
the atomic resolution detail of the interaction between epitope and paratope. 
These studies would guide future structural vaccinology work and the design of 
experimental vaccines against PfRipr. 
 
Looking further ahead, an ideal experimental vaccine for testing on the blood stage 
of infection should include an in-tandem or combination design of EGF7 with 
CyRPA (an individual domain may be problematic given that the interface between 
the mAb and the protein spans several regions (Chen, et al., 2017)), and the ~45 
kDa PfRh5 truncation (potentially using only the second and third α-helices due to 
their epitope interacting with the inhibitory mAbs QA5 and 9AD4 as described in 
Wright, et al., 2014). These could further be coupled with CSP and an antigen that 
targets the sexual cycle of the parasite in order to test a multi-life cycle stage, multi-
valent vaccine based on both immunological evidence and rational, structural 
vaccinology principles (as reviewed in Dormitzer, et al., 2008) 
 
Malaria has proven to be a highly-complicated foe, one that has led to an 
enormous amount of resources spent on trying to fight it on various fronts (i.e. 
vector control, drugs, vaccines and diagnostics). If it is to be cut like the Gordian-
knot (a reference to the apocryphal tale of Alexander the Great and his approach 
to solving a complicated problem; of note, Alexander is said to have possibly died 
from malaria, ironic given the metaphor presented here (Cunha, 2004)), it will 
likely require a precisely targeted attack. This will only be attainable with continued 
financial and intellectual contribution, directed cross-institutional collaboration, 
and a willingness to drop so-called “pet proteins” when they are no longer ideal as 
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No. Hybridoma ELISA OD  No. Hybridoma ELISA OD 
1 28/13-1A4 1.415  25 2H10 1.673 
2 1A6 1.865  26 2H11 0.597 
3 1A10 1.383  27 3A6 1.502 
4 1E11 1.773  28 3A10 1.524 
5 1H1 1.428  29 3D2 1.796 
6 1H6 1.038  30 3G5 0.974 
7 1H9 1.463  31 3G6 2.141 
8 2A1 2.036  32 3F11 1.951 
9 2A4 1.764  33 4C5 1.688 
10 2A6 1.391  34 5D2 1.875 
11 2A7 1.021  35 5D6 1.794 
12 2A10 1.913  36 5G12 1.646 
13 2A12 1.758  37 5H12 1.720 
14 2B1 1.388  38 6A5 1.630 
15 2E2 1.190  39 6A6 1.578 
16 2E4 1.299  40 6A12 1.540 
17 2E10 1.746  41 6F3 1.257 
18 2E11 1.850  42 6F12 1.357 
19 2H1 1.489  43 6H1 1.076 
20 2H3 2.198  44 6H2 1.292 
21 2H6 2.140  45 8D1 1.142 
22 2H7 1.788  46 9F1 1.951 
23 2H8 1.676  47 9G9 2.063 
24 2H9 1.092  48 10H1 1.934 
     CM 0.041 
     F.S 1:6400 1.443 
Table A1. ELISA Screen of PfRh4.9 Fusions: The list provided by staff at the WEHI Antibody 
facility of all mAbs raised against PfRh4.9 and their reactivity. Also included is the control media 
(CM) corresponding to sera from unvaccinated mice, and a polyclonal antibody batch of fusion 




Figure A1. SAXS Data Fit for EGF5-7: The graph displays the fit to the data for the rigid body 
model to a χ2 value of 1.0. CRYSOL was used to fit the best conformer of EGF5-7 (solid blue line) 
from homology-based modelling using SWISS-PROT and I-TASSER, and the best DAMMIF 
model from the SAXS data itself is given as grey lines. 
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• Eschericia coli remains a staunch workhorse for the production of 
recombinant proteins given its ease of handling, access and genetic 
manipulation using standard laboratory techniques. 
• Disulfide-rich proteins can be difficult to produce in E. coli, in large part 
due to the reducing environment of the bacterial cytoplasm. 
• Refolding from insoluble inclusion bodies can be a viable strategy for 
generating substantial quantities of disulfide-rich protein. 
• In order to have the best chance of successfully refolding a protein, it is 
vital to carry out a variety of small-scale test refolds under a swathe of 
conditions. 
• These conditions include altering the concentration of urea, salts, reduced 
and oxidized glutathione, inclusion of protease inhibitors, temperature 
alteration, length of refold time and protein dilution factor. 
• Once a protein has undergone refolding it is vital to determine that the 
final product is natively folded since there is always the chance of soluble 
misfolded protein. 
• For determination of correct folding a variety of techniques can be 
employed, and ideally, numerous should be used together.  
• For proteins that possess enzymatic function the gold standard to assess 
correct folding is an activity assay. Non-enzymatic proteins can be 
assessed using a combination of circular dichroism and nuclear magnetic 
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resonance spectroscopy. These techniques should be utilized alongside 
mass spectrometry, Western blotting and SDS-PAGE. 
 





The first recombinant expression of a protein in E. coli occurred in 1976 at 
Genentech, where researchers produced somatostatin (Itakura K et al, 1977), 
thus revolutionizing the field of biotechnology and allowing for a great leap 
forward in biochemistry research. Since then, more advanced systems have 
been developed for recombinant protein production, such as the use of yeast, 
insect cells, plants, mammalian cells and even cell-free systems (Bill RM, 2014). 
But despite these advancements, E. coli remains a workhorse for biochemists to 
make proteins with. Today up to 30% of biopharmaceuticals, 50% of commercial 
proteins and over 70% of proteins produced in research settings are made in E. 
coli (Bill RM, 2014).  
 
However, the system is not without its limitations. If one requires post-
translational modifications, then a eukaryotic system would be preferred, and 
other issues such as incorrect disulfide bond formation and insoluble inclusion 
body production can present significant obstacles to the protein biochemist 
working with an E. coli expression system (these and other issues are reviewed 
in Rosano GL and Ceccarelli EA, 2014). Proteins that are rich in disulfides may 
incur difficulty in cysteine oxidation (which occurs in the periplasm) due to the 
reducing environment of the bacterial cytoplasm, which can lead to production of 
misfolded protein or inclusion body formation (Rosano GL and Ceccarelli EA, 
2014).  
 
Inclusion body formation may also occur due to the paucity of spatio-temporal 
control over foreign gene expression given that the recombinant protein is being 
manufactured in a potentially very different microenvironment (Rosano GL and 
Ceccarelli EA, 2014). There are numerous strategies to ameliorate these issues, 
including optimization of protein expression (i.e. altering concentration of the 
inducer and induction temperature), use of certain tags (such as MBP and MalE), 
using another organism, and of course, attempting to refold your desired protein 
from the inclusion bodies. Whilst challenging, it is can be possible to obtain 
sizeable and pure protein yields from inclusion bodies, and so carrying out a 
refolding trial should always be considered before abandoning E. coli as a 
production system (Burgess RR, 2009). This methods paper will outline one such 
refolding strategy that is scalable, suitable for disulfide-rich proteins, as well as 
downstream purification methods and the biophysical characterization of a final 
product. This method assumes use of a polyhistidine tag on the recombinant 










After plating freshly transformed E. coli containing your synthetic gene onto LB 
agar with a suitable selective marker (i.e. kanamycin), inoculate a colony into a 
50 - 100 ml flask (preferably baffled) with 10 ml of super broth plus antibiotic, 
growing overnight at 37 °C with agitation. The following day prepare 9 x 300 ml 
baffled flasks each with 30 ml of super broth plus antibiotic and inoculate 1 ml of 
the starter culture into each and then place in a 37 °C incubator at 220 rpm (see 
fig. 1 for an overall flow-chart). Grow until an optical density at 600 nm (OD600) of 
0.6 – 0.8, then split the flasks so three will remain at 37 °C, three are to be 
placed in a 30 °C incubator and three are to be placed in an 18 °C incubator (for 
the latter two incubators, remove the flasks from the 37 °C incubator when the 
OD600 is just before 0.6 so as to pre-equilibrate the temperature before induction). 
Of each three lots of flasks, induce one of each with 0.25 mM, 0.5 mM and 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) after taking a 1 ml pre-induction 
sample. For the flasks at 37 °C, grow for 4 hours, take a 1 ml post-induction 
sample and then harvest the rest by centrifugation (8 – 10 000 rpm for 10 
minutes). For the flasks at 30 °C, and 18 °C, grow for 8 and 16 hours respectively 
before collecting a post-induction sample, measuring the final OD600 and 




Figure 1. Flow-chart of Protein Test Expression: This figure presents the overall 
initial setup from post-transformed E. coli colony picking and starter culture, to 
optimization screening of both IPTG concentration and temperature. 
 
Take 250 μl of each pre-induction sample, and 50 ul of post-induced sample, 
centrifuge, remove supernatant and add 10 μl of 1 x reducing sample buffer 
(RSB), then boil for 1 minute at ~97 °C. Carry out an SDS-PAGE analysis on 
these samples. For each sample showing evidence of induction for recombinant 
protein production, centrifuge and resuspend in 2 ml lysis buffer (50 mM Tris pH 
8, 250 mM NaCl, 0.1% triton X-100, 2 mM EDTA, spatula tip of lysozyme and 1.5 
ul of DNaseI), then process via sonication (90 sec on/100 sec off at 35% 
amplitude for 7.5 minutes) or mechanical cell disruption. Take a 50 ul sample 
post-lysis and centrifuge at 13 000 rpm for 1 minute, then separate the 
supernatant from the pellet. Take 6 ul of the supernatant and add 10 ul of 1 x 
RSB; for the pellet, add 50 ul of water, resuspend thoroughly so that 6 ul can be 
taken and added to 10 ul of 1 x RSB. Boil samples for 1 minute at ~97 °C. Carry 
out an SDS-PAGE analysis on these samples to determine that you have protein 
expressing in the inclusion body fraction. 
 
 
Protein production scale-up and inclusion body production 
 
Set up 1 x 500 ml of your culture media broth with antibiotic (per construct) and 
inoculate each with a starter culture grown overnight from your transformed 
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bacteria. Grow at the temperature and induce with an IPTG concentration as 
previously determined. Process as described in the “test expression” section 
(adding protease inhibitors such as PMSF or a protease inhibitor cocktail at the 
cell lysis step, and scaling up the volumes).  
 
Once you have a pellet post-lysis, carry out 2 - 3 more washes with 25 mls of 
lysis buffer and if possible, sonicate between each wash before spinning the 
pellet down. Weigh out the pellet and if you need to store, do so at -20 °C.  
Solubilize the pellets with 5 ml/g of solubilization buffer (5 M guanidine HCl, 250 
mM NaCl, and 20 mM Tris pH 8, and 20 mM Beta-mercaptoethanol βME). Leave 
this on a rotor for over an hour at room temperature then centrifuge at 9000 rpm 
for 10 mins. Transfer supernatant to a tube with 3 mls settled Ni-NTA resin 






Let the resin settle and set up disposable tubes for the resin and sample. Add 
most of the fluid above the resin to the columns and collect the first 2 CVs (6 ml) 
as breakthrough fractions (BT) and collect the rest in a separate tube. Now mix 
the resin and add to the column, allowing it to run empty into the aforementioned 
tube. Get fresh collection tubes, add 10 CVs (30 ml) of solubilization buffer and 
collect as the guanidine wash fraction. Add 10 CV of 8M Urea 
wash/concentration buffer (8 M urea, 250 mM NaCl, 20 mM Tris pH 8 and 20 mM 
βME) and collect. Add 10 CVs of elute buffer with 20 mM BME and use 20 x 1.5 
ml tubes to collect fractions. 
 
Add 5 x 0.5 CV of elute buffer (8 M urea, 250 mM NaCl, 20 mM Tris pH 8, 1 M 
imidazole 20 mM βME), mix and leave for 15 minutes, elute and collect in tubes. 
Add 10 CV of solubilization buffer and wash through (collect in a tube), then add 
5 ml more, mix and reapply the breakthrough (after taking samples for gels) and 
re-bind overnight. You may get numerous batches of protein this way. 
 
Run samples on a gel via SDS-PAGE; either take neat samples if you think there 
is significant protein (measure Abs280), or carry out a TCA precipitation. Combine 





Take 1 ml of your eluted protein sample and add 100 ul of 200 mM DTT (made in 
solubilization buffer without βME) and call this your reducing sample (R). Take 1 
ml of another aliquote and add 100 ul solubilization buffer to make your Non-
Reducing sample (NR). Leave at room temperature for 2 hours. 
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In a tube, prepare 4 mls of 0.1 M reduced glutathione, and in another make up 
500 ul of 0.1 M oxidized glutathione. Get 8 x 50 ml tubes and label half R and 
half NR. Of the R half, label each one as follows (then do the same for the NR 
tubes)- 0 M Urea, 1 M Urea, 2 M Urea, 3 M Urea. These tubes are to hold 20 mls 
of solution by the end of the set up. 
 
Add urea salts to the tubes (0 g for the 0 M tubes, 1.2012 g for the 1 M tubes, 
2.4024 g for the 2 M tubes and 3.6036 g for the 3 M tubes). Next, add 200 ul of 
the reduced glutathione solution to each, then 20 mM Tris pH 8 (pH depends on 
the isoelectric point of your protein; the proteins used in this paper were all 
around was 5.25 - 5.75) and 100 mM NaCl. Top the tubes up to 20 mls with 
purified water and adjust pH. See fig. 2 for an overall schematic of the steps up 




Figure 2. Schematic of Protein Refolding Set-up: The pool of Ni-affinity purificed 
fractions of protein should be used for the optimization set-up of the various 
refolding conditions (R or NR and concentration of Urea).  
 
 
Slowly add 200 ul of your protein to each tube in a slow drop-by-drop fashion. 
Add 200 ul of the oxidized glutathione solution to each tube. Take a 2 ml sample 
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from each tube and carry out a TCA precipitation; this will be your t0 sample and 
you should have enough to run an R and NR sample next to each other on a gel.  
 
Leave the tubes mixing at room temperature. Each day, for 3 days, take a 2 ml 
sample from each tube, carry out a TCA and analyse R and NR samples.  By the 
end of these trials you will see if the addition of urea is necessary. Further you 
will look for the conditions that give you the best collapse of bands over time. 
Note; you may not need to do a TCA if you have a great deal of protein. It is 
worth taking 30 ul samples and running them neat on reducing gels. Once you 
have the above conditions worked out, then you need to optimize the levels of 
glutathione used. Try the following- 1 mM R glut/1 mM Ox glut, 1 mM R glut/ 0.5 
mM Ox glut, and 1 mM R glut/ 0.25 mM Ox glut. 
 
By now you should know the conditions for scaling up the refold. The final major 
step that can be optimized here is the dilution factor (i.e. how much protein goes 
into how much refold buffer). It is good to start off with 1:100, but also try 1:50 
and 1:25. Also, generally it is good not to go too large with the bottle size. Only 
use 250 ml bottles with 250 ml of buffer (don’t use 1 L bottles with 1 L buffer 





(Note, this assumes a 1:25 dilution factor so if you are using 1:100 just alter the 
amount of protein being added to the mix).  
 
Make up your 20 mM Tris/100 mM Nacl buffer, filter then chill on ice whilst 
bubbling through nitrogen gas for 20 mins. Get clean 250 ml bottles (the amount 
depends on how much protein you plan to make, often it is good only to start with 
2 bottles until you have successfully made 1 batch) each with clean magnetic 
stirrers in them. Fill with 250 ml of the aforementioned Tris/Nacl buffer, stir in the 
cold room and add a protease inhibitor tablet into each. 
 
Add 100th of the volume (2.5 mls) of the stock 0.1 M reduced glutathione (if this is 
the concentration you determined was best) to each bottle. Next, add 10 mls of 
your protein to each bottle (if this is your first time you might want to try 2.5 mls) 
in a very slow, drop-wise fashion, whilst the magnetic stirrer is on. Finally, add 
2.5 mls of stock oxidized glutathione (concentration will depend on what you 
previously worked out during optimization). Aerate the top of each bottle with 
nitrogen gas for 1 min, put cap on and parafilm. Leave stirring at room temp for 3 
days (or the amount of days you optimized before; additionally you can try 
carrying the refold out at 4 °C, or without the magnetic stirrer). You can take R 






After taking pre-dialysis samples to run R and NR SDS-PAGE gels of, put 2 x 
250 ml refold into dialysis tubes of a suitable molecular weight cut-off and then 
these into a 5000 ml beaker with 20 mM Tris pH 8 and 20 mM NaCl, with two 
buffer changes a day for 2 days. Carry out the dialysis at 4 °C and place a 
magnetic stirrer in the bottom of the large beaker. 
 
Take samples out of dialysis bags, centrifuge at top speed to remove particulates 
(filtering can work, but beware if your protein non-specifically binds the filter). 
Now take your post-dialysis samples for SDS-PAGE.  
 
 
Ion exchange and size exclusion chromatography  
 
The final step in the purification is to obtain a purified protein sample for 
biophysical characterization to assess the folding of your protein (i.e. nuclear 
magnetic resonance, circular dichroism, mass spectrometry, and/or Western 
blotting) or an enzymatic activity assay if suitable for your protein. Disulfide 
mapping can also be extremely informative and an example of a methodology is 
provided by Hodder AN et al., 1996. This is beyond the scope of this methods 
paper, however in general, one can first utilize ion exchange followed by size 
exclusion chromatography to obtain highly pure samples. An example of how the 




Figure 3. Protein purification steps: The Ni-affinity fractions eluted from the 
column can be run under R conditions on SDS-PAGE where both an analysis of 
the size of the protein can be assessed (shown as the predominant band), in 
addition to the higher-order species. During refolding the disulfides should shuffle 
and reorganize into lower order species, but generally will still include monomer, 
dimer and trimer. Ion exchange chromatography can be used to obtain monomer 
and dimer, however a final purification step may be needed to get pure 





This method, whilst not all-inclusive of potential refolding methods, should 
provide the biochemist with a reasonable level of options for trialing the refolding 
of their inclusion bodies. Many other conditions can be attempted, including the 
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temperature that the refold is occurring at, or the use of L-arginine buffers. Of 
course, if one experiences little progress in attempting refolding, they could 
contact the authors for further options or move to another expression system, 
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Background: PfRh4 binds complement receptor 1 to mediate malaria parasite entry into red blood cells.
Results: Monoclonal antibodies and inhibitors either block or enhance PfRh4 interaction with complement receptor 1.
Conclusion: Identification was made of critical regions and residues within PfRh4 and CR1 that mediate successful P. falcipa-
rum entry.
Significance: Understanding functional regions within PfRh4 will aid in design of vaccine subunits.
Plasmodium falciparum parasites must invade red blood cells
to survive within humans. Entry into red blood cells is governed
by interactions between parasite adhesins and red blood cell
receptors. Previously we identified that P. falciparum reticulo-
cyte binding protein-like homologue 4 (PfRh4) binds to comple-
ment receptor 1 (CR1) to mediate entry of malaria parasites into
human red blood cells. In this report we characterize a collec-
tion of anti-PfRh4 monoclonal antibodies and CR1 protein frag-
ments that modulate the interaction between PfRh4 and CR1.
We identify an anti-PfRh4 monoclonal that blocks PfRh4-CR1
interaction in vitro, inhibits PfRh4 binding to red blood cells,
and as a result abolishes the PfRh4-CR1 invasion pathway in
P. falciparum. Epitope mapping of anti-PfRh4 monoclonal anti-
bodies identified distinct functional regions within PfRh4
involved in modulating its interaction with CR1. Furthermore,
we designed a set of protein fragments based on extensive
mutagenesis analyses of the PfRh4 binding site on CR1 and
determined their interaction affinities using surface plasmon
resonance. These CR1 protein fragments bind tightly to PfRh4
and also function as soluble inhibitors to block PfRh4 binding to
red blood cells and to inhibit the PfRh4-CR1 invasion pathway.
Our findings can aid future efforts in designing specific single
epitope antibodies to block P. falciparum invasion via comple-
ment receptor 1.
Malaria parasites are obligate intracellular microbes exqui-
sitely adapted for invasion and survival within the red blood cell
of the host. To gain entry into red blood cells, the parasite must
recognize and bind to these cells as well as activate a complex
series of steps that involve multiple protein-protein interac-
tions between parasite and host cells (for review see Ref. 1). The
subsequent cycles of growth, replication of parasites, and egress
from infected blood cells are responsible for the symptoms
associated with malaria (for review see Ref. 2).
Parasite invasion begins with initial recognition and attach-
ment of merozoites, the invasive form of malaria parasites, to
red blood cells (3). This interaction is dynamic and involves
considerable deformation of the red blood cell membrane as
the parasite rolls across the host cell surface (4). After initial
attachment, the merozoite orientates itself to juxtapose its api-
cal prominence with the red blood cell surface. This allows par-
asite adhesins localized at the apical tip to interact with their
cognate receptors to mediate irreversible attachment and com-
mitment to invasion (5, 6). After this, a tight junction is formed
between the parasite and the red blood cell membrane (7).
Active invasion proceeds through an invagination of the surface
and the tight junction moves from the apical to posterior pole of
the merozoite, powered by the parasite’s acto-myosin motor.
Once the merozoite is inside the red blood cell, the red blood
cell membrane is sealed behind it, completing invasion.
Remarkably, the entire invasion process is accomplished within
a few minutes (4).
Of the five human malaria species, Plasmodium falciparum
is the most lethal. In P. falciparum, two gene families encode
important parasite adhesins utilized for engagement with red
blood cell receptors: erythrocyte binding-like antigens (EBAs;
EBA175, EBA181, EBA140, EBL-1) (8, 9) and P. falciparum
reticulocyte binding-like homolog proteins (PfRhs; Rh1,
Rh2a/b, Rh4, Rh5) (10 –12). During invasion these adhesins
localize to the apical tip of the merozoite and bind specific
receptors to initiate parasite entry into human red blood cells.
Several red blood cell receptors have been identified as entry
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points for P. falciparum. The glycophorins were the first iden-
tified and exclusively bind members of the PfEBA2 family of
proteins (glycophorin A to EBA-175, glycophorin B to EBL-1,
and glycophorin C to EBA-140) (13–16). For the PfRh family of
proteins, only two cognate adhesion-receptor pairs have been
identified: PfRh4 to complement receptor 1 (CR1) and PfRh5 to
basigin (17–19).
Molecular studies show that EBA and PfRh proteins are
potential vaccine candidates because: (i) they play a crucial role
in merozoite invasion; (ii) anti-EBA and anti-PfRhs antibodies
inhibit parasite invasion; (iii) epidemiological studies show that
most anti-EBA and anti-PfRhs antibodies in human cohort
studies correlate with protection from clinical disease (1,
20 –25). In addition to clinical applications, monoclonal anti-
bodies (mAbs) have provided unique tools with which to study
molecular pathways of parasite invasion, and some of the func-
tional regions of PfRh family members have been recently char-
acterized. Anti-PfRh1 mAbs affect rhoptry secretion and cal-
cium signaling after merozoite attachment to erythrocytes,
suggesting that PfRh1 plays a role in downstream signaling
events (26). Anti-PfRh5 antibodies that interfere with the
PfRh5-basigin interaction completely inhibit the ability of
P. falciparum parasites to invade red blood cells (23, 27), and
the mechanism by which inhibition occurs has been elucidated
by the recent crystal structures of PfRh5 alone and with either
its receptor basigin or neutralizing antibodies (28, 29). PfRh5
adopts a novel fold using a -helical scaffold that provides bind-
ing sites at the tips of helices for basigin and some inhibitory
monoclonal antibodies (29). The high resolution structures of
PfRh5-basigin and PfRh5-mAbs binding interfaces will clearly
allow future structure-guided design of inhibitory epitopes for
more potent neutralizing mAbs.
Characterization of the PfRh4-CR1 invasion pathway has
validated the potential of PfRh4 as a vaccine candidate (for
review see Ref. 30). A soluble fragment of the PfRh4 ectodo-
main (rPfRh4) that encompasses the red blood cell binding
region can be successfully expressed in Escherichia coli, and
rabbit polyclonal antibodies raised against this fragment are
able to inhibit PfRh4 binding to red blood cells (31). Further-
more, affinity-purified anti-rPfRh4 human antibodies from
individuals in malaria endemic regions inhibited P. falciparum
invasion via the PfRh4-CR1 pathway and correlated with pro-
tection (24). Immunization (in rabbits) with a combination of
EBA-175, PfRh2a/b, and PfRh4 recombinant proteins induced
antibodies that potently blocked merozoite invasion in vitro
(22).
Previous work has mapped the PfRh4-interacting region on
CR1 and also identified soluble forms of CR1 that are able to act
as competitive inhibitors (Refs. 17, 31, and 32 and reviewed in
Ref. 30). CR1 is a type one integral membrane glycoprotein
composed of an N-terminal ectodomain that has a number of
allelic variants, a transmembrane region, and a C-terminal
cytoplasmic domain. The most common allelic variant of CR1
is composed of 28 –30 structural modules called complement
control protein (CCP) modules in the extracellular domain. A
truncated form of CR1 (sCR1) lacking the transmembrane and
cytoplasmic domain, inhibits PfRh4 binding to CR1 on the red
blood cell surface (17). Clinical isolates from Kenya also dem-
onstrated a significant utilization of CR1 for invasion of intact
erythrocytes that was inhibited in the presence of sCR1 (34).
Initial mapping studies identified the first three modules of CR1
(CCPs 1–3) as the most specific inhibitor of the PfRh4-CR1
invasion pathway (33). Recent work using CCPs 1–3 helped
define the role of PfRh4 in the deformation of red blood cell
membrane during P. falciparum invasion into red blood cells
(35). Further mapping of the PfRh4 binding site on CR1 using
truncation and deletion constructs pinpoint CCP 1 as the major
binding site for PfRh4, and extensive mutagenesis experiments
within this domain clearly delineated the PfRh4 binding site
(32). These studies employed ELISA, co-immunoprecipitation
and surface plasmon resonance (SPR) to characterize muta-
tions that affected PfRh4-CR1 complex formation and showed
that clustered mutations in residues 6 –9 or single mutations in
residues 18 and 20 resulted in a dramatic loss in affinity for
rPfRh4. Park et al. (32) were able to engineer an artificial bind-
ing site within CCPs 8 –14 by substituting residues within CCP
1 that are critical for PfRh4 interaction to their homologous
position in CCP 8. Strikingly, this engineered site within CCPs
8 –14 showed a 30-fold higher affinity for rPfRh4. Although the
effects of the mutations are well understood in biochemical
protein-protein interaction assays, it will be important to deter-
mine in a cellular context if any of these mutations lose their
ability to block PfRh4-CR1 invasion or, in the case of the engi-
neered site, lead to a potentially better inhibitor of P. falcipa-
rum invasion.
The availability of anti-PfRh4 mAbs that interfere with the
PfRh4-CR1 interaction would provide an important tool in the
identification of inhibitory epitopes in the binding interface. In
this paper we generated anti-PfRh4 mAbs and tested their abil-
ity to modulate the interaction between PfRh4 and CR1 in vitro
and to inhibit P. falciparum invasion. Furthermore, we charac-
terize a collection of CR1-based inhibitors that will be invalu-
able in determining structure-function relationships between
this ligand-receptor pair. Our results will identify distinct func-
tional regions within PfRh4 and CR1 that are important for
mediating entry of P. falciparum parasites into human red
blood cells.
Experimental Procedures
Anti-PfRh4 Mouse Monoclonal Antibodies Production—
Anti-PfRh4 mAbs were produced at the Monoclonal Antibody
Facility at the Walter and Eliza Hall Institute. BALB/c and
C57Bl6 mice received three immunizations of recombinant
PfRh4 purified as described below. At day 0, Complete Freund’s
adjuvant was mixed with the antigen into an emulsion and
injected intraperitoneally. At day 30 and day 60 the antigen was
mixed with incomplete Freund’s adjuvant, and the emulsion
was injected intraperitoneally. Serum ELISA titrations were
performed at day 72. The mouse with the best response
received a final injection of antigen in saline, and splenocytes
2 The abbreviations used are: EBA, erythrocyte binding-like antigen; PfRh,
P. falciparum reticulocyte binding-like homolog protein; rPfRh, recombi-
nant PfRh; CR1, complement receptor 1; mAb, monoclonal antibody; CCP,
complement control protein; SPR, surface plasmon resonance; Bis-Tris.
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol.
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were harvested 3 days later. Spleen cells were fused with SP2/0
myeloma cells to form B-cell-myeloma fused cells (hybrido-
mas). Hybridomas were grown in hypoxanthine-aminopterin
thymidine growth medium. ELISA was used to select hybrido-
mas producing antibodies specific to PfRh4. Hybridomas were
cloned by limiting dilution in multiwell plates aiming for one
cell or less per well. The subcloning supernatants were screened
by ELISA. Two or more rounds of limiting dilution cloning
were generally required before the hybridomas were deemed
monoclonal. The antibodies were purified from monoclonal
hybridoma supernatants with protein A-Sepharose.
ELISA—96-Well flat-bottomed plates (Maxisorp; Nunc)
were coated with rPfRh4 (1 g/well) resuspended in PBS and
incubated for 2 h at room temperature. Plates were incubated
with 5% skim milk, 0.01% Tween 20 for 1 h at room temperature
to block nonspecific binding. After washing, anti-PfRh4 mAbs
were added at 1:1000 dilution for 1 h at room temperature.
Plates were washed 3 times before the addition of HRP-conju-
gated goat anti-mouse secondary antibodies (1:1000 dilution)
for 1 h at room temperature. Azino-bis-3-ethylbenthiazoline-
6-sulfonic acid (ABTS liquid substrate; Sigma) was used to
detect HRP activity. 1% SDS was used to stop the reaction, and
absorbance was measured at 405 nm. All washes were done in
PBS, 0.01% Tween 20, and dilutions of antibodies were done in
0.5% skim milk, 0.01% Tween 20. All samples were performed
in duplicate.
For competitive binding experiments with mAbs, the ELISA
protocol was performed as above with the following modifica-
tions. Microtiter wells were coated with CCPs 1–3 (1 g/well).
After washing and blocking, rPfRh4 was added at a final con-
centration of 1 g/well together with anti-PfRh4 mAbs. Bind-
ing of rPfRh4 was detected using an anti-PfRh4 rabbit poly-
clonal antibody followed by addition of HRP conjugated goat
anti-rabbit secondary antibody.
Indirect Immunofluorescence Assay—Indirect immunofluo-
rescence assay samples were prepared from magnet-purified
parasites as described previously (36). Briefly, parasites were
smeared on glass slides and fixed using 100% ice-cold methanol
for 30 s. After fixation, samples were blocked overnight in 3%
BSA (Sigma) in PBS at 4 °C. Primary antibodies were diluted in
blocking solution and applied to slides. After a 1-h incubation at
room temperature, the slides were washed 3 times in PBS. This
was followed with a 1-h incubation with secondary antibodies
diluted in blocking solution; slides were protected from light
during the incubation. The slides were washed three times with
PBS and mounted in VectaShield (Vector Laboratories) with
0.1 ng/l 4,6-diamidino-2-phenylindole (DAPI, Invitrogen).
Primary antibodies used in indirect immunofluorescence assay
imaging were diluted in 3% BSA in PBS, and the concentrations
were as follows: mouse anti-PfRh4 (2 mg/ml, 1:500), rabbit anti-
PfRh2 (2 mg/ml, 1:500). Secondary antibodies were used at the
following concentrations: Alexa Fluor 488 goat anti-mouse
(1:500) and Alexa Fluor 594 goat anti-rabbit (1:500). Fluores-
cence images were obtained using DeltaVision Elite widefield
fluorescence microscope. Z stacks were taken above and below
parasites and processed using Axiovision deconvolution soft-
ware package.
Immunoblotting and Antibodies—Proteins larger than 100
kDa were run on 3– 8% Tris acetate, whereas smaller proteins
were run on 4 –12% Bis-Tris SDS-PAGE gels (Invitrogen).
Western blotting was performed using standard protocols, and
the blots were processed with an enhanced chemiluminescence
(ECL) system (Amersham Biosciences). Western blots probed
with anti-PfRh4 mouse mAbs were conducted 2 mg/ml at
1:1000 dilution followed by HRP-conjugated goat anti-mouse
secondary antibody at a 1:1000 dilution.
Immunoprecipitation Assays—In a reaction volume of 100
l, anti-PfRh4 mAbs were incubated with recombinant PfRh4
at 0.1 and 0.05 mg/ml, respectively, for 1 h at room tempera-
ture. 5 l of packed Protein G-Sepharose beads were added to
capture the anti-PfRh4 mAbs; this incubation proceeded for 1 h
at room temperature. Beads were washed five times with PBS,
and proteins were eluted with equivalent volumes of 2 non-
reducing sample buffer and boiled for 5 min before separating
on SDS/PAGE gels. Protein eluates were visualized using Sim-
plyBlue SafeStain (Life Technologies), performed according to
the manufacturer’s protocol.
Fluorescence Resonance Energy Transfer (FRET) Assay—To
screen for antibodies that disrupt the PfRh4 interaction with
CR1, we labeled rPfRh4 and the CCPs 1 and 2 with NHS ester
derivatives of DyLight 594 and DyLight 488 (Life Technolo-
gies), respectively, to assess the rPfRh4-CCPs 1 and 2 interac-
tion by FRET. rPfRh4 (2 mg/ml) was labeled at a 1:3 molar ratio
with DyLight 594 in 50 mM MES, pH 6.0, 150 mM sodium chlo-
ride. Buffer exchange to 50 mM MES pH 6.0 and free dye
removal was achieved using a Micro Bio-Spin P-6 column (Bio-
Rad). CCPs 1 and 2 were similarly labeled with DyLight 488, and
each preparation was assessed by spectrophotometry to deter-
mine the average number of dye molecules per protein mole-
cule. After labeling, each rPfRh4 molecule carried an average of
2.6 DyLight-594 molecules, whereas CCPs 1 and 2 carried 1.8
DyLight 488 molecules. 10-l binding reactions of rPfRh4
DyLight-594 and CCPs 1 and 2DyLight488, each at 125 nM in
50 mM MES, pH 6.0, 150 mM sodium chloride, were placed in
Corning 384-well plates (#3820), and fluorescence intensity at
the following wavelengths were measured using an EnVision
plate reader (PerkinElmer Life Sciences): DyLight-488 (donor)
485/14-nm excitation filter and 535/25-nm emission filter,
DyLight-594 (acceptor) 590/20-nm excitation filter and 615/
9-nm emission filter, and sensitized emission 485/14-nm exci-
tation filter and 615/9-nm emission filter. In an ideal situation
sensitized emission should only be measured when DyLight-
488 and DyLight-594 are in close proximity, but in practice we
measured a significant contribution to FRET-mediated sensi-
tized emission from DyLight-594 in the absence of DyLight-488
and chose to correct for this by calculating FRET as a ratio of
sensitized emission over DyLight-594 fluorescence intensity.
This creates a unit-less FRET ratio that can be used to compare
binding of rPfRh4DyLight-594 to CCPs 1 and 2DyLight-488 in
the presence or absence of candidate inhibitors that disrupt the
interaction.
Flow Cytometry-based Erythrocyte Binding Assay—The flow
cytometry-based erythrocyte binding assay was performed as
described with the following modifications (17). 40 l of packed
erythrocytes were washed twice with 400 l of 1% BSA/PBS and
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resuspended to a final volume of 1  107 cells/ml. Meanwhile,
1.25 g of rPfRh4 was preincubated with 10 g of mAb at room
temperature for 10 min. 100 l of the resuspended erythrocytes
was added to the recombinant protein/antibody mix and incu-
bated for 30 min. After binding, erythrocytes were washed three
times with 1% BSA, PBS. To detect rPfRh4 binding, anti-PfRh4
rabbit IgG R550 (1:100 dilution) was added and incubated for
30 min followed by 3 washes with 1% BSA, PBS. Alexa Fluor 488
goat anti-rabbit secondary antibody (1:100, Life Technologies)
was added and incubated at room temperature and protected
from light for 30 min. Erythrocytes were washed twice with 1%
BSA. PBS followed by 1 wash in PBS and resuspended in 500 l
of PBS before being transferred to FACS tubes. A total of 50,000
erythrocytes were read on the FACSCalibur flow cytometer
(BD Biosciences), and the results were analyzed using FlowJo
software (Three Star). The percentage of erythrocytes with
bound rPfRh4 was determined by normalizing the number of
erythrocytes exhibiting a positive Alexa Fluor 488 signal that is
above the background (which is Alexa Fluor 488 signal of eryth-
rocytes without rPfRh4 added) on the total number of
erythrocytes.
Parasite Culture and Growth Inhibition Assay—P. falcipa-
rum asexual stages were maintained in human O erythrocytes
in RPMI-HEPES medium with 50 g/ml hypoxanthine, 25 mM
NaHCO3, 20 g/ml gentamicin, and 0.5% Albumax II (Gibco;
Invitrogen) in 1% O2, 4% CO, and 95% N2 at 37 °C and synchro-
nized by standard methods. We used the D10-PHG for the
majority of our assays, which are GFP-positive (37).
Growth inhibition assays were performed as described with
the following modifications (33). Starting parasitemia for the
growth assays was 0.2% with a hematocrit of 1%. CR1 con-
structs, anti-PfRh4 mAbs, bovine serum albumin (BSA, Sigma),
and heparin were added at the beginning of the assay. Growth
inhibition assays were performed in 96-well round-bottom
microtiter plates (BD Biosciences) over 2 cycles of parasite
growth. After 96 h the parasitemia was determined by flow
cytometry of GFP-positive and EtBr-stained trophozoite-stage
parasites using a FACSCalibur (BD Biosciences) and a plate
reader. For each well 40,000 cells or more were counted.
Growth was expressed as mean parasitemia obtained from trip-
licate readings. At least two independent assays were per-
formed, each in triplicate. % Growth refers to the % parasitemia
in the presence of CR1 constructs or anti-PfRh4 mAbs relative
to the % parasitemia with the addition of PBS (no mAb control,
which was arbitrarily set to be 100%).
Mapping of mAb Epitopes—An overlapping peptide array
consisting of 15-mer biotinylated peptides with a SGSG linker
was synthesized by Mimotopes Pty Ltd, Clayton, Australia.
Peptides were resuspended and applied to streptavidin-coated
plates. ELISA was performed as stated above.
Antibody Affinity Measurements—Binding of rPfRh4 to anti-
PfRh4 mAbs 5H12 and 10C9 was monitored by SPR using the
Biacore 3000 system (GE Healthcare), where experiments were
performed at 25 °C in PBS-p . CMD-500 (XanTec bioanalyt-
ics GmbH, Dusseldorf, Germany) chip surfaces were prepared
by immobilization of anti-mouse IgG at 30 g/ml in 10 mM
sodium acetate, pH 5.0, using standard NHS-EDC (EDC, 1-eth-
yl-3-(3-dimethylaminopropyl)-carbodiimide) amine coupling
methods, where a final immobilization of 7542.2 resonance
units was achieved. The antibody affinity assay was performed
using an indirect capture method where antibodies 5H12 and
10C9 were diluted to 30 g/ml in PBS-p  and injected for 120 s
at 5 l/min with a 300-s stabilization time. After stabilization,
rPfRh4 in PBS-p  was injected at 20 l/min for 420 s followed
by a 7200-s dissociation over 2-fold increases in concentration
between 1.5625 nM and 50 nM. The chip surface was regener-
ated before each run with a single 20-s injection of 10 mM gly-
cine, pH 1.7 at 30 l/min where baseline was achieved. The
buffer difference was subtracted from blank cell lanes that had
been activated and deactivated using standard amine coupling
methods. Each concentration series was performed in dupli-
cate. Data generated were processed using the BIAevaluation
software (GE Healthcare), where multicycle kinetics were
obtained using a 1:1 Langmuir binding model.
Protein Expression and Purification—Recombinant PfRh4
was previously expressed using expression vector pET-45b()
as described (17, 31, 33). For this paper we digested this clone
using BamHI and XhoI and cloned the DNA-encoding PfRh4
in-frame into a pProEX HTa vector, which contains a hexa-His
tag and tobacco etch virus cleavage site at the N-terminal end.
The fusion protein was expressed in BL21 (DE3) bacteria cells
and purified over a nickel-nitrilotriacetic acid column (Qiagen)
under native conditions. The purified protein underwent
tobacco etch virus protease cleavage overnight at 4 °C to
remove 23 amino acids including the hexa-His tag. Cleaved
rPfRh4 was further purified on a Superdex 200 gel filtration
column (Hiload 16/60; GE Healthcare), and appropriate frac-
tions concentrated and loaded onto a cation exchange column
(Mono S 5/50 GL; GE Healthcare). Recombinant rPfRh4 eluted
from the column as a monomer and purity was determined
using SDS-PAGE.
Protein constructs CCPs 1 and 2 and CCPs 1–3 were ex-
pressed and purified as described before (33). In brief, existent
Pichia pastoris clones were fermented as described in Schmidt
et al. (38), and the recombinant proteins were secreted into the
supernatant and captured by ion chromatography with Sephar-
ose beads. The capture step was followed by cation and size
exclusion chromatography. The coding DNA for CCPs 8 and 9
and the mutant versions of CCPs 1 and 2, i.e. m6 –9, m18, and
m20, as well as the revertant mutant CCPs 8 and 9 m7–9 and
18 –20r, were codon-optimized, gene-synthesized (IDT Tech-
nologies), and subcloned into the P. pastoris expression vector
pPICZB. Within CCPs 1 and 2 and its mutant versions the
N-glycosylation sites were removed by substituting relevant
Asn to Gln residues. The novel expression cassettes were trans-
formed into the P. pastoris strain KM71H according to the
manufacturer’s instructions (Life Technologies). Protein
expression and purification was carried out as for CCPs 1 and 2
and yielded between 10 and 52 mg of a highly pure protein
preparation per liter fermenter supernatant. N-Glycosylation
(CCP 8 and 9 constructs) was removed with the endoglycosi-
dase EndoHf (New England BioLabs) when applicable in
between purification steps using a published procedure (38).
All CCP 1 and 2 and CCP 8 and 9 constructs were submitted to
mass spectrometry analysis. Purified proteins were analyzed on
an LTQ-Orbitrap Velos Pro (Thermo Scientific) online coupled
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to an RSLCnano uPLC (Thermo Scientific) equipped with a
Vydac MS C4 column (300 Å, 5 m, 5 mm  300 m) (Grace).
After desalting the samples at 5% acetonitrile, 0.1% formic acid
with a flow of 10 l/min for 10 min, proteins were eluted from
the column by raising the concentration of acetonitrile to 43%
for 5 min. MS spectra were acquired in the Orbitrap part of the
instrument at a resolution of 30,000. The acquired data were
processed using the QualBrowser (Thermo Scientific) in com-
bination with in-house written VBA-script for MSExcel
(Microsoft Corp.). These analyses confirmed the identity of the
protein preparations with a maximal deviation from the theo-
retical molecular mass of 12.5 ppm (or 0.18 Da). Additionally,
one-dimensional NMR spectroscopy shows that line widths
and signal dispersion (measured at 30 °C in PBS with addition
of 7% D2O) are consistent with mono-dispersed, well folded
protein molecules.
Surface Plasmon Resonance Measurement of CCP Mutants
and rPfRh4 —To analyze the interactions between rPfRh4 with
recombinant CR1 constructs, SPR experiments were carried
out at 25 °C using a Reichert SR7500DC SPR instrument
(Reichert Technologies, Buffalo, New York). Recombinant Rh4
was covalently immobilized onto one flow cell of a carboxy-
methyldextran hydrogel biosensor chip (CMD500m, purchased
from XanTec bioanalytics GmbH, Dusseldorf, Germany) by
standard amine coupling according to the manufacturer’s
instructions. Amine coupling in the absence of any protein
(dummy coupling) was performed on a second flow cell yielding
a reference flow cell. Signals obtained for the rPfRh4 surface
were subtracted by signals obtained for the reference flow cell
according to standard procedure. Only reference-subtracted
sensorgrams are shown throughout. As running buffer 10 mM
HEPES, pH 7.4, 150 mM NaCl, 1 mM MgCl2, and 0.005% Tween
20 was used throughout, apart from one protein series of CCPs
1 and 2 (indicated), which was assayed in the same buffer but
with MgCl2 substituted with 3 mM EDTA. Proteins were diluted
into running buffer before assaying and were injected on the
chip for 3 min at a flow rate of 25 l/min. The dissociation
phase consisted of buffer flow at 25 l/min for 5 min and was
followed by a regeneration step with 1 M NaCl. CCPs 1 and 2,
CCPs 1 and 2 m6 –9, CCPs 1 and 2 m18, CCPs 8 and 9
m7–9,18 –20r (CCPs 8 and 9 Rev) and CCPs 8 and 9 were
assayed at 1:1 dilution series from 10 M to 0.61 nM. CCP 1 and
2 m20 and CCP 8 and 9 were assayed at 1:1 dilution series from
10 M to 9.8 nM. Affinity constants were extracted by plotting
the response at steady state against the molar concentration
and subsequent fitting the affinity with the TRACEDRAWER
software using a 1:1 steady state affinity model. To probe repro-
ducibility the binding of double injections (at same concentra-
tion) were probed for all analytes at the highest concentration
assayed (apart from CCP 1 and 2 m18 and CCPs 1–3) and at the
lowest concentration assayed (for all).
Results
Characterization of Anti-PfRh4 Monoclonal Antibodies—
PfRh4 binds to CR1 to mediate entry of P. falciparum parasites
into red blood cells (17). We previously generated a recombi-
nant fragment of PfRh4 (rPfRh4) that binds to red blood cells
and forms a complex with sCR1 and CCPs 1–3 (17, 31). We
immunized mice with rPfRh4, generated 10 murine mAbs that
could detect rPfRh4 by ELISA (Fig. 1A), and proceeded to
examine whether they bound native PfRH4 or interfered with
receptor engagement. 2E8 mAb is specific to the C-terminal
end of native PfRh4, which does not include the region encom-
passed by rPfRh4 and as expected did not show significant reac-
tivity to rPfRh4 (Fig. 1A) (17).
PfRh4 together with the other PfRh family of proteins local-
ize to the rhoptries of P. falciparum parasites (6). Using an indi-
rect immunofluorescence assay we showed that all mAbs
except 6F12 detected PfRh4 in an apical localization that pre-
dominantly co-localized with PfRh2, another rhoptry protein
(Fig. 1B) (39). We tested the ability of the mAbs to detect
unfolded PfRh4 from solubilized P. falciparum schizont lysate
by Western blotting. Native PfRh4 migrates as a doublet at 180
and 190 kDa (31), which was detected by all the mAbs except for
5H12 in a P. falciparum strain expressing PfRh4 (Fig. 1C). This
PfRh4-specific doublet is not present in parasite lysates har-
vested from a PfRh4 knock-out strain. We hypothesize that
5H12 recognizes a conformational epitope that is not present
under SDS-PAGE conditions and which denatures PfRh4.3 To
examine if these mAbs are able to immunoprecipitate folded
rPfRh4, we incubated rPfRh4 with mAbs and used protein
G-Sepharose beads to capture the antigen-antibody complexes.
Only 5H12, 6A5, and 10C9 were able to immunoprecipitate
rPfRh4 as seen by its presence in the eluate lane (Fig. 1, D and E
lanes). We also performed similar assays using parasite culture
supernatants, which contain a processed 160-kDa fragment of
PfRh4 (31), and were able to show that 2E8, 5H12, 6A5, and
10C9 were able to immunoprecipitate PfRh4 (Fig. 1E). Collec-
tively these results show that all anti-PfRh4 mAbs have specific
reactivity to both rPfRh4 and native PfRh4 from P. falciparum
parasites. In addition, 5H12 may recognize a conformational
epitope on PfRh4.
Modulation of Recombinant PfRh4 and CR1 Interaction with
Monoclonal Antibodies—To determine whether anti-PfRh4
mAbs inhibited the interaction between PfRh4 and CR1, we
developed a FRET assay where 125 nM rPfRh4 labeled with
DyLight-594 could be shown to bind to the same concentration
of recombinant CCPs 1 and 2 labeled with DyLight-488 (Fig. 2,
A–D, No inh columns). We validated this assay by introducing
50-fold molar excess of unlabeled rPfRh4 and CCPs 1 and 2 to
compete with the FRET pair and found a marked decrease in
FRET ratio (Fig. 2D, unRh4 and CCPs 1 and 2, respectively).
Denaturants such as 3 M guanidinium chloride and 1% sodium
dodecyl sulfate also reduced FRET to similar levels. In contrast,
proteins that were unable to bind PfRh4 such as CCPs 8 and 9
and bovine serum albumin had no effect on FRET (Fig. 2D) (33).
For the following FRET assays, we arbitrarily defined 100%
binding as the level of binding measured when no inhibitor was
added and 0% binding as the level of binding measured in dena-
turing concentrations of sodium dodecyl sulfate (Fig. 2D, dotted
lines). This assay allowed rapid screening of the mAbs and iden-
tified 5H12 mAb as an inhibitor of the rPfRh4-CR1 interaction
(Fig. 2E).
3 5H12 mAb did not detect native PfRh4 by Western blotting in both reducing
and non-reducing conditions.
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To confirm the results obtained from the FRET-based assay,
we examined the effect of mAbs on PfRh4-CR1 interaction by
ELISA (Fig. 2F). Recombinant PfRh4 was incubated briefly with
each mAb before binding to immobilized CCPs 1–3, and bound
PfRh4 was detected using a polyclonal anti-PfRh4 antibody.
The addition of CCPs 1–3 as a known inhibitor showed the
expected marked reduction in PfRh4-CR1 binding (Fig. 2F)
(33). 5H12 showed similar levels of inhibition of the PfRh4-CR1
interaction as in the FRET assay. We observed that two mAbs,
6A5 and 10C9, appeared to enhance the interaction between
rPfRh4 and CCPs 1–3 (Fig. 2F).
We examined whether the inhibitory mAb 5H12 and the
enhancing mAb 10C9 were able to co-immunoprecipitate
PfRh4 and CCPs 1–3. Both 5H12 and 10C9 immunoprecipitate
rPfRh4 with similar efficiencies as indicated by the depletion
of rPfRh4 in the unbound fraction (lane U) and an enrichment
of rPfRh4 in the eluate fraction (Fig. 2G, left panel, lane E).
When CCPs 1–3 was added into the assay, 10C9 was able to
immunoprecipitate the rPfRh4-CCPs 1–3 complex (Fig. 2G,
right panel). In contrast, although 5H12 successfully immuno-
precipitated rPfRh4, we did not detect a corresponding CCPs
1–3 protein (Fig. 2G, right panel). 5H12 was less efficient at
FIGURE 1. Characterization of monoclonal antibodies specific to PfRh4. A, detection of rPfRh4 by anti-PfRh4 mAbs by ELISA. Anti-PfRh4 mAbs were added
to microtiter wells coated with rPfRh4. Bound antigen-antibody complexes were detected with anti-mouse HRP. Error bars represent the mean  S.E. of three
independent assays repeated in triplicate. B, localization of native PfRh4 was assessed by wide-field immunofluorescence assay using the anti-PfRh4 mAbs.
PfRh4 (green) was co-stained with rhoptry protein, PfRh2 (red), and nuclei-stain DAPI (blue). Differential interference contrast (DIC) shows the differential
interference contrast view of the same field. Scale bar  5 m. C, native PfRh4 is detected by all anti-PfRh4 mAbs except for 5H12. Western blot of saponin-lysed
schizont pellet lysates from wild type and PfRh4 strains were separated by SDS-PAGE and probed with anti-PfRh4 mAbs under reducing conditions. D,
immunoprecipitation of rPfRh4 using anti-PfRh4 mAbs. Recombinant PfRh4 was incubated with anti-PfRh4 mAbs and protein G-Sepharose. Protein eluates
were fractionated on SDS-PAGE and visualized using SimplyBlue SafeStain. I, input. U, unbound. E, eluate. E, immunoprecipitation of PfRh4 from culture
supernatants using anti-PfRh4 mAbs. Culture supernatants were incubated with anti-PfRh4 mAbs and protein G-Sepharose. Protein eluates were fractionated
on SDS-PAGE and probed with anti-PfRh4 polyclonal antibody. The asterisk marks the processed fragment of PfRh4 present in culture supernatants. For all
panels, molecular weight is indicated on the left in kDa.
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immunoprecipitating rPfRh4 when CCPs 1–3 were present,
suggesting that 5H12 binds to a region of rPfRh4 that is also
bound by CCPs 1–3 (Fig. 2G, right panel versus left panel).
Blocking the Red Blood Cell Binding Capabilities of PfRh4 —
We utilized a flow cytometry-based red blood cell binding assay
to determine the effects of the mAbs on PfRh4 interaction with
native CR1 on the surface of red blood cells. This method
entailed incubating rPfRh4 with red blood cells in the presence
of mAbs; rPfRh4 binding was detected using an anti-PfRh4 rab-
bit polyclonal antibody followed by an anti-rabbit secondary
antibody conjugated to a fluorophore, which was detected by
flow cytometry. This assay was used previously to show that the
levels of rPfRh4 binding to erythrocytes directly correlates with
the levels of CR1 on the red blood cell surface (17). For this assay
we used an intermediate amount of rPfRh4 that allows both
increases and decreases in rPfRh4 binding to be measured. As
expected, the addition of soluble CCPs 1 and 2 was able to
inhibit rPfRh4 binding to red blood cells (Fig. 3, A and B). 1D11,
5H12, 6A5, and 10C9 were all able to affect PfRh4 binding to red
blood cells. Consistent with previous results, 5H12 was able to
inhibit rPfRh4 binding to a similar extent as CCPs 1 and 2 (Fig.
3, A and B). On the other hand, 1D11 and 10C9 showed strong
enhancement of rPfRh4 erythrocyte binding, whereas 6A5
increased rPfRh4 binding more modestly (3.6, 19.5, and 1.5-fold
increase, respectively).
We tested if the mAbs could inhibit the PfRh4-CR1 invasion
pathway in P. falciparum growth assays. As a negative control
in these experiments we used the 2E8 mAb, which is specific to
the C-terminal end of native PfRh4 (not present in rPfRh4) and
has previously been shown to be unable to inhibit parasite
growth (17). P. falciparum parasites invade red blood cells via
several redundant invasion pathways mediated by EBA and
PfRh proteins. To abolish the pathways mediated by the EBA
family of proteins, red blood cells were treated with neuramin-
FIGURE 2. Inhibition of the PfRh4-CR1 interaction with anti-PfRh4 mAbs. Novel FRET-based assay to monitor the interaction between PfRh4 and CR1 where
CCPs 1 and 2 (A) and rPfRh4 (B) were labeled with Dylight 488 and 594, respectively, and incubated at 1:1 molar concentration (no inh) either in the presence
of unlabeled proteins (CCPs 1 and 2, BSA, CCPs 8 and 9, unRh4) or denaturants (guanidine hydrochloride (GndCL) and SDS). The fluorescence intensity (FI) of
DyLight-488 (donor) was measured with a 485/14-nm excitation filter and a 535/25-nm emission filter and DyLight-594 was measured with a 590/20-nm
excitation filter and 615/9-nm emission filter. C, measurement of FRET fluorescence intensity using the DyLight-488 (donor) 485/14-nm excitation filter and the
DyLight 594 (acceptor) 615/9-nm emission filter. D, FRET ratio on the y axis represents “excitation 488/emission 615” value over Dylight 594 value. Unlabeled
CCPs 1 and 2 and rPfRh4 (unRh4) were able to inhibit labeled PfRh4-CR1 interaction on a similar level to denaturants, SDS and guanidine hydrochloride (GndCL).
Error bars represent the S.E. of three independent repeats. E, 5H12 inhibits the PfRh4-CR1 interaction in the FRET-based assay. Dylight-labeled rPfRh4 and CCPs
1 and 2 were incubated with various anti-PfRh4 mAbs. Percentage binding refers to the FRET ratio relative to “no mAb” and SDS controls. Error bars represent
S.E. of three independent repeats. F, 5H12 inhibits PfRh4-CR1 interaction in ELISA-based assay. Microtiter wells were coated with CCPs 1–3. Recombinant PfRh4
was added in the presence of anti-Rh4 mAbs. Bound rPfRh4 was detected with an anti-PfRh4 rabbit polyclonal primary antibody followed by an anti-rabbit-HRP
secondary antibody. Error bars represent S.E. of two independent repeats. G, 5H12 disrupts PfRh4-CR1 complex formation. The immunoprecipitation assay was
performed by incubating rPfRh4 with 5H12 and 10C9 (left panel) and subsequently in conjunction with CCPs 1–3 (right panel). I, input. U, unbound. E, eluate.
Antibodies and Inhibitors Modulate PfRh4 Binding to CR1














idase to remove sialic acid residues from the glycophorins,
which are cognate receptors for EBA proteins. Upon neuramin-
idase treatment, 90% of the invasion events are dependent on
PfRh4 for entry into red blood cells via CR1 (17, 33). When all
10 mAbs and 2E8 were tested in neuraminidase-treated red
blood cells, we observed inhibition of the PfRh4-CR1 pathway
only when 5H12 was added to the growth medium (Fig. 3C). In
subsequent growth assays we additionally tested CR1 frag-
ments, 5H12, and the enhancing mAb 10C9. The addition of
CCPs 1 and 2, CCPs 1–3, sCR1 inhibited 	90% of the invasion
events in neuraminidase-treated red blood cells as expected
(Fig. 3, C and D), whereas the addition of 2E8 and 10C9 mAb did
not perturb growth in a statistically significant manner. 5H12
again exhibited similar levels of growth inhibition as soluble
forms of CR1 (Fig. 3D). Titration of 5H12 showed dose-depen-
dent inhibition of P. falciparum invasion events and growth in
neuraminidase-treated red blood cells (Fig. 3E).
Mapping the Epitopes for Monoclonal Antibody Binding—
Having characterized the functional outcomes of mAb binding
to PfRh4, we next utilized a panel of overlapping 15-mer pep-
tides completely encompassing rPfRh4 to identify epitopes rec-
ognized by the anti-PfRh4 mAbs (Fig. 4). Using ELISA we
detected specific binding to either a single peptide or a set of
overlapping peptides for all of the mAbs except 1D11, 1H3, and
5H12. Both 1A6 and 3A6 bound two overlapping peptides:
N238 (NEKLEKYTNKFEHNI) and E242 (EKYTNKFEHNIKP-
HI). 5D2 bound a single peptide (Y266, YINNSDCHLTCSK-









































































































1A6 1D11 1H3 2A1 2E8 3A6 5D2






















































































































































FIGURE 3. Inhibition of the PfRh4 invasion pathway. A, dot plots show the binding of rPfRh4 to red blood cells in the presence of anti-PfRh4 mAbs. Binding
was detected using an anti-PfRh4 rabbit IgG antibody followed by a secondary anti-rabbit Alexa 488 antibody. Numbers outside of the purple box refer to the
percentage of red blood cells with bound rPfRh4 relative to the full red blood cell population. B, recombinant PfRh4 binding to erythroid CR1 was inhibited by
5H12. Binding assays were performed by incubating rPfRh4 and red blood cells in the presence of various anti-PfRh4 mAbs, and the level of red blood cell
binding was determined by flow cytometry. Percentage RBC binding on the y axis refers to the percentage of rPfRh4-erythroid CR1 binding relative to the no
mAb control (arbitrarily set to be 100%). Error bars represent S.E. of three independent repeats. C, anti-PfRh4 mAbs were tested with untreated (black bars) or
neuraminidase-treated erythrocytes (gray bars) at a final concentration of 0.2 mg/ml. Growth inhibition assays were performed using the D10-PHG strain of
P. falciparum. D, anti-PfRh4 mAb, 5H12, inhibits the PfRh4-CR1 pathway to similar levels as the recombinant CR1 constructs. D10-PHG strain was tested in
untreated (black bar) or neuraminidase-treated erythrocytes (gray bar) in the presence of anti-PfRh4 mAbs (at a final concentration of 0.2 mg/ml) and
recombinant CR1 constructs (at a final concentration of 0.1 mg/ml). Error bars represent S.E. from five independent repeats. E, titration of 5H12 in growth
inhibition assays in the presence of untreated (black bar) or neuraminidase-treated red blood cells (gray bar). Error bars represent S.E. from four independent
repeats. For panels C, D, and E, percent growth on the y axis refers to the percentage parasitemia relative to the no mAb control, which is arbitrarily set at 100%.
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KQKFLNK), Y526 (YIILKQKFLNKLNEI), and K530 (KQKFL-
NKLNEIIQNH). 10C9 bound two overlapping peptides, N662
(NFTHKTIQQILQQQY) and K666 (KTIQQILQQQYKNNT),
whereas 6A5 also recognized peptide K666. It is interesting to
note that both 10C9 and 6A5 enhance rPfRh4 red blood cell
binding. 6F12 bound to novel epitopes encompassed by two
overlapping peptides, N718 (NIEHIKQILINYIQE) and I722
(IKQILINYIQECKPI).
To determine if any of the mAbs share a similar epitope to
5H12, we also performed competition ELISA between 5H12
(which was directly conjugated to HRP, 5H12-HRP) and all the
other mAbs. Using rPfRh4-coated microtiter plates, we exam-
ined the level of 5H12-HRP binding in the presence of each
mAb by ELISA. Although the addition of 5H12 itself success-
fully competed with 5H12-HRP, none of the other mAbs
showed a similar phenotype (data not shown).4 These data
show that the 5H12 epitope is unique and does not overlap with
other epitopes bound by the collection of anti-PfRh4 mAbs.
Antibody Affinities for PfRh4 —The affinity of two mAbs,
5H12 and 10C9, to rPfRh4 was evaluated using SPR. 5H12 and
10C9 showed clear binding (Fig. 5, A and B, respectively).
rPfRh4 bound to 5H12 with low nanomolar affinity (KD  1.34
nM) and with association (ka  1.29  105 M
1s
1) and dissoci-
ation (kd  1.73  10
4 s
1) (Table 1). In comparison, 10C9
showed an even higher affinity for rPfRh4 (KD  0.48 nM), with
association (ka  5.64  104 M
1s




CR1-based Inhibitors That Block PfRh4-CR1 Interaction—
Mutagenesis analyses within CCPs 1–7 identified several resi-
dues essential for PfRh4 binding within CCP 1 (Fig. 6A) (32).
Although these mutations clearly abolished PfRh4-CR1 inter-
action in vitro as shown by ELISA, immunoprecipitation, and
SPR measurements, the mutant proteins were not assessed for
their functional effects in red blood cell binding or growth
assays. To this end we generated recombinant CCPs 1 and 2
proteins in P. pastoris that contained mutations of these critical
residues (Fig. 6B). These mutations (m) are named in relation to
their positions in CCP 1 that were substituted with the respec-
tive amino acids in CCP 8 (Fig. 6C) (32). We produced correctly
folded CCPs 1 and 2 m6 –9, CCPs 1 and 2 m18, and CCPs 1 and
2 m20. In addition, we also expressed an engineered PfRh4
binding site in CCPs 8 and 9 by introducing CCP 1 residues at
7–9 and 18 –20 to their homologous site within CCP 8 (32).
This mutant is called CCPs 8 and 9 m7–9,18 –20r but will be
referred to as CCPs 8 and 9 Rev for simplicity. The proteins
were purified to a high degree of purity, as judged by prominent
single protein bands under reducing and non-reducing condi-
tions after SDS-PAGE analysis (Fig. 6B). The faster mobility
under non-reducing conditions is indicative of disulfide bridges
being formed within these constructs. Protein identity and
quality have additionally been confirmed by mass spectrometry
with a maximal deviation of 12.5 ppm (equating to 0.18 Da)
from the theoretical molecular mass.
Using immunoprecipitation assays, we examined whether
these mutants could still form a complex with rPfRh4. We
observed that CCPs 1 and 2 was able to form a stable complex
with rPfRh4 (Fig. 6, D and E). Unexpectedly CCPs 1 and 2 m6 –9
and CCPs 1 and 2 m18 were still able to interact with rPfRh4
(32). Mutation of residue 20 (CCPs 1 and 2 m20) completely
abolished complex formation. As expected, CCPs 8 and 9 did
not interact with rPfRh4, whereas CCPs 8 and 9 Rev was able to
form a stable complex with rPfRh4 (Fig. 6D, right panel), indi-
cating that the substituted residues from CCP 1 to CCP 8 are
sufficient to mediate PfRh4 binding.
To determine if CCPs 8 and 9 Rev bound to PfRh4 using the
same binding site as recognized by the inhibitory antibody, we
examined if the addition of mAb 5H12 would interfere with the
rPfRh4-CCPs 8 and 9 Rev complex. 10C9 was able to immuno-
precipitate rPfRh4-CCPs 8 and 9 Rev complex (Fig. 6E). How-
ever, 5H12 successfully immunoprecipitated rPfRh4, but we
did not detect a corresponding CCPs 8 and 9 Rev fragment (Fig.
6E), suggesting that 5H12 inhibits the interaction between
rPfRh4 and CCPs 8 and 9 Rev.
We utilized the flow cytometry-based red blood cell binding
assay described earlier to determine the effects of the mutant
proteins. As expected, the addition of soluble CCPs 1 and 2,
CCPs 1 and 2 m6 –9, CCPs 1 and 2 m18, and CCPs 8 and 9 Rev
was able to inhibit rPfRh4 binding to red blood cells (Fig. 6F).
Proteins that did not bind rPfRh4 such as CCPs 8 and 9 and
CCPs 1 and 2 m20 were not able to inhibit rPfRh4 binding to red
blood cells (Fig. 6F). Consistent with these results, we observed
4 Using competition ELISA, only unlabelled 5H12 mAb could outcompete



























































































































































































































































































































































































































































































































































































































































































FIGURE 4. Epitope mapping of PfRh4 monoclonal antibodies. Detection of
anti-PfRh4 mAbs binding to an overlapping peptide array encompassing
rPfRh4 by ELISA. Peptides are named by the single-letter code and numerical
position of their first amino acid within PfRh4; e.g. K30 indicates the peptide
KEKKNDPEADSKNSQ starting at amino acid position 30. Significant binding of
anti-PfRh4 mAbs to peptides is highlighted with the peptide sequence.
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that the addition of CCPs 1 and 2, CCPs 1 and 2 m6 –9, CCPs 1
and 2 m18, and CCPs 8 and 9 Rev was able to inhibit the major-
ity of P. falciparum invasion events into neuraminidase-treated
red blood cells (Fig. 6G). This was similar to the level of inhibi-
tion seen upon the addition of CCPs 1–3 and sCR1. As
expected, we did not observe any inhibition of the PfRh4-CR1
invasion pathway with the addition of CCPs 8 and 9 or CCP 1
m20 (Fig. 6G).
To ensure that the protein fragments that were used in all the
assays above were properly folded, we also performed one-di-
mensional NMR spectroscopy. One-dimensional NMR spec-
troscopy shows that line widths and signal dispersion are con-
sistent with monodispersed, well folded protein molecules (Fig.
7, A–F).
Affinity of CR1-based Inhibitors for Binding to PfRh4 —We
expected that mutations in CCPs 1 and 2 and CCPs 8 and 9
would directly influence each mutant protein’s affinity for
PfRh4. To determine the binding constants of the wild type and
mutant proteins, we employed SPR. rPfRh4 was immobilized
onto a carboxymethyldextran hydrogel sensorchip surface, and
the CR1 constructs were assayed in HEPES-buffered saline con-
taining 1 mM MgCl2 (Fig. 8). CCPs 1 and 2, CCPs 1 and 2 m6 –9,
and the revertant mutant CCPs 8 and 9 Rev exhibited the high-
est affinities for rPfRh4 binding (20.0, 33.5, and 64.9 nM; Fig. 8,
A, B, and F, respectively), which is in accordance with their
inhibitory potential. CCPs 1 and 2 m18 interacts with rPfRh4
with an affinity of 336 nM (Fig. 8C), which is markedly reduced
from the CCPs 1 and 2 binding constant of 20 nM. As expected
CCPs 1 and 2 m20 and CCPs 8 and 9 failed to produce any
substantial binding response (Fig. 8, D and E). Although the
determined affinity constants for the CR1-based inhibitors are
in excellent correlation with their biological activities in this
study, we noted that the binding constants differ from previous
studies, in which CCPs 1–7 or CCPs 1–3 were found to interact
with PfRh4 with affinities in the range from 0.5 to 11 M (32,
33). To rule out that the presence of CCP 3 (within the con-
struct CCPs 1–3) alters the binding affinities to rPfRh4, we also
performed affinity measurements using CCPs 1–3 (Fig. 8G).
With a KD of 39.2 nM CCPs 1–3 exhibit similar binding prop-
erties when compared with CCPs 1 and 2, ruling out a promi-
nent influence of CCP 3 on the underlying interaction. Because
the previous studies have assayed the binding behavior in HEPES
buffer in the absence of MgCl2, we also interrogated if the presence
of magnesium ions could have modified the interaction. However,
the presence or absence of magnesium ions did not influence the
binding of CCPs 1 and 2 to rPfRh4 with the KD in 1 mM MgCl2 or
3 mM EDTA buffer being fitted to 20.0 or 16.9 nM (Fig. 8, A and H,
respectively). Thus, the markedly tighter association between the
CR1 constructs and rPfRh4 observed in this study likely originates
from a modified purification protocol of the rPfRh4 construct,
which is discussed below. Using SPR, we determined that the
inhibitory biological activity for the CCPs 1 and 2 and CCPs 8 and
9 mutant constructs correlates remarkably well with the affinities
for their binding partner rPfRh4, which are in the lower nanomolar
range.
Discussion
Parasite entry into red blood cells is an essential component of
the P. falciparum life cycle in humans. P. falciparum has evolved to
use redundant invasion pathways, and through the ability to
switch pathways via differential expression of parasite adhesins,
the parasite has more opportunities for successful invasion in the
face of the human immune response and red blood cell polymor-
phisms prevalent in malaria endemic regions. By activating
expression of PfRh4, the parasite is able to switch receptor usage
from sialic acid-dependent to sialic acid-independent pathways,
thus providing a mechanism for the parasite to invade via non-
glycophorin mediated entry. In the work reported here we charac-
terize a repertoire of anti-PfRh4 mAbs including the first anti-
PfRh4 neutralizing antibody (summarized in Table 2) and describe
a collection of CR1-based inhibitors, which are able to block PfRh4
interactionwithCR1andinhibitP. falciparumsialic-acid indepen-
dent invasion pathways. Collectively, these results will guide future
work on the development of single epitope inhibitors of the CR1-
PfRh4 invasion pathway.
5H12 mAb represents the first anti-PfRh4 neutralizing anti-
body. Using three robust PfRh4-CR1 interaction assays based
on ELISA, FRET, and immunoprecipitation, we show that 5H12
A









































FIGURE 5. Kinetics of mAb-PfRh4 interactions. Sensorgrams of multi-cycle kinetic measurements of 5H12 (A) and 10C9 (B) with PfRh4. The sensorgrams
represent duplicate runs obtained on separate days with increasing concentrations of rPfRh4 (1.5625, 3.125, 6.25, 12.5, 25, 50 nM) flowed over 5H12 and 10C9
captured on anti-mouse IgG. Solid lines represent the observed binding, and dots represent 1:1 Langmuir model-fitted binding with kinetic values reported in
Table 1. R.U., resonance units.
TABLE 1
Multicycle kinetic measurements of mAb-PfRh4 interactions
Kinetic parameters (ka and kd) and KD values extracted from 5H12-rPfRh4 and
10C9-rPfRh4 sensogram fitted to a global 1:1 interaction model are reported. Max-
imum resonance values (Rmax) and 2 values of goodness of fit (10% Rmax) for the
models are also presented. RU, resonance units.
mAb ka kd Rmax KD 2
M
1 s
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is able to disrupt PfRh4 interaction with CR1. The addition of
5H12 also blocks PfRh4 binding to red blood cells and inhibits
the PfRh4-CR1 pathway in P. falciparum growth assays. A
recent study reporting the atomic resolution structure of PfRh5
in complex with its inhibitory antibodies QA1 and QA5 show
that the epitopes for these antibodies overlap with the basigin
N- and C-terminal domain binding site, respectively. We
hypothesize that 5H12 would bind to a conformation-depen-
dent epitope that overlaps with the CR1 binding site in PfRh4
and in effect blocks the ability for the receptor to bind. Epitope
mapping of 5H12 with PfRh4 using x-ray crystallography will
allow us to identify the binding interface and guide the design of
inhibitory antibody epitopes.
6A5 and 10C9 mAb are able to enhance PfRh4 binding to
CR1 on red blood cells. Epitope mapping shows that 10C9
bound two overlapping peptides, N662 (NFTHKTIQQ-
ILQQQY) and K666 (KTIQQILQQQYKNNT), whereas 6A5
recognized only peptide K666. The striking feature of these
peptides is the presence of polyglutamine repeats. As these
epitopes are present outside of the minimal red blood cell bind-
ing domain of PfRh4 (31), the binding of the mAbs may elicit an
allosteric conformational change that enhances the binding
capabilities of PfRh4 to red blood cells. Previously we observed
that the addition of rabbit polyclonal antibodies raised to the
C-terminal end of native PfRh4 were able to enhance the bind-
ing of PfRh4 to red blood cells (data not shown).5 Examination
5 The addition of rabbit polyclonal antibodies raised to the C-terminal end of
PfRh4 was able to enhance binding of native PfRh4 to red blood cells with
no effect on EBA-175 binding.
QCNAPEWLPFARPTQLTDEFEFPIGCCP 1-2 
QCNAPDHFLFARPTQLTDEFEFPIGCCP 1-2 m6-9 
QCNAPEWLPFARPTQLTNEFEFPIGCCP 1-2 m18 
QCNAPEWLPFARPTQLTDESEFPIGCCP 1-2 m20
CCP 8-9 HCQAPDHFLFAKLKTQTNASDFPIG  
CCP 8-9 Rev HCQAPDWLPFAKLKTQTDEFDFPIG  
B C
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FIGURE 6. CR1-based inhibitors of PfRh4-CR1 interaction. A, schematic of CR1 polypeptide. Each box labeled 1–30 represents a CCP module of 60 –70 amino
acid residues. The first 28 CCPs are organized based on homology into four long homologous repeats (LHR) A–D, each consist of seven CCPs. The functional sites
of CR1 are labeled Site 1 and Site 2 with their respective activities. The transmembrane domain and cytoplasmic tail are represented as a curvy line at the
C-terminal end. B, SDS-PAGE gel of purified CCP constructs. 2 g of each construct were loaded onto a NuPAGE® gradient gel (4 –12%) under reducing and
non-reducing conditions and stained with Coomassie Brilliant Blue. Molecular weight markers are indicated in kDa in the middle of the gel. C, the first 25 amino
acids within CCPs 1 and 2 and CCPs 8 and 9 are shown. Wild type CCP 1 and CCP 8 sequence is in black and orange, respectively. Numbers after the m, for
mutants, denote the position of the amino acids. D, immunoprecipitation assay to monitor PfRh4-CR1 complex formation. Anti-PfRh4 antibody 10C9 was
incubated with rPfRh4 in the presence of either CCPs 1 and 2, CCPs 1 and 2 m6 –9, CCPs 1 and 2 m18, CCPs 1 and 2 m20, CCPs 8 and 9, or CCPs 8 and 9 Rev. Proteins
were stained with SimplyBlue SafeStain. I, input. U, unbound. E, eluate. E, inhibitory antibody 5H12 is able to block complex formation between CCPs 8 and 9
Rev and rPfRh4. F, effects of mutagenesis within CCPs 1 and 2 on rPfRh4 binding to red blood cells. Percentage RBC binding of rPfRh4 on the y axis refers to the
percentage of rPfRh4-erythroid CR1 binding relative to the rPfRh4 only control (arbitrarily set to be 100%). Error bars represent  S.E. from three independent
repeats. G, growth assays in the presence of CR1 recombinant constructs. Various CCP mutants and soluble CR1 were tested with untreated (black bars) or
neuraminidase-treated erythrocytes (gray bars) at a final concentration of 0.1 mg/ml. Growth (percentage of control) on the y axis refers to the percentage
parasitemia relative to the PBS control. Error bars represent S.E. from three independent repeats.
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of the protein sequence highlighted the presence of QQXXXX-
QQQ and a triple QQQ site within the recombinant protein
used as immunogen. Antibodies that bind to these sites may
elicit an allosteric change in full-length PfRh4, resulting in
enhanced binding to CR1, although the molecular mechanism
remains to be experimentally verified. It will be important to
exclude the epitopes above in future immunizations as not to
generate antibodies that enhance the interaction between
PfRh4 and CR1.
We also describe four CR1-based inhibitors; CCPs 1 and 2,
CCPs 1 and 2 m6 –9, CCPs 1 and 2 m18, and CCPs 8 and 9 Rev.
These inhibitors competed for PfRh4 binding to erythroid CR1
and block the use of the PfRh4-CR1 invasion pathways in P. fal-
ciparum. Their inhibitory effects directly correlate with their
affinity for PfRh4. The least potent inhibitor CCPs 1 and 2 m18
has a KD of 336 nM compared with the 33, 65, and 20 nM for
CCPs 1 and 2 m6 –9, CCPs 8 and 9 Rev, and CCPs 1 and 2,
respectively. In contrast to the affinity constants for the rPfRh4-
CR1 interaction being in the lower nanomolar range as deter-
mined in this study, two previous studies have found the bind-
ing constants for the interaction of CR1 CCPs 1–7 or CCPs 1–3
to be in the range between 0.5 and 11 M (32, 33). This former
work has also employed SPR to measure the affinity constants
for the binding of sensor chip-immobilized rPfRh4 to CR1
CCPs 1–3 or CCP s1–7. Although the CCPs 1–3 construct was
overexpressed by P. pastoris and purified to homogeneity, the
CCPs 1–7 wild type and mutant constructs were expressed by
HEK293T with the proteins being directly harvested from
serum-free supernatants or captured by metal affinity chro-
matograph facilitated by a hexa-His tag. Despite differences in
glycosylation status and purity, the CCPs 1–3 and CCPs 1–7
preparations exhibited an overall similar binding behavior for
rPfRh4 (0.5–11 M).
In our present study we measured the affinity of Pichia-pro-
duced CCPs 1–3 for rPfRh4 alongside the novel wild type and
mutant constructs within CCPs 1 and 2 and observed a mark-
edly tighter interaction than described before (32, 33). Because
the CCP 1 and 3 proteins in all studies have been prepared by
the same procedures, a possible reason for this remarkable
shift toward higher affinity likely originates in the modification
of the purification protocol for rPfRh4, which now includes
tobacco etch virus cleavage of the N-terminal hexa-His tag fol-
lowed by ion exchange chromatography. The fact that the
removal of 23 amino acids including the purification tag leads
to a substantial increase in affinity argues that accessibility of
the N terminus in PfRh4 is critical for its interaction with CR1.
In terms of specific amino acids within CCP 1 that are critical
for binding PfRh4, previous work identified that m6 –9 exhib-
ited a 	60% loss of affinity for rPfRh4, whereas m18 and m20
mutants completely abolished the interaction in vitro.
Although we are able to establish that m20 is a critical residue
involved in mediating PfRh4 interaction, we observed that
m6 –9 and m18, although lowering the affinity to various
degrees, were not essential. We do note, however, that m18 did
result in a strong reduction in PfRh4 binding, whereas the effect
of the m6 –9 substitution is negligible. Possible reasons for the
different outcomes may originate from the different prepara-
tions of rPfRh4, resulting in the presence or absence of the
purification tag.
Structurally, our study refines the previously proposed bind-
ing site and suggests that the surface-exposed, hydrophobic
residue Phe-20 plays the primary role in binding PfRh4 with
some contribution from the negatively charged side chain of
Asp-18, which on the surface of CCP 1 lies directly next to the
aromatic side chain of Phe-20.
Park et al. (32) were able to engineer an artificial binding site
within CCPs 8 –14 by substituting residues within CCP 1 that
are critical for PfRh4 interaction to their homologous position
in CCP 8. This artificial binding site carrying six CCP 1 amino
acid substitutions, m7–9,18 –20r, bound 30-fold better than
the wild type binding site as measured by SPR. Consistent with
this, our results show that CCPs 8 and 9 Rev was able to form a
stable complex with rPfRh4, whereas CCPs 8 and 9 did not.
With 20 and 65 nM we found the affinities between rPfRh4 and
CCPs 1 and 2 or CCPs 8 and 9 Rev, respectively, to be in a similar
range. This observation is in agreement with the comparable
biological activity observed for these two constructs. Although
we also observed conversion of CCPs 8 and 9 into an active
PfRh4 binding partner upon homologous substitution of six
amino acids, we were unable to confirm that CCPs 8 and 9 Rev
bound substantially tighter to PfRh4 than CCPs 1 and 2. A pos-
FIGURE 7. 1H NMR spectra of CR1 protein fragments. Spectra for the CR1
constructs CCPs 1 and 2 (A), CCPs 1 and 2 m6 –9 (B), CCPs 1 and 2 m18 (C), CCPs
1 and 2 m20 (D), CCPs 8 and 9 (E), and CCPs 8 and 9 Rev (F). The spectra were
recorded on a 800-MHz spectrometer from Bruker at 303 K in PBS with the
addition of D2O to 7%. All samples were measured at a protein concentration
of 50 M. The dispersion and line shape as well as peak intensities are com-
parable among the different samples and indicate comparable high quality of
the sample preparations. The overall good signal dispersion and the sharp
line widths are consistent with mono-dispersed, well folded protein mole-
cules. The spectrum of CCPs 1 and 2 (A) exhibits two strong signals between 3
and 4 ppm. These signals relate to a small contamination with glycerol that
derives from the protein concentration process using a commercial spin con-
centrator (which typically use glycerol to preserve the filtration membrane of
the spin concentrator). The signal at 4.8 ppm relates to residual water signal.
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sible reason for this discrepancy may be that the novel purifica-
tion method used for rPfRh4 produces a protein that more
closely reflects the physiological conformation of the parasite
adhesin on merozoites. Another reason may lie in a potential
contribution of CCP domains 10 –14 in binding to PfRh4. How-
ever, this is unlikely as the addition of 5H12 mAb is sufficient to
prevent the formation of the complex, suggesting that CCPs 8
and 9 Rev and CCPs 1 and 2 essentially bind in the same mode to
the exact same epitope on PfRh4. Furthermore, CCPs 8 and 9
Rev is able to block PfRh4 binding to red blood cells and func-
tions as an inhibitor of P. falciparum PfRh4-CR1 invasion path-





3002001000 400 500 10



































































B. CCP 1-2 m6-9
C. CCP 1-2 m18
D. CCP 1-2 m20
F. CCP 8-9 Rev
E. CCP 8-9
G. CCP 1-3











































KD = 33.5 nM  
(+/- 0.65 nM) 
KD = 336 nM  
(+/- 0.54 nM) 
KD = 64.9 nM  
(+/- 1.13 nM) 
KD = 39.2 nM  
(+/- 0.98 nM) 
KD = 16.9 nM  
(+/- 0.21 nM) 
KD = 20.0 nM  
(+/- 0.61 nM) 
FIGURE 8. Binding activity of CR1 constructs for rPfRh4 as measured by SPR. A, 2900 resonance units (RU) rPfRh4 were coupled covalently to a carboxym-
ethyldextran hydrogel biosensor chip. Reference subtracted sensorgrams of a 2-fold analyte dilution series for CCPs 1 and 2 binding to rPfRh4 are shown. The
right plot is the respective response at steady state versus molar concentration fitted to a 1:1 steady state affinity model. CCPs 1 and 2 m6 –9 (B), CCPs 1 and 2
m18 (C), CCPs 1 and 2 m20 (D), CCPs 8 and 9 (E), and CCPs 8 and 9 Rev (F), are as described above. G, 1700 resonance units resonance units of rPfRh4 were coupled
covalently to a carboxymethyldextran hydrogel biosensor chip, and a 2-fold concentration series of CCPs 1–3 in running buffer containing 1 mM MgCl2 was
probed for binding. Reference-subtracted sensorgrams are shown. The corresponding right plots are of responses achieved in panel G at steady state versus
molar concentration fitted to a 1:1 steady state affinity model. H, binding was assayed for CCPs 1 and 2 in running buffer containing 3 mM EDTA MgCl2 over a
chip immobilized with 1950 resonance units of rPfRh4. A 2-fold concentration series was probed for binding, and reference subtracted sensorgrams are shown.
The right-hand graph shows a plot of responses achieved in panel H at steady state versus molar concentration, which was fitted to a 1:1 steady state affinity
model.
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Our results highlight distinct regions within PfRh4 and CR1
that are important for mediating entry of P. falciparum para-
sites. We have demonstrated that it is possible to generate anti-
PfRh4 neutralizing antibodies and a repertoire of CR1-based
inhibitors that both block PfRh4-CR1 interaction and show
functional inhibition in P. falciparum growth. Furthermore, we
identified distinct epitopes within PfRh4 that should not be
included in future vaccinations because of their ability to gen-
erate antibodies that enhance the interaction with CR1. This
collection of anti-PfRh4 mAbs and CR1 constructs will be
invaluable tools in the efforts to obtain an atomic resolution
structure of the binding interface between PfRh4 and CR1 that
will further inform the rational design of potent inhibitors.
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